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1 
Summary 
Background 
Urticaria and psoriasis are two of the most common chronic skin disorders that have a great 
impact on patients’ quality of life. Western medicine (WM) provides short-term symptomatic 
relief. However, a long-term strategy for managing refractory urticaria is lacking and 
unwanted side effects have been associated with long-term use of such therapies for psoriasis. 
In WM, chronic urticaria and psoriasis vulgaris are attributed to immune dysfunction (as the 
underlying internal factor) and are triggered by external factors. In Chinese medicine (CM), 
these two conditions share the same pathogenesis of an underlying deficiency of healthy, 
protective qi with an external pathogenic factor. 
In terms of treatment principle, the concept of using the same treatment for different diseases 
(异病同治) is very common in CM clinical practice. This is defined as applying the same 
treatment method to patients who suffer from different disease but have the same patterns. As 
both conditions result from immune dysfunction in WM, and share the same treatment 
principle from a CM perspective, the clinical management of these two conditions was 
evaluated to explore the current state of clinical evidence of Chinese herbal medicine (CHM). 
To provide the best available evidence on the efficacy and safety of CHM for both conditions, 
‘whole evidence’ from both classical literature and clinical studies was evaluated 
systematically. Pre-clinical evidence was briefly summarised to explain potential mechanisms 
of CHM. In addition, practicability, such as patients’ experiences of using CHM, should be 
considered when CHM is considered as part of clinical practice.  
2 
Objectives 
The objectives of this study are to: 
1. evaluate the evidence of CHM for chronic urticaria and psoriasis vulgaris in the 
classical CM literature 
2. evaluate the current clinical trial evidence of CHM for chronic urticaria 
3. evaluate the current clinical trial evidence of compound glycyrrhizin (CG) (extract 
from Chinese herb gan cao甘草, radix glycyrrhizae) for psoriasis vulgaris 
4. summarise the current experimental evidence of CHM for chronic urticaria and 
psoriasis vulgaris 
5. explore patients’ experiences of using CHM for the treatment of chronic urticaria and 
psoriasis vulgaris. 
Methods 
Evidence Evaluation of CHM in Classical Literature 
Classical literature research was conducted based on the Zhong Hua Yi Dian. Citations 
related to chronic urticaria and psoriasis vulgaris were found by searching the Zhong Hua Yi 
Dian. Descriptive analysis was performed to calculate the frequency of formulae and herbs 
used in the Zhong Hua Yi Dian citations likely to involve chronic urticaria and psoriasis 
vulgaris. 
Evidence Evaluation of Chinese Herbal Medicine in Clinical Trials 
Clinical evidence was evaluated and synthesised through systematic reviews (SRs) of 
randomised controlled trials (RCTs). All SRs were conducted following the rigorous 
3 
methodology of the Cochrane Collaboration. In addition, experimental evidence from modern 
literature was also summarised and incorporated into the SRs. 
Experiences of using Chinese Herbal Medicine 
A qualitative description method was used to explore patients’ experiences living with these 
two conditions and using CHM. Data were collected through individual semi-structured 
interviews. 
Results 
Evidence from Classical Literature 
The findings indicate that Xiao feng san消风散 is the most commonly reported formula for 
urticaria in the classical literature, and is still used in current clinical practice. For psoriasis 
vulgaris, the most frequently reported formula is Sou feng shun qi wan 搜风顺气丸, which 
differs from contemporary practice. The CHM treatments for these two conditions have 
several herbs in common, including fang feng 防风, jing jie 荆芥, gan cao 甘草, qiang huo 
羌活, dang gui 当归 and chuan xiong 川芎. 
Evidence from Clinical Trials 
Two SRs on CHM for chronic urticaria included 100 RCTs (10,258 participants). The results 
suggested that CHM alone (RR: 1.21 [1.15, 1.29], I
2
=0%) or as an add-on therapy to second-
generation antihistamines (RR: 1.19 [1.10, 1.27], I
2 
= 54%) improved symptoms of chronic 
urticaria by 30% or more when compared with second-generation antihistamines. CHM was 
well tolerated by patients with chronic urticaria. Methodological flaws of the included studies 
and uncertain validity of outcomes limited the certainty of the findings. The key herbs used in 
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the formulae for chronic urticaria in included studies appeared to have anti-inflammatory, 
anti-allergenic and antipruritic actions. 
The third SR focused on the add-on effect of CG to conventional therapy for psoriasis 
vulgaris. Eleven RCTs (1,200 participnats) were included in this SR. CG plus conventional 
therapy enhanced clinical response in terms of psoriasis area severity index (PASI) 60 (RR: 
1.30 [1.21, 1.40], I
2 
= 6%) and90 (RR: 1.37 [1.21, 1.56], I
2 
= 0%), and did not increase the 
frequency of adverse events for patients with psoriasis vulgaris. However, the findings should 
be interpreted with caution due to methodological flaws in the included studies. The long-
term add-on effect was uncertain. CG was considered to have an anti-inflammatory and 
immune-modulating effect based on experimental evidence. 
Experience of using Chinese Herbal Medicine 
The findings suggested that patients living with psoriasis vulgaris or chronic urticaria were 
burdened by physical and psychological effects. Long-term use of conventional treatments 
resulted in unpleasant side effects, which undermined participants’ confidence in 
conventional treatments. Based on participants’ own beliefs and experiences, they sought 
CHM as treatment. Most participants experienced satisfactory responses to CHM, but some 
found it hard to manage. 
Conclusions 
Evidence from classical literature showed the most frequently used formulae and herbs for 
both conditions in ancient times, which could guide contemporary clinical practice and drug 
discovery. SRs of clinical evidence produced through this research suggested that CHM was 
well tolerated and had promising benefits in improving clinical outcomes. These provided the 
evidence of efficacy and safety necessary for clinical decision-making, CM education and 
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further research. A general summary of pharmacological action of key herbs indicated that 
the herbs possessed anti-inflammatory, anti-allergenic, antipruritic and immune-modulating 
actions. When choosing CHM, patients expected accessible treatments which could reduce 
relapse rates with no side effects. Understanding patients’ expectations and experiences is 
helpful when communicating with patients about their therapeutic options. Further, it 
provides direction for future research. 
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Chapter 1. Introduction 
1.1 Introduction 
Chronic urticaria and psoriasis vulgaris are two common chronic and recurrent skin 
conditions, which have similar prevalence in the global population (1–9). The pathogenesis of 
both conditions is related to immune dysfunction and is triggered by external factors (10–13). 
In addition to the considerable health-related (physical and psychological) burdens these 
conditions inflict on patients, both chronic urticaria and psoriasis vulgaris place significant 
economic burdens on individuals and healthcare systems (13–22). 
For both conditions, Western medicine (WM) can provide rapid relief of symptoms. However, 
long-term use of WM remains a challenge due to uncomfortable side effects and a lack of 
treatment response from some patients (10, 12, 13, 23). Patients may look to complementary 
and alternative medicines (CAM) when WM treatment does not meet their expectations. 
Studies show the use of CAM, including herbal medicine for skin conditions, is increasing 
(24–26). 
Chronic urticaria and psoriasis vulgaris are two examples of dermatological diseases with 
similarities in WM pathogenesis and Chinese herbal medicine (CHM) management. One 
Chinese medicine (CM) treatment principle can be applied to both conditions, that is to deal 
with presenting symptoms during the acute phase of the condition, and address the root cause 
(underlying internal factors) during the chronic phase of the condition. Treatment must 
address both symptoms and root causes but be guided by the primary cause of the condition 
(急则治其标, 缓则治其本, 标本兼治, 治病必求于本). 
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Moreover, the concept of using the same treatment for different diseases (异病同治) is very 
common in CM clinical practice. This is defined as applying the same treatment method to 
patients who suffer from different disease that have the same patterns. As both conditions 
result from immune dysfunction in WM, and share the same treatment principle from a CM 
perspective, it is valuable to explore the current state of clinical evidence of Chinese herbal 
medicine (CHM). 
CM has a long history in treating dermatological diseases. CM classical literature contains an 
abundance of information on CHM for chronic urticaria and psoriasis vulgaris in ancient 
times. Many of the formulae described in contemporary textbooks and guidelines have their 
origins in classical literature. However, classical literature has not been evaluated using a 
systematic approach. Meanwhile, evidence from clinical trials of CHM for chronic urticaria 
and psoriasis vulgaris is increasing. Synthesis of information from classical literature and 
clinical trials is lacking. A ‘whole evidence’ approach was used in this project, which was to 
search, evaluate and systematically analyse evidence from classical literature and modern 
literature. This included randomised controlled trials (RCTs), non-randomised controlled 
trials and non-controlled studies. This comprehensive approach can identify potential 
therapies for further evaluation and guide clinical practice. 
1.2 Rationale of the Research 
This project addresses several gaps in the understanding of CHM use for chronic urticaria and 
psoriasis vulgaris. The classical literature includes discussions of CM concepts in texts, 
dating back to the Spring and Autumn periods (770–476 BC) (27). Books are written in 
Chinese. Many texts do not have an English translation and hard copies may be difficult to 
obtain. The Zhong Hua Yi Dian (ZHYD) provides a digitalised and searchable collection of 
more than 1,100 books. This project provides a summary of the information from classical 
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literature. Many of these sources would not otherwise be accessible to people who do not 
read Chinese. 
Further, systematic reviews (SRs) of clinical evidence provide the best available indication of 
efficacy and safety for clinical decision-making, CM education and further research. For 
psoriasis vulgaris, several SRs have evaluated the efficacy and safety of CHM (28–31). 
Reviews have focused on evaluation of CHM as an intervention. No reviews that examined 
the efficacy of a particular herb, formula or product were identified. For example, a CHM 
product called compound glycyrrhizin (CG), with its key constituent glycyrrhizin extracted 
from gan cao甘草, is commonly used in clinical practice in China for psoriasis vulgaris. No 
reviews published in English have evaluated the efficacy of this compound. For chronic 
urticaria, two SRs have focused on a particular formula (Dang gui yin zi当归饮子) (32, 33) 
and the third review evaluated CHM but with a narrow scope (34). To address these gaps, this 
project will undertake additional evaluation to provide a more comprehensive evaluation of 
best available evidence for treatment of these two conditions. 
Through previously published SRs of psoriasis vulgaris, the researcher identified key herbs 
that may be promising for both conditions. To examine the pharmacological actions of the 
key herbs used in the SRs, the researcher reviewed a selection of experimental studies that 
reported actions relevant to chronic urticaria and psoriasis vulgaris. This could inform drug 
discovery research and ensure the most relevant active compounds are extracted for CHM 
preparation. 
Most studies focus on the efficacy and safety of CHM for the conditions. However, little 
attention has been paid to the end-users, including patients. A qualitative study was 
conducted to explore the use of CHM for chronic urticaria and psoriasis vulgaris. The 
qualitative study highlighted the motivators for people to use CHM and their experiences of 
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using CHM to manage their skin condition. The findings from this component of the project 
will help inform CM clinical practice and contribute valuable information for future research 
study design. 
Finally, the project integrated the classical literature with current clinical practice guidelines, 
clinical evidence and patients’ experiences. This information can guide contemporary 
practice and clinical research. 
1.3 Aim 
This project aims to evaluate the efficacy and safety of CHM for chronic urticaria and 
psoriasis vulgaris. Further, it aims to explore patients’ experiences of using CHM for the 
treatment of these two conditions. 
1.4 Research Questions 
1. What is the understanding of CHM for chronic urticaria and psoriasis vulgaris in the 
classical CM literature? 
2. What is the current clinical trial evidence of CHM for chronic urticaria? 
3. What is the current clinical trial evidence of compound glycyrrhizin (extract from 
Chinese herb gan cao甘草, radix glycyrrhizae) for psoriasis vulgaris? 
4. What is the current experimental evidence of CHM for chronic urticaria and psoriasis 
vulgaris? 
5. What are patients’ experiences using CHM for the treatment of chronic urticaria or 
psoriasis vulgaris? 
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1.5 Organisation of the Thesis 
This thesis includes 10 chapters. Chapter 1 introduces the research background of this project. 
The rationale and aim of the research are highlighted. The research questions are included 
and an overview of the thesis is presented. 
Chapter 2 describes the understanding of chronic urticaria and psoriasis vulgaris from a WM 
perspective, including the definition, epidemiology, aetiology, pathophysiology, diagnosis 
and classification/subtypes. Current conventional management and its limitations are also 
identified and reviewed. 
Chapter 3 describes the understanding of chronic urticaria and psoriasis vulgaris from a CM 
perspective through a general review of contemporary clinical guidelines and key textbooks. 
The contents include the terminology, aetiology, pathophysiology, syndrome differentiation, 
treatment principles, CHM treatments (oral and topical), acupuncture and other therapies. 
Chapter 4 evaluates the evidence of CHM for both conditions in over 1,100 classical 
literature books contained in a compact disc (CD) version of ZHYD (Encyclopaedia of 
traditional Chinese medicine). The classical literature research procedure for both conditions 
is described in detail. ZHYD citations related to urticaria and psoriasis vulgaris are identified. 
The frequently used formulae and herbs are calculated through descriptive analysis. 
Chapter 5 describes the general methodology used to evaluate the clinical evidence. All SRs 
follow the procedure suggested by Cochrane handbook for systematic reviews of 
interventions (89). 
Chapter 6 and Chapter 7 are two SRs on CHM for chronic urticaria. Chapter 6 evaluates the 
efficacy and safety of CHM alone for chronic urticaria when compared with second-
generation antihistamines. Chapter 7 evaluates the efficacy and safety of CHM add-on 
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therapy to second-generation antihistamines. Further, the main pharmacological actions of the 
key formulae and herbs are summarised in these two chapters. Chapter 8 systematically 
evaluates the clinical evidence on the add-on effect of CG to conventional therapy for 
psoriasis vulgaris and its safety. 
Chapter 9 presents a qualitative study, which explores the patients’ experiences of living with 
chronic urticaria and psoriasis vulgaris and using CHM to manage the conditions. The 
research method and findings are described in this chapter. 
Chapter 10 summarises and discusses the research findings, similarities and differences 
across chapters, and limitations of this project. Implications for clinical practice and further 
research are also highlighted. This chapter also includes conclusions drawn from this research.   
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Chapter 2. Chronic Urticaria and Psoriasis 
Vulgaris in Western Medicine 
2.1 Definition of Chronic Urticaria and Psoriasis Vulgaris 
Urticaria and psoriasis are two common skin disorders. The typical characteristic of urticaria 
is the development of wheals (also called hives), either alone or accompanied by angioedema 
(10). The feature of wheals is a central swelling area, which is surrounded by erythema and 
usually accompanied by pruritus (itching) and/or a burning sensation (10). Wheals vary in 
size from a few millimetres to several centimetres (35). They develop quickly and usually 
resolve within 24 hours. In contrast, angioedema may present with erythematous or skin-
coloured swelling of the lower dermis and subcutis, with pain rather than pruritus (10). 
Angioedema can take up to 72 hours to resolve (10). Wheals may develop in response to a 
stimulus (induced urticaria) or there may be no identifiable trigger (spontaneous urticaria). 
Depending on duration of the condition, urticaria is classified as acute or chronic (10). Acute 
urticaria is defined as the spontaneous onset of wheals and/or oedema that lasts less than six 
weeks (10). Chronic urticaria refers to the occurrence of symptoms lasting for six or more 
weeks and is categorised as either spontaneous (chronic spontaneous urticaria) or inducible 
(10). Symptoms can occur daily or almost daily (36), or at irregular intervals (37). In clinical 
appearance, chronic urticaria is not different from acute urticaria (37). 
Psoriasis is a chronic, genetic, systemic and inflammatory disorder that can be influenced by 
environmental factors (13). It may have potential associations with other inflammatory 
disorders or metabolic syndromes, such as psoriatic arthritis or diabetes (12, 13). Psoriasis 
vulgaris is the most common type of psoriasis, observed in approximately 80–90% of patients 
(13). Psoriasis vulgaris appears as sharply marginated, erythematous patches or plaques with 
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a characteristic silvery-white micaceous scale. The plaques are round or oval and are 
typically located on the scalp, trunk, buttocks and limbs, especially on extensor surfaces of 
the elbows and knees (13). Psoriasis vulgaris may progress to other types of psoriasis, such as 
erythrodermic or pustular types, due to inappropriate therapies or infection (12, 13). 
2.2 Epidemiology of Chronic Urticaria and Psoriasis Vulgaris 
2.2.1 Prevalence of Chronic Urticaria and Psoriasis Vulgaris 
The prevalence of various types of urticaria ranges from 0.5% (8) to 8.8% (9). For psoriasis, 
it ranges from 0.47% (2) to 8.5% (1–7). According to the National Hospital Morbidity 
Database from the Australian Institute of Health and Welfare, urticaria hospitalisation rates 
increased from 5.6 in 1993–1994 to 10.3 in 2004–2005 (per 100,000 people), with an average 
annual increase of 5.7% (38). In China, the prevalence of urticaria is unknown. The 
prevalence of psoriasis in Victoria (Australia) is 6.6% (6), while in China it is 0.47% (2). 
Prevalence of psoriasis vulgaris is higher in young females than males (1); for chronic 
urticaria, prevalence is higher in females overall, regardless of age (9, 37).  
Prevalence of psoriasis vulgaris is also influenced by geographical location (for example, 
cooler climate [39] and ethnicity [4]). It appears that variables, including physical 
environment, genetic factors and behavioural patterns, play a role in the progression of 
psoriasis (39). 
2.2.2 Impact of Chronic Urticaria and Psoriasis Vulgaris on Health-related Quality of Life 
The impact of chronic urticaria on quality of life (QoL) has been rated as comparable to that 
of coronary artery disease (17). Functional limitation has been reported in mobility, pain, 
energy, sleep, and mood changes including depression, life stress, social interaction and 
emotional reactions (14–17). Patients were not always aware of the level of limitation 
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experienced due to urticaria (14). The prevalence of psychosocial factors in people with 
chronic spontaneous urticaria was estimated to be 46.09% in an SR conducted in Canada (40). 
Although psoriasis is not life threatening, research has linked it to an increased risk of 
cardiovascular disease, diabetes and cancer, among other morbidities (13). In addition to the 
burden of symptoms such as scaling, itching and skin redness, the amount of time required to 
treat extensive skin or scalp lesions and to maintain clothing and bedding also adversely 
affects QoL. Psychological wellbeing can be affected, including lowered self-esteem, anxiety, 
sexual dysfunction and depression (18, 19). Suicide may occur if the illness is severe (18, 19). 
Patients with psoriasis suffer physical and mental disabilities that are comparable to (or 
greater than) those found in patients with other chronic diseases, such as tumour, arthritis, 
hypertension, cardiovascular disease and diabetes (41). 
2.2.3 Economic Burden of Chronic Urticaria and Psoriasis Vulgaris 
Medication costs accounted for nearly two thirds (US$1,280) of the total annual direct cost of 
US$2,047 per patient (20) for chronic spontaneous urticaria. This is likely to be an 
underestimation because factors such as waiting time and costs accrued by carers and family 
were not considered. The direct average annual costs of mild psoriasis vulgaris per patient 
ranged from €500 to €2,000, and for severe disease from €4,000 to €10,000 in Germany (21, 
22). Indirect costs, including work absenteeism, early retirement and unemployment due to 
psoriasis, added a further €1,600 on average (22). 
2.2.4 Similarities in Chronic Urticaria and Psoriasis Vulgaris 
The prevalence of chronic urticaria and psoriasis vulgaris is similar (0.5–8.8% v. 0.47–8.5%) 
(1–7). Both conditions have a significant impact on patients’ QoL, including physical and 
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psychological influences. The economic burden of chronic urticaria and psoriasis vulgaris is 
high in both direct and indirect costs. 
2.3 Aetiology and Pathophysiology of Chronic Urticaria and Psoriasis Vulgaris 
2.3.1 Risk Factors 
Chronic urticaria is more commonly observed in women than men (9, 37). For around one to 
two per cent of patients, symptoms of chronic urticaria seem to be caused by ingestion or 
contact with certain substances (such as food, medication and cosmetics etc.), infection, 
hormonal changes or systemic disease (42). A food must be ingested regularly to cause 
chronic urticaria (42). In endemic regions, multicellular parasites may cause chronic urticaria 
as they can trigger strong immunoglobulin type E (IgE) response (42). In rare cases, menses 
has been reported to cause or worsen chronic urticaria symptoms (42). The occurrence of 
chronic urticaria can be associated with rheumatic or other autoimmune diseases (42).  
A risk factor of psoriasis is possibly genetics because most patients have a family history (39). 
Obesity does not appear to be a factor that triggers the onset of psoriasis, but patients with 
psoriasis tend to be overweight. In contrast, smoking is more likely to play a role in the onset 
of psoriasis (43), while alcohol can influence the progression of the disease (44). Stress is 
another important trigger factor of psoriasis and may influence the development of the 
condition (45). Apart from the internal factors, some medications may be associated with the 
onset or exacerbation of psoriasis, including anti-malarial drugs, nonsteroidal anti-
inflammatory drugs, β-blockers, lithium salts and the withdrawal of steroids (46). Acute 
infections, mainly bacterial (streptococcal), may trigger or exacerbate psoriasis, especially 
guttate-type psoriasis (46). Conversely, the consumption of fruit and vegetables, carrots, 
tomatoes or other foods containing β-carotene can decrease the risk of psoriasis (47). 
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2.3.2 Pathophysiological Process of Chronic Urticaria and Psoriasis Vulgaris 
The pathophysiology of urticaria is complicated. According to conventional medical 
knowledge, urticaria is considered a mast cell driven disease (10, 11). Although the trigger 
and signals of mast cell activation remain unknown, inflammatory cytokines, histamine, 
platelet-activating factor (PAF) and other mediators have been shown to be released from 
activated dermal mast cells (10). This process may lead to sensory nerve activation, 
vasodilation and extravasation of fluid and cell recruitment to urticarial lesions (10, 11). 
Between 30 and 50% of chronic urticaria can be attributed to autoimmune disease based on 
the most accepted hypothesis (11, 48). Chronic urticaria has been associated with other 
autoimmune diseases, such as systemic lupus erythematosus, Still disease and Sjögren 
syndrome (8). Thyroid antibody levels are higher in patients with chronic urticaria (48). In 
autoimmune-origin urticaria, IgE receptors or IgE bound to receptors are activated by 
histamine-releasing auto-antibodies, which can stimulate the degranulation of mast cells and 
basophils (49). 
Pruritus observed in the clinical manifestation of urticaria is caused by the rapid release of 
histamine, which induces the vasodilatation and extravasation of fluid (50). Histamine acts on 
H1-receptors of endothelial cells and sensory nerves, leading to the development of wheals. 
Further, it induces the symptoms of pruritus and neurogenic flare (10). Inflammation 
infiltrates the lesion site and longer lasting wheals are usually caused by the delayed secretion 
of inflammatory cytokines (10, 50). At the wheal site, dilatation of postcapillary venules and 
lymphatic vessels occurs in the upper dermis, and oedema in the upper- and mid-dermis (10). 
An inflammatory infiltration of neutrophils, eosinophils, macrophages and T cells can also be 
identified at the wheal site. 
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The pathogenesis of psoriasis has not been completely defined. Previous research has 
suggested that psoriasis involves a complex immunological and inflammatory reaction, and 
epidermal hyperproliferation, which is influenced by genetic factors or environmental factors 
(infection, smoking, drugs, skin trauma and stress) (12, 13). The human leukocyte antigen 
(HLA-Cw6 allele/HLA-Cw0602–Cw0613), also known as ‘psoriasis susceptibility 1’ 
(PSORS1), is the key susceptibility gene for psoriasis (51). The most likely pathogenesis of 
psoriasis involves the following process. T cells are activated and migrate into the skin after 
the activation of elements of the innate immune system (keratinocytes and dendritic cells) (12, 
52). Certain functional T-cell subpopulations (type 1 helper T cell and type 17 helper T cell, 
that is, Th1 and Th17) grow under the influence of interleukin (IL)-12 and IL-23 (12, 52). 
Pro-inflammatory cytokines (tumour necrosis factor α, IL-17 and IL-22) secreted by Th1 
cells and Th17 cells may promote the inflammatory process in psoriasis. The local cells (such 
as endothelial cells, fibroblasts and keratinocytes) involved in the inflammatory process will 
then enhance the cutaneous immune response through expression of adhesion molecules and 
other mediators (12, 52). 
2.4 Diagnosis of Chronic Urticaria and Psoriasis Vulgaris 
2.4.1 Chronic Urticaria 
The diagnosis of chronic urticaria is based on a comprehensive patient history and clinical 
examination (8, 10). The history should include information about the clinical features of 
disease, medication usage and family history. The clinical manifestations of disease include 
the onset and duration of symptoms, frequency and characteristics of wheals (shape, size and 
distribution) and presence of itch or pain (10). 
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Clinical examination for diagnosis mainly consists of laboratory tests. Routine diagnostic 
tests for chronic spontaneous urticaria include differential blood count, erythrocyte 
sedimentation rate or C-reactive protein (8, 10). Additional tests could be taken into 
consideration when indicated by patient history or when a differential diagnosis is needed. 
These tests include autologous serum skin test, pseudo-allergen-free diet, functional auto-
antibodies, thyroid hormones and auto-antibodies. For inducible urticarias, diagnostic tests 
are used to confirm the threshold for the triggers or eliciting factors, in addition to differential 
blood count, erythrocyte sedimentation rate or C-reactive protein (10). 
2.4.2 Psoriasis Vulgaris 
The diagnosis of plaque psoriasis (psoriasis vulgaris) is based on typical lesion morphology 
and clinical history (12, 53). Consultations that investigate the onset of lesions, possible 
triggering contributors, related symptoms (that is, itch, pain, sensitivity and irritation) and 
family history are necessary (53). The Auspitz sign is regarded as the key to diagnosing 
psoriasis. It comprises numerous symptoms: red plaques covered with silvery-white scales; a 
candle wax phenomenon that appears after scratching; punctate bleeding that occurs when the 
outer-most layer of skin is removed; pinpoint bleeding (12). Differential diagnosis should 
focus on nummular eczema, tinea, mycosis fungoides and pityriasis rosea. Predilection sites 
(scalp, trunk, buttocks and limbs) and the nails manifestation may aid diagnosis. To confirm 
diagnosis, a biopsy may be necessary (12). Psoriasis vulgaris may develop into or accompany 
other types of psoriasis. The phenotypes of psoriasis are based on historical morphologic 
descriptions (13). 
19 
2.5 Subtypes/Classification 
2.5.1 Chronic Urticaria 
According to the triggers of onset, chronic urticaria can be classified as spontaneous (chronic 
spontaneous urticaria) and inducible (10). The clinical manifestations of chronic spontaneous 
urticaria are not different to those of acute urticaria (37) and occur without eliciting factors. 
Many factors can trigger chronic inducible urticaria, with subtypes of inducible urticaria 
named according to their triggers. Subtypes include cold urticaria, heat urticaria, aquagenic 
urticaria, solar urticaria, symptomatic dermographism, delayed pressure urticaria, vibratory 
angioedema, cholinergic urticaria and contact urticaria. Temperature is a common factor to 
induce urticaria, where exposure to cold wind/water or heat may result in cold urticaria or 
heat urticaria. Similarly, solar urticaria is triggered by exposure to sunlight. Symptomatic 
dermographism is caused by pressure applied to the skin or minor trauma. Sitting or tight 
clothing may induce delayed pressure urticaria. Vibratory angioedema is associated with the 
use of vibrating tools. The occurrence of cholinergic urticaria is due to exercise or emotional 
change. The intake of food or interaction with animals can cause contact urticaria. Contact 
with water can also trigger aquagenic urticaria, regardless of water temperature (10). 
2.5.2 Psoriasis Vulgaris 
Psoriasis can be classified into different subtypes based on visual lesion morphology and 
symptoms. The features of each subtype are described below. 
Plaque 
Plaque psoriasis (psoriasis vulgaris) is the most common type, observed in approximately 80 
to 90% of patients (13). Plaque psoriasis appears as sharply marginated, erythematous 
patches or plaques with characteristic silvery-white micaceous scales (53). The plaques are 
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irregular and round or oval. Most are often located on the scalp, trunk, buttocks and limbs, 
especially on extensor surfaces such as the elbows and knees (13). Active inflammatory 
psoriasis is characterised by the Koebner phenomenon, with new lesions occurring or 
developing at sites of trauma or pressure (54). 
Inverse 
Inverse psoriasis may commonly appear in the inframammary and abdominal folds, groin, 
axillae and genitalia. Lesions are erythematous plaques with little scales (12, 13). 
Erythodermic 
Chronic plaque psoriasis may develop into erythrodermic psoriasis. The patients’ entire body 
surface area could nearly be covered with erythema, accompanied by varying degrees of 
scaling. The dysfunction of erythrodermic skin might lead to hypothermia and dehydration 
(13). 
Pustular 
Pustular psoriasis consists of generalised and localised lesions. The widespread pustules may 
be solitary on an erythematous background. If the pustules coalesce, accompanied by fever 
and toxicity, it is known as psoriasis pustulosa generalisata (von Zumbusch pustular 
psoriasis). In terms of localised pustular psoriasis, pustules develop on the palms of hands 
and/or soles of feet (12, 13). 
Guttate 
Guttate psoriasis typically manifests in dew-drop-like salmon-pink papules, usually 1–15 mm 
long, with a fine scale. It is found primarily on the trunk and the proximal extremities. 
Guttate psoriasis is triggered by β-haemolytic streptococcal infection. The disease is very 
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common during childhood or adolescence, which can transition into psoriasis vulgaris (12, 
13). 
Nail disease 
The characteristics of nail psoriasis include pitting, onycholysis, subungual hyperkeratosis, 
and the oil-drop sign. Psoriatic disease of the fingernails is more common than toenails (50% 
v. 35% of all patients). It is observed in 90% of patients with psoriatic arthritis (13). 
Psoriatic arthritis 
Psoriatic arthritis (PsA) is an inflammatory seronegative spondyloarthropathy associated with 
psoriasis. The characteristics of PsA are stiffness, pain, swelling, and tenderness of the joints 
and surrounding ligaments and tendons (dactylitis and enthesitis). The severity of the arthritis 
usually does not correlate with the skin disease. Nail damage is very common in PsA. The 
radiographic features of PsA mainly include joint erosions, joint space narrowing and bony 
proliferation (55). 
2.6 Current Management for Chronic Urticaria and Psoriasis Vulgaris 
2.6.1 Management for Chronic Urticaria 
Management of chronic urticaria consists of two aspects: identification and avoidance of 
causes and triggers, and symptom control, which is recommended by five international 
guidelines (8, 10, 11, 56, 57). Once the eliciting factor has been identified for inducible 
urticarias, it is advised that the trigger be avoided (8, 10, 11). Practically, this may be 
virtually impossible, especially when the threshold of exposure that triggers urticaria is low 
(56). As the cause of chronic spontaneous urticaria is unlikely to be identified, treatment is 
aimed at controlling the symptoms (11, 56). 
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Management of chronic urticaria is with a ‘step-care’ approach (8, 10, 11). A step change 
occurs when symptom control is inadequate or when greater control is needed (see Table 2.1). 
Overall, there is a consensus that oral non-sedating second-generation H1 antihistamines are 
first-line therapy for chronic urticaria, with a low level of side effects (23). 
While oral pharmacotherapy is the mainstay of treatment for chronic urticaria, other 
treatments are available and can be used in addition to antihistamine therapy. These include 
phototherapy (ultraviolet [UV]-A, psoralen and ultraviolet A [PUVA] and narrow-band 
ultraviolet [UV]-B] [10, 57]), topical antipruritic lotions to soothe itch (11, 56) and relaxation 
therapies (11, 56). 
Table 2.1: A ‘Step-care’ Approach to Treatment 
Step Treatment 
First-line therapy Second-generation antihistamines 
Transfer to second-line therapy if symptoms persist after two weeks  
Second-line therapy 
Increased dosage (up to fourfold) of second-generation 
antihistamines 
Transfer to third-line therapy if symptoms persist after 1–4 weeks  
Third-line therapy 
Omalizumab 
Cyclosporin A 
Montelukast 
Short course systemic corticosteroid (max 10 days) 
Adapted from the EAACI/GA
2
LEN/EDF/WAO Guideline (10) 
2.6.2 Management for Psoriasis Vulgaris 
Psoriasis cannot be cured, so the main goal of treatment is to relieve symptoms, reduce 
relapse rates with minimal side effects, improve QoL and reduce comorbidity (12). 
Management of psoriasis depends on a variety of factors, such as disease severity, 
comorbidities, patient preference or opinion, realistic expectations about the efficacy of 
therapy and the use of other medication (12). Many treatment options exist for the 
management of psoriasis vulgaris. Topical applications are typically used for mild disease, 
phototherapy for moderate disease and systemic agents for severe disease (12). 
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Commonly used topical medications include vitamin D3 and vitamin D3-analogues, 
calcineurin inhibitors, corticosteroids, tazarotene, dithranol/anthralin, coal tar, salicylic acid 
and non-medicated topical moisturisers (12, 13). Phototherapy has also been used for the 
management of psoriasis vulgaris, which involves UV-A and UV-B wavelengths. 
Photochemotherapy, where psoralens from plants are administered before UVA phototherapy 
(PUVA), has been shown to be more effective for clearing psoriasis lesions than 
phototherapy alone (12, 58). Commonly used systemic medications include retinoids (vitamin 
A derivatives, such as acitretin), methotrexate (MTX), cyclosporine and fumaric acid esters. 
Systemic treatments, alone or in combination with topical treatments, are usually used for 
severe psoriasis vulgaris cases. Biologics such as TNF inhibitors and T-cell inhibitors are also 
used in the treatment of psoriasis vulgaris (12, 13, 55). Further, several therapies could be 
considered as complementary or alternative options, including climatotherapy and 
psychosocial therapy. However, the evidence of efficacy and safety is not sufficient (12). 
2.6.3 Similarities in the Management of Chronic Urticaria and Psoriasis Vulgaris 
Current management of chronic urticaria and psoriasis vulgaris is generally based on disease 
severity, QoL or patients’ response. Biologics have been used in the treatment of both 
conditions. 
2.7 Limitations of Current Management 
2.7.1 Chronic Urticaria 
Oral non-sedating second-generation H1 antihistamines are first-line therapy for chronic 
urticaria (23). However, debate on the treatment for refractory urticaria still exists (second-
line therapy). Concerns involve the safety profile of updosing second-generation H1 
antihistamines and the long-term use of first-generation H1 antihistamines (10, 23). In 
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addition, initiating adjunctive therapy with alternative agents remains a challenge for patients 
who do not respond to antihistamines. This mainly includes the risks of somnolence and 
psychomotor obstruction caused by first-generation H1 antihistamines as additional therapy 
to second-generation H1 antihistamines (10, 23). Evidence is lacking for third-line therapies 
and high costs have been noted for omalizumab and ciclosporin A (10, 23). Moreover, further 
studies are needed to evaluate the short-term use of systemic corticosteroids as third-line 
therapy for chronic urticaria or acute exacerbation (10). 
2.7.2 Psoriasis Vulgaris 
Although pharmacological therapy and phototherapy recommended by four international 
guidelines (12, 13, 55, 58) have been shown to be effective in short-term use, they often are 
associated with side effects when used long term. Two compound agents, such as 
calcipotriene/betamethasone dipropionate, have a better safety profile than single agents 
alone; however, studies have shown a high relapse rate (46.6%) (59). Oral retinoids (acitretin) 
have been associated with birth defects and liver damage. Further, oral MTX may cause liver 
toxicity and bone marrow suppression. NB-UVB phototherapy is associated with itching and 
blistering of the treated skin, irritation of the eyes and cold sores, while PUVA is associated 
with nausea, headache, fatigue, burning and itching. Biologics have been associated with a 
small increase in the risk of infection, tuberculosis and cardiac insufficiency. Clinical 
guidelines regard biologics as a third-line treatment for plaque psoriasis following inadequate 
response to topical treatment, phototherapy and non-biologic systemic treatments (12, 13). 
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2.7.3 Similarities in the Limitations of Current Management on Chronic Urticaria and 
Psoriasis Vulgaris 
The conventional medical therapeutics for both conditions can provide rapid relief of 
symptoms. However, long-term use of conventional managements remains a challenge due to 
unpleasant side effects and lack of treatment response in some patients. 
2.8 Summary 
Chronic urticaria and psoriasis vulgaris are two common chronic skin conditions. They have 
similar prevalence (0.5–8.8% v. 0.47–8.5%) in global population. Both conditions inflict 
significant health-related (physical and psychological) and economic burdens on patients and 
healthcare systems. 
First-line therapy for chronic urticaria is second-generation H1 antihistamines (23). Updosing 
of second-generation H1 antihistamines or initiating adjunctive therapy with alternative 
agents are considered for refractory urticaria (10, 23). Current treatment options for psoriasis 
vulgaris are mainly based on disease severity. Generally, topical agents are applied for mild 
disease, phototherapy for moderate disease and systemic agents or biologics for severe 
disease (12).  
Conventional therapies could provide rapid temporary relief of symptoms for most patients 
with these conditions. However, as recurrence or exacerbation of both conditions is likely, 
long-term conventional management is required. This may lead to undesirable adverse events 
(AEs) or lack of treatment response from some patients. Therefore, patients may seek CAM 
treatment options. Studies indicate the use of CAM, including herbal medicine for skin 
conditions, is increasing (24–26). 
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Chapter 3. Chronic Urticaria and Psoriasis Vulgaris in Chinese Medicine 
The contents for this chapter have been published in two books in the Evidence-based clinical 
Chinese medicine series: Volume 2 Psoriasis vulgaris (60) and Volume 3 Chronic urticaria 
(61). 
3.1 Introduction of Chronic Urticaria and Psoriasis Vulgaris 
The CM term for urticaria is ‘yin zhen’ 瘾疹. There has been little change in terminology 
over time. Yin zhen 瘾疹 has been cited throughout classical CM literature and is the most 
likely of all classical terms to correspond with the modern understanding of urticaria (62, 63). 
Urticaria is usually associated with either internal or external wind. Wind as a pathogenic 
factor is characterised by a sudden onset of and rapid changes in symptoms. When resulting 
from an internal deficiency, it often leads to dryness. A constitutional weakness, inherited at 
conception and/or during pregnancy, may predispose a person to urticaria. 
‘Bai bi’ 白疕  is the most likely of all classical terms to correspond with the modern 
understanding of psoriasis (63, 64). Despite diversity in the understanding of the pathogenesis 
of psoriasis, the fundamental pathogenesis is attributed to Blood syndromes. Blood originates 
from the food qi 气 produced by the Spleen. Through the descent of Lung qi, the food qi is 
sent to the Heart and transformed into Blood. Blood performs a nourishing and moistening 
function. Besides the nourishing action of qi, Blood can moisten the skin and hair, which 
ensures the tissues are not too dry (65). Multiple pathogenic factors may cause Blood heat, 
Blood deficiency or Blood stasis, which will affect the function of Blood. 
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3.2 Aetiology and Pathophysiology 
3.2.1 Chronic Urticaria 
Urticaria can be caused by constitutional weakness, deficiency of qi and Blood or failure of 
defensive qi in protecting the exterior (66–68). Urticaria may develop because of an external 
pathogenic attack, where the defensive qi is unable to prevent the pathogen from entering the 
body through the pores of the skin. When deficiency of defensive qi is prolonged, the patient 
will become more susceptible to repeated external wind attacks (chronic urticaria). Wind 
dries the skin, leading to the development of wheals and pruritus (66, 67). 
An underlying deficiency or constitutional weakness can lead to the development of internal 
wind (66, 67). Urticarial wheals can occur when a deficiency of Blood fails to nourish the 
skin or when internal wind dries the skin. Overindulgence in spicy or fatty foods or seafood 
can impair the transforming and transporting functions of the Stomach and Spleen, leading to 
dampness. Subsequently, dampness can transform into heat when prolonged, which may 
further lead to internal wind. Dampness can also stagnate in the skin, with a clear fluid 
exuding from the wheals (66, 67). 
Emotional disharmony can lead to qi stagnation, which can develop into heat over time and 
cause wind (66–68). When heat stagnates in the Heart channel, this can lead to fire, which 
enters the Blood. Heat in the Blood can dry the skin and may turn to wind. Finally, 
disharmony between the ‘Thoroughfare vessel’ (Chong mai 冲脉) and ‘Conception vessel’ 
(Ren mai 任脉) fails to adequately nourish the skin. This, combined with defensive qi 
deficiency, leads to the development of wheals when external wind attacks or internal wind is 
provoked (66, 67). 
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3.2.2 Psoriasis Vulgaris 
Blood heat can be caused by multiple factors. For instance, depression and long-term 
emotional disturbance causes stasis of qi, which can transform into heat and result in Heart 
Fire. Overindulgence in seafood or meat may lead to disharmony between the Spleen and 
Stomach, resulting in stagnation of qi, which can transform into heat (69, 70). For people 
with a constitutional predisposition to Blood heat syndromes, the coupling of a Blood heat 
syndrome with an external invasion of wind can cause internal wind, leading to dryness. 
Wind-dryness will exhaust the body fluids and Blood, resulting in further yin 阴 deficiency 
and Blood dryness. Therefore, the lack of nourishment from body fluids and Blood will lead 
to the psoriasis symptoms of dry skin and scaly skin (71). Heat in the nutrient Blood can 
scorch the fluid and result in Blood stasis. Long-term Blood stasis may transform into heat 
and exacerbate Blood heat. Blood stasis is an important factor when the disease is 
complicated and/or of prolonged duration (64, 72, 73). 
3.2.3 Similarities in Chronic Urticaria and Psoriasis Vulgaris 
Both chronic urticaria and psoriasis vulgaris share the same pathogenesis of an underlying 
deficiency with an external pathogenic factor. The onset and progress are closely associated 
with deficiency of healthy, protective qi and external pathogen attack. The deficiency of 
healthy qi makes the body vulnerable to attack from factors such as wind, cold and dampness, 
resulting in urticaria syndrome of various types: exterior heat, exterior cold and dampness 
heat. In psoriasis, the deficiency of healthy qi allows invasion by toxic pathogens, with the 
syndrome types of Blood heat, Blood stasis and Blood dryness. 
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3.3 Syndrome Differentiation and Treatments 
3.3.1 Chronic Urticaria 
Syndrome differentiation is an important feature of diagnosis in CM dermatology. The 
Standard of diagnosis and assessment of treatment effects of dermatological conditions in 
Chinese medicine (中医皮肤科病证诊断疗效标准) was published in 1994 by the State 
Administration of Traditional Chinese Medicine of the People’s Republic of China. This 
book identified the main syndrome types of yin zhen瘾疹 (urticaria) as ‘syndrome of wind-
heat attacking the exterior’ (exterior heat syndrome), ‘syndrome of blockage of the exterior 
by wind and cold’ (exterior cold syndrome) and ‘syndrome of Blood deficiency and wind-
dryness’ (63). In 2012, the China Association of Chinese Medicine issued the Guidelines for 
diagnosis and treatment of common diseases of dermatology in traditional Chinese medicine 
(中医皮肤科常见病诊疗指南) (62). In addition to the two exterior syndromes described 
above, four additional syndrome types have been described in this guideline. These include 
‘damp-heat in Stomach and Intestine’, ‘defense-exterior insecurity’ (defensive qi deficiency), 
‘deficiency of qi and Blood’, and ‘qi and Blood stagnation and stasis’ (62). 
CM guidelines do not distinguish between acute and chronic urticaria. Rather, diagnosis is 
made according to traditional CM principles. The treatment principle for urticaria should 
identify whether the condition is one of ‘exterior or interior’, ‘cold or heat’, ‘defense, qi, 
nutrient or Blood’, ‘the tip or root’, ‘acute or chronic’, or ‘healthy qi (zheng qi 正氣) 
deficiency or pathogen excess’ (62). The treatment of chronic urticaria is largely reliant on 
identification of the underlying deficiency syndrome type. Therefore, treatment principles 
should include ‘tonify qi and secure the exterior’, ‘tonify yin and moisten dryness’, and 
‘dispel wind and stop itch’ (67). 
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3.3.2 Psoriasis Vulgaris 
For psoriasis vulgaris, the Standard of diagnosis and assessment of treatment effects of 
dermatological conditions in Chinese medicine (中医皮肤科病证诊断疗效标准) stated that 
the main syndrome types of Bai bi (psoriasis) were ‘wind-heat and Blood dryness’, ‘Blood 
deficiency and wind-dryness’ and ‘stasis in the skin’ (63). In 2011, Evidence-based 
guidelines of clinical practice in Chinese medicine (中医循证临床实践指南), published by 
the Chinese Academy of Chinese Medicine, also described the same syndromes (64). In 
describing the treatment principles for these syndromes, slightly different terminology was 
used (Blood heat, Blood dryness and Blood stasis). However, the clinical presentations were 
consistent with the described syndromes (64). Findings from a review of syndromes included 
reports of expert experience, case control studies and RCTs from 1979–2010. The review 
indicated that Blood heat, Blood dryness and Blood stasis were the basic syndrome types (74). 
Therefore, the treatment principle of psoriasis vulgaris mainly targets the Blood. 
3.3.3 Similarities in Chronic Urticaria and Psoriasis Vulgaris 
The external manifestation of chronic urticaria and psoriasis vulgaris results from a 
combination of both internal and external causes, with the deficiency of healthy qi as the 
underlying cause or root of the disease. The overall treatment principle of these two 
conditions should ‘deal with superficial symptoms for acute conditions, and deal with the root 
for chronic condition; treatment should focus both on superficial symptoms and the root (急
则治其标，缓则治其本，标本兼治，治病必求于本)’ (65). 
The following guidelines on the diagnosis and treatment of chronic urticaria and psoriasis 
vulgaris were used as references in the following section. They include the Standard of 
diagnosis and assessment of treatment effects of dermatological conditions in Chinese 
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medicine (中医皮肤科病证诊断疗效标准), published in 1994 by the State Administration of 
Traditional Chinese Medicine of the People’s Republic of China (63), Evidence-based 
guidelines of clinical practice in Chinese medicine (中医循证临床实践指南), published by 
the Chinese Academy of Chinese Medicine (64), and the Guidelines for diagnosis and 
treatment of common diseases of dermatology in traditional Chinese medicine (中医皮肤科
常见病诊疗指南), published by the China Association of Chinese Medicine (62). 
Note that the use of some herbs, such as ma huang 麻黄, may be restricted in some countries. 
In addition, some herbs, such as bai ji li 白蒺藜, are restricted under the provisions of the 
Convention on International Trade in Endangered Species of Wild Fauna and Flora. Readers 
are advised to comply with relevant regulations. 
3.4 Oral Chinese Herbal Medicine Treatment Based on Syndrome 
Differentiation 
3.4.1 Chronic Urticaria 
Exterior Heat Syndrome 
Definition: Invasion of exterior part of the body by wind-heat (75). 
Clinical manifestations: Fresh red skin rashes, pruritus accompanied by fever, sore throat, dry 
mouth and upset mood. Heat or wind induces or exacerbates the condition, while cool or cold 
environments relieve it. Red tongue with a thin white or yellow coating, superficial and rapid 
pulse (62, 66, 68, 76, 77). 
Treatment principle: Dispel wind and clear heat, cool Blood and stop itch (62). 
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Formula: Modified Xiao feng san 消风散 (62, 68) and modified yin qiao san 银翘散 (62, 76, 
77). 
Herbs: Herb ingredients were not listed for each formula. Herbs included in both formulae 
include sheng di huang 生地黄, fang feng 防风, chan tui 蝉蜕, zhi mu 知母, jing jie 荆芥, 
niu bang zi 牛蒡子, shi gao 石膏, jin yin hua 金银花, lian qiao 连翘, chi shao 赤芍, mu dan 
pi 牡丹皮, and huang qin 黄芩. 
Main actions of herbs: Sheng di huang 生地黄, chi shao 赤芍 and mu dan pi 牡丹皮 clear 
heat, cool the Blood and relieve toxicity. Jin yin hua 金银花, lian qiao 连翘 and huang qin 
黄芩 clear heat and relieve toxicity. Jing jie 荆芥, fang feng 防风, niu bang zi 牛蒡子 and 
chan tui 蝉蜕 disperse external wind to stop itch. Shi gao 石膏 and zhi mu 知母 clear qi level 
heat. 
Manufactured medicines: Xiao feng zhi yang ke li 消风止痒颗粒 (76) and Yin qiao jie du 
wan 银翘解毒丸 (66). 
Exterior Cold Syndrome 
Definition: Invasion of exterior part of the body by wind-cold (75). 
Clinical manifestations: Wheals are slightly red or pale, which is exacerbated by exposure to 
wind-cold or chilled water, and relieved by warmth. Other symptoms may include an 
aversion to wind and cold, and absence of thirst. The condition will be more severe in winter 
and mild in summer. Slightly red tongue, thin and whitish coating, superficial and tight pulse 
(62, 66, 68, 76, 77). 
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Treatment principle: Dispel wind and cold, regulate and harmonise protective and nutritive 
levels (62, 76, 77). 
Formula: Modified Gui zhi ma huang ge ban tang 桂枝麻黄各半汤 (62, 68, 76, 77) and 
modified Jing fang bai du san 荆防败毒散 (62). 
Herbs: Herb ingredients were not listed for each formula. Herbs included in both formulae 
include gui zhi 桂枝, bai shao 白芍, sheng jiang 生姜, zhi gan cao 炙甘草, ma huang 麻黄, 
da zao 大枣, xing ren 杏仁, jing jie 荆芥, fang feng 防风, qiang huo 羌活, chan tui 蝉蜕, 
and ji li 蒺藜. 
Main actions of herbs: Gui zhi 桂枝 and bai shao 白芍 regulate and harmonise protective and 
nutritive levels. Ma huang 麻黄, jing jie 荆芥 and fang feng 防风 dispel external wind and 
cold. Qiang huo 羌活 dispels wind and removes dampness. Chan tui 蝉蜕 and ji li 蒺藜 
disperse wind to stop itch. Da zao 大枣, sheng jiang 生姜 and zhi gan cao 炙甘草 regulate 
the Stomach and Spleen. 
Dampness Heat in Stomach and Intestine 
Definition: A syndrome caused by a combination of dampness and heat, affecting both the 
Stomach and Intestine (75). 
Clinical manifestations: Wheals are fresh, red and spread throughout the whole body, with 
severe pruritus. Accompanying symptoms are abdominal pain and distention, diarrhoea, 
nausea, fatigue and decreased appetite. Scanty and brown urine, decreased bowel movements. 
Red tongue with yellowish and greasy coating, slippery and rapid pulse, or soft and rapid 
pulse (62, 66, 68, 76, 77). 
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Treatment principle: Clear and relieve exterior and interior, promote bowel movement and 
drain dampness (62). 
Formula: Modified Fang feng tong sheng san 防风通圣散 (62, 68) and modified Chu shi wei 
ling tang 除湿胃苓汤 (62). 
Herbs: Herb ingredients were not listed for each formula. Herbs included in both formulae 
include jing jie 荆芥, fang feng 防风, bai shao 白芍, da huang 大黄 (to be added to 
decoction after the other herbs have been boiling for some time), lian qiao 连翘, huang qin 
黄芩, bai zhu 白朮, zhi zi 栀子, chen pi 陈皮, hou po 厚朴, di fu zi 地肤子, yi yi ren 薏苡仁 
and gan cao 甘草. 
Main actions of herbs: Jing jie 荆芥 and fang feng 防风 disperse wind and release the 
exterior. Da huang 大黄 and zhi zi 栀子 clear heat and drain dampness, and promote bowel 
movement to relieve interior heat. Lian qiao 连翘 and huang qin 黄芩 clear heat and relieve 
toxicity. Bai zhu 白朮, yi yi ren 薏苡仁, chen pi 陈皮 and hou po 厚朴 tonify the Spleen qi 
and drain dampness. Di fu zi 地肤子 clears heat and removes dampness. Gan cao 甘草 
harmonises each herb. 
Manufactured medicines: Fang feng tong sheng wan 防风通圣丸 (62). 
Defense-Exterior Insecurity 
Definition: A syndrome characterised by symptoms such as spontaneous sweating, lack of 
strength and shortness of breath (75). 
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Clinical manifestations: Wheals are mostly small. Patients have spontaneous sweating and are 
prone to colds. Skin rash occurs after sweating or is induced by wind and cold. Pale tongue 
with thin, white coating, sunken and fine pulse (62, 76). 
Treatment principle: Tonify qi and secure the exterior, dispel wind and cold (62). 
Formula: Modified Yu ping feng san 玉屏风散 plus Gui zhi tang 桂枝汤 (62). 
Herbs: Modified Yu ping feng san 玉屏风散: huang qi 黄芪, bai zhu 白朮 and fang feng 防
风. 
Modified Gui zhi tang: gui zhi 桂枝, bai shao 白芍, sheng jiang 生姜, da zao 大枣, gan cao 
甘草, zhi ma huang 炙麻黄, jing jie 荆芥, chan tui 蝉蜕, ji li 蒺藜, dang gui 当归, wu mei 
乌梅 and wu wei zi 五味子. 
Main actions of herbs: Huang qi 黄芪 tonifies Lung and Spleen qi to secure exterior. Wu mei 
乌梅 and wu wei zi 五味子 stop sweating. Bai zhu 白朮 tonifies Spleen qi to assist securing 
the exterior. Fang feng 防风 and zhi ma huang 炙麻黄 dispel external wind and cold. Gui zhi 
桂枝 and bai shao 白芍 regulate and harmonise the protective and nutritive levels. Da zao 大
枣, sheng jiang 生姜 and gan cao 甘草 regulate Stomach and Spleen. Chan tui 蝉蜕 and ji li 
蒺藜 disperse wind to stop itch. 
Manufactured medicines: Yu ping feng ke li 玉屏风颗粒 (62). 
Dual Deficiency of Qi and Blood 
Definition: A syndrome characterised by symptoms such as listlessness, shortness of breath, 
weakness and dizziness (75). 
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Clinical manifestations: Recurrent wheals lasting several months or years. The condition 
occurs in the afternoon or evening, or when the individual is tired. Patients usually have weak 
constitutions. Generalised symptoms include pale face, palpitations, insomnia, fatigue and 
disturbed appetite. Pale tongue with thin white coating, soft and fine pulse, or fine and weak 
pulse (62, 76, 77). 
Treatment principle: Tonify qi and nourish Blood, tonify Heart and Spleen (62). 
Formula: Modified Ba zhen tang 八珍汤 plus Dang gui yin zi 当归饮子 (62). 
Herbs: Herb ingredients were not listed for each formula. Herbs included in both formulae 
include dang gui 当归, chuan xiong 川芎, bai shao 白芍, shu di huang 熟地黄, huang qi 黄
芪, dang shen 党参, bai zhu 白朮, fu ling 茯苓, he shou wu 何首乌, zhi gan cao 炙甘草, ji li 
蒺藜, fang feng 防风, and chan tui 蝉蜕. 
Main actions of herbs: Dang shen 党参 and shu di huang 熟地黄 tonify qi and nourish 
Blood. Bai zhu 白朮 and fu ling 茯苓 tonify Spleen and drain dampness. Dang gui 当归, he 
shou wu 何首乌 and bai shao 白芍 nourish Blood and harmonise nutritive level. Chuan 
xiong 川芎 invigorates Blood and promotes qi movement. Fang feng 防风, chan tui 蝉蜕 and 
ji li 蒺藜 disperse wind to stop itch. Zhi gan cao 炙甘草 harmonises each herb. 
Manufactured medicines: Ba zhen he ji 八珍合剂 (mixture) (76). 
Qi-Blood Stagnation and Stasis 
Definition: A syndrome characterised by symptoms such as dark or purple wheals. 
Clinical manifestations: Dark or purple-red wheals typically occur around the waist and 
wrists due to pressure from belts and watches. Generalised symptoms include a dull face or 
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blue-violet lips, dry mouth and reduced desire to drink. Symptoms for women include 
irregular menstruation and dysmenorrhea, with purple-red or blood clots. Dark purple tongue 
with petechia or ecchymosis, little coating, fine and rough pulse (62, 76). 
Treatment principle: Regulate qi and invigorate Blood, dispel wind and stop itch (62). 
Formula: Modified Xue fu zhu yu tang 血府逐瘀汤 (62). 
Herbs: Dang gui 当归, sheng di huang 生地黄, tao ren 桃仁, hong hua 红花, zhi ke枳壳, 
chi shao 赤芍, chai hu 柴胡, chuan xiong 川芎, di long 地龙, bai xian pi 白鲜皮, di fu zi 地
肤子, wu shao she 乌梢蛇, chan tui 蝉蜕 and gan cao 甘草. 
Main actions of herbs: Dang gui 当归, chi shao 赤芍, chuan xiong 川芎, tao ren 桃仁 and 
hong hua 红花 invigorate the Blood and transform Blood stasis. Chai hu 柴胡 and zhi ke 枳
壳 soothe the Liver and regulate qi. Sheng di huang 生地黄 and dang gui 当归 nourish the 
yin and moisten dryness, preventing loss of yin by removing Blood stasis. Di long 地龙, chan 
tui 蝉蜕 and wu shao she 乌梢蛇 disperse wind to stop itch. Bai xian pi 白鲜皮 and di fu zi 
地肤子 clear heat, remove dampness and stop itch. Gan cao 甘草 harmonises each herb. 
Blood Deficiency and Wind-Dryness 
Definition: A syndrome characterised by symptoms such as dry and itchy skin, lustreless 
complexion and pale nails (75). 
Clinical manifestations: The condition occurs repeatedly, with a long duration. The skin rash 
is exacerbated in the afternoon or evening. Can be accompanied by emotional upset and 
irritability, dry mouth, feverishness in palms and soles; red tongue with scanty fluid, deep and 
fine pulse (66, 68). 
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Treatment principle: Nourish Blood and dispel wind, moisten dryness and stop itch (68). 
Formula: Modified Dang gui yin zi 当归饮子 (68). 
Herbs: Dang gui 当归, sheng di huang 生地黄, bai shao 白芍, chuan xiong 川芎, he shou 
wu 何首乌, jing jie 荆芥, fang feng 防风, bai ji li 白蒺藜, huang qi 黄芪 and sheng gan cao 
生甘草. 
Main actions of herbs: Dang gui 当归, he shou wu 何首乌 and huang qi 黄芪 nourish the 
Blood and moisten dryness. Sheng di huang 生地黄, bai shao 白芍 and chuan xiong 川芎 
clear heat, cool and invigorate the Blood. Jing jie 荆芥, fang feng 防风 and bai ji li 白蒺藜 
dispel wind. Sheng gan cao 生甘草 clears heat and harmonises the actions of the other herbs. 
3.4.2 Psoriasis Vulgaris 
Blood Heat 
Clinical manifestations: New bright red papules or maculopapules of varying sizes develop 
continuously, Auspitz’s sign appears when the scale is removed and there is an occasional 
occurrence of Koebner’s phenomenon. Accompanying symptoms include itching, anxiety, 
dry mouth, constipation, yellow urine and red tongue with yellow or greasy coating. The 
pulse is slippery, stringy or rapid (63, 64, 78, 79). 
Treatment principle: Clear heat and cool the Blood, relieve toxicity and reduce erythema (78, 
79). 
Formula: Modified Xiao feng san 消风散 plus Xi jiao di huang tang 犀角地黄汤 (78, 79) 
and modified Liang xue di huang tang 凉血地黄汤 (62). 
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Herbs: Dang gui 当归, sheng di huang 生地黄, fang feng 防风, chan tui 蝉蜕, zhi mu 知母, 
ku shen 苦参, hu ma ren 胡麻仁, jing jie 荆芥, cang zhu 苍术, niu bang zi 牛蒡子, shi gao 
石膏, xi jiao 犀角 [shui niu jiao instead 水牛角代], chi shao 赤芍 and mu dan pi 牡丹皮 
Main actions of herbs: Sheng di huang 生地黄, shui niu jiao 水牛角, chi shao 赤芍 and mu 
dan pi 牡丹皮 clear heat, cool the Blood and relieve toxicity. Dang gui 当归 and hu ma ren 
胡麻仁 nourish the Blood and moisten dryness. Jing jie 荆芥, fang feng 防风, niu bang zi 牛
蒡子 and chan tui 蝉蜕 disperse external wind to stop itch. Cang zhu 苍术 and ku shen 苦参 
clear damp-heat. Shi gao 石膏 and zhi mu 知母 clears qi level heat.  
Manufactured products: Fu fang qing dai wan 复方青黛丸 (pill) (64, 67) and Qing kai ling 
zhu she ye 清开灵注射液 (IV injection) (64, 67). 
Blood Dryness 
Clinical manifestations: Long-term disease, lesions manifest as light red and patchy, covered 
with plenty of dry silvery-white scales. Parts of lesions have disappeared. Dry and chapped 
skin with itch or pain. Accompanying symptoms include dry mouth, constipation; red tongue 
body with thin and white coating. The pulse is wiry and slow (63, 64, 78, 79). 
Treatment principle: Tonify yin and nourish the Blood, moisten dryness and dispel wind (78, 
79). 
Formula: Modified Dang gui yin zi 当归饮子 (62, 78) and Yang xue run fu yin 养血润肤饮 
(62). 
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Herbs: Dang gui 当归, sheng di huang 生地黄, bai shao 白芍, chuan xiong 川芎, he shou 
wu 何首乌, jing jie 荆芥, fang feng 防风, bai ji li 白蒺藜, huang qi 黄芪, sheng gan cao 生
甘草, tian dong 天冬, mai dong 麦冬, tian hua fen 天花粉. 
Main actions of herbs: Dang gui 当归, he shou wu 何首乌 and huang qi 黄芪 nourish the 
Blood and moisten dryness. Sheng di huang 生地黄, bai shao 白芍 and chuan xiong 川芎 
clear heat, cool and invigorate the Blood. Jing jie 荆芥, fang feng 防风 and bai ji li 白蒺藜 
dispel wind. Tian dong 天冬, mai dong 麦冬 and tian hua fen 天花粉 tonify yin and moisten 
dryness. Sheng gan cao 生甘草 clears heat and harmonises the actions of the other herbs. 
Manufactured products: Xiao yin ke li 消银颗粒 (granule) (64), Dang gui zhu she ye 当归注
射液 (IV injection) and Shen mai zhu she ye 参麦注射液 (IV injection) (67). 
Blood Stasis 
Clinical manifestations: The disease duration is long and at the stable stage, dull red, itchy, 
hard and thick plaques are covered by thick, dry, silvery-white scales. There are no obvious 
general symptoms but there is a dark purple or red tongue body with petechial spots. The 
pulse is uneven, or wiry and slow (63, 64, 78, 79). 
Treatment principle: Invigorate the Blood and transform Blood stasis, nourish the Blood and 
moisten dryness (67, 78, 79). 
Formula: Modified Tao hong si wu tang 桃红四物汤 (67, 78, 79). 
Herbs: Shu di huang 熟地黄, dang gui 当归, bai shao 白芍, chuan xiong 川芎, tao ren 桃 
and hong hua 红花. 
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Main actions of herbs: Shu di huang 熟地黄 tonifies the yin and nourishes the Blood. Bai 
shao 白芍 tonifies the Liver, Blood and preserves the yin. Dang gui 当归 tonifies the Blood 
and nourishes the Liver. Chuan xiong 川芎  invigorates the Blood and promotes the 
movement of qi. Tao ren 桃仁 and hong hua 红花 have a very strong effect on invigorating 
the Blood and transforming Blood stasis. 
Manufactured products: Lei gong teng duo gan pian 雷公藤多苷片 (tablets) (67) and Dan 
shen zhu she ye 丹参注射液 (IV injection) (64, 67). 
3.5 Topical Chinese Herbal Medicine Treatment 
3.5.1 Chronic Urticaria 
Calamine lotion could be used topically (68). 
3.5.2 Psoriasis Vulgaris 
In external CHM, psoriasis can be treated with topical preparations such as baths, fumigation 
and other methods. Among these, CHM ointments and CHM baths are the most commonly 
used therapies (64). 
CHM ointment: Mild ointment or moisturiser could be used at the progressive stage (67, 78, 
79), such as Huang bo ointment 黄柏膏, Qing dai ointment 青黛膏, Qing dai ma you 青黛麻
油 (67, 79), Shi du ointment 湿毒膏, Pu lian ointment 普连软膏 or Bing huang fu le 
ointment 冰黄肤乐软膏 (64). For the stable and regressive stage, 10 % sulphur ointment 
could be used (67, 79). 
CHM baths: Herbs used for CHM baths are usually based on syndrome differentiation. 
Herbs commonly used in CHM bath decoctions are xu chang qing 徐长卿, qian li guang 千
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里光, di fu zi 地肤子, huang bo 黄柏, she chuang zi 蛇床子, cang er zi 苍耳子, lang du 狼
毒, bai xian pi 白鲜皮, tu jin pi 土槿皮, and/or huai hua 槐花 (79). 
3.6 Acupuncture and Other Chinese Medicine Therapies 
In addition to CHM, acupuncture and other CM therapies are also used in the management of 
chronic urticaria and psoriasis vulgaris. An overview of acupuncture and other CM therapies 
recommended by clinical practice guidelines and textbooks is provided below. 
 
3.6.1 Chronic Urticaria 
Acupuncture and ear acupuncture have been recommended to treat urticaria. Other therapies 
that may be beneficial for urticaria include cupping therapy (see Table 3.1). There are several 
actions of key acupuncture points (65): 
 LI11 Quchi 曲池—expels exterior wind, clear heat, cools Blood, resolves dampness, 
regulates nutritive qi and Blood. 
 SP10 Xuehai 血海—cools Blood, removes Blood stasis and tonifies Blood. 
 ST36 Zusanli 足三里—benefits the Stomach and Spleen, tonifies qi and Blood, 
dispels cold, regulates nutritive and defensive qi, expels wind and damp. 
 
3.6.2 Psoriasis Vulgaris 
Acupuncture and related therapies, including acupuncture (body and auricular) and 
acupuncture point injection therapy (the injection of a substance into an acupuncture point) 
have been recommended to treat psoriasis. Care must be taken when new lesions are 
developing because skin penetration may be more likely to result in Koebner’s phenomenon. 
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Other therapies that may be beneficial for psoriasis include catgut embedding (embedding of 
fibre threads subcutaneously), pricking-to-bleed and cupping therapy (see Table 3.2). Some 
therapies are not commonly used outside China. Readers should comply with the relevant 
regulations before use. 
 
Table 3.1: Summary of Acupuncture Therapies and other Chinese Medicine Therapies 
for Urticaria 
Intervention Acupuncture points/body area Treatment frequency 
Body acupuncture 
(67, 68) 
LI11 Quchi 曲池, PC6 Neiguan 内关 can be 
used for urticaria in the upper part of the 
body; SP10 Xuehai 血海, ST36 Zusanli 足三
里, SP6 Sanyinjiao 三阴交 can be used for 
urticaria in the lower part of the body; GB31 
Fengshi 风市, GB20 Fengchi 风池, GV14 
Dazhui 大椎, BL25 Dachangshu 大肠俞 can 
be used for the whole body 
Not specified 
Ear acupuncture 
(67, 68) 
CO12 Ganqu 肝区, CO13 Piqu 脾区, CW7 
Shenshangxian 肾上腺, AT4 Pizhixia 皮质下
, TF4 Shenmen 神门, CO14 Fei 肺, CO18 
Neifenmi 内分泌, Kangguomindian 抗过敏点 
(anti-allergic point) 
Not specified 
Cupping (68)  CV8 Shenque 神阙 Once a day, 15 
minutes for each 
treatment 
Table 3.2: Summary of Acupuncture and other Chinese Medicine Therapies for 
Psoriasis 
Intervention Acupuncture points/body area Treatment frequency 
Body acupuncture 
(67, 78) 
Main points: LI11 Quchi曲池, LI4 Hegu合
谷, GV14 Dazhui大椎, BL13 Feishu肺俞, 
SP10 Xuehai血海, SP6 Sanyinjiao三阴交; 
supplementary points for lesions on the head 
and face: LI20 Yingxiang迎香, GB20 
Fengchi风池, SI18 Quanliao颧髎; 
supplementary point for lesions on upper 
limbs: TE6 Zhigou支沟; supplementary 
points for lesions on lower limbs: ST36 
Zusanli足三里, ST40 Fenglong丰隆  
Treatment is applied 
once a day with 10 days 
as one treatment course 
Auricular 
acupuncture (67, 
CO14 Fei肺, TF4 Shenmen神门, CO18 Every other day, with 10 
days as one treatment 
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78) Neifenmi内分泌, CO15 Xin心, CO7 
Dachang大肠 etc. 
course 
Acupuncture point 
injection therapy 
(67) 
Dang gui zhu she ye 当归注射液 (injection) 
can be injected into the points: BL13 Feishu
肺俞, LI11 Quchi曲池, ST36 Zusanli足三
里  
7–10 days as one 
treatment session, one 
week break between 
sessions 
Catgut embedding 
(67) 
Apply to acupuncture points, mainly on 
back and limbs 
Not specified 
 
3.7 Summary 
In CM, the key principle of pathogenesis theory is that ‘maintaining good health will help to 
prevent disease (正气存内，邪不可干 )’. This principle is particularly relevant for 
dermatological conditions such as chronic urticaria and psoriasis vulgaris. The causes of 
disease can be internal (for example, organ dysfunction) or external (for example, exposure to 
environmental factors as cold, wind or emotional factors), or a combination of both. These 
two conditions share the same pathogenesis of an underlying deficiency with an external 
pathogenic factor. From a CM perspective, they also share the same treatment principle. 
Overlap in formulae recommended in clinical practice guidelines and textbooks was 
observed, with both Xiao feng san 消风散  and Dang gui yin zi 当归饮子  being 
recommended for both chronic urticaria and psoriasis vulgaris. These two conditions will 
provide valuable insight into CHM management of dermatological diseases. 
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Chapter 4. Data Mining of Classical Literature 
Contents in this chapter have been included in two published books: Evidence-based clinical 
Chinese medicine series: Volume 2 Psoriasis vulgaris (60) and Volume 3 Chronic urticaria 
(61). 
4.1 Chronic Urticaria and Psoriasis Vulgaris in Classical Literature 
CM has a long history in the treatment of dermatological conditions such as chronic urticaria 
and psoriasis vulgaris. A wealth of information on clinical cases and relevant treatments in 
ancient times has been recorded in CM classical literature. Treatments for these conditions 
have included CHM and acupuncture. The descriptions of conditions and treatments in the 
classical literature continue to guide current clinical practice and drug discovery. For example, 
the herb qing hao 青蒿 was described as a malaria treatment in CM classical book Zhou hou 
bei ji fang肘后备急方 (Handbook of prescriptions for emergencies) (363 AD). Inspired by 
this book, scientist Tu Youyou extracted artemisinin (also known as qing hao su) from qing 
hao 青蒿, which has been used globally to treat malaria. She was awarded the Nobel Prize 
for her breakthrough discovery. 
To explore ancient CHM treatments for chronic urticaria and psoriasis vulgaris, a thorough 
exploration of CM classical works was required. The number of CM classical literature 
sources is vast. Digitalised collections provide greater access to the classical works, making 
systematic searches and evaluations more efficient to perform (80, 81). The ZHYD 
(Encyclopaedia of traditional Chinese medicine) was used in this study (82). This is the 
largest collection of CM classical literature, comprising more than 1,100 ancient and pre-
modern CM electronic books on CD (80, 81). The ZHYD was used to identify formulae and 
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herbs recorded in classical citations that were most likely related to chronic urticaria and 
psoriasis vulgaris. This study aimed to provide evidence on CHM treatments for chronic 
urticaria and psoriasis vulgaris in ancient times through the data mining of classical literature. 
The findings from this study highlight treatments that could be considered for use in 
contemporary clinical practice. 
4.2 Method 
4.2.1 Identification of Search Terms 
The terminology for chronic urticaria and psoriasis vulgaris in CM classical literature is not 
the same as language and labels used in modern times. To retrieve as many ZHYD citations as 
possible related to the targeted conditions, search terms included a set of all names potentially 
used to describe the conditions in ancient times. A list of terms referring to chronic urticaria 
and psoriasis vulgaris were identified after reviewing authoritative dictionaries, such as 
Zhong xi yi bing ming dui zhao da ci dian 中西医病名对照大辞典 (2002) (83) and Zhong yi 
fang ji da ci dian 中医方剂大辞典 (84). Contemporary CM works that focused on urticaria, 
psoriasis or dermatological conditions, including guidelines, key textbooks, monographs and 
journal articles, were hand searched. In addition, CM dermatologists were consulted to 
identify any additional search terms. A pilot search of each term was conducted to detect the 
accuracy in retrieving citations for urticaria and psoriasis. In the pilot search, no information 
on disease duration was found for the citations related to urticaria. Considering the 
complexity involved in identifying the specific citations of chronic urticaria (as opposed to 
acute urticaria), the search scope included both acute and chronic urticaria. After the pilot 
search, eight terms for urticaria and 13 terms for psoriasis vulgaris were selected for the 
formal search (see Tables 4.1 and 4.2). 
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Table 4.1: Terms Used to Identify Urticaria in Classical Literature Citations 
Pinyin Chinese characters 
Pei lei 1  
Pei lei 2  
Yin zhen 1 瘾疹 
Yin zhen 2 隐疹 
Feng cheng ge da 风乘疙瘩 
Feng zhen kuai 风疹块 
Bai zhen 白轸 
Chi zhen 赤轸 
Table 4.2: Terms Used to Identify Psoriasis Vulgaris in Classical Literature Citations 
Pinyin Chinese characters  
Bai bi  白疕  
Bai ke chuang 白壳疮 
Bai xuan 白癣  
Bi feng 疕风 
Feng xuan 风癣 
Gan xuan 干癣 
Gou xuan 狗癣 
Gou pi xuan 狗皮癣 
Niu pi xuan 牛皮癣 
She feng 蛇风 
She shi 蛇虱 
Song pi xuan 松皮癣 
Yin qian feng 银钱疯 
4.2.2 Search of the Zhong Hua Yi Dian 
The psoriasis search was conducted in 2012, when the latest version of the ZHYD was the 
fourth edition. When the search for urticaria was conducted in 2014, the fifth edition had 
been released with software improvements, and this enhanced version was used for the 
urticaria search. Accordingly, the methods used differed, as described below. 
Searching of the ZHYD involves search of terms one at a time. Search strategies which 
combine multiple terms, as used in electronic biomedical databases, are not possible. A 
comprehensive search of the ZHYD was conducted by entering the search terms (individually) 
into the search boxes for ‘headings’ (目录搜索) and ‘body text’ (正文搜索). Headings or text 
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containing search terms were retrieved, with the number of search terms hits (that is, each 
instance of the term) being displayed. The number of hits for each search term was recorded 
in a Microsoft Excel file. For psoriasis, search results were copied into a Word document 
manually and entered into the Excel spread sheet for further analysis. For urticaria, the search 
results were imported directly from the CD to a pre-defined Excel spreadsheet. The imported 
data included search terms (key words), the source (book title and chapter) and full text of the 
citation. 
4.2.3 Data Management 
For both conditions, the following information was extracted from the original citation in 
Excel: symptom description, formula name, formula ingredients and preparation type. 
Citations were screened to identify duplicates according to three criteria: 
 If one citation was retrieved through both ‘headings’ and ‘body text’ search, it was 
deemed a duplicate. 
 Several books have multiple names. If a citation appeared in a book that has multiple 
names in the ZHYD, it was marked as a duplicate. For instance, the You ke zheng zhi 
zhun sheng 幼科证治准绳 and the Zheng zhi zhun sheng·you ke 证治准绳·幼科 are 
the same book. However, both book names can be found in the ZHYD. In this instance, 
the citation would be considered a duplicate. 
 If one citation was identified by multiple search terms, it was treated as one citation, 
and the multiple search terms that identified it were noted. 
After removal of duplicates, citations that contained more than one herbal formula were 
separated into different rows in Excel for analysis. Citations written after 1949, and those that 
did not contain CHM treatment information, were excluded from further analysis. 
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4.2.4 Coding 
To facilitate statistical analysis, text information of all citations was transferred into 
numerical data (codes and score). All citations related to urticaria and psoriasis vulgaris were 
coded using the same procedure (81). Codes were allocated to items according to a pre-
defined coding system (81): book name, dynasty, treatment type (formula or multiple herbs; 
formula with no ingredients; single herb; other treatment), formula ingredients and search 
terms. Other descriptions of each citation were coded with 0 (unclear), 1 (yes) and 2 (not 
present). The coding items involved the administration of CHM and characteristics of each 
condition described in modern medical texts or clinical guidelines (see Table 4.3). 
Table 4.3: Basic Information Coding for Classical Literature Citations 
Chronic urticaria Psoriasis vulgaris 
Citation describes a topical CHM treatment? Citation describes a topical CHM treatment? 
Citation describes an oral CHM treatment? Citation describes an oral CHM treatment? 
Symptom 1: skin rash Symptom 1: skin rash 
Symptom 2: wheals Symptom 2: red skin 
Symptom 3: pruritus Symptom 3: white skin 
Symptom 4: history of similar occurrences Symptom 4: scaly skin  
Symptom 5: red skin Symptom 5: itch 
Symptom 6: sudden onset Symptom 6: pain 
Symptom 7: pain Symptom 7: dry skin 
Symptom 8: oedema/swelling  
Based on the symptoms described, each citation was evaluated to determine the likelihood of 
the citation being urticaria or psoriasis vulgaris. The judgment criteria of each condition were 
the presence of core symptoms mentioned in modern clinical guidelines (10, 13). For 
urticaria, possible urticaria citations referred to those describing both pruritus plus skin 
rash/wheals and any of the following symptoms: history of similar occurrences, red skin, 
sudden onset, and pain or oedema/swelling. If both wheals and pruritus were described in one 
citation, urticaria was considered most likely. 
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For psoriasis, each citation was allocated a code to represent the judgment (see Table 4.4). 
Citation was coded as ‘0’ (no information to judge), ‘1’ (most likely psoriasis vulgaris 
citation), ‘2’ (not psoriasis citation), ‘3’ (possible psoriasis vulgaris citation). Since most 
citations contained limited information or did not provide explicit descriptions of symptoms, 
it was not appropriate to make judgments on description of symptoms only. In addition, the 
symptoms of psoriasis may vary due to the type, stage and severity of the disease. Therefore, 
an overall judgment by two experienced clinicians was incorporated into the judgment 
criteria. Two clinicians took all citation data into consideration when making overall 
judgments. Any disagreements were resolved through discussion with a CM dermatology 
professor. 
Table 4.4: Judgment Coding for Psoriasis Vulgaris Citations 
Citation 
judgement 
Definition 
No information to 
judge 
- 
Not psoriasis -  
Possibly it is 
psoriasis 
Both skin lesion/rash and scaly skin were described; 
clinician’s overall judgment to be possible citations 
Most likely it is 
psoriasis 
Description of skin lesion/rash and scaly skin (as per 
possibly psoriasis citations; clinician’s overall judgment 
to be most likely citations  
Finally, all text data extracted from the ZHYD were converted into numerical codes, except 
for formula names in the citations related to urticaria. All data were transferred into Statistical 
Package for the Social Sciences software (SPSS) statistical analysis. 
4.2.5 Statistical Analysis 
Descriptive statistics were used to analyse data for CHM formulae and standardised herbal 
ingredients. Treatment information (formula and herb frequency) were analysed according to 
the judgment of possible or most likely urticaria/psoriasis. Formulae with identical names 
were regarded as the same formula when calculating the frequency of formulae, which 
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allowed variation in herb ingredients. The ingredient list was examined for each of the named 
formulae. Several formulae had variations in the herbal ingredients, although they shared the 
same formula name. In this instance, the herb ingredients of formulae cited by the earliest 
citation were listed. Where multiple variants of formulae ingredients were found in one book, 
all variants were presented. Further, where the herb ingredients were not available, these were 
sourced from another citation in the same book. 
The standardisation of herbal ingredients was conducted using a nomenclature list of 
commonly used CHMs provided by the Chinese Medicine Board of Australia (CMBA). This 
list was last updated in September 2015. This was done to account for differences in herb 
names between classical literature and modern use. In addition, one herb could be described 
with multiple names in classical works. For instance, wu shi恶实, niu bang zi 牛蒡子, shu 
nian zi鼠粘子, da li zi 大力子 and da niu zi 大牛子 were various names of Arctium lappa L. 
used in ancient CM works. Niu bang zi 牛蒡子 is used currently and suggested by the CMBA. 
Therefore, other names of Arctium lappa L. were standardised to niu bang zi 牛蒡子 . 
Excipients were also included in the analysis of herb frequency, such as feng mi 蜂蜜 (honey) 
and zhu you 猪油 (lard). While they did not possess specific therapeutic properties, they were 
important ingredients of the treatment and used to blend the herbs. 
4.3 Results of Chronic Urticaria 
4.3.1 Characteristics of Citations 
Analysis of the ZHYD retrieved 2,285 instances of eight search terms (see Table 4.5). The 
greatest number of hits was produced by the search term yin zhen 1 瘾疹 (1,790 hits, 78.3%). 
Search terms ‘feng cheng ge da风乘疙瘩’, ‘feng zhen kuai 风疹块’, ‘bai zhen 白轸’ and ‘chi 
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zhen 赤轸’ accounted for less than one per cent of all hits, which indicated these terms were 
not commonly used in classical terminology. 
Table 4.5: Hit Frequency by Search Term for Urticaria 
Pinyin Chinese characters  Citation frequency n (%) 
Yin zhen 1 瘾疹 1790 (78.3) 
Yin zhen 2 隐疹 243 (10.6) 
Pei lei 2  184 (8.0) 
Pei lei 1  51 (2.2) 
Feng zhen kuai 风疹块 11 (0.5) 
Chi zhen 赤轸 3 (0.1) 
Feng cheng ge da 风乘疙瘩 2 (0.1) 
Bai zhen 白轸 1 (0.04) 
After excluding duplicate citations and those irrelevant to urticaria, 881 citations considered 
possible urticaria citations (according to the pre-defined criteria) were retained. Of these 
citations, 332 included treatments (CHM and acupuncture) for urticaria. After citations 
containing multiple treatments were split into separate citations, 540 treatment citations were 
identified. Of these citations, 533 descriptions of CHM treatment were identified and seven 
citations were related to acupuncture therapies. Among these citations, 29 were deemed most 
likely to relate to urticaria because both wheals and pruritus were described in the citations. 
Four search terms identified the 29 most likely urticaria citations: ‘feng cheng ge da 风乘疙
瘩’ (two citations), ‘pei lei 2 ’ (seven citations), ‘yin zhen 1瘾疹’ (15 citations) and ‘yin 
zhen 2 隐疹’ (five citations). Both citations identified by ‘feng cheng ge da 风乘疙瘩’ were 
considered most likely urticaria citations. The earliest citation possibly related to urticaria 
treatment appeared in Zhou hou bei ji fang 肘后备急方 (Handbook of prescriptions for 
emergencies) (363 AD). The most recent citation was sourced from Ben cao jian yao fang 本
草简要方 (1938). 
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4.3.2 Representative Citations 
Yin zhen 1 (瘾疹) was described in You you ji cheng 幼幼集成 (1750) by Chen Fuzheng in 
the Qing dynasty. Chen pointed out the characteristics of the condition and its treatment as: 
Yin zhen comes out mostly due to [the] Spleen, which is faintly visible among the 
skin, with pruritus. It might not be red and commonly called as feng dan 风丹. Jia 
wei qiang huo san 加味羌活散 can be used. 清•陈复正《幼幼集成》 (1750) 瘾疹 
多属于脾, 以其隐隐在皮肤之间, 发而多痒。或不红者,俗人名为风丹。加味羌
活散。. 
The aetiology of yin zhen 1 瘾疹 was believed to be related to the Spleen, which aligns with 
current understandings. Contemporary literature indicates that dampness can trigger urticaria 
due to impairment of the transforming and transporting function of the Stomach and Spleen. 
Jia wei qiang huo san 加味羌活散 was suggested for the treatment; this formula is not used 
in contemporary literature. 
In Tong yuan yi shu wai ke 彤园医书•外科 (1795), the symptoms, aetiology and treatments 
of pei lei 2  were described as: 
Pimple comes after pruritus. It looks like segments of a bean, which pile up to a 
larger area. The lesion is blush and swelling. Person with [a] deficiency of defensive 
exterior is more likely to suffer this condition due to [a] wind attack after sweating 
or laying without keeping warm. Qin jiao niu bang tang 秦艽牛蒡汤 is commonly 
used for the case with more pruritus at daily time, and Dang gui yin 当归饮 for the 
night case. 《彤园医书（外科）》(1795) ,初起皮肤作痒,次发扁疙瘩,形如豆
瓣,堆垒成片,红晕宣肿,由汗出受风或露卧乘凉,风邪多袭,表虚之人,每易患此。
如日间痒甚,常服秦艽牛蒡汤 (见五卷云字号), 夜间痒甚,常服当归饮 (见五卷阳
字号). 
This citation provided a vivid description for pimples (wheals) that closely matches the 
appearance of urticaria described in conventional medicine textbooks. 
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4.3.3 Frequently Used Formulae and Herbs 
Frequently Used Formulae in Possible Urticaria Citations 
The administration of CHM in the 533 possible urticaria citations mainly included formulae 
for oral (274 citations, 51.4%) or topical use (220 citations, 41.3%). No description of 
administration method was provided for the remaining 39 citations. Among all citations, 326 
herb formulae were identified, of which 55 were unnamed formulae. These were excluded 
from further analysis. 
The most frequently cited formulae and their ingredients are presented in Tables 4.6 and 4.7. 
Xiao feng san 消风散 was the most frequently cited formula for oral use, described in 37 
citations with six variants (see Table 4.6). The earliest citation of Xiao feng san 消风散 was 
found in Tai ping hui min he ji ju fang 太平惠民和剂局方  (1,107 AD). For topical 
application, Mang cao gao 莽草膏 was the most commonly reported formula (see Table 4.7). 
The earliest citation of Mang cao gao 莽草膏 was found in Tai ping sheng hui fang 太平圣
惠方 (992 AD). 
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Table 4.6: Oral Formulae Frequently Used in Possible Urticaria Citations 
Formula 
name  
Route of 
administration 
Herb ingredients Citation 
frequency n 
Xiao feng san  Oral Jing jie, fang feng, qiang huo, hou po, 
ren shen, jiang can, chuan xiong, gan 
cao, fu ling, huo xiang, chen pi, chan tui, 
jiang 
37  
Hu ma san  Oral Hu ma, jing jie, bo he, ku shen, gan cao, 
wei ling xian, he shou wu, jiu, mi (honey)  
13  
Hua pi san  Oral Hua pi, jing jie, zhi ke, gan cao, xing 
ren , jiu 
12  
Zui xian san  Oral Hu ma, niu bang zi, man jing zi, gou qi zi, 
ji li, ku shen, gua lou, fang feng, cha 
9 
Jia wei qiang 
huo san  
Oral Qiang huo, qian hu, bo he, tian ma, 
chuan xiong, zhi ke, jie geng, chan tui, 
ren shen, gan cao, sheng jiang, fu ling 
8  
Ren shen xiao 
feng san 
Oral Ren shen, jing jie, gan cao, chen pi, jiang 
can, fu ling, fang feng, chuan xiong, huo 
xiang, chan tui, hou po, qiang huo 
5  
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Table 4.7: Topical Formulae Frequently Used in Possible Urticaria Citations 
Formula 
name  
Route of 
administration 
Herb ingredients Citation 
frequency n 
Mang 
cao gao  
Topical Variant A: (3 citations): Mang cao, chuan 
xiong, ku shen, dang gui, shuo diao, xi 
xin, fu zi, da ji, yuan hua, hua jiao, zhi 
zhu hua, zhu zhi, jing tian 
8  
Variant B (1 citation): Mang cao, chuan 
xiong, ku shen, dang gui, shuo diao, xi 
xin, fu zi, da ji, yuan hua, hua jiao, zhi 
zhu hua, zhu zhi, chi shao 
Variant C (1 citation): Mang cao, chuan 
xiong, dang gui, shuo diao, xi xin, fu zi, 
da ji, yuan hua, hua jiao, zhi zhu hua, zhu 
zhi, chi shao 
Shuo 
diao gao  
Topical Shuo diao, fang feng, bai zhi, jiu, ku shen, 
sheng ma, she chuang zi, yin yu, du huo, 
fu zi, xi jiao, mang cao, hua jiao, zhu zhi , 
ji li, zhi shi, chong wei zi, qiang wei gen, 
fang ji, mu xiang, she xian cao, bai lian, 
ji ji 
5  
Liu zhi 
tang xi 
fang  
Topical Liu zhi, yin chen, ku shen, lang ya cao, 
qing xiang ye, tao zhi, huai bai pi, shuo 
diao, ma huang, yan, mang xiao  
3  
Yin yu 
tang yu 
fang 
Topical Yin yu, fang feng, fu zi, mu li, mang cao  3  
Ye ge 
gao fang  
Topical Ye ge, niu li zi bing gen, fu zi, cu, zhu zhi  3  
Frequently Used Herbs in Possible Urticaria Citations 
A total of 296 herbs were identified in possible urticaria citations (533 citations). Most herbs 
(223 herbs) were used orally and 135 herbs were indicated for topical use. Some herbs were 
used both orally and topically. The most frequently reported herbs for oral and topical use are 
presented separately. Gan cao 甘草 was the most frequently cited herb for oral use (see Table 
4.8), while shuo diao 蒴藋 was most frequently cited herb for topical use (see Table 4.9). 
Several herbs could be used both orally and topically, including fang feng 防风, chuan xiong 
川芎, jiu 酒, ku shen 苦参 and dang gui 当归. 
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Table 4.8: Oral Herbs Frequently Used in Possible Urticaria Citations 
Herb name Scientific name Citation 
frequency n 
Gan cao 甘草 Glycyrrhiza spp 151 
Fang feng 防风 Saposhnikovia divaricata (Turcz.) Schischk. 141 
Jing jie 荆芥 Schizonepeta tenuifolia Briq. 112 
Chuan xiong 川芎 Ligusticum chuangxiong Hort. 98 
Qiang huo 羌活 Notopterygium spp 87 
Ren shen 人参 Panax ginseng C. A. Mey. 87 
Fu ling 茯苓 Poria cocos (Schw.) Wolf. 75 
Zhi ke 枳壳 Citrus aurantium L. (dried fruit) 72 
Jiu酒 Wine 71 
Chan tui 蝉蜕 Cryptotympana pustulata Fabricius. 63 
Ku shen 苦参 Sophora flavescens Ait. 50 
Jiang can 僵蚕 Bombyx mori Linnaeus. or Beauveria bassiana 
(Bals.) 
50 
Chen pi 陈皮 Citrus reticulata Blanco.  48 
Dang gui 当归 Angelica sinensis (Oliv.) Diels. 46 
Hou po 厚朴 Magnolia officinalis spp 43 
Bai ji li 白蒺藜 Tribulus terrestris L. (dried fruit) 42 
Huo xiang 藿香 Pogostemon cablin (Blanco) Benth. or 
Agastache rugosa (Fisch. & Mey.) O. Ktze. 
38 
Bo he 薄荷 Mentha haplocalyx Briq. 37 
Niu bang zi 牛蒡
子 
Arctium lappa L. 36 
Man jing zi 蔓荆子 Vitex trifolia spp 34 
 
Table 4.9: Topical Herbs Frequently Used in Possible Urticaria Citations 
Herb name Scientific name Citation 
frequency n 
Shuo diao 蒴藋 Sambucus javanica Reinw. 29 
Ku shen 苦参 Sophora flavescens Ait. 27 
Fu zi 附子 Aconitum carmichaelii Debx. 26 
Feng xiang zhi 枫
香脂 
Liquidambar formosana Hance. 25 
Hua jiao 花椒 Zanthoxylum spp 21 
Zhu zhi猪脂 Fat 20 
Mang cao 莽草   Illicium lanceolatum A.C. Smith. 19 
Fang feng 防风 Saposhnikovia divaricata (Turcz.) Schischk. 18 
Jiu酒 Wine 18 
Bai fan 白矾 Potassium aluminium sulphate 18 
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Chuan xiong 川芎 Ligusticum chuangxiong Hort. 16 
Bai zhi 白芷 Angelica dahurica spp 16 
Xi xin 细辛 Asarum spp 16 
Dang gui 当归 Angelica sinensis (Oliv.) Diels. 15 
Yuan hua 芫花 Daphne genkwa Sieb. et Zucc. 14 
Chong wei zi 茺蔚
子 
Leonurus japonicus Houtt. 13 
Can sha 蚕沙 Bombyx mori L. 13 
Mang xiao 芒硝 Hydrated sodium sulphate 12 
Yin yu 茵芋 Skimmia reevesiana Fortune. 12 
Frequently Used Formulae in Most Likely Urticaria Citations 
In total, 15 formulae were cited in the 29 most likely urticaria citations. Eleven citations 
named multi-herb formulae identified for oral use. Qiang huo dang gui san 羌活当归散 was 
the most frequently used oral formula to treat urticaria, as cited in 12 citations (see Table 
4.10). This formula could be used on its own to treat wheals and pruritus or in combination 
with modified Xiao yao san 加味逍遥散 or Bu zhong yi qi tang 补中益气汤. While the herbs 
used in these formulae were not specified with symptom descriptions, they were identified 
from another section of the same classical book. Four topically used formulae were found 
with three single-herb formulae, including bai bu 百部 (three citations), bi yi tang 筚衣汤 
(two citations) and xian zi 蚬子 (one citation). Only one multi-herb formula was applied 
topically, which was unnamed. 
Table 4.10: Oral Formulae Frequently Used in Most Likely Urticaria Citations 
Herbal formulae Herb ingredients Citation 
frequency n 
Qiang huo dang gui 
san 
Qiang huo, dang gui, chuan xiong, huang lian, niu 
bang zi, fang feng, jing jie, gan cao, huang qin, lian 
qiao, bai zhi, sheng ma 
4  
Qiang huo dang gui 
san + Jia wei xiao 
yao san 
Qiang huo, dang gui, chuan xiong, huang lian, niu 
bang zi, fang feng, jing jie, gan cao, huang qin, lian 
qiao, bai zhi, sheng ma, gou teng, shao yao, fu ling, 
bai zhu, chai hu, mu dan pi, shan zhi zi 
4  
Qiang huo dang gui Qiang huo, dang gui, chuan xiong, huang lian, niu 4  
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san + Bu zhong yi qi 
tang  
bang zi, fang feng, jing jie, gan cao, huang qin, lian 
qiao, bai zhi, sheng ma, shan zhi zi, gou teng, huang 
qi, ren shen, bai zhu, zhi gan cao, dang gui, chen pi, 
sheng ma, chai hu, sheng jiang, da zao 
Qin jiao niu bang 
tang  
Qin jiao, niu bang zi, ma huang, ling yang jiao, zhi 
ke, huang qin, sheng ma, fang feng, gan cao, xuan 
shen 
2  
Dang gui yin Dang gui, sheng di huang, chi shao, chuan xiong, 
jing jie, fang feng, bai zhi, ji li, shou wu, huang qi, 
gan cao, jiu 
2  
Frequently Used Herbs in Most Likely Urticaria Citations 
Among the most likely urticaria citations, oral CHM treatments were described in 21 citations, 
while topical treatments appeared in seven citations. In one citation, the administration 
method was unclear due to the absence of a description. Sheng ma 升麻 became the most 
frequently cited herb for oral use (18 citations) out of all citations (see Table 4.11). This 
replaced gan cao 甘草 as the most frequently cited herb. However, several key herbs were 
consistent with those reported in all citations, such as gan cao 甘草, dang gui 当归 and jing 
jie 荆芥. Bai bu 百部 and jiu 酒 were the most commonly applied topical herbs (see Table 
4.12). 
Table 4.11: Oral Herbs Frequently Used in Most Likely Urticaria Citations 
Herb name Scientific name Citation 
frequency n 
Sheng ma 升麻 Cimicifuga spp 18 
Gan cao 甘草 Glycyrrhiza spp 17 
Dang gui 当归 Angelica sinensis (Oliv.) Diels. 17 
Jing jie 荆芥 Schizonepeta tenuifolia Briq. 14 
Fang feng 防风 Saposhnikovia divaricata (Turcz.) Schischk. 14 
Chuan xiong 川芎 Ligusticum chuangxiong Hort. 13 
Qiang huo 羌活 Notopterygium spp 13 
Bai zhi 白芷 Angelica dahurica spp 13 
Huang lian 黄连 Coptis spp 13 
Huang qin 黄芩 Scutellaria baicalensis Georgi. 12 
Lian qiao 连翘 Forsythia suspensa (Thunb.) Vahl. 12 
Niu bang zi 牛蒡子 Arctium lappa L. 9 
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Gou teng 钩藤 Uncaria spp 8 
Chai hu 柴胡 Bupleurum spp 5 
Ren shen 人参 Panax ginseng C. A. Mey. 5 
Bai zhu 白朮 Atractylodes macrocephala Koidz. 4 
Huang qi 黄芪 Astragalus spp 4 
Chen pi 陈皮 Citrus reticulata Blanco.  4 
Sheng jiang 生姜 Zingiber officinale Rosc. 4 
Da zao 大枣 Ziziphus jujuba Mill. 4 
Table 4.12: Topical Herbs Frequently Used in Most Likely Urticaria Citations 
Herb name Scientific name Citation 
frequency n 
Bai bu 百部 Stemona spp 3 
Jiu 酒 Wine 3 
Chui fan bi yi 炊饭筚
衣 
[Scientific name not able to identified] 2 
 
4.3.4 Summary 
The greatest number of classical citations was produced by the search term ‘yin zhen 1瘾疹’. 
It was also the most commonly observed term in the most likely urticaria citations. The term 
‘yin zhen 1瘾疹’ is still used to represent urticaria in contemporary literature (current clinical 
textbooks and guidelines) (see Chapter 3). As citations containing feng cheng ge da 风乘疙
瘩 were found only in most likely urticaria citations, this suggests that feng cheng ge da 风乘
疙瘩 could be closely corresponded to urticaria in ancient times. 
Among all citations, Xiao feng san 消风散 was the most frequently used formula. As the 
citations containing Xiao feng san 消风散 failed to describe wheals, Xiao feng san 消风散 
did not appear in the citations that were most likely related to urticaria. In the citations with 
the richest description of wheals and pruritus (most likely urticaria citations), the most 
commonly observed formulae were Qiang huo dang gui san 羌活当归散, Qiang huo dang 
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gui san 羌活当归散 plus Jia wei xiao yao san 加味逍遥散, and Qiang huo dang gui san 羌
活当归散  plus Bu zhong yi qi tang 补中益气汤 . None of these three formulae are 
recommended in contemporary literature. Due to the limited information included in the 
citations, the reason for this remains uncertain. 
Many of the most commonly reported herbs were included in the most frequently cited 
formulae, such as Xiao feng san 消风散, Mang cao gao莽草膏 and Qiang huo dang gui san 
羌活当归散. These herbs could be categorised as expelling wind and relieving exterior (jing 
jie 荆芥, fang feng 防风), dispersing external wind to stop itch (niu bang zi 牛蒡子, chan tui 
蝉蜕, jiang can 僵蚕, bai ji li 白蒺藜), dispelling wind and removing dampness (qiang huo 
羌活), tonifying Spleen qi and draining dampness (fu ling 茯苓, chen pi 陈皮, hou po 厚朴), 
and invigorating the Blood (dang gui 当归, chuan xiong 川芎). 
The most frequently reported herb, gan cao 甘草 , was commonly used to harmonise 
formulae and had other actions relevant to skin conditions, including tonifying the Spleen and 
clearing heat. It possesses steroid-like effects, which are useful in the treatment of chronic 
skin conditions such as urticaria (85). The above herbs are still used in contemporary clinical 
practice, suggesting little has changed over time in the understanding of urticaria aetiology. 
Several herbs could be used both orally and topically, including fang feng 防风, chuan xiong 
川芎, jiu 酒, ku shen 苦参 and dang gui 当归. This suggests that these herbs could relieve 
symptoms regardless of administration method. Many herbs were not commonly found in 
current clinical guidelines and textbooks, including sheng ma 升麻 for oral use, and shuo 
diao 蒴藋, feng xiang zhi 枫香脂, mang cao 莽草, chong wei zi 茺蔚子 and yin yu 茵芋 for 
topical use. Sheng ma 升麻 releases the exterior and disperses heat, promoting eruption and 
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resolving toxicity, which is beneficial for relieving skin rashes, including wheals (86). Shuo 
diao 蒴藋, mang cao 莽草 and yin yu 茵芋 expel wind and remove dampness. Feng xiang zhi 
枫香脂 and chong wei zi 茺蔚子 could be used to invigorate the Blood. As current clinical 
guidelines and textbooks place greater emphasis on oral CHM rather than topical CHM, these 
topically used herbs were not identified. It was uncertain whether they might be still used in 
current practice based on practitioners’ preference or experience.  
4.4 Results of Psoriasis Vulgaris 
4.4.1 Characteristics of Citations 
The search of the ZHYD identified 655 instances of 13 search terms (see Table 4.13). The 
greatest number of hits was produced by the search term ‘feng xuan风癣’ (301 hits, 46.0%). 
Search terms ‘gou pi xuan 狗皮癣’, ‘bai ke chuang 白壳疮’, ‘bi feng疕风’, ‘she feng 蛇风’, 
‘song pi xuan 松皮癣’ and ‘yin qian feng 银钱疯’ accounted for less than one per cent of all 
hits, which indicated these terms were not commonly observed in classical terminology. 
Table 4.13: Hit Frequency by Search Term for Psoriasis Vulgaris 
Pinyin Chinese characters  Citation frequency  
n (%) 
Feng xuan 风癣 301 (46.0) 
Gan xuan 干癣 108 (16.5) 
Niu pi xuan 牛皮癣 104 (15.9) 
Bai xuan 白癣  57 (8.7) 
Bai bi  白疕  29 (4.4) 
Gou xuan 狗癣 16 (2.4) 
She shi 蛇虱 16 (2.4) 
Bai ke chuang 白壳疮 6 (0.9) 
Gou pi xuan 狗皮癣 6 (0.9) 
She feng 蛇风 4 (0.6) 
Song pi xuan 松皮癣 4 (0.6) 
Bi feng 疕风 2 (0.3) 
Yin qian feng 银钱疯 2 (0.3) 
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After excluding duplicate citations and those irrelevant to psoriasis vulgaris, 530 citations 
considered related to CHM for psoriasis were retained. According to pre-defined criteria, 
each citation was evaluated to select ‘possible’ or ‘most likely’ psoriasis vulgaris citations for 
further analysis. Based on the overall judgment, 68 ‘possible’ and 60 ‘most likely’ psoriasis 
citations were included. 
Eight terms were used to identify citations of psoriasis vulgaris in the 60 most likely psoriasis 
vulgaris citations: ‘bai bi白疕’ (29 citations), ‘gan xuan 干癣’ (28 citations), ‘she shi 蛇虱’ 
(16 citations), ‘feng xuan 风癣’ (nine citations), ‘she feng蛇风’ (two citations), ‘bi feng疕风’ 
(two citations), ‘bai ke chuang 白壳疮’ (one citation) and ‘bai xuan 白癣’(one citation). 
Several citations contained more than one term. All citations containing ‘bai bi 白疕’, ‘she 
shi 蛇虱’ and ‘bi feng 疕风’ were considered most likely to be related to psoriasis vulgaris. 
The earliest citation possibly related to psoriasis vulgaris treatment appeared in Zhu bing 
yuan hou lun 诸病源候论 (610 AD), while the most recent one was sourced from Wai ke shi 
san fang kao 外科十三方考 (1947 AD). 
4.4.2 Representative Citations 
In Wai ke zheng zhi quan shu 外科证治全书 (1831) written by Xu Kechang, the symptoms, 
aetiology and treatments of bai bi 白疕 were described: 
Bai bi is also called bi feng, featuring dry and itchy skin. It looks like rash but with 
white colour. Scales occur after scratching. The skin will become cracked and 
bleeding with pain over time due to dryness and lack of nourishment. It will be 
difficult to scratch as the skin among the 10 fingers become thick. The disease is 
caused by excess dryness in late autumn. People with Blood deficiency and thin 
body shape tend to suffer this disease. Sheng xue run fu yin can be used orally, and 
Zhu zhi can be applied topically. 清•许克昌《外科证治全书》(1831) 白疕（一名
疕风）皮肤燥痒，起如疹疥而色白，搔之屑起，渐至肢体枯燥坼裂，血出痛
楚，十指间皮厚而莫能搔痒。因岁金太过，至秋深燥金用事，乃得此证。多
患于血虚体瘦之人，① 生血润肤饮主之，②用生猪脂搽之。. 
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Xu pointed out that internal Blood deficiency and external dryness could trigger bai bi白疕 
easily. This was similar to syndrome Blood deficiency and wind-dryness mentioned in 
contemporary literature (see Chapter 3). 
4.4.3 Frequently Used Formulae and Herbs 
Frequently Used Formulae in Possible Psoriasis Vulgaris Citations 
In the possible psoriasis citations, 27 named herbal formulae were identified, with 10 for oral 
use and 17 for topical use. The most frequently cited formulae and their ingredients are 
presented in Tables 4.14 and 4.15. Sou feng shun qi wan 搜风顺气丸 was the most frequently 
cited formula for oral use, reported in five citations (see Table 4.14). The earliest citation of 
this formula was from Wai ke zheng zong 外科正宗 (1,617 AD). Bai bu gao 百部膏 was the 
most commonly reported formula for topical use, cited in Yi xue xin wu 医学心悟 (1,732 AD) 
(see Table 4.15). 
Table 4.14: Oral Formulae Frequently Used in Possible Psoriasis Vulgaris Citations 
Formula 
name  
Herb ingredients Citation 
frequency 
n 
Sou feng 
shun qi wan  
Da huang, jiu, shan yao, da zao, niu xi, tu si zi, zhi ke, yu 
li ren, qiang huo, fang feng, du huo, che qian zi, bing lang, 
feng mi 
5 
Fang feng 
tong sheng 
san  
Fang feng, chuan xiong, dang gui, shao yao, da huang, bo 
he, ma huang, lian qiao, mang xiao, shi gao, huang qin, 
jie geng, hua shi, gan cao, jing jie, bai zhu, zhi zi 
3  
Ku shen 
wan  
Ku shen, zao jiao 2  
La fan wan Huang la, ming fan, zhu sha 2 
Zhu shen 
san 
Fu zi, jiao hong, zhu shen, yan 2 
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Table 4.15: Topical Formulae Frequently Used in Possible Psoriasis Vulgaris Citations 
Formula 
name  
Herb ingredients Citation 
frequency 
n 
Bai bu gao Bai bu, bai xian pi, bi ma zi, he shi, huang bo, dang gui, 
sheng di huang, huang la, xiong huang, ma you 
3 
Fu zi san  Fu zi, liu huang, cang er zi 2 
Yi mo san  Tian nan xing, cao wu tou, yang ti gen 2  
Hai ai tang  Ai cao, ju hua, bo he, fang feng, gao ben, huo xiang, gan 
song, man jing zi, jing jie sui 
2 
Yi sao 
guang 
Ku shen, huang bo, da feng zi, mu bie, she chuang zi, diao 
yang chen, ku fan, xiong huang, hua jiao, liu huang, zhang 
nao, qing fen, zhu you 
2 
Frequently Used Herbs in Possible Psoriasis Vulgaris Citations 
In total, 65 herbs were used orally and 75 herbs were applied topically in possible psoriasis 
citations. The most commonly reported herbs for oral and topical use are presented separately 
(see Tables 4.16 and 4.17). Da huang 大黄 was the most frequently cited herb for oral use 
(see Table 4.16), while wu tou 乌头 was the most frequently cited herb for topical use (see 
Table 4.17). Several herbs were used both orally and topically, including fang feng 防风, and 
dang gui 当归. 
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Table 4.16: Oral Herbs Frequently Used in Possible Psoriasis Vulgaris Citations 
Herb name Scientific name Citation 
frequency n 
Da huang 大黄 Rheum officinale Baill. 10 
Chen jiu 酒 Wine 10 
Feng mi 蜂蜜  Apis cerana Fabricius. 9 
Fang feng 防风 Saposhnikovia divaricata (Turcz.) 
Schischk. 
8 
Yu li ren郁李仁 Prunus japonica Thunb. 7 
Qiang huo 羌活 Notopterygium spp 7 
Zhi shi 枳实 Citrus aurantium L. 7 
Huo ma ren火麻仁 Cannabis sativa L. 7 
Tu si zi 菟丝子 Cuscuta chinensis Lam. 7 
Du huo 独活 Angelica pubescens Maxim. f. 
biserrata Shan et Yuan. 
6 
Che qian zi 车前子 Plantago asiatica L. 6 
Niu xi 牛膝 Cyathula officinalis Kuan. 6 
Bing lang 槟榔 Areca catechu L.  6 
Shan zhu yu 山茱萸 Cornus officinalis Sieb. et Zucc. 6 
Shan yao 山药 Dioscorea opposita Thunb. 6 
Huang qin 黄芩 Scutellaria baicalensis Georgi. 5 
Dang gui 当归 Angelica sinensis (Oliv.) Diels. 5 
Zhi zi 栀子 Gardenia jasminoides Ellis.  4 
Chuan xiong 川芎 Ligusticum chuangxiong Hort. 4 
Bai shao 白芍 Paeonia lactiflora Pall. 4 
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Table 4.17: Topical Herbs Frequently Used in Possible Psoriasis Vulgaris Citations 
Herb name Scientific name Citation 
frequency n 
Wu tou 乌头  Aconitum carmichaelii Debx. 13 
Zhu you 猪油  Pig fat 9 
Cu 醋  Vinegar 8 
(Shi) liu huang (石)硫
黃  
Sulphur 7 
Ban mao 斑蝥  Mylabris phalerata Pallas. 7 
Yang ti gen 羊蹄根  Rumex japonicus Meisn. 7 
Huang bo 黄柏  Phellodendron chinense Schneid. 5 
Xiong huang 雄黄  Arsenic disulphide 5 
Zao jiao皂角  Gleditsia sinensis Lam. 5 
Bai fan 白矾  Potassium aluminium sulphate 5 
She chuang zi 蛇床子 Cnidium monnieri (L.) Cuss. 5 
Bi ma zi 蓖麻子 Ricinus communis L. 5 
Huang lian 黄连  Coptis chinensis Franch.  4 
Shui yin fen水银粉  [Scientific name not able to be 
identified] 
4 
Dang gui 当归  Angelica sinensis (Oliv.) Diels. 4 
Jin tuo 津唾  Saliva 4 
Huang la 黄蜡  [Scientific name not able to be 
identified] 
4 
Xing ren 杏仁  Prunus armeniaca L. 3 
Tian nan xing 天南星  Arisaema erubescens (Wall.) Schott. 3 
Hua jiao花椒  Zanthoxylum bungeanum Maxim. 3 
Bai xian pi 白鲜皮  Dictamnus dasycarpus Turcz.  3 
Gao ben 藁本  Ligusticum sinense Oliv. 3 
Quan xie 全蝎  Buthus martensii Karsch. 3 
Wu zhu yu 吴茱萸 Euodia rutaecarpa (Juss.) Benth. 3 
Bo he 薄荷  Mentha haplocalyx Briq. 3 
Qian dan 铅丹  [Scientific name not able to be 
identified] 
3 
Zhang nao 樟脑  Cinnamomum camphora (L.) Presl 
Laurus camphora L. 
3 
Di huang 地黄 Rehmannia glutinosa Libosch.  3 
He shi 鹤虱  Carpesium abrotanoides L. 3 
Fang feng 防风  Saposhnikovia divaricata (Turcz.) 
Schischk. 
3 
Ma you 麻油  Sesame oil 3 
Bai bu 百部  Stemona sessilifolia (Miq.) Miq. 3 
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Frequently Used Formulae in Most Likely Psoriasis Vulgaris Citations 
Among the 60 most likely psoriasis citations, seven formulae were defined as for oral use, 
while 15 were designated for topical use. The most frequently cited formulae and their 
ingredients are presented in Tables 4.18 and 4.19. The formulae list for oral use is consistent 
with those in possible psoriasis citations. In line with the possible psoriasis citations, Sou feng 
shun qi wan 搜风顺气丸 was the most frequently cited formula for oral use. The formulae 
list for topical applications in most likely psoriasis citations was slightly different to that of 
possible psoriasis citations. Fu zi san 附子散 was the most frequently reported formula for 
topical application, described in Sheng ji zong lu 圣济总录 (1,117 AD). 
69 
Table 4.18: Oral Formulae Frequently Used in Most Likely Psoriasis Vulgaris Citations 
Formula 
name  
Herb ingredients Citation 
frequency 
n 
Sou feng 
shun qi 
wan  
Da huang, jiu, shan yao, da zao, niu xi, tu si zi, zhi 
ke, yu li ren, qiang huo, fang feng, du huo, che qian 
zi, bing lang, feng mi 
5 
Fang feng 
tong sheng 
san 
Fang feng, chuan xiong, dang gui, shao yao, da 
huang, bo he, ma huang, lian qiao, mang xiao, shi 
gao, huang qin, jie geng, hua shi, gan cao, jing jie, 
bai zhu, zhi zi 
3  
Ku shen 
wan  
Ku shen, zao jiao  2  
La fan 
wan  
Huang la, ming fan, zhu sha 2 
Zhu shen 
san 
Fu zi, jiao hong, zhu shen, yan 2 
 
Table 4.19: Topical Formulae Frequently Used in Most Likely Psoriasis Vulgaris 
Citations 
Formula 
name  
Herb ingredients Citation 
frequency 
n 
Fu zi san Fu zi, liu huang, cang er zi 2 
Jiang can 
san 
Man jing zi, huang qi, fu ling, ren shen, tian nan 
xing, tian ma, jiang can, du huo, qiang huo, ge gen, 
gan cao, jing jie, etc. 
2 
Yi mo san Tian nan xing, cao wu tou, yang ti gen 2  
Hai ai 
tang  
Ai cao, ju hua, bo he, fang feng, gao ben, huo 
xiang, gan song, man jing zi, jing jie sui 
2 
Frequently Reported Herbs in Most Likely Psoriasis Vulgaris Citations 
The most frequently reported herbs for oral use in most likely psoriasis citations were 
completely consistent with those in possible psoriasis citations (see Table 4.20). In terms of 
topical application, the herb list also overlapped with the list for possible psoriasis citations. 
For instance, the top three herbs were wu tou 乌头, zhu you 猪油 and cu 醋 (see Table 4.21). 
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Table 4.20: Oral Herbs Frequently Used in Most Likely Psoriasis Vulgaris Citations 
Herb name Scientific name Citation 
frequency n 
Da huang 大黄 Rheum officinale Baill. 10 
Chen jiu 酒 Wine 10 
Feng mi 蜂蜜  Apis cerana Fabricius. 9 
Fang feng 防风 Saposhnikovia divaricata (Turcz.) 
Schischk. 
8 
Yu li ren郁李仁 Prunus japonica Thunb. 7 
Qiang huo 羌活 Notopterygium spp 7 
Zhi shi 枳实 Citrus aurantium L. 7 
Huo ma ren火麻仁 Cannabis sativa L. 7 
Tu si zi 菟丝子 Cuscuta chinensis Lam. 7 
Du huo 独活 Angelica pubescens Maxim. f. 
biserrata Shan et Yuan. 
6 
Che qian zi 车前子 Plantago asiatica L. 6 
Niu xi 牛膝 Cyathula officinalis Kuan. 6 
Bing lang 槟榔 Areca catechu L.  6 
Shan zhu yu 山茱萸 Cornus officinalis Sieb. et Zucc. 6 
Shan yao 山药 Dioscorea opposita Thunb. 6 
Huang qin 黄芩 Scutellaria baicalensis Georgi. 5 
Dang gui 当归 Angelica sinensis (Oliv.) Diels. 5 
Zhi zi 栀子 Gardenia jasminoides Ellis. 4 
Chuan xiong 川芎 Ligusticum chuangxiong Hort. 4 
Bai shao 白芍 Paeonia lactiflora Pall. 4 
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Table 4.21: Topical Herbs Frequently Used in Most Likely Psoriasis Vulgaris Citations 
Herb name Scientific name Citation 
frequency n 
Wu tou 乌头  Aconitum carmichaelii Debx. 13 
Zhu you 猪油  Pig fat 9 
Cu 醋  Vinegar 8 
Ban mao 斑蝥  Mylabris phalerata Pallas. 6 
Yang ti gen 羊蹄根  Rumex japonicus Meisn. 6 
(Shi) liu huang (石)硫
黃  
Sulphur 5 
She chuang zi 蛇床子 Cnidium monnieri (L.) Cuss. 5 
Huang lian 黄连  Coptis chinensis Franch.  4 
Zao jiao皂角  Gleditsia sinensis Lam. 4 
Bai fan 白矾  Potassium aluminium sulphate 4 
Shui yin fen水银粉  [Scientific name not able to be 
identified] 
4 
Xing ren 杏仁  Prunus armeniaca L. 3 
Tian nan xing 天南星  Arisaema erubescens (Wall.) Schott. 3 
Gao ben 藁本  Ligusticum sinense Oliv. 3 
Quan xie 全蝎  Buthus martensii Karsch. 3 
Wu zhu yu 吴茱萸 Euodia rutaecarpa (Juss.) Benth. 3 
Qian dan 铅丹  [Scientific name not able to be 
identified] 
3 
Bo he 薄荷  Mentha haplocalyx Briq. 3 
Jin tuo 津唾  Saliva 4 
Zhang nao 樟脑  Cinnamomum camphora (L.) Presl 
Laurus camphora L. 
3 
Fang feng 防风  Saposhnikovia divaricata (Turcz.) 
Schischk. 
3 
 
4.4.4 Summary 
The greatest number of overall classical citations was produced by the search term ‘feng xuan 
风癣’. However, after applying symptom and clinical judgment, few citations that were 
identified by ‘feng xuan 风癣 ’ remained. This suggests that this term could refer to 
conditions other than psoriasis vulgaris. ‘Bai bi白疕’, ‘she shi 蛇虱’ and ‘bi feng疕风’ were 
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all cited in most likely psoriasis vulgaris citations, indicating these could be the terms that 
most closely referred to the condition. 
It was surprising that the commonly reported formulae in the most likely psoriasis vulgaris 
citations were not consistent with current clinical practice (see Chapter 3). For instance, the 
most frequently reported formula, Sou feng shun qi wan 搜风顺气丸, promotes qi movement 
and is often used to treat gastrointestinal disease in contemporary practice. Although some 
herb ingredients of main formulae (jing jie 荆芥, fang feng 防风 and huang qi 黄芪) are still 
used in modern times, it is uncertain if formulae in current practice originated or were 
modified from those in classical literature. 
The most frequently used herbs for oral use in the most likely psoriasis vulgaris citations 
could be categorised as clearing heat (da huang 大黄, huang qin 黄芩 and zhi zi 栀子), 
dispersing external wind (fang feng 防风), removing dampness (qiang huo 羌活, du huo 独
活 and che qian zi 车前子) and herbs for tonifying (tu si zi菟丝子, niu xi 牛膝, shan zhu yu 
山茱萸, shan yao 山药). Blood syndrome herbs were dang gui 当归, chuan xiong 川芎 and 
bai shao 白芍. These were observed at a lower frequency and were not commonly cited in 
the classical literature, although they are commonly used in current practice. This might be 
due to the variation in the environment or historical development of CM etiology of psoriasis 
vulgaris. External wind invasion was believed to the etiological factor for psoriasis vulgaris 
in the Sui and Tang dynasties. In the Ming and Qing dynasties, the internal factor of Blood 
syndrome rose in prominence (87). The treatment principle of psoriasis vulgaris in current 
clinical practice mainly targets Blood syndromes, especially Blood stasis (see Chapter 3). 
Several herbs for topical use in classical citations are still utilised in current clinical practice. 
For instance, fang feng 防风, she chuang zi 蛇床子 and shi liu huang 石硫黃 are often used 
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to disperse wind and stop itch; and huang lian 黄连 to eliminate heat. Cu 醋, zhu you (pig fat) 
猪油 and jin tuo (saliva) 津唾 were used as excipients to bind herbs in classical times, but jin 
tuo (saliva) 津唾 is no longer utilised for health reasons. Due to the toxicity of herbs, wu tou
乌头, ban mao斑蝥, qian dan铅丹 and shui yin 水银粉 (86) are rarely used in the treatment 
of psoriasis vulgaris in modern clinical settings. 
4.5 Discussion and Conclusion 
In current clinical guidelines and textbooks, Xiao feng san 消风散 and Dang gui yin zi 当归
饮子 could be used to treat urticaria and psoriasis vulgaris. Interestingly, Xiao feng san 消风
散 was most frequently reported in the citations related to urticaria, which suggests Xiao feng 
san 消风散 has stood the test of time and might become a promising formula for the 
treatment of urticaria. Neither of these formulae were identified in the psoriasis vulgaris 
classical citations. This might be due to the contemporary clinical practice principle of 
focusing on Blood syndromes. Xiao feng san 消风散 and Dang gui yin zi 当归饮子 are 
currently used for Blood heat and Blood dryness of psoriasis vulgaris. 
Other formulae in the citations related to urticaria and psoriasis vulgaris are no longer used in 
current clinical practice, such as Qiang huo dang gui san 羌活当归散 and Mang cao gao 莽
草膏 for urticaria, and Sou feng shun qi wan 搜风顺气丸 for psoriasis vulgaris. This might 
be due to management of urticaria and psoriasis vulgaris evolving in line with CM etiology 
for these two conditions. As the information contained in the classical citations is limited, this 
is an area that needs to be explored in the future research on classical literature. 
In the most likely urticaria and psoriasis vulgaris citations, the CHM treatments for these two 
conditions had several herbs in common, including fang feng 防风, jing jie 荆芥, gan cao 甘
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草, qiang huo 羌活, dang gui 当归 and chuan xiong 川芎. This suggests similarities in the 
treatments of urticaria and psoriasis vulgaris in classical literature. It should be noted that gan 
cao 甘草 was the most frequently used herb for urticaria in classical works. Gan cao 甘草 
can harmonise ingredients in a formula, but also has steroid-like effects (85, 86), which could 
be used to treat skin conditions, including urticaria and psoriasis. While gan cao 甘草 was 
not the most frequently cited in the classical psoriasis citations, the commercial products 
extracted from gan cao 甘草 have been used in current clinical practice (85).  
Although the ZHYD is a comprehensive collection of a wide range of books across multiple 
eras, it does not encompass all classical books since classical literature was vast. In addition, 
the search terms used for the ZHYD might not be comprehensive enough to return all relevant 
citations. Only 68 citations related to psoriasis vulgaris were found. Therefore, formulae used 
in current practice were not identified in classical literature. 
The formulae and herbs identified in classical literature can be taken into consideration when 
prescribing formulae for these two conditions in contemporary clinical practice. The efficacy 
and safety of the less frequently used herbs or formulae in current practice should be 
evaluated through experimental and clinical studies. 
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Chapter 5. Methods for Evaluating Clinical Evidence of Chinese Herbal 
Medicine for Chronic Urticaria and Psoriasis Vulgaris 
5.1 Introduction 
Clinical evidence refers to information gathered from various types of studies, such as SRs, 
RCTs, CCTs, case reports and case-series studies (non-controlled studies). SRs are deemed 
the highest level of clinical evidence (88). According to a pre-defined review protocol, SRs 
synthesise clinical evidence through systematic search and evaluation of methodology quality. 
SRs could answer specific clinical and research questions, and assist clinical decision-making 
and healthcare policymakers (89). As a world leader in SR methodology, the Cochrane 
Collaboration provides the best available evidence for practitioners, researchers and 
policymakers. Following the rigorous methodology provided by the Cochrane Collaboration, 
three SRs were conducted to gather and summarise clinical evidence of CHM for chronic 
urticaria and psoriasis vulgaris. All three review protocols have been registered in 
PROSPERO (see Chapters 6, 7 and 8 for PROSPERO registration numbers). This chapter 
describes the general methods used to evaluate clinical evidence. The overall procedures are 
the same for all SRs. Inclusion criteria of the included studies differed in SRs due to the 
diversity of chronic urticaria and psoriasis vulgaris.  
5.2 Inclusion Criteria 
5.2.1 Chronic Urticaria 
5.2.1.1 Types of Study 
RCTs on CHM for people with chronic urticaria were included. Non-randomised CCTs, non-
controlled studies and experimental studies were excluded.  
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5.2.1.2 Participants 
People with chronic urticaria were considered regardless of subtypes because clinical 
management is the same for spontaneous and inducible urticarias. Chronic urticaria was 
defined as the occurrence of hives and/or angioedema for six weeks or longer (8, 10). 
5.2.1.3 Interventions 
Any forms of CHM alone or in combination with conventional therapies were accepted. The 
administration of CHM included oral decoction, capsule, granule and topical application 
alone, or the combination of various preparation types. Studies employing conventional 
therapies as co-interventions were included. The conventional therapies were consistent with 
those in the control group. Studies that used other CM therapies (for example, acupuncture) 
as co-interventions were excluded. 
5.2.1.4 Comparators 
Studies using the following comparators were considered: placebo, no treatment or 
conventional therapies. Conventional therapies were limited to those recommended in 
international clinical practice guidelines (for example, non-sedating second-generation H1 
antihistamines, omalizumab and ciclosporin A) for chronic urticaria (8, 10, 11). 
5.2.1.5 Outcomes 
All pre-specified outcomes were clinically oriented, including those recognised 
internationally and used in China most commonly, such as effective rate (ER) based on 
symptoms (see Table 5.1). Disease activity was measured by three outcomes: Urticaria 
Activity Score (UAS) (0–6 points)/UAS7 (0–42 points) (10), Urticaria Severity Score (USS) 
77 
(0–93 points) (90), and Urticaria Control Test (UCT) (0–16 points) (91). For all outcomes, a 
lower score indicated improvement in urticaria symptoms. 
Similarly, patients’ health-related QoL (HR-QoL) was evaluated using one urticaria-specific 
outcome measure, Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) (0–100 points) 
(92), and one general dermatology questionnaire, Dermatology Life Quality Index (DLQI) 
(0–30 points) (93). Again, a lower score indicated better HR-QoL. 
Global assessment of symptoms (effective rate, ER) included two approaches. The first 
approach followed the Standard of diagnosis and assessment of treatment effects of 
dermatological conditions in Chinese medicine «中医皮肤科病证诊断疗效标准» (63), 
which describes criteria for improvement in wheals and pruritus. ‘ER 30’ was defined as the 
number of people who achieved a 30% (or more) improvement according to the criteria of 
this approach. The second involved a calculation of change from baseline in symptom scores 
of wheals and pruritus (with or without other symptoms) (Symptom Severity Reduction Index 
[SSRI]). The evaluation domains of the scoring systems varied across studies, which included 
pruritus, quantity and diameter of wheals, oedema-size, dermatographism, frequency or 
duration of symptoms. A score was allocated to each symptom, from 0 (no symptoms) to 3 or 
4 (worst possible symptoms), and the score change was calculated. SSRI 30 was defined as 
the number of people who achieved a 30% (or higher) score change. As no consensus was 
reached on the ER threshold, SSRI 30 was chosen for the SRs based on criteria described in 
CM guidelines (63). If the rate of people who achieved a 30% score change was not available, 
the number of people who achieved more than a 30% score change was used for analysis. In 
the Standard of diagnosis and assessment of treatment effects of dermatological conditions in 
Chinese medicine «中医皮肤科病证诊断疗效标准» (63), the definition of clinical cure was 
provided. Therefore, the relapse rates based on this guideline were also evaluated. 
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Table 5.1: Pre-specified Outcomes for Systematic Reviews of Chronic Urticaria 
Outcome categories Outcome measures 
Disease activity Urticaria Activity Score (UAS)/UAS7 
Urticaria Severity Score (USS) 
Urticaria Control Test (UCT) 
Health-related quality 
of life (HR-QoL) 
Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) 
Dermatology Life Quality Index (DLQI) 
Effective rate Effective rate (ER 30): 30% or greater improvement in 
wheals and pruritus 
Symptom Severity Reduction Index (SSRI 30): 30% or 
greater change in symptom score from baseline 
Relapse rate
 
Calculated based on ER 30 
Adverse events
 
Number and type of adverse events 
 
5.2.2 Psoriasis Vulgaris 
5.2.2.1 Types of Study 
RCTs comparing CG plus guidelines recommended conventional therapy with the same 
conventional therapy alone for psoriasis vulgaris were included (12, 13). CCTs, non-
controlled studies and experimental studies were excluded.  
5.2.2.2 Participants 
People with a diagnosis of psoriasis vulgaris were considered without limitation on psoriasis 
stages. 
5.2.2.3 Interventions 
CG, regardless of preparation type, plus international guidelines recommended conventional 
therapies were used in the intervention group. 
5.2.2.4 Comparators 
The comparators were conventional therapies that corresponded with those in the intervention 
group. The conventional therapies included topical therapies (for example, corticosteroids), 
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phototherapy (narrow-band ultraviolet (UV)-B: NB-UVB) and systemic agents (for example, 
acitretin) (12, 13). 
5.2.2.5 Outcomes 
The primary outcome was the proportion of patients achieving a PASI rate of 60 (that is, 60% 
or greater reduction of PASI score). PASI 60 is recommended in the Consensus of diagnosis 
and treatment of psoriasis vulgaris in integrative medicine 寻常性银屑病中西医结合诊疗
共识, published in China (94). Based on international guidelines, PASI 50/75 are considered 
treatment goals (12, 95). As previous SRs (28, 96) suggested that PASI 60 was frequently 
used in RCTs in China, PASI 60 was selected as the primary outcome. Secondary outcomes 
included PASI 90 (clinically cured) measures of HR-QoL (that is, DLQI, relapse rates and 
AEs). 
5.3 Search Strategy 
An initial search of English and Chinese databases was conducted for clinical evidence 
relating to chronic urticaria from inceptions to May 2014, and an update search was 
performed in July 2015. The five English databases were PubMed, Excepta Medica Database 
(Embase), Allied and Complementary Medicine Database (AMED), Cumulative Index of 
Nursing and Allied Health Literature (CINAHL) and Cochrane Central Register of 
Controlled Trials (CENTRAL). Four Chinese databases were searched: China BioMedical 
Literature (CBM), China National Knowledge Infrastructure (CNKI), Chongqing VIP 
(CQVIP) and Wanfang Databases. Search terms (see Appendix 1) were grouped according to 
intervention (herbal medicine, CM, CM treatment and variants), condition (urticaria, hives, 
wheals and variants) and study design (randomly, randomised, controlled and variants). 
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For psoriasis vulgaris, five English databases (PubMed, Embase, CINAHL, CENTRAL and 
AMED), one Japanese database (CiNii) and four Chinese databases (CBM, CNKI, CQVIP 
and Wanfang Database) were searched from inceptions to July 2015. Search terms (see 
Appendix 2) were grouped according to intervention (glycyrrhizin and variants), condition 
(psoriasis and variants) and study design (randomly, randomised and variants), with 
adjustments for each database search. 
5.4 Data Collection and Analysis 
5.4.1 Selection of Studies 
Identified citations were exported to Endnote reference management software for further 
screening. Through reading titles and abstracts, two reviewers (Jingjie Yu and Yiqi Du for 
chronic urticaria citations, Jingjie Yu and Claire Zhang for psoriasis vulgaris citations) 
independently screened the studies against the inclusion criteria. Full-text articles were 
obtained to ensure potentially relevant citations were included in further evaluation. Any 
disagreement was resolved through discussion or consultation with the third reviewer 
(Meaghan Coyle). 
5.4.2 Data Extraction 
Data from the eligible studies were extracted by two reviewers (Jingjie Yu and Yiqi Du for 
chronic urticaria studies, Jingjie Yu and Claire Zhang for psoriasis vulgaris studies) 
independently using a pre-defined Excel form designed by China-Australia International 
Research Centre for Chinese Medicine (see Appendix 3). The data extraction form covered 
the details relating to the characteristics of the studies, interventions, comparators and 
outcomes. For missing or incomplete data, the author of the study was contacted to seek more 
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detailed information or clarification via email. If additional data or further reply could not be 
obtained from the authors, the data were excluded from final analysis.  
5.4.3 Risk of Bias Assessment 
The risk of bias of each included study was independently evaluated by two reviewers 
(Jingjie Yu and Yiqi Du for chronic urticaria studies, Jingjie Yu and Claire Zhang for 
psoriasis vulgaris studies) using the Cochrane Collaboration’s risk of bias assessment tool 
(89). The assessment tool for risk of bias contains six domains (see Table 5.2). Each study 
was assessed as ‘low risk of bias’, ‘unclear’ or ‘high risk of bias’. Disagreement arising 
during the assessments was resolved via discussion between the two reviewers. If consensus 
could not be reached, consultation was made with the third reviewer (Meaghan Coyle). 
Table 5.2: Tool for Assessment of Risk of Bias  
Bias categories Domain 
Selection bias Random sequence generation 
Allocation concealment 
Performance bias Blinding of participants and personnel 
Detection bias Blinding of outcome assessment 
Attrition bias Incomplete outcome data 
Reporting bias Selective reporting 
 
 
5.4.4 Statistical Analysis 
Data related to CHM formulae and herbs were analysed for frequency of usage using 
descriptive statistics. The herbal names were standardised according to a nomenclature list of 
commonly used CHMs (last updated in September 2015) provided by the CMBA. This was 
done to account for different names of herbs in each study. Moreover, a herb prepared with 
different processing methods was regarded as the same herb when calculating the frequency. 
For instance, zhi gan cao 炙甘草 is processed through frying sheng gan cao 生甘草 with 
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honey. Zhi gan cao 炙甘草 and sheng gan cao 生甘草 were merged as gan cao 甘草 for 
analysis. The most frequently used formulae or herbs were presented.  
Outcome data were analysed using Review Manager 5.3 software(97). Dichotomous data 
were reported as risk ratio (RR) and continuous data reported as mean difference (MD), with 
95% confidence intervals (CI). To present a clear difference of effects between intervention 
and comparator, risk difference (RD) was also used in the SR on psoriasis vulgaris. RD was 
presented as the actual difference in risk between the intervention and control groups. 
Random or fixed effects analysis was selected, taking into account clinical and statistical 
heterogeneity. The clinical heterogeneity was considered based on the demographics of 
participants, and study design, such as allocation concealment, blinding, treatment duration 
and outcome assessments. Statistical heterogeneity was evaluated using the I
2
 statistic. 
Sensitivity analysis was performed where moderate to substantial statistical heterogeneity 
was detected (I
2
>50%), based on risk of bias for sequence generation. Where possible, 
subgroup analysis was planned according to characteristics of participants (demographic 
data), interventions (CHM formula, preparation type) or comparators (dosage, subclass of 
conventional therapy). Publication bias was explored by visual inspection of funnel plots 
when a meta-analysis included 10 or more studies. 
5.5 Summary 
This chapter introduces the general methods used to evaluate the clinical evidence. Clinical 
evidence was evaluated and synthesised through SRs of RCTs following the rigorous 
methodology of the Cochrane Collaboration. Up to 10 databases (English, Chinese and 
Japanese) were searched to identify relevant articles. Three SRs were conducted: 
1. CHM alone for chronic urticaria 
2. CHM as add-on therapy for chronic urticaria 
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3. CG for psoriasis vulgaris. 
Statistical analyses were performed in Review Manager 5.3.  
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Chapter 6. Systematic Review 1: 
Chinese Herbal Medicine for Chronic Urticaria 
6.1 Introduction 
Urticaria is defined by the rapid onset of wheals, with or without angio-oedema (10). Wheals 
are typically accompanied by pruritus and are transient in nature, with the skin returning to its 
normal appearance in one to 24 hours (8). Acute urticaria is defined as the occurrence of 
hives and/or angioedema for less than six weeks, while episodes lasting six weeks or longer 
are regarded as chronic urticaria (8, 10). 
According to a representative cross-sectional sample of 13,300 people, the lifetime 
prevalence rate of urticaria is 8.8% for all types of urticaria and 1.8% for chronic urticaria (9). 
Chronic urticaria is observed more commonly in women than in men (9, 37). Frequent 
recurrences have a significant impact, including high economic and health burdens (9, 20). 
The burden of chronic urticaria on HR-QoL has been estimated as similar to that of coronary 
artery disease (17). 
In approximately 75% of cases, the cause of chronic urticaria is unknown (98). Even when a 
cause has been identified, it can be difficult to avoid recurrence. Second-generation 
antihistamines are recommended as first-line therapy for chronic urticaria (8, 10). Second-
generation antihistamines are effective in reducing wheals and pruritus and are safe for use (8, 
10). Despite demonstrated effect, some patients do not achieve adequate symptom control, or 
may experience a worsening of symptoms (57). 
CAM use among people with skin conditions is common and herbal medicine is becoming a 
popular option (24–26). To date, no SRs of CHM for chronic urticaria have been published in 
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English. Three SRs of CHM (32–34) have been identified from the Chinese databases. All 
SRs concluded that CHM had superior efficacy compared with antihistamines. Among them, 
two SRs (32, 33) focused on one formula (Dang gui yin zi 当归饮子) for chronic urticaria, 
with narrow inclusion criteria. The reliability of the findings is uncertain due to meta-analysis 
including data from diverse outcome measures with different outcome criteria. Further, the 
outcomes were not recognised internationally. The third SR evaluated the efficacy and safety 
of CHM for chronic urticaria (34). However, only one English database (PubMed) was 
searched for this SR, and the search of Chinese databases did not include major databases, 
such as CQVIP. Statistical heterogeneity meant that meta-analysis was not performed. 
However, the researchers did not explore possible reasons for heterogeneity. 
Overall, the evidence on the efficacy and safety of CHM for chronic urticaria from current 
modern literature is lacking. SRs based on comprehensive searches and rigorous 
methodology are required to provide solid evidence. The objective of this SR is to evaluate 
the efficacy and safety of CHM alone for chronic urticaria using rigorous methods. 
6.2 Methods 
The methods for SR of CHM for chronic urticaria were described in Chapter 5. This review 
has been registered in PROSPERO (CRD42015027764). 
6.3 Results 
Extensive database searches revealed 7,631 potentially relevant citations. After removing 
duplicates, 5,666 records were screened and full texts of 1,925 were retrieved (see Figure 6.1). 
Twenty-six RCTs met the inclusion criteria. All studies were conducted in China and 
published in Chinese journals between 2002 and 2015. Two studies adopted a three-arm 
design (99, 100) and the remaining studies used a two-arm parallel design. In total, 2,761 
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patients with chronic urticaria were recruited from the outpatient or inpatient departments of 
hospitals. The sample size of included studies ranged from 55 (101) to 400 (102). Participants’ 
age ranged from six to 70 years (see Table 6.1). Median treatment duration was four weeks, 
with treatments ranging from 10 days (103) to three months (102). Follow-up assessment was 
mentioned in 19 studies, which ranged from four weeks to one year (see Table 6.1). All 
studies except one reported the number of participants suffering relapse (104). 
6.3.1 Intervention and Co-intervention/Comparator 
CHM were administrated orally as decoction in 21 studies, as granules in three studies (103, 
105, 106), as capsules in one study (107) and one study (108) did not report the preparation 
type (see Table 1). Although CHM formulae were diverse across the studies (see Table 6.2), 
the most frequently used herbs were fang feng 防风  (Saposhnikovia divaricata [Turcz.] 
Schischk.) (19 studies), gan cao 甘草 (Gycyrrhiza spp) (17 studies), dang gui 当归 (Angelica 
sinensis [Oliv.] Diels.) (13 studies), huang qi 黄芪 (Astragalus membranaceus [Fisch.]) (13 
studies) and jing jie 荆芥  (Schizonepeta tenuifolia Briq.) (13 studies). All studies used 
second-generation H1-antihistamines as the comparator, most commonly cetirizine, 
levocetirizine or loratadine. Oral administration of antihistamines was administered in 
dosages of five milligrams (mg) or 10 mg daily. 
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Figure 6.1: PRISMA Flow Chart of Study Selection Process: Chinese Herbal Medicine v. 
Second-Generation Antihistamines for Chronic Urticaria 
Notes: CHM: Chinese herbal medicine; RCT: randomised controlled trial 
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Table 6.1: Characteristics of Included Randomised Controlled Trials: Chinese Herbal Medicine v. Antihistamines for Chronic Urticaria 
First 
author, 
publication 
year 
Blinding; 
number 
of arms 
Treatment 
duration; 
follow-up 
duration 
Duration of 
condition 
(mean [SD] 
or range) 
No. of 
participants 
randomised/
assessed; 
dropouts  
Age (mean (SD) 
or range); 
gender (M/F) 
Intervention  Control  Adverse 
events 
Bian XL 
2006 (107) 
NS; 2  4 w; 3 m–
6m  
I: 5.21 y I: 54/54; 0 I: 41.5 y; 32/22 Dan long zhi yang 
jiao nang (capsule): 
capsule; four 
capsules, three times 
daily 
Cetirizine: 10 mg 
qd, po 
NS 
 
C: 4.83 y C: 30/30; 0 C: 42 y; 18/12 
Chen H 
2009 (109) 
NS; 2 4 w; 6 m–
1.5y 
I: 5 m–12 y 
 
I: 41/41; 0 I: 29.6 (3.2) y; 
17/24 
Gui zhi tang 
(modified): 
decoction; twice 
daily 
Loratadine: 
adults, 10 mg qd, 
po; children 
(age<12), 5 mg 
qd, po 
NS 
C: 4 m–10 y C: 37/37; 0 C: 30.4 (2.8) y; 
16/21 
Chen XJ 
2009 (101) 
NS; 2  4 w; NS Total: 1–3 y I: 35/35; 0 Total: 18–65 y; 
23/32 
Dang gui yin zi 
(modified): 
decoction; twice 
daily 
Desloratadine 
dispersible 
tablets: 5 mg qd, 
po 
NS 
C: 20/20; 0 
Huang N 
2011 (110) 
NS; 2  4 w; 8 w I: 5 y I: 63/63; 0 I: 42 y (14–63 
y); 42/21 
Qu shi hua zhi jie du 
tang: decoction; 
three times daily 
Levocetirizine: 5 
mg daily 
None 
C: 6.5 y C: 63/63; 0 C: 40.5 y (13–59 
y); 38/25 
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First 
author, 
publication 
year 
Blinding; 
number 
of arms 
Treatment 
duration; 
follow-up 
duration 
Duration of 
condition 
(mean [SD] 
or range) 
No. of 
participants 
randomised/
assessed; 
dropouts  
Age (mean (SD) 
or range); 
gender (M/F) 
Intervention  Control  Adverse 
events 
Jin RJ 2006 
(111) 
NS; 2  4 w; 12 w I: 8.2 m I: 46/46; 0 I: 12–35 y; 
22/24 
Wu wei zi tang: 
decoction; twice 
daily 
Loratadine 
tablets: 10 mg qn 
I: diarrhoea 
(4), sick (1) 
C: 8.6 m C: 40/40; 0 C: 12–40 y; 
25/15 
C: 
somnolence 
(1), 
hyperphagia 
(1), 
dizziness 
and tired (1) 
Kong DY 
2015 (105) 
NS; 2  4 w; 4 w I: 1.04 (0.4) 
y 
I: 64/64; 0 I: 26.8 (8.5) y; 
33/31 
Yu ping feng san 
(modified): granule; 
twice daily 
Levocetirizine 
dihydrochloride: 
5 mg daily 
I: gastro 
discomfort 
(1), 
somnolence 
(2) 
C: 1.05 
(0.8) y 
C: 64/64; 0 C: 27.2 (6.5) y; 
32/32 
C: dizziness 
(5), 
somnolence 
(3)  
Li AJ 2012 
(112) 
NS; 2  4 w; 1 y I: 6 m–4 y I: 40/40; 0 I: 23.5 (3.5) y; 
18/22 
Ma huang fu zi xi xin 
tang (modified): 
decoction; twice 
daily 
Loratadine: 10 
mg qd, po  
NS 
 
C: 7 m–5 y C: 36/36; 0 C: 24.7 (2.9) y; 
16/20 
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First 
author, 
publication 
year 
Blinding; 
number 
of arms 
Treatment 
duration; 
follow-up 
duration 
Duration of 
condition 
(mean [SD] 
or range) 
No. of 
participants 
randomised/
assessed; 
dropouts  
Age (mean (SD) 
or range); 
gender (M/F) 
Intervention  Control  Adverse 
events 
Li JY 2009 
(103) 
NS; 2  10-40 d; 6 
m  
I: 11.3 m I: 130/130; 0 I: 33.4 y (12–59 
y); 63/67 
Kang guo min ke li 
(granule): granule; 
30 g, twice daily 
Cetirizine 
hydrochloride: 10 
mg qd, po  
NS 
C: 9.3 m C: 66/66; 0 C: 36.5 y (15–53 
y); 30/36 
Li YB 2013 
(102) 
NS; 2  3 m; NS I: 9 m–15 y I: 300/300; 0 I: 7–58 y; 
183/117 
Man xun yin: 
decoction; three 
times daily 
Loratadine: one 
tablet qd, po  
NS 
C: 6 m–13 y C: 100/100; 0 C: 6–57 y; 61/39 
Luo B 2006 
(106) 
NS; 2  30 d; 3 m I: 24.6 
(41.4) m 
I: 80/80; 0 I: 32.1 (17.2) y; 
28/52 
Xiao feng zhi yang 
ke li (granule): 
granule; 12g each 
time, three times 
daily 
Loratadine: 10 
mg qn 
 
I: mild 
diarrhoea (5)  
C: 23.5 
(48.1) m 
C: 80/80; 0 C: 31.6 (15.4) y; 
23/57 
C: tired (13), 
thirsty (4) 
Luo MY 
2006 (113) 
NS; 2  4 w; 3 m I: 6.35 m I: 42/42; 0 I: 35.2 y (12 y–
58 y); 14/28 
Kang xun tang: 
decoction; three 
times daily 
 
Mizolastine: 10 
mg daily 
I: none 
C: 6.26 m C: 38/38; 0 C: 35.7 y (13y–
57 y); 11/27 
C: 
somnolence 
(3), 
dizziness 
and tired (2), 
thirsty (2) 
  
91 
 
First 
author, 
publication 
year 
Blinding; 
number 
of arms 
Treatment 
duration; 
follow-up 
duration 
Duration of 
condition 
(mean [SD] 
or range) 
No. of 
participants 
randomised/
assessed; 
dropouts  
Age (mean (SD) 
or range); 
gender (M/F) 
Intervention  Control  Adverse 
events 
Shi CR 
2013 (99) 
NS; 3  28 d; 3 m, 6 
m 
I: 1.60 
(0.56) y 
I: 25/21; 4 I: 34.14 (12.64) 
y; 13/12 
Dang gui yin zi: 
decoction; twice 
daily 
C1: Cetirizine 
hydrochloride: 10 
mg daily 
C2: Dang gui yin 
zi; cetirizine 
hydrochloride 
I: diarrhoea 
(2) 
C1: 1.50 
(0.62) y 
C1: 25/24; 1 C1: 36.63 
(13.98) y; 12/13 
C1: 
dizziness 
(1), 
somnolence 
(1) 
C2: 1.80 
(0.45) y 
C2: 25/22; 3 C2: 35.37 
(13.54) y; 11/14 
C2: none 
Wang HL 
2010 (104) 
NS; 2  36 d; 6 m I: 3.1 y I: 60/60; 0 I: 36 y (16–62 
y); 34/26 
Ma huang lian qiao 
chi xiao dou tang: 
decoction; twice 
daily 
Cetirizine: 10 mg 
qd, po 
NS 
C: 2.9 y C: 30/30; 0 C: 34 y (14–66 
y); 16/14 
 
Wang L 
2006 (115) 
NS; 2  30 d; 3 m I: 3 m–3 y I: 52/52; 0 I: 19–54 y; 
32/20 
Shu feng chu shi 
tang: decoction; 
twice daily 
Loratadine 
tablets: 10 mg qn 
I: diarrhoea 
(10) 
C: 3 m–2.5 
y 
C: 52/52; 0 C: 19–55 y; 
28/24 
C: 
somnolence 
(11), 
hyperphagia 
(12), 
dizziness 
and weak 
(6) 
92 
First 
author, 
publication 
year 
Blinding; 
number 
of arms 
Treatment 
duration; 
follow-up 
duration 
Duration of 
condition 
(mean [SD] 
or range) 
No. of 
participants 
randomised/
assessed; 
dropouts  
Age (mean (SD) 
or range); 
gender (M/F) 
Intervention  Control  Adverse 
events 
Wo LY 
2008 (116) 
NS; 2 1 m; NS I: 2–36 m I: 56/56; 0 I: 11–58 y; 
24/32 
Investigator-
designed formula 
Ping min jian 
(modified): 
decoction; NS 
Cetirizine 
hydrochloride: 10 
mg daily 
NS 
C: 2–38 m C: 44/44; 0 C: 13–57 y; 
15/29 
Wu H 2003 
(114) 
NS; 2  8 w; NS Total: 13m–
6 y 
I: 40/40; 0 Total: 44 y (23–
65 y); 28/52 
Yu ping feng guo 
min jian: decoction; 
twice daily 
Cetirizine 
hydrochloride: 10 
mg qd, po 
NS 
Xiao HL 
2002 (117) 
NS; 2  4 w; 3 m NS 
 
I: 30/30; 0 I: NS; 12/18 Dang gui yin zi: 
decoction; twice 
daily  
Loratadine: 10 
mg qd, po 
NS 
C: 30/30; 0 C: NS; 15/15 
Xue CL 
2009 (100) 
NS; 3  30 d; NS I: 4.58 y I: 43/43; 0 I: 24.25 y (8–53) 
y; 20/23 
Kang man min jian: 
decoction; 150 ml, 
three times daily 
C1: Cetirizine: 10 
mg, three times 
daily 
C2: Kang man 
min jian; 
cetirizine 
NS 
C1: 3.36 y C1: 45/45; 0 C1: 22.16 y (11–
49) y; 23/22 
C2: 5.24 y C2: 51/51; 0  
 
C2: 23.74 y (13–
57) y; 23/28 
Yan X 
2009 (118)  
NS; 2 6 w; 6 w I: 2.77 (1.4) 
y 
I: 34/34; 0 I: 36.87 (12.98) 
y; 11/23 
Xiao xun fang: 
decoction; twice 
daily 
Loratadine: one 
tablet daily 
I: NS  
C: 2.69 
(1.32) y 
C: 34/34; 0 C: 37.33 (15.56) 
y; 9/25 
C: 
somnolence, 
thirst, sick, 
anepithymia 
(NS)  
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First 
author, 
publication 
year 
Blinding; 
number 
of arms 
Treatment 
duration; 
follow-up 
duration 
Duration of 
condition 
(mean [SD] 
or range) 
No. of 
participants 
randomised/
assessed; 
dropouts  
Age (mean (SD) 
or range); 
gender (M/F) 
Intervention  Control  Adverse 
events 
Yang GH 
2012 (120)     
NS; 2 2 w; NS I: 2 m–12 y I: 36/36; 0 I: 18–70 y; 
16/20 
Yang zhen tang: 
decoction; twice 
daily 
Cetirizine or 
Mizolastine 
Sustained-release 
Tablets: 10 mg 
daily 
I: none 
C: 2.4 m– 
11 y 
C: 36/36; 0 C: 20–69 y; 
15/21 
C: dry 
mouth, 
constipation 
(NS)  
Yang SR 
2014 (121) 
NS; 2  4 w; 1 m NS 
 
I: 36/36; 0 I: 39.4 (12.1) y; 
17/19 
Ma xing shi gan tang 
(modified): 
decoction; twice 
daily 
Levocetirizine 
dihydrochloride 
drops: 10 mg qn 
NS 
C: 32/32; 0 C: 38.2 (11.6) y; 
16/16 
Yu GH 
2009 (119) 
NS; 2 1 m; NS I: 2 m–36 m I: 52/52; 0 I: 11–58 y; 
22/30 
Investigator-
designed formula 
Ping min jian 
(modified): 
decoction; three 
times daily 
Cetirizine 
hydrochloride: 10 
mg daily 
NS 
C: 2 m–38 
m 
C: 44/44; 0 C: 13–57 y; 
15/29 
Zhang BX 
2013 (123) 
NS; 2 4 w; 4 w I: 7 w–4.5 y I: 42/42; 0 I: 18–68 y; 
17/25 
Mang huang lian 
qiao chi xiao dou 
tang plus Dang gui 
yin zi (modified): 
decoction; 300 ml 
twice daily 
Levocetirizine 
dihydrochloride: 
5 mg daily 
I: loose stool 
(1) 
C: 8 w–5.3 
y 
C: 35/35; 0 C:20–66 y; 
16/19 
C: 
somnolence, 
dry mouth 
(NS) 
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First 
author, 
publication 
year 
Blinding; 
number 
of arms 
Treatment 
duration; 
follow-up 
duration 
Duration of 
condition 
(mean [SD] 
or range) 
No. of 
participants 
randomised/
assessed; 
dropouts  
Age (mean (SD) 
or range); 
gender (M/F) 
Intervention  Control  Adverse 
events 
Zhang CJ 
2011 (108) 
NS; 2 4 w; 6 m NS I: 76/76; 0 I: NS; NS Shu gan huo xue qu 
feng fang: NS; NS  
Levocetirizine 
dihydrochloride: 
5 mg daily 
I: none 
C: 67/67; 0 C: NS; NS C: dizziness 
and 
headache 
(2), thirsty 
and tired (1) 
Zhang EH 
2007 (122) 
NS; 2 4 w; 8 w I: 1.70 
(2.59) y 
I: 30/30; 0 I: 36.87 (12.98) 
y; 8/22 
Guo min jian 
(modified): 
decoction; twice 
daily 
Cetirizine 
hydrochloride: 10 
mg qd 
I: sick (1)  
C: 1.73 
(2.05) y 
C: 30/30; 0 C: 37.33 (15.56) 
y; 11/19 
C: 
somnolence 
(3), thirsty 
(1), sick (1), 
poor 
appetite (1) 
Zhu WR 
2011 (124) 
NS; 2 4 w; 1 m  I: 2–64 m I: 30/30; 0 I: 19–60 y; 
11/19 
Di shen qu feng he ji 
(mixture): 
decoction;150 ml bid 
Loratadine: 10 
mg qn 
None  
C: 2–60 m C: 30/30; 0 C: 20–62 y; 
14/16 
Notes: C: Control; I: Intervention; m: months; mg: milligram; ml: milliliter; NS: not stated; po: administrated orally; qd: once daily; qn: once per night; tid: three times daily; 
w: weeks, y: years. 
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Table 6.2: Details of Chinese Herbal Medicine Formula: Chinese Herbal Medicine v. Antihistamines for Chronic Urticaria 
First author, 
publication year  
Key ingredients of Chinese herbal medicine 
Bian XL 2006 (107) Dan long zhi yang jiao nang (capsule): he shou wu, bai shao, mu dan pi, di long, quan xie, bai xian pi, and other (NS) 
Chen H 2009 (109) Gui zhi tang modification: huang qi, gui zhi, bai shao, dang gui, sheng jiang, fang feng, mu dan pi, quan xie, da zao, 
zhi gan cao  
Chen XJ 2009 (101) Dang gui yin zi (modified): dang gui, mu dan pi, bai shao, sheng di huang, bai ji li, huang qi, jing jie, fang feng, he 
shou wu, ji xue teng, yu zhu 
Huang N 2011 (110) Qu shi hua zhi jie du tang: fu ping, xu chang qing, wei ling xian, dan shen, ji xue teng, san qi, sheng di huang, tu fu 
ling, bai xian pi, chen pi, hua shi, gan cao 
Jin RJ 2006 (111) Wu wei zi tang: wu wei zi, fang feng, bai zhu, bai shao, huang qi, dang shen, gui zhi, zhi gan cao, sheng jiang, da zao 
Kong DY 2015 (105) Yu ping feng san modification: huang qi, jing jie, dang gui, bai zhu, fang feng, chen pi, fu ling, gui zhi, da fu pi, sang 
bai pi, gan cao 
Li AJ 2012 (112) Ma huang fu zi xi xin tang modification: ma huang, fu zi, xi xin, dang gui, he shou wu  
Li JY 2009 (103) Kang guo min ke li (granule): jing jie, fang feng, huang qin, huang bo, ku shen, bai xian pi, zi cao, di fu zi, chan tui, 
bai zhu, gan cao 
Li YB 2013 (102) Man xun yin: huang qi, bai xian pi, fang feng, wu wei zi 
Luo B 2006 (106) Xiao feng zhi yang ke li : huang qi, fang feng, jing jie, mu dan pi, bai ji li, fu ping, bai zhu, yin chai hu, zi cao, zhi gan 
cao and other (NS) 
Luo MY 2006 (113) Kang xun fang: sheng di huang, bai shao, dang gui, chuan xiong, jing jie, fang feng, he shou wu, bai ji li, gan cao   
Shi CR 2013 (99) Dang gui yin zi: dang gui, bai shao, chuan xiong, sheng di huang, bai ji li, fang feng, jing jie, he shou wu, huang qi, 
zhi gan cao  
Wang HL 2010 (104) Ma huang lian qiao chi xiao dou tang: ma huang, lian qiao, xing ren, sang bai pi, sheng jiang, chi xiao dou, zhi gan 
cao, da zao  
Wang L 2006 (115) Shu feng chu shi tang: jing jie, fang feng, yi yi ren, zhi ke, bai zhu, huang bo, sang ye, xu chang qing, sheng di huang, 
yin chen, gan cao 
Wo LY 2008 (116) Self-designed Ping min jian modification: long gu, mu li, he shou wu, chai hu, fang feng, jing jie, bai xian pi, jiang 
can, zhi ke, fu ping, wu mei, wu wei zi, mu dan pi, di gu pi, dang gui 
Wu H 2003 (114) Yu ping feng guo min jian: huang qi, bai zhu, fang feng, wu mei, wu wei zi, yin chai hu, zhi gan cao  
Xiao HL 2002 (117) Dang gui yin zi: dang gui, bai shao, chuan xiong, sheng di huang, bai ji li, fang feng, jing jie, he shou wu, huang qi, 
gan cao  
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First author, 
publication year  
Key ingredients of Chinese herbal medicine 
Xue CL 2009 (100) Kang man min jian: chai hu, bai shao, fang feng, chan tui, di long, bai xian pi, tu fu ling, lian qiao, mu dan pi, huang 
qi, dang shen, bai zhu, dang gui, gan cao  
Yan X 2009 (118) Xiao xun fang: gui zhi, bai shao, di fu zi, sang bai pi, di gu pi, bai zhu, chi shao, gan cao  
Yang GH 2012 (120) Yang zhen tang: sheng di huang, dang gui, bai shao, sang ji sheng, chuan xiong, jing jie, fang feng, cang zhu, ku 
shen, zhi mu, niu bang zi, chan tui, gan cao  
Yang SR 2014 (121) Ma xing shi gan tang modification: ma huang, xing ren, shi gao, gan cao, shui niu jiao, xiao hong shen, bai xian pi, 
di fu zi, sheng di huang, mu dan pi, jiu li guang, bai hua she she cao  
Yu GH 2009 (119) Ping min jian modification: long gu, mu li, he shou wu, chai hu, fang feng, jing jie, bai xian pi, jiang can, zhi ke, fu 
ping, wu mei, wu wei zi, mu dan pi, di gu pi, dang gui 
Zhang BX 2013 (123) Ma huang lian qiao chi xiao dou tang plus modified Dang gui yin zi: ma huang, lian qiao, he shou wu, bai ji li, sang 
bai pi, sheng di huang, di gu pi, fu ling pi, chi xiao dou, fang feng, jing jie, huang qi, dang gui, chi shao, zhi zi, da 
qing ye, bai zhu, chan tui, bian dou yi, chuan xiong  
Zhang CJ 2011(108) Shu gan huo xue qu feng fang: chai hu, dang gui, chi shao, hong hua, bai zhu, chen pi, fang feng, jiang can, bai ji li, 
he huan pi  
Zhang EH 2007 (122) Guo min jian modification: jing jie, fang feng, yin chai hu, wu wei zi, wu mei, huang qi, bai zhu, huang qin, gan cao  
Zhu WR 2011 (124) Di shen qu feng he ji: sheng di huang, ku shen, cang er zi, and other (NS) 
Notes: NS: not stated 
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6.3.2 Outcome Measures 
One study (99) used UAS to assess disease activity, reporting the change in UAS rather than 
the actual score. Another study (121) used a modified UAS as an outcome measure, which 
added the diameter of wheals into the UAS scoring system. All studies reported on ER, which 
was calculated using two approaches (see Chapter 5). Eleven studies reported ER 30 (100–
104, 107, 109, 112, 114, 117, 120), while 15 reported SSRI 30 (99, 105, 106, 108, 110, 111, 
113, 115, 116, 118, 119, 121–124). Relapse rate based on ER 30 was reported in three studies 
(103, 107, 117). None of the included studies assessed participants’ HR-QoL. 
6.3.3 Risk of Bias Assessment 
While all studies claimed to be randomised, only five (99, 108, 112, 121, 124) described the 
methods for random sequence generation. Four of them used random number tables (108, 121, 
124) or computer software (99), and these four studies (99, 108, 121, 124) were assessed as 
low risk for sequence generation (see Table 6.3). One study (112) was deemed high risk due 
to its use of consultation date to allocate participants. The remaining studies were assessed as 
posing an unclear risk due to lack of description for sequence generation. In terms of 
allocation concealment, one study (112) was considered high risk. The treatments in this 
study were predictable because visiting date was used to allocate participants. No detailed 
information of allocation concealment was provided for the remaining studies and all were 
judged as unclear risk. None of the studies used methods to blind participants and personnel 
to group allocation. Therefore, all studies were deemed high risk. All studies were judged as 
posing an unclear risk in terms of blinding of outcome assessors due to lack of information 
(see Table 6.3). One study (99) reported dropouts with reasons, and the numbers of dropouts 
was balanced between groups. There were no dropouts for the remaining studies. Therefore, 
the risk of bias for incomplete outcome data was assessed as low. All studies were considered 
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to pose an unclear risk in terms of selective outcome reporting due to lack of protocols or trial 
registration (see Table 6.3).  
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Table 6.3: Risk of Bias Assessment Results: Chinese Herbal Medicine v. Antihistamines for Chronic Urticaria 
First author, 
publication year 
Sequence 
generation 
Allocation 
concealment 
Blinding of 
participants 
Blinding of 
personnel 
Blinding of 
outcome 
assessors 
Incomplete 
outcome data 
Selective 
outcome 
reporting 
Bian XL 2006 (107) Unclear Unclear High risk  High risk  Unclear Low risk Unclear 
Chen H 2009 (109) Unclear Unclear High risk High risk Unclear Low risk Unclear 
Chen XJ 2009 (101) Unclear Unclear High risk High risk Unclear Low risk Unclear 
Huang N 2011(110) Unclear Unclear High risk High risk Unclear Low risk Unclear 
Jin RJ 2006 (111) Unclear Unclear High risk High risk Unclear Low risk Unclear 
Kong DY 2015 (105) Unclear Unclear High risk High risk Unclear Low risk Unclear 
Li AJ 2012 (112) High risk High risk High risk High risk Unclear Low risk Unclear 
Li JY 2009 (103) Unclear Unclear High risk High risk Unclear Low risk Unclear 
Li YB 2013 (102) Unclear Unclear High risk High risk Unclear Low risk Unclear 
Luo B 2006 (106) Unclear Unclear High risk High risk Unclear Low risk Unclear 
Luo MY 2006 (113) Unclear Unclear High risk High risk Unclear Low risk Unclear 
Shi CR 2013 (99) Low risk Unclear High risk  High risk  Unclear Low risk  Unclear 
Wang HL 2010 (104) Unclear Unclear High risk High risk Unclear Low risk Unclear 
Wang L 2006 (115) Unclear Unclear High risk High risk Unclear Low risk Unclear 
Wo LY 2008 (116) Unclear Unclear High risk High risk Unclear Low risk Unclear 
Wu H 2003 (114) Unclear Unclear High risk High risk Unclear Low risk Unclear 
Xiao HL 2002 (117) Unclear Unclear High risk High risk Unclear Low risk Unclear 
Xue CL 2009 (100) Unclear Unclear High risk  High risk  Unclear Low risk  Unclear 
Yan X 2009 (118) Unclear Unclear High risk High risk Unclear Low risk Unclear 
Yang GH 2012 (120) Unclear Unclear High risk High risk Unclear Low risk Unclear 
Yang SR 2014 (121) Low risk Unclear High risk High risk Unclear Low risk Unclear 
Yu GH 2009 (119) Unclear Unclear High risk High risk Unclear Low risk Unclear 
Zhang BX 2013 (123) Unclear Unclear High risk High risk Unclear Low risk Unclear 
Zhang CJ 2011 (108) Low risk Unclear High risk High risk Unclear Low risk Unclear 
Zhang EH 2007 (122) Unclear Unclear High risk High risk Unclear Low risk Unclear 
Zhu WR 2011 (124) Low risk Unclear High risk High risk Unclear Low risk Unclear 
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6.3.4 Effects of the Intervention 
Urticaria Activity Score 
Two studies reported on UAS (99, 121). One study reported UAS percentage score change from 
baseline (99), which differs from the prescribed use of the outcome measure. The difference 
between groups was not statistically different (MD: -0.13 [-0.84, 0.58]). The other (121) found 
no difference between CHM and levocetirizine (MD: -0.77 [-1.64, 0.10]) in terms of modified 
UAS score at the end of treatment. 
Effective Rate 30 
The pooled data of 11 studies (100–104, 107, 109, 112, 114, 117, 120) showed that CHM was 
superior to antihistamines in improving symptoms by 30% or more (RR: 1.21 [1.15, 1.29], 
I
2
=0%) (see Figure 6.2). One CHM formula (Dang gui yin zi) was used in two studies (101, 117) 
and analysis found no significant difference between groups (RR: 1.18 [0.93, 1.50], I
2
 = 49%) 
(see Figure 6.2). 
Symptom Severity Reduction Index 30 
Meta-analysis of 15 studies (99, 105, 106, 108, 110, 111, 113, 115, 116, 118, 119, 121–124) 
found significant improvement in favour of CHM when compared with antihistamines (RR: 1.18 
[1.07, 1.29], I
2 
= 72%) (see Figure 6.3). Statistical heterogeneity was detected, which was 
explored by sensitivity and subgroup analyses. When only studies assessed as having a low risk 
of bias for sequence generation were included (99, 108, 121, 124), statistical heterogeneity 
reduced (I
2 
= 61%), although the treatment effect was no longer significant (RR: 1.12 [0.91, 
1.39]). 
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Subgroup group analysis according to comparator types found significant difference when 
comparing CHM to levocetirizine (RR: 1.32 [1.20, 1.45], I
2 
= 0%) (105, 108, 110, 121, 123) and 
no difference for loratadine (RR: 1.07 [1.00, 1.14]; I
2 
= 0%) (106, 111, 115, 118, 124), with low 
statistical heterogeneity (see Figure 6.3). No benefit was observed for CHM compared with 
cetirizine (RR: 1.36 [0.94, 1.97], I
2 
= 80%) (99, 116, 119, 122), but statistical heterogeneity was 
considerable (see Figure 2.2). One investigator-designed CHM formula, Ping min jian 
(modified), was used in two studies (116, 119), with no difference found (RR: 1.39 [0.94, 2.05], 
I
2 
= 86%). Considerable heterogeneity was detected, which could not be explored due to the 
small number of studies. 
Relapse Rate 
The pooled data of three studies suggested that CHM reduced the risk of relapse compared with 
antihistamines (RR: 0.31 [0.16, 0.63], I
2 
= 22%) (103, 107, 117). 
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Figure 6.2: Effect Size Analysis Results of Chinese Herbal Medicine v. Second-Generation 
Antihistamines for Chronic Urticaria: ER 30 
Notes: CHM: Chinese herbal medicine; ER 30: effective rate based on Chinese Medicine guideline 
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Figure 6.3: Effect Size Analysis Results of Chinese Herbal Medicine v. Second-Generation 
Antihistamines for Chronic Urticaria: SSRI 30 
Notes: CHM: Chinese herbal medicine; SSRI 30: effective rate based on Symptom Severity Reduction Index
6.3.5 Adverse Events 
Thirteen studies (99, 105, 106, 108, 110, 111, 113, 115, 118, 120, 122–124) reported on adverse 
events (AEs), with two reporting no AEs (110, 124). In the remaining studies, 29 AEs were 
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reported in the CHM groups and 77 AEs in antihistamines groups. The AEs that occurred in the 
CHM groups included diarrhoea (21 cases), somnolence (five cases), nausea (two cases) and 
gastrointestinal discomfort (one case). In the antihistamines groups, the most commonly 
observed AE was somnolence (22 cases). Other AEs involved weakness (13 cases), hyperphagia 
(12 cases), dizziness and weakness (nine cases), thirst (nine cases), dizziness (six cases), 
dizziness and headache (two cases), nausea (two cases), poor appetite (one case) and loose stool 
(one case). 
6.3.6 Publication Bias 
The funnel plot for ER 30 (11 studies) was symmetrical (see Figure 6.4), which suggests a low 
risk of publication bias. Potential bias should be noted for SSRI 30 (15 studies) and relapse rate 
based on SSRI 90 (11 studies). This is illustrated in the funnel plot, with a slight asymmetrical 
distribution of the studies (see Figure 6.5). 
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Figure 6.4: Funnel Plot of Chinese Herbal Medicine v. Antihistamines for Chronic 
Urticaria: ER 30 
Notes: CHM: Chinese herbal medicine; ER 30: effective rate based on Chinese medicine guideline 
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Figure 6.5: Funnel Plot of SSRI 30 (Chinese Herbal Medicine v. Antihistamines for 
Chronic Urticaria) 
Notes: CHM: Chinese herbal medicine; SSRI 30: effective rate based on Symptom Severity Reduction Index   
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6.4 Discussion 
Meta-analysis indicated that CHM increased the chance of achieving improvement in wheals and 
pruritus compared with second-generation antihistamines. Studies reporting on ER 30 were 
homogenous, while those reporting on SSRI 30 were heterogeneous. The heterogeneity was 
reduced somewhat through sensitivity and subgroup analyses. The source of heterogeneity may 
be attributed to selection bias and antihistamine use. When sensitivity analysis was conducted 
using studies with low risk of bias for sequence generation, heterogeneity reduced. Further, 
heterogeneity decreased dramatically when subgroup analysis was performed by antihistamine 
type. It was noted that the heterogeneity was 80% for the subgroup comparing CHM with 
cetirizine, despite consistency in dosage and frequency. The reason for heterogeneity was still 
unclear. 
In addition, the effectiveness threshold of SSRI was not consistent across studies. Some studies 
reported a 20% improvement in symptoms, some reported a 25% improvement, while others 
cited a 30% improvement. To ensure uniformity in outcomes, only data that reported an 
improvement rate of 30% or more were pooled for analysis. This meant that for studies reporting 
a 20% change, only data for the next tier (for example, 60% improvement) were included. This 
may have contributed to statistical heterogeneity in the meta-analysis. However, when additional 
subgroup analysis was performed according to tier, heterogeneity was not reduced (data not 
presented). 
As data for studies reporting on the same outcome were pooled regardless of CHM formula used, 
it was reassuring to observe that statistical heterogeneity was low for many analyses. When 
individual formulae were examined in meta-analysis, Dang gui yin zi 当归饮子 and Ping min 
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jian 平 敏 煎  modification failed to demonstrate benefit, with considerable statistical 
heterogeneity. This may be due to the small sample size of included studies, although a lack of 
benefit for these formulae cannot be ruled out. 
Only one study used UAS (99), and no difference was found between groups in terms of score 
change. Another study used modified UAS (121) to evaluate the effect but did not discover a 
significant difference. There is a clear need for well-designed RCTs that report on validated 
outcome measures such as the UAS. 
The number of AEs in participants who received CHM was lower than in those who received 
antihistamines. The high number of cases of somnolence with antihistamines was surprising, as 
second-generation antihistamines are not considered to have sedating effects. Most AEs in CHM 
groups were gastrointestinal symptoms, which has been observed in other health conditions 
(125). Based on the studies that reported this outcome, CHM was well tolerated by patients with 
chronic urticaria. 
The most frequently reported herbs in CHM formulae included in the studies appear to have anti-
inflammatory, anti-allergenic and antipruritic actions. Inhibition of inflammatory mediator nitric 
oxide (NO) has been found in murine macrophage RAW 264.7 cells with fang feng 防风 
(Saposhnikovia divaricata [Turcz.] Schischk) (126), gan cao 甘草 (Glycyrrhiza spp) (127) and 
dang gui 当归 (Angelica sinensis [Oliv.] Diels) (128). Pro-inflammatory cytokines tumour 
necrosis factor (TNF)-α and interleukin-6 (IL-6) have also been reduced by fang feng 防风 (126), 
gan cao 甘草 (127), dang gui 当归 (128), jing jie 荆芥 (Schizonepeta tenuifolia Briq.) (129), 
and huang qi 黄芪 (Astragalus membranaceus [Fisch] Bge.) (130). Gan cao 甘草, huang qi 黄
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芪 and jing jie 荆芥 inhibited histamine levels and histamine release in RBL-2H3 cell line and 
rat peritoneal mast cells (131), in rats with haemorrhagic shock (132) and in a rat model (133). 
Scratch behaviour was inhibited with gan cao 甘草 (131) and jing jie 荆芥 (134). The anti-
inflammatory, anti-allergenic and antipruritic actions of these herbs are likely to contribute to the 
clinical effect observed in this review. 
6.4.1 Limitations and Implications for Research and Clinical Practice 
The methodological issues of included studies must be carefully considered for these findings. 
Only four studies described detailed and appropriate methods of sequence generation, despite all 
studies claiming to be RCTs. Potential selection bias may exist since the generation of a 
randomised sequence might be inadequate for most studies. Outcome assessment might be less 
reliable due to insufficient information of blinding (89). Moreover, most studies had small 
sample sizes. Randomised, double-blinded, placebo-controlled trials with large sample sizes are 
necessary to verify the treatment effect of CHM for chronic urticaria. 
UAS was used in two studies, but was modified or calculated differently from prescribed use. 
The outcomes (ER 30 and SSRI 30) were commonly used in the included studies. Although these 
two outcomes evaluated the disease activity of the two main urticaria symptoms (wheals and 
pruritus) and reflected the clinical focus, they are not recognised internationally and have not 
been validated. This limits the findings’ comparability with other international studies. Validated 
outcomes should be introduced into future clinical trials to evaluate the efficacy of CHM for 
chronic urticaria. 
110 
None of the included studies assessed participants’ HR-QoL. This is an important outcome for 
which validated measures are available and should be included in future trials. The challenge of 
chronic urticaria is to achieve effective control to prevent recurrence of symptoms. Relapse rates 
were reported by several studies. However, the definition of relapse rate varied. Greater 
consistency is needed to examine the potential long-term benefits of CHM for chronic urticaria. 
In clinical practice, CHM formula is prescribed based on CM syndrome type, ensuring 
individualised treatment. Few studies included in this review reported information related to 
syndrome types and meta-analysis could not be performed according to syndrome. The findings 
from this review may not reflect the clinical efficacy of CHM when used according to CM 
principles and may introduce potential clinical heterogeneity. Further, clinical trials that consider 
syndrome type in study design and analysis may provide results that are more reflective of 
clinical practice. 
6.5 Conclusion 
Considering the limitations mentioned above, the findings from this review suggest that CHM 
can improve symptoms of chronic urticaria (based on ER 30) when compared with second-
generation antihistamines. However, the methodological flaws of included studies and lack of 
validated outcome measures limit the certainty of these findings. CHM appears to be well 
tolerated by patients with chronic urticaria, as illustrated by the low number of AEs reported in 
the included studies. Future research following rigorous study design with validated outcomes is 
needed to provide robust evidence. 
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Chapter 7. Systematic Review 2: 
Chinese Herbal Medicine as Add-on Therapy for Chronic Urticaria 
7.1 Introduction  
For people with chronic urticaria, CHM is a treatment option commonly used in clinical practice 
in China. Chapter 6 evaluated the evidence of CHM alone for chronic urticaria when compared 
with second-generation antihistamines. CHM is also commonly used in combination with 
conventional treatments. To date, no SRs were identified that evaluated the additional benefits of 
adding CHM to conventional therapy. The objective of this SR is to evaluate the efficacy and 
safety of CHM as an add-on therapy to second-generation antihistamines for chronic urticaria. 
7.2 Method 
The methods for SR of CHM for chronic urticaria were described in Chapter 5. This review has 
been registered in PROSPERO (CRD42015027765). 
7.3 Results 
Extensive database searches retrieved 7,631 potentially relevant citations. After removing 
duplicates, 5,666 records were screened and full texts of 1,925 were identified (see Figure 7.1). 
Seventy-four RCTs met the inclusion criteria and were included in this review. Four were 
excluded from meta-analysis due to a lack of usable data (135–138). All studies were conducted 
in China. They were published between 2004 and 2015 in Chinese except for two published in 
English (138, 139). Two-arm parallel design was applied for most studies and eight studies 
include three or more arms (99, 100, 135, 140–144). Blinding was only described in one study 
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(138), with participants, researchers and outcome assessors being blinded to group allocation 
(see Table 7.1). 
In total, 7,497 patients with chronic urticaria from outpatient or inpatient departments of 
hospitals were recruited in the included studies. The sample size of included studies ranged from 
37 (145) to 360 (140). Participants’ ages ranged from one (146) to 78 years (147) (see Table 7.1). 
Treatment duration ranged from seven days (148) to 12 weeks (142, 149–151). The most 
common treatment duration was four weeks. Follow-up assessments were mentioned in 51 
studies, ranging from two weeks to 52 weeks after the initial treatment (see Table 7.1). Two 
studies reported the number of participants suffering relapse after achieving a clinical cure for 
the outcome ER 30 (152, 153). 
7.3.1 Intervention and Co-intervention/Comparator 
CHM was administered orally in all studies (see Table 7.1). CHM was used as decoction in 33 
studies, as capsules in 21 studies, as granules in 13 studies, as tablets in five studies and as pills 
in two studies. A variety of CHM formulae and compound products were used in the 74 included 
studies (see Table 7.2). The most frequently used CHM formulae or compound products were 
total glycosides of paeony (from bai shao白芍) 白芍总苷 (10 studies), Yu ping feng san 玉屏风
散  (nine studies), CG (from gan cao 甘草) 复方甘草酸苷  (six studies) and tripterygium 
glycosides (from lei gong teng 雷公藤) 雷公藤多苷 (four studies). The most frequently used 
herbs in the included studies were fang feng 防风 (Saposhnikovia divaricata [Turcz.] Schischk.) 
(35 studies), huang qi 黄芪 (Astragalus membranaceus [Fisch] Bge.) (27 studies), dang gui 当归 
(Angelica sinensis [Oliv.] Diels.) (26 studies), gan cao 甘草 (Glycyrrhiza spp) (25 studies), jing 
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jie 荆芥 (Schizonepeta tenuifolia Briq.) (22 studies) and bai zhu 白术 (Atractylodes 
macrocephala Koidz.) (20 studies). Three herbs used together comprise Yu ping feng san 玉屏风
散: fang feng 防风, huang qi 黄芪 and bai zhu 白术. Most studies adopted a two-arm design and 
used second-generation H1-antihistamines as co-intervention in the intervention group and the 
comparator in the control group. The most commonly used agents were cetirizine, levocetirizine 
or loratadine. Oral administration of antihistamines was in dosages of five mg or 10 mg daily 
(see Table 7.1). The antihistamine agents used as co-intervention were the same as the 
comparator, as were the dosages. A few studies employed two or more control groups, including 
various antihistamines agents or CHM (99, 100, 140–144). The usage of CHM in the control was 
also same as in the intervention group, but these data were not analysed in this SR. 
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Figure 7.1: PRISMA Flow Chart of Study Selection Process: Chinese Herbal Medicine as 
Add-on Therapy v. Second-Generation Antihistamines for Chronic Urticaria 
Notes: CHM: Chinese herbal medicine; RCT: randomised controlled trial 
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Table 7.1: Characteristics of Included Randomised Controlled Trials: Chinese Herbal Medicine as Add-on Therapy v. 
Antihistamines for Chronic Urticaria 
First 
author, 
publication 
year 
Blinding; 
number 
of arms 
Treatment 
duration; 
follow-up 
duration 
Duration of 
condition 
(mean [SD] 
or range) 
No. of 
participants 
randomised/
assessed; 
dropouts  
Age (mean 
[SD] or 
range); 
gender (M/F) 
Intervention Control 
Bai WJ 
2011 (177) 
NS; 2  21 d; 4 w Total: 4.5 y I: 34/34; 0 Total: 31.4 y; 
32/36 
Xiao feng san 
(decoction): bid, po 
Loratadine: 10 mg 
qd, po C: 34/34; 0 
Bao LX 
2008 (176) 
NS; 2  4 w; NS Total: 19.2 
m 
I: 87/87; 0 Total: 36. 3y; 
77/90 
Tripterygium glycosides 
(tablets): 10 mg tid, po 
Desloratadine: five 
mg qd, po C: 80/80; 0 
Chen CS 
2015 (194) 
NS; 2 8 w; 4 w Total: NS I: 42/42; 0 I: 31 (1) y; 
20/22 
Yu ping feng ke li 
(granule): five gm tid, po 
Azelastine 2 mg 
bid, po 
C: 41/41; 0 C: 30 (2) y; 
20/21 
Chen JY 
2014 (181) 
NS; 2 4 w; NS I: 1 y I: 47/47; 0 I: 26 y; 23/24 Xiao yin ke li (granule): 
3.5 g tid, po 
Ebastine: 10 mg 
qd, po C: 1.5 y C: 46/46; 0 C: 28 y; 22/24 
Chen XB 
2011 (145) 
NS; 2  21 d; NS I: 8 m–3 y I: 22/22; 0 I: 25–45; 9/13 Unnamed formula 
(decoction): bid, po; qd, 
topical use (bath) 
Loratadine: 10 mg 
qd, po C: 6 m–2 y C: 15/15; 0 C: 25–45; 8/7 
Cheng Y 
2010 (175) 
NS; 2  4 w; 1 m I: 13.3 m 
 
I: 30/30; 0 I: 8.5 y; NS Ba zhen san plus si wu 
xiao feng san 
(decoction): usage not 
specified 
Loratadine: 2–6 
years old: syrup, 
>6 years old: 
tablets; <2 years 
old:2.5 mg daily; 
2–8 years old: 5 
mg daily; >8 years 
old: 10 mg daily 
C: 13.1 m C: 30/30; 0 C: 7.5 y; NS 
Deng D 
2012 (174) 
NS; 2  4 w; 2 m Total: 2 m-
10 y 
I: 42/42; 0 Total: 18–65 y; 
38/45 
Pi min xiao jiao nang 
(capsule): 4 capsules tid, 
po 
Fexofenadine: 60 
mg bid, po  C: 41/41; 0 
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First 
author, 
publication 
year 
Blinding; 
number 
of arms 
Treatment 
duration; 
follow-up 
duration 
Duration of 
condition 
(mean [SD] 
or range) 
No. of 
participants 
randomised/
assessed; 
dropouts  
Age (mean 
[SD] or 
range); 
gender (M/F) 
Intervention Control 
Ding QY 
2007 (173) 
NS; 2  28 d; NS Total: 1.7 y I: 50/50; 0 Total: 18–70 y; 
56/44 
Run zao zhi yang jiao 
nang (capsule): four 
capsule, tid, po 
Levocetirizine: 10 
mg qd, po C: 50/50; 0 
Feng S 2015 
(195) 
NS; 2 8 w; 6 m I: 15.22 
(21.51) m 
I: 54/52; 2 I: 39.59 
(14.45) y; 
25/29 
Qu feng qing re wei ling 
tang (decoction): bid, po 
Loratadine: 10 mg 
qd, po 
C: 1.39 
(1.45) y 
C: 54/52; 2 C: 38.80 
(14.41) y; 
23/31 
Fu YH 2011 
(141)* 
NS; 4  8 w; 3 m Total: NS I: 30/30; 0 Total: 12–65 y; 
NS 
Fortifying the Spleen and 
nourishing Blood or 
dispelling wind 
(modified decoction): 
bid, po; cetirizine: used 
as control group 1 
C1: Cetirizine: 10 
mg qd, po 
C2: Fortifying the 
Spleen and 
nourishing Blood 
(modified 
decoction): bid, po 
C3: Dispelling 
wind: bid, po 
C1: 30/30; 1 
C2: 30/30; 0 
C3: 30/30; 0 
Guo XY 
2014 (182) 
NS; 2 4 w; NS Total: NS I: 42/42; 0 Total: NS; NS Compound glycyrrhizin 
(tablets): 75 mg, tid, po 
Mizolastine: 10 mg 
qd, po C: 25/25; 0 
Huang SY 
2012 (206) 
NS; 2  7 d; NS  I: 3 m–2.5 y I: 35/35; 0 I: 21–65 y; 
18/17 
Guo min jian 
(decoction): 200 ml tid, 
po 
Cetirizine: 10 mg 
qd, po 
C: 3 m–3 y C: 35/35; 0 C: 20–63 y; 
16/19 
Jiang YP 
2009 (172) 
NS; 2  4 w; 4 w Total: 2 m–
6 y 
I: 76/76; 0 Total: 14-60 y; 
78/62 
Qi feng ke li (granules): 
10 g tid, po  
Cetirizine: 10 mg 
qd, po C: 64/64; 0 
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First 
author, 
publication 
year 
Blinding; 
number 
of arms 
Treatment 
duration; 
follow-up 
duration 
Duration of 
condition 
(mean [SD] 
or range) 
No. of 
participants 
randomised/
assessed; 
dropouts  
Age (mean 
[SD] or 
range); 
gender (M/F) 
Intervention Control 
Jiang YP 
2011 (151) 
NS; 2  12 w; 3 m I: 25.89 
(44.55) m  
I: 43/43; 0 I: 25.44 
(11.25) y; 
20/23 
Compound glycyrrhizin 
(capsule): 50 mg tid, po 
Setastine: one mg 
bid, po 
C: 27.71 
(45.26) m  
C: 37/37; 0 C: 34.53 
(13.26) y; 
20/17 
Jie SH 2014 
(135) 
NS; 3 4 w/12 w; 
52 w 
I1: 1.3 (0.5) 
y 
I1: 50/50; 0 I1: 31.0 (8.9) 
y; 26/24 
I1: Total glycosides of 
paeony (capsule): 600 
mg bid, po for 12 weeks; 
desloratadine: used as per 
control group 
I2: Total glycosides of 
paeony (capsule): 600 
mg bid, po for four 
weeks; desloratadine: 
used as per control 
groups 
Desloratadine: 8.8 
mg qd, po for four 
weeks I2: 1.4(0.4) 
y 
I2: 50/50; 0 I2: 29.0 (7.8) 
y; 25/25 
C: 1.5 (0.5) 
y 
C: 50/50; 0 C: 35.0 (8.7) y; 
24/26 
Leng J 2014 
(136) 
NS; 2 4 w; 4 w Total: 1.5 y I: 50/50; 0 Total: 36y; 
54/46 
Run zao zhi yang jiao 
nang (capsule): four 
capsules tid, po 
Ebastine: 10 mg 
qd, po C: 50/50; 0 
Li CH 2014 
(183) 
NS; 2 4 w; 4 w I: 1.15 
(0.76) y 
I: 61/61; 0 I: 39.36 
(16.89) y; 
28/23 
Yu ping feng ke li 
(granule): five g tid, po 
Cetirizine: 10 mg 
qd, po 
C: 1.08 
(0.48) y 
C: 61/61; 0 C: 36.10 
(15.27) y; 
25/26 
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First 
author, 
publication 
year 
Blinding; 
number 
of arms 
Treatment 
duration; 
follow-up 
duration 
Duration of 
condition 
(mean [SD] 
or range) 
No. of 
participants 
randomised/
assessed; 
dropouts  
Age (mean 
[SD] or 
range); 
gender (M/F) 
Intervention Control 
Li ZL 2013 
(171) 
NS; 2  1 m; 1 m I: 13.5 
(10.6) m 
I: 54/54; 0 I: 32.6 (16.5) 
y; 28/26 
Qing re xiao feng san 
(decoction): 200 ml bid, 
po 
Desloratadine: five 
mg qd, po 
C: 14.3 
(11.2) m 
 
C: 46/46; 0 C: 34.3 (15.7) 
y; 25/21 
Liao C 2014 
(184) 
NS; 2 4 w; 3 m Total: 0.57 
(0.30) y 
I: 58/58; 0 Total: 35.25 
(6.82) y; 50/66 
Yu ping feng ke li 
(granule): 10 g tid, po 
Cetirizine: 10 mg 
bid, po C: 58/58; 0 
Lin YP 2012 
(149) 
NS; 2  12 w; NS I: 23 m I: 26/26; 0 I: 32.76 y; 9/17 Total glycosides of 
paeony (capsule): 600 
mg tid, po 
Cetirizine: 10 mg 
qd, po C: 27 m 
 
C: 21/21; 0 C: 27.13 y; 
7/14 
Lin ZF 2014 
(142) 
NS; 3 12 w; NS  I: 8.9 w I: 65/63; 2 I 29 y; 22/43 Yu ping feng ke li 
(granule): five g tid, po; 
levocetirizine: used as 
per control group 1 
C1: Levocetirizine: 
five mg qd, po 
C2: Yu ping feng 
ke li (granule): 5 g 
tid, po; 
levocetirizine: 5 
mg qd, po; 
increasing one day 
interval to use 
every other week 
C1: 9.5 w C1: 65/60; 5 C1: 27.8 y; 
25/40 
C2: 9.1 w C2: 65/65; 0 C2: 30 y; 
28/37 
Liu Y 2014 
(185) 
NS; 2 4 w; NS  I: 3.4 (1.8) 
y 
I: 53/53; 0 I: 31.8 (10.6) 
y; 27/26 
Fu fang di fu zi tang 
(decoction): bid, po 
Mizolastine: 10 mg 
qd, po 
C: 3.6 (1.9) 
y 
C: 53/53; 0 C: 31.9 (10.9) 
y; 28/25 
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First 
author, 
publication 
year 
Blinding; 
number 
of arms 
Treatment 
duration; 
follow-up 
duration 
Duration of 
condition 
(mean [SD] 
or range) 
No. of 
participants 
randomised/
assessed; 
dropouts  
Age (mean 
[SD] or 
range); 
gender (M/F) 
Intervention Control 
Long JW 
2010 (139) 
NS; 2 4 w; 1 m I: 8.9 (7.8) 
m 
I: 65/63; 2 I: 36.5 (13.3); 
37/28 
Total glucosides of 
peony (capsule): two 
capsules tid, po 
Cetirizine: 10 mg 
qd, po 
C: 9.6 (9.2) 
m 
C: 55/48; 7 C: 35.3 (12.6); 
32/22 
Lu JM 2007 
(180) 
NS; 2  4 w; NS I: 8 w–7 y I: 48/48; 0 I: 13–75 y; 
20/28 
Qu feng xiao zhen tang 
(decoction): bid, po 
Cetirizine: 10 mg 
qd, po 
C: 8 m–6 y C: 48/48; 0 C: 12-69y; 
21/27 
Lu XY 2010 
(205) 
NS; 2  4 w; 1 m Total: 3.5 
(2.7) y 
I: 74/74; 0 Total: 30.48 
(7.61) y; 63/85 
Yu ping feng san 
(modified decoction): 
200ml bid, po  
Levocetirizine: 5 
mg qd, po  C: 74/74; 0 
Ma LB 2012 
(170) 
NS; 2  4 w; 2 w I: 2 m–6 y I: 43/43; 0 I: 42 y; 19/24 Qi feng ke li (granules): 
10 g tid, po 
Mizolastine: 
dosage not 
specified, qd, po  
C: 2.5 m–5 
y 
C: 41/41; 0 C: 42 y; 18/23 
Ma WH 
2010 (169) 
NS; 2  4 w; NS I: 6 w–3 y I: 35/35; 0 I: 15–62 y; 
19/16 
Wu she zhi yang wan 
(pills): 2.5 g tid, po 
Mizolastine: 10 mg 
qd, po 
C: 6 m–3.2 
y 
C: 35/35; 0 C: 14-61 y; 
20/15 
Ma XM 
2013 (178) 
NS; 2  4 w; 6 m I: 2.95 y I: 62/62; 0 I: 32.5 y; 33/29 Yu ping feng san 
(decoction): bid, po  
Mizolastine: 10 mg 
qd, po C: 3 y C: 58/58; 0 C: 31.8 y; 
32/26 
Mei T 2014 
(186) 
NS; 2 6 w; 6 m Total: 6 m–
1 y 
I: 30/30; 0 Total: 20–58 y; 
32/28 
Yu ping feng jiao nang 
(capsule): two capsules 
bid, po 
Mizolastine: 10 mg 
qd, po C: 30/30; 0 
Mou Y 2011 
(168) 
NS; 2  NS; 4 w I: 3.3 (1.76) 
y 
I: 30/30; 0 I: 30.6 (10.5) 
y; 13/17 
Total glycosides of 
paeony (capsules): 0.6 g 
tid, po 
Mizolastine: 10 mg 
qd, po 
C: 3.1 
(1.56) y 
C: 30/30; 0 C: 31.8 (10.2) 
y; 10/20 
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First 
author, 
publication 
year 
Blinding; 
number 
of arms 
Treatment 
duration; 
follow-up 
duration 
Duration of 
condition 
(mean [SD] 
or range) 
No. of 
participants 
randomised/
assessed; 
dropouts  
Age (mean 
[SD] or 
range); 
gender (M/F) 
Intervention Control 
Mi L 2008 
(204) 
NS; 2  4 w; 6 m I: 2.92 
(0.81) y 
I: 35/35; 0 I: 35.16 (1.21) 
y; 19/16 
Jia wei yang he tang 
(decociton): bid, po 
Cetirizine: 10 mg 
qd, po  
C: 2.74 
(0.69) y 
C: 35/35; 0 C: 32.11 (2.23) 
y; 18/17 
Qian M 
2011 
(140) 
NS; 6  4 w; 4 w Total: 6.62 
(3.66) m 
I1: 62/62, 0; 
I2: 61/61, 0; 
I3: 57/61, 0 
C1: 61/60, 0; 
C2: 60/57, 0; 
C3: 59/59, 0 
Total: 35.6 
(9.7) y; 
192/168 
I1: Tripterygium 
glycosides (tablets): 60 
mg qd, po; loratadine: 
used as per control group 
1 
C1: loratadine: 10 
mg qd, po 
I2: Tripterygium 
glycosides (tablets): 60 
mg qd, po; mizolastine: 
used as per control group 
2 
C2: mizolastine: 
10 mg qd, po 
I3: Tripterygium 
glycosides(tablets): 60 
mg qd, po; cetirizine: 
used as per control group 
3 
C3: cetirizine: 10 
mg qd, po 
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First 
author, 
publication 
year 
Blinding; 
number 
of arms 
Treatment 
duration; 
follow-up 
duration 
Duration of 
condition 
(mean [SD] 
or range) 
No. of 
participants 
randomised/
assessed; 
dropouts  
Age (mean 
[SD] or 
range); 
gender (M/F) 
Intervention Control 
Shi CR 2013 
(99) 
NS; 3  28 d; 3 m, 6 
m 
I: 1.80 
(0.45) y 
I: 25/22; 3 I: 35.37 
(13.54) y; 
11/14 
Dang gui yin zi 
(decoction): bid, po; 
cetirizine: used as control 
group 1 
C1: Cetirizine: 10 
mg qd, po 
C2: Dang gui yin 
zi (decoction): bid, 
po 
C1: 1.50 
(0.62) y 
C1: 25/24; 1 C1: 36.63 
(13.98) y; 
12/13 
C2: 1.60 
(0.56) y 
C2: 25/21; 4 C2: 34.14 
(12.64) y; 
13/12 
Song SH 
2015 
(144) 
NS; 3 30 d; 6 m I: 3.4 (1.5) 
y 
I: 52/52; 0 I: 36.5 (13.9) 
y; 27/25 
Xiao yin fang 
(decoction): bid, po; 
ebastine: used as per 
control group 1 
C1: Ebastine: 10 
mg qd, po 
C2: Xiao yin fang 
(decoction): bid, 
po 
C1: 3.6 
(1.2) y 
C1: 43/42; 1 C1: 34.6 (12.7) 
y; 23/20 
C2: 3.5 
(1.4) y 
C2: 38/38; 0 C2: 35.8 (13.2) 
y; 20/18 
Sun H 2015 
(196) 
NS; 2 8 w; 4 w I: 1.45 
(1.01) y 
I: 118/118; 0 I: 35.80 (9.67) 
y; 56/62 
Qu feng kang min jian 
(decoction): bid, po 
Ebastine: 10 mg 
qd, po 
C: 1.39 
(1.45) y 
C: 116/116; 0 C: 36.53 
(10.25) y; 
54/62 
Sun RF 
2007 (203) 
NS; 2  28 d; 2 m I: 10.2 m I: 36/36; 0 I: 34 y; 14/22 Unnamed formula 
(decoction): bid, po  
Levocetirizine: 10 
mg qd, po (week 
1–2); 10 mg qod, 
po (week 3); 10mg 
every two days, po 
(week 4); 
C: 9.9 m C: 32/32; 0 C: 33.6 y; 
12/20 
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First 
author, 
publication 
year 
Blinding; 
number 
of arms 
Treatment 
duration; 
follow-up 
duration 
Duration of 
condition 
(mean [SD] 
or range) 
No. of 
participants 
randomised/
assessed; 
dropouts  
Age (mean 
[SD] or 
range); 
gender (M/F) 
Intervention Control 
Sun RH 
2014 (187) 
NS; 2 4 w; NS I: 27 m I: 42/42; 0 I: 29.7 y; 28/14 Run zao zhi yang jiao 
nang (capsule): four 
capsules tid, po 
Desloratadine: 8.8 
mg qd, po  C: 22 m C: 39/39; 0 C: 28.1 y; 
21/18 
Sun RL 
2014 (188) 
NS; 2 8 w; NS I: 19.6 m I: 88/88; 0 I: 38.5 y; 36/52 Total glycosides of 
paeony (capsule): 600 
mg tid, po 
Fexofenadine: 60 
mg bid, po  C: 17.8 m C: 80/80; 0 C: 39.8 y; 
31/49 
Tian AP 
2011 (202) 
NS; 2  14 d; 6 m I: 3.6 y I: 45/45; 0 I: 36 y; 24/21 
C: 36.5 y; 
27/18 
Fang ci yin hua fang 
(decoction): bid, po 
Levocetirizine: 
five mg qd, po  C: 3.5 y C: 45/45; 0 
Tian J 2015 
(197) 
NS; 2 4 w; 4 w I: 13.5 m I: 53/53; 0 I: 36.5 y; 26/27 Compound glycyrrhizin 
(capsule): 50 mg tid, po 
Mizolastine: 10 mg 
qd, po  C: 15 m C: 53/53; 0 C: 18–63 y; 
25/28 
Wang N 
2011 (167) 
NS; 2  4 w; 1 m I: 13.5 m I: 23/23; 0 I: 9.2 y; 11/12 
C: 9.8 y; 10/7 
Si wu xiao feng san 
(decoction): 50 ml bid, 
po 
Setastine: one mg 
qd, po (age: <8 y); 
1mg bid, po (age: 
8–14 y) 
C: 14.4 m C: 17/17; 0 
Wang NL 
2010 (201) 
NS; 2  4 w; NS I: 5 m–18 y I: 32/32; 0 I: 38.6 y; 14/18 Kang min ling he ji 
(mixture): 30 ml tid, po 
Ebastine: 10 mg 
qd, po C: 6 m–17 y C: 28/28; 0 C: 39.2 y; 
12/16 
Wang YF 
2011 (166)  
NS; 2  28 d; NS Total: 1.8 y I: 60/60; 0 Total: 37 y; 
62/58 
Fu yang ke li (granules): 
nine g tid, po 
Epinastine: 20 mg 
qd, po C: 60/60; 0 
Wang YJ 
2011 (165) 
NS; 2  4 w; 1 m I: 3.8 (1.73) 
y 
I: 60/60; 0 I: 34.7 (11.3) 
y; 27/33 
Total glycosides of 
paeony (capsule): 0.6 g 
tid, po 
Fexofenadine: 60 
mg bid, po  
C: 3.1 
(1.56) y 
C: 56/56; 0 C: 31.8 (10.5) 
y; 25/31 
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First 
author, 
publication 
year 
Blinding; 
number 
of arms 
Treatment 
duration; 
follow-up 
duration 
Duration of 
condition 
(mean [SD] 
or range) 
No. of 
participants 
randomised/
assessed; 
dropouts  
Age (mean 
[SD] or 
range); 
gender (M/F) 
Intervention Control 
Wei X 2013 
(164) 
NS; 2  4 w; 4 w NS I: 41/41; 0 I: 34.5 (10.7) 
y; 20/21 
Yu ping feng jiao nang 
(capsules): 1000 mg, tid 
po  
Desloratadine: 8.8 
mg qd, po 
C: 40/40; 0 C: 37.2 (12.9) 
y; 20/20 
Wu CY 
2014 (189) 
NS; 2 4 w; NS I: 8.25 
(2.11) m 
I: 60/60; 0 I: 36.25 
(18.35) y; 
29/31 
Ma huang xi xin fu zi 
tang (decoction): bid or 
tid, po  
Desloratadine: 10 
mg qd, po 
C: 8.45 
(2.38) m 
C: 60/60; 0 C: 37.15 
(18.33) y; 
28/32 
Wu GZ 
2012 (200) 
NS; 2  4 w; 4 w I: 2.1 y I: 80/80; 0 I: 33.94 y; 
51/29 
Unnamed formula 
(decoction): bid, po  
Levocetirizine: 10 
mg qd, po  
C: 2.3 y C: 74/74; 0 C: 34.14 y; 
48/26 
Wu YX 
2007 (163) 
NS; 2  28 d; NS I: 12.5 
(13.2) m 
I: 33/33; 0 I: 44.7 (10.4); 
12/21 
Xiao feng zhi yang ke li 
(granules): 30 g bid, po 
Loratadine: 10 mg 
qd, po 
C: 13.1 
(14.3) m 
C: 30/30; 0 C: 42.9 (11.6); 
13/17 
Wu YX 
2015 (198) 
NS; 2 15 d; 1 m Total: 6.26 
(0.85) y  
I: 93/93; 0 Total: 43.62 
(3.05) y; 
102/84 
Compound glycyrrhizin 
(capsule): 50 mg tid, po 
Mizolastine: 10 mg 
qd, po C: 93/93; 0 
Xiao HW 
2010 (162) 
NS; 2  4 w; 3 m I: 2.5 y I: 49/49; 0 I: 30.3 y; 28/21 Yu ping feng ke li 
(granules): 5 g tid, po 
Epinastine: 10 mg 
qd, po C: 2.4 y C: 32/32; 0 C: 32.8 y; 
19/13 
Xu JJ 2014 
(190) 
NS; 2 8 w; 1 m I: 1.2 y I: 45/45; 0 I: 8.33 (2.27) 
y; 24/21 
Fu yang ke li (granule): 
6–12 g tid, po 
Loratadine: 5 mg 
qd, po (≤30 kg); 10 
mg qd, po (≥30 kg) C: 1.3 y C: 41/41; 0 C: 7.75 (2.80) 
y; 23/18 
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First 
author, 
publication 
year 
Blinding; 
number 
of arms 
Treatment 
duration; 
follow-up 
duration 
Duration of 
condition 
(mean [SD] 
or range) 
No. of 
participants 
randomised/
assessed; 
dropouts  
Age (mean 
[SD] or 
range); 
gender (M/F) 
Intervention Control 
Xue CL 
2009 
(100) 
NS; 3  30 d; NS I: 5.24 y I: 51/51; 0 I: 23.74 y; 
23/28 
Kang man min jian 
(decoction): 150 ml tid, 
po; cetirizine: used as 
control group per 2 
C1: Kang man min 
jian (decoction): 
150 ml tid, po; 
C2: cetirizine: 10 
mg tid, po 
C1: 4.58 y C1: 43/43; 0 C1: 24.25 y; 
20/23 
C2: 3.36 y C2: 45/45; 0 C2: 22.16 y; 
23/22 
Yang L 
2011 (161) 
NS; 2  4 w; 3 m NS I: 48/48; 0 Total: NS; NS Tripterygium glycosides 
(tablets): 20 mg tid, po 
Desloratadine: five 
mg qd, po C: 48/48; 0 
Yang MF 
2014 
(143) 
NS; 3 4 w; 4 w I: 0.88 
(0.26) y 
I: 45/45; 0 I: 38.41 (4.05) 
y; 20/25 
Zhen qi fu zheng ke li 
(granule): 15 g bid, po; 
levocetirizine: used as 
per control group 
C1: Levocetirizine: 
five mg qd, po  
C2: Zhen qi fu 
zheng ke li 
(granule): 15 g bid, 
po 
C1: 1.01 
(0.17) y 
C1: 45/45; 0 C1: 41.65 
(3.01) y; 23/22 
C2: 0.98 
(0.32) y 
C2: 45/45; 0 C2: 40.51 
(3.89) y; 20/25 
Yang YS 
2014 (150) 
NS; 2 12 w; NS I: 6 w–1 y I: 65/65; 0 I: 48.2 (10.2) 
y; 27/38 
Total glycosides of 
paeony (capsule): 600 
mg bid, po 
Desloratadine: five 
mg qd, po 
C: 6 w–1 y C: 65/65; 0 C: 44.5 (12.5) 
y; 25/40 
Ye WW 
2009 (160) 
NS; 2  6 w; 3 m I: 7.6 y I: 60/60; 0 I: 45.6 y; 37/23 Di huang yin zi 
(decoction): bid, po 
Cetirizine: 10 mg 
qd, po C: 7.2y C: 56/56; 0 C: 44.4 y; 
30/26 
Yuan JQ 
2013 (146) 
NS; 2  4 w; NS I: 2 m–2 y I: 32/32; 0 I: 1–13 y; 
18/14 
Xiao feng san 
(decoction): bid, po 
Desloratadine: 
1.25 mg qd, po 
(age: 1–5 y); 
2.5mg qd, po (age: 
6–11 y); five mg 
qd, po (age: over 
12 y)  
C: 3 m–2 y C: 32/32; 0 C: 1–12 y; 
20/12 
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First 
author, 
publication 
year 
Blinding; 
number 
of arms 
Treatment 
duration; 
follow-up 
duration 
Duration of 
condition 
(mean [SD] 
or range) 
No. of 
participants 
randomised/
assessed; 
dropouts  
Age (mean 
[SD] or 
range); 
gender (M/F) 
Intervention Control 
Zhang HB 
2011 (159) 
NS; 2  4 w; 1 m NS I: 43/43; 0 I: 34.6 (10.9) 
y; 24/19 
Qing feng tang 
(decoction): qd, po 
Setastine: one mg 
bid, po 
C: 43/43; 0 C: 37.1 (13.1) 
y; 18/25 
Zhang HX 
2014 (191) 
NS; 2 8 w; 4 w I: 22.6 m I: 30/30; 0 I: 36.8 y; 14/16 Total glycosides of 
paeony (capsule): 600 
mg tid, po 
Ebastine: 10 mg 
qd, po C: 25.2 m C: 30/30; 0 C: 38.3 y; 
13/17 
Zhang L 
2014 (137) 
NS; 2 4 w; NS Total: 3 m–
5 y 
I: 56/56; 0 Total: 12–70 y; 
54/58 
Total glycosides of 
paeony (capsule): 600 
mg tid, po 
Mizolastine: 10 mg 
qd, po C: 56/54; 2 
Zhang Q 
2011 (148) 
NS; 2  7 d; 1 m I: 6 m I: 50/50; 0 I: 9 y or 4–12 
y; 25/25 
Jia wei yu ping feng tang 
(decoction): tid, po 
Desloratadine: 
1.25–5 mg qd, po  
C: NS C: 50/50; 0 NS 
Zhang TL 
2011 (158) 
NS; 2  4 w; 8 w I: 15 m I: 44/44; 0 I: 26.8 y; 21/23 Dang gui yin zi 
(decoction): qd, po 
Levocetirizine: 
five mg qd, po  C: 14 m C: 44/44; 0 C: 27.1 y; 
22/22 
Zhao HW 
2010 (157) 
NS; 2  28 d; 1 m I: 16.3 m I: 80/80; 0 I: 35.8 y; 52/28 Man xun tang 
(decoction): 100 ml bid, 
po 
Ebastine: 10 mg 
qd, po C: 16.3 m C: 40/40; 0 C: 36.2 y; 
26/14 
Zhao JH 
2010 (156) 
NS; 2  28 d; 2 w I: 3m-5y I: 88/88; 0 I: 35.1 y; 48/40 Yu ping feng (dripping 
pills): 2.4 g tid, po 
Mizolastine: 10 mg 
qd, po C: 3 m–4.5 
y 
C: 84/84 ;0 C: 34.3 y; 
46/38 
Zhao YY 
2014 (192) 
NS; 2 4 w; 2 m I: 1 (0.3) y I: 44/44; 0 I: 36.4 (9.5) y; 
20/24 
Total glycosides of 
paeony (capsule): 600 
mg tid, po 
Fexofenadine: 120 
mg qd, po 
C: 1.2 
(0.45) y 
C: 47/47; 0 C: 35.3 (8.7) y; 
21/26 
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First 
author, 
publication 
year 
Blinding; 
number 
of arms 
Treatment 
duration; 
follow-up 
duration 
Duration of 
condition 
(mean [SD] 
or range) 
No. of 
participants 
randomised/
assessed; 
dropouts  
Age (mean 
[SD] or 
range); 
gender (M/F) 
Intervention Control 
Zhao ZY 
2004 (152) 
NS; 2  3 w; 3 m I: 2.6 y I: 42/42; 0 I: 44.5 y; 23/19 Yong an zhi yang ke li 
(granule): 3 g bid or tid, 
po  
Mizolastine: 10 mg 
qd, po  C: 2.8 y C: 40/40; 0 C: 45.6 y; 
21/19 
Zheng Y 
2008 (155) 
NS; 2  28 d; 4 w Total: 4.3 y I: 51/51;0 Total: 27.4 y; 
40/58 
Urticaria basic formula 
(modified decoction): 
bid, po 
Cetirizine: 10 mg 
qd, po C: 47/47; 0 
Zheng ZY 
2014 (193) 
NS; 2 2 w; NS I: 6 w–2.5 y I: 41/41; 0 I: 30.5 y; 24/17 Compound glycyrrhizin 
(capsule): 50 mg tid, po  
Fexofenadine: 60 
mg bid, po  C: 6 w–2.3 
y 
C: 38/38; 0 C: 31.2 y; 
23/15 
Zhong JQ 
2011 (138) 
PRA-B; 2 4 w; 20 w I: 67 (13-
361) w 
I: 40/37; 3 I: 36 (21–58); 
19/21 
Tripterygium 
hypoglaucum Hutch 
(tablet): three tablets tid, 
po; cetirizine: used as 
control group 
Placebo: used as 
intervention group; 
cetirizine: 10 mg 
qd, po  
C: 65 (9-
312) w 
C: 38/32; 6 C: 35 (23–56); 
20/18 
Zhong X 
2005 (153) 
NS; 2  14 d; 3 m I: 2.3 (1.4) 
y 
I: 51/51; 0 I: 27.4 (12.5) 
y; 27/24 
Yi qi yang xue huo xue 
qu feng tang (decoction): 
bid, po 
Mizolastine: 10 mg 
qd, po 
C: 2.5 (1.6) 
y 
C: 48/48; 0 C: 26.7 (11.4) 
y; 26/22 
Zhou JW 
2011 (199) 
NS; 2  15 d; NS Total: NS I: 35/35; 0 I: 34.64 (3.31) 
y; 20/15 
Ma huang fu zi xi xin 
tang (decoction): tid, po 
Loratadine: 10 mg 
qd, po 
C: 35/35; 0 C: 34.74 (2.24) 
y or 13–64 y; 
21/14 
Zhou L 
2012 (147) 
NS; 2  30 d; 3 w I: 3.5 y I: 30/30; 0 I: 38 y; 16/14 Yi qi huo xue qu feng 
tang (decoction): bid, po 
Mizolastine: 10 mg 
qd, po C: 3.6 y C: 30/30; 0 C: 37.5 y; 
18/12 
Zhu JF 2012 
(154) 
NS; 2  4 w; 3 m 1.79 (0.62) 
y 
I: 82/82; 0 Total: 35.87 
(8.38) y; 87/77 
Compound glycyrrhizin 
(capsule): 50 mg tid, po 
Cetirizine: 10 mg 
qd, po C: 82/82; 0 
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First 
author, 
publication 
year 
Blinding; 
number 
of arms 
Treatment 
duration; 
follow-up 
duration 
Duration of 
condition 
(mean [SD] 
or range) 
No. of 
participants 
randomised/
assessed; 
dropouts  
Age (mean 
[SD] or 
range); 
gender (M/F) 
Intervention Control 
Zhuang Q 
2011 (179) 
NS; 2  8 w; 2 m I: 15.91 
(3.23) m 
I: 36/30; 7 I: 36.82 
(13.26) y; 
15/15 
Xiao chai hu tang 
(decoction): bid, po 
Mizolastine: 10 mg 
qd, po 
C: 13.49 
(4.59) m 
C: 36/30; 5 C: 34.58 
(14.97); 16/14 
Notes: * Formula name not stated, formula based on Chinese medicine treatment principle;  study with three or more arms; C: Control; I: Intervention; m: 
months; mg: milligram; ml: milliliter; NS: not stated; po: administrated orally; PRA-B: all blinded; qd: once daily; qn: once per night; tid: three times daily; w: 
weeks, y: years;  
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Table 7.2: Details of Chinese Herbal Medicine formula: Chinese Herbal Medicine as Add-on Therapy v. Antihistamines for 
Chronic Urticaria 
First author 
publication year 
Ingredients of CHM 
Bai WJ 2011 (177) Xiao feng san: huang qi, fang feng, bai zhu, dan shen, dang gui, mu dan pi, sheng di huang, shu di huang, 
chan yi, ku shen, gan cao 
Bao LX 2008 (176) Tripterygium glycosides: NS 
Chen CS 2015 (194) Yu ping feng ke li (granule): huang qi, bai zhu, fang feng 
Chen JY 2014 (181) Xiao yin ke li (granule): NS 
Chen XB 2011 (145) Unnamed formula: sheng di huang, qin jiao, xu chang qing, fu ping, yi yi ren, chan tui, gan cao 
Cheng Y 2010 (175) Ba zhen san plus si wu xiao feng san: fu ling, bai zhu, jing jie, fang feng, chan tui, niu bang zi, cang zhu, ku 
shen, dang gui, sheng di, chi shao, chuan xiong, bo he, sheng gan cao 
Deng D 2012 (174) Pi min xiao jiao nang (capsule): ku shen, cang zhu, fang feng, jing jie, ji li, bai xian pi, she chuang zi, cang er 
zi, wu gong, qing dai, pu gong ying, zi hua di ding, huang qin, huang bo, huang lian, di huang, mu dan pi, 
chan tui, xi he liu, zi cao, di gu pi  
Ding QY 2007 (173) Run zao zhi yang jiao nang (capsule): sheng di huang, he shou wu, zhi he shou wu, sang ye, ku shen, hong 
huo ma, (etc.) 
Feng S 2015 (195) Qu feng qing re wei ling tang: huang qin, lian qiao, chen pi, fa ban xia, bai zhu, jing jie, fang feng, ku shen, 
bai xian pi, huang bo, zhi zi, fu ling, zhu ling, cang shu, gan cao, sheng ma  
Fu YH 2011 (141)* 1. Fortifying the Spleen and nourishing Blood: huang qi, da zao, shan yao, fu ling, dang gui, zhi shou wu  
2. Dispelling wind: jing jie, fang feng, chan tui, niu bang zi, hu ma ren, ci ji li  
Guo XY 2014 (182) Compound glycyrrhizin: NS 
Huang SY 2012 (206) Guo min jian: yin chai hu, fang feng, wu mei, wu wei zi, gan cao  
Jiang YP 2009 (172) Qi feng ke li (granules): huang qi, fang feng, bai zhu, fu ling, chen pi, gui zhi, da fu pi, sang bai pi, (etc.)  
Jiang YP 2011 (151) Compound glycyrrhizin: NS 
Jie SH 2014 (135) Total glycosides of paeony: NS 
Leng J 2014 (136) Run zao zhi yang jiao nang (capsule): sheng di huang, he shou wu, zhi he shou wu, sang ye, ku shen, huo 
hong ma, (etc.) 
Li CH 2014 (183) Yu ping feng ke li (granule): huang qi, bai zhu, fang feng 
Li ZL 2013 (171) Qing re xiao feng san: jing jie, niu bang zi, chan tui, fang feng, sheng di huang, dang gui, hong hua, mu dan 
pi, zi cao, jiang can, dan zhu ye, gan cao  
Liao C 2014 (184) Yu ping feng ke li (granule): huang qi, bai zhu, fang feng 
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First author 
publication year 
Ingredients of CHM 
Lin YP 2012 (149) Total glycosides of paeony: NS 
Lin ZF 2014 (142) Yu ping feng ke li (granule): huang qi, bai zhu, fang feng 
Liu Y 2014 (185) Fu fang di fu zi tang: di fu zi, huai mi, sang bai pi, chan tui, (etc.) 
Long JW 2010 (139) Total glycosides of paeony: NS 
Lu JM 2007 (180) Qu feng xiao zhen tang: fang feng, chan tui, jiang can, xu chang qing, dan shen, dang gui, bai xian pi, bai ji 
li, di fu zi 
Lu XY 2010 (205) Yu ping feng san (modified): fang feng, huang qi, bai zhu, jing jie, chai hu, bai shao, dang gui, bai xian pi, 
chan tui, tu fu ling, mu dan pi, lian qiao, gan cao  
Ma LB 2012 (170) Qi feng ke li (granules): huang qi, fang feng, bai zhu, fu ling, chen pi, gui zhi, da fu pi, sang bai pi, (etc.) 
Ma WH 2010 (169) Wu she zhi yang wan (pills): wu qiao she, fang feng, she chuang zi, huang bo, cang zhu, ren shen xu, mu dan 
pi, she dan juice, ku shen, man-made niu huang, dang gui  
Ma XM 2013 (178) Yu ping feng san: huang qi, fang feng, bai zhu  
Mei T 2014 (186) Yu ping feng jiao nang (capsule): NS 
Mi L 2008 (204) Jia wei yang he tang: shu di huang, ma huang, lu jiao jiao, bai jie zi, rou gui, sheng gan cao, pao tan jiang, 
bai shao, bai xian pi 
Mou Y 2011 (168) Total glycosides of paeony: NS 
Qian M 2011 (140) Tripterygium glycosides: NS 
Shi CR 2013 (99) Dang gui yin zi: dang gui, bai shao, chuan xiong, sheng di huang, bai ji li, fang feng, jing jie, he shou wu, 
huang qi, zhi gan cao  
Song SH 2015 (144) Xiao yin fang: fang feng, chan tui, bai xian pi, di fu zi, ye jiao teng, huang qi, dang gui, mu dan pi, ci ji li, dan 
shen, shan yao, sheng gan cao  
Sun H 2015 (196) Qu feng kang min jian: huang qi, dang gui, bai zhu, bai shao, fang feng, yin chai hu, wu mei, jing jie, wu wei 
zi, gan cao  
Sun RF 2007 (203) Unnamed formula: sheng di huang, bai shao, dang gui, chuan xiong, huang qi, fu ling pi, jing jie, fang feng, 
bai zhu, dang shen, ci ji li, sheng gan cao  
Sun RH 2014 (187) Run zao zhi yang jiao nang (capsule): sheng di huang, he shou wu, zhi he shou wu, sang ye, ku shen, hong 
huo ma, (etc.)  
Sun RL 2014 (188) Total glycosides of paeony: NS 
Tian AP 2011 (202) Fang ci yin hua fang: fang feng, ci ji li, jin yin hua, shou wu teng, bai xian pi, dang gui, mu dan pi, fu ping, 
chan tui, gan cao 
Tian J 2015 (197) Compound glycyrrhizin: NS 
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publication year 
Ingredients of CHM 
Wang N 2011 (167) Si wu xiao feng san: jing jie, fang feng, chi shao, chuan xiong, dang gui, sheng di huang, cang zhu, bai xian 
pi, di fu zi 
Wang NL 2010 (201) Kang min ling he ji (mixture): dang gui, da zao, dang shen, huang qi, gui zhi, ma huang, jing jie, gan cao, 
(etc.) 
Wang YF 2011 (166) Fu yang ke li (granules): cang er zi, di fu zi, hong hua, chuan xiong, bai ying, (etc.) 
Wang YJ 2011 (165) Total glycosides of paeony: NS 
Wei X 2013 (164) Yu ping feng jiao nang (capsules): NS 
Wu CY 2014 (189) Ma huang xi xin fu zi tang: ma huang, xi xin, chan tui, lu jiao shuang, dang gui, huang qi, he shou wu 
Wu GZ 2012 (200) Unnamed formula: huang qi, chi shao, dang shen, dang gui, lian qiao, huang bo, jing jie, di fu zi, chen pi, 
gan cao 
Wu YX 2007 (163) Xiao feng zhi yang ke li (granules): fang feng, jing jie, sheng di huang, di gu pi, dang gui, chan tui, cang zhu, 
shi gao, mu tong, gan cao 
Wu YX 2015 (198) Compound glycyrrhizin: NS 
Xiao HW 2010 (162) Yu ping feng ke li (granules): NS 
Xu JJ 2014 (190) Fu yang ke li (granule): di fu zi, cang er zi, chuan xiong, hong hua, bai ying (etc.)  
Xue CL 2009 (100) Kang man min jian: chai hu, bai shao, fang feng, chan tui, di long, bai xian pi, tu fu ling, lian qiao, mu dan 
pi, huang qi, dang shen, bai zhu, dang gui, gan cao  
Yang L 2011 (161) Tripterygium glycosides: NS 
Yang MF 2014 (143) Zhen qi fu zheng ke li (granule): huang qi, nv zhen zi 
Yang YS 2014 (150) Total glycosides of paeony: NS 
Ye WW 2009 (160) Di huang yin zi: shu di huang, ba ji tian, shan zhu yu, shi hu, rou cong rong, fu zi, wu wei zi, rou gui, bai fu 
ling, mai men dong, shi chang pu, yuan zhi, sheng jiang, da zao, bo he, (etc.)  
Yuan JQ 2013 (146) Xiao feng san: jing jie, fang feng, niu bang zi, chan tui, cang shu, ku shen, duan shi gao, zhi mu, dang gui, hu 
ma ren, sheng di huang, gan cao 
Zhang HB 2011 (159) Qing feng tang: sheng huang qi, jing jie, fang feng, chan tui, zi bei fu ping, bai ji li, bai shu, bai shao, gan 
cao, dang gui, sheng di huang, chuan xiong, wu wei zi 
Zhang HX 2014 (191) Total glycosides of paeony: NS 
Zhang L 2014 (137) Total glycosides of paeony: NS 
Zhang Q 2011 (148) Jia wei yu ping feng tang: huang qi, bai zhu, fang feng, jing jie, gan cao, di fu zi, huang qin, fu ling, shan zha, 
chen pi  
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publication year 
Ingredients of CHM 
Zhang TL 2011 (158) Dang gui yin zi: dang gui, chuan xiong, bai shao, sheng di huang, fang feng, bai ji li, jing jie, he shou wu, 
huang qi, gan cao  
Zhao HW 2010 (157) Man xun tang: huang qi, bai shu, fang feng, jing jie, sheng di huang, dang gui, dan shen, chuan xiong, chi 
shao, ma huang, gui zhi, ye jiao teng, bai ji li, bai jiang can, gan cao, fu ping, ma chi xian  
Zhao JH 2010 (156) Yu ping feng (dripping pills): fang feng, huang qi, bai shu  
Zhao YY 2014 (192) Total glycosides of paeony: NS 
Zhao ZY 2004 (152) Yong an zhi yang ke li (granule): ma huang, jing jie, fang feng, cang zhu, jiang can, tao ren, hong hua, chi 
shao, dang gui 
Zheng Y 2008 (155) Urticaria basic formula (modified decoction): huang qi, bai shu, dang gui, chi shao, jing jie, fang feng, chan 
tui, bai xian pi, zi cao, mu dan pi, huang qin, gan cao 
Zheng ZY 2014 (193) Compound glycyrrhizin: NS 
Zhong JQ 2011 (138) Tripterygium hypoglaucum Hutch: NS 
Zhong X 2005 (153) Yi qi yang xue huo xue qu feng tang: huang qi, bai zhu, chuan xiong, dang gui, zhi he shou wu, sheng di 
huang, chi shao, jing jie, fang feng, di fu zi, bai xian pi, chan tui, mu dan pi 
Zhou JW 2011 (199) Ma huang fu zi xi xin tang: ma huang, shu fu zi, xi xin, gui zhi, bai shao, gan cao, sheng jiang, da zao 
Zhou L 2012 (147) Yi qi huo xue qu feng tang: huang qi, dang gui, chuan xiong, sheng di huang, chi shao, shou wu, jing jie, fang 
feng, ji xue teng, chan tui  
Zhu JF 2012 (154) Compound glycyrrhizin: NS 
Zhuang Q 2011 (179) Xiao chai hu tang: chai hu, ban xia, dang shen, huang qin, sheng jiang, da zao, gan cao 
* Formula name not stated, formula based on Chinese medicine treatment principle; NS not stated 
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7.3.2 Outcome Measures 
UAS was used in four studies (99, 140, 181, 184) to assess disease activity, but only one 
study reported actual scores (140). The other study reported UAS percentage score change 
from baseline (99), and two studies reported the number of participants who achieved UAS 
changes of 30% or more after receiving treatments (181, 184). This is not consistent with the 
prescribed use of the outcome measure UAS. All studies reported on ER and two approaches 
were used to calculate this (see Chapter 5). ER 30 was reported in 13 studies (100, 145, 148, 
152, 153, 199–206) and SSRI 30 was used in the remaining studies. Relapse rate, based on 
ER 30, was reported in two studies (152, 153). DLQI was used in one study to assess 
participants’ HR-QoL. AEs were reported in all but 22 studies (100, 145, 148, 151–154, 161, 
167, 171, 174, 179, 184, 189, 194, 196, 198, 200, 201, 204, 206). 
7.3.3 Risk of Bias Assessment 
While all studies claimed that participants were randomly allocated, only 12 studies described 
the appropriate methods of random sequence generation (99, 138, 139, 141, 157, 178, 186, 
189, 190, 192, 195, 197) (see Table 7.3). Three studies used a computer to generate random 
numbers (99, 138, 141), eight studies used a random number table to allocate participants 
(157, 178, 186, 189, 190, 192, 195, 197) while lottery was used in one study (139). These 12 
studies were judged as low risk for sequence generation (see Table 7.3). Eleven studies were 
assessed as high risk for generation of allocation sequence (147, 151–153, 156, 161, 166, 171, 
173, 179, 206), while six studies allocated participants based on the order of visiting (147, 
156, 166, 171, 173, 179). Participants could select their group allocation in two studies (152, 
153) and randomisation was only mentioned in the abstracts of three studies (151, 161, 206). 
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The remaining studies did not provide detailed prescriptions for sequence generation and 
were judged to pose an unclear risk. In relation to allocation concealment, eight studies were 
assessed as high risk since research personnel or participants could predict the treatments 
(147, 152, 153, 156, 166, 171, 173, 179). Six of these studies determined participants’ 
allocations based on visiting order (147, 156, 166, 171, 173, 179) and two studies allowed 
participants to choose (152, 153). All remaining studies were considered to carry unclear risk 
for allocation concealment due to lack of information. Participants and researchers involved 
in one study (138) were blinded. Therefore, this study was judged as low risk for all the 
blinding domains. The remaining studies did not use methods to blind participants and 
personnel to group allocation; thus, they were judged as high risk. In terms of blinding 
outcome assessors, except for Zhong (2011) (138), all studies were assessed as unclear risk 
due to lack of information. Three studies (139, 142, 179) were deemed an unclear risk for 
incomplete outcome data. Two (142, 179) reported the number of withdrawals and dropouts 
in both groups but did not discuss reasons. Another study (139) reported an imbalance in the 
numbers and reasons for withdrawal. However, it was unable to be determined if this was 
related to the true outcome. Intention-to-treat (ITT) analysis was not used to manage the data 
in these three studies (139, 142, 179). The remaining studies were considered at low risk of 
bias since all outcome data were available. Protocols and registration information could not 
be identified for all studies. Further, three studies (147, 156, 179) did not report the results of 
outcomes mentioned in the ‘method’ section of the articles. These studies (147, 156, 179) 
were judged as high risk for selective outcome reporting and the rest of studies were unclear 
risk (see Table 7.3).  
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Table 7.3: Risk of Bias Assessment Results: Chinese Herbal Medicine as Add-on Therapy v. Antihistamines for Chronic 
Urticaria 
First author, 
publication year 
Sequence 
generation 
Allocation 
concealmen
t 
Blinding of 
participant
s 
Blinding of 
personnel 
Blinding of 
outcome 
assessors 
Incomplete 
outcome 
data 
Selective 
outcome 
reporting 
Bai WJ 2011 (177) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Bao LX 2008 (176) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Chen CS 2015 (194) Unclear Unclear High risk  Unclear Unclear Low risk  Unclear 
Chen JY 2014 (181) Unclear Unclear High risk  Unclear Unclear Low risk  Unclear 
Chen XB 2011 (145) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Cheng Y 2010 (175) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Deng D 2012 (174) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Ding QY 2007 (173) High risk High risk  High risk  High risk Unclear Low risk  Unclear 
Feng S 2015 (195) Low risk Unclear High risk  Unclear Unclear Low risk  Unclear 
Fu YH 2011 (141) Low risk  Unclear High risk  High risk Unclear Low risk  Unclear 
Guo XY 2014 (182) Unclear Unclear High risk  Unclear Unclear Low risk  Unclear 
Huang SY 2012 (206) High risk  Unclear High risk  High risk Unclear Low risk  Unclear 
Jiang YP 2009 (172) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Jiang YP 2011 (151) High risk Unclear High risk  High risk Unclear Low risk  Unclear 
Jie SH 2014 (135) Unclear Unclear High risk  Unclear Unclear Low risk  Unclear 
Leng J 2014 (136) Unclear Unclear High risk  Unclear Unclear Low risk  Unclear 
Li CH 2014 (183) Unclear Unclear High risk  Unclear Unclear Low risk  Unclear 
Li ZL 2013 (171) High risk  High risk  High risk  High risk Unclear Low risk  Unclear 
Liao C 2014 (184)  Unclear Unclear High risk  Unclear Unclear Low risk  Unclear 
Lin YP 2012(149) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Lin ZF 2014 (142) Unclear Unclear High risk  Unclear Unclear Unclear Unclear 
Liu Y 2014 (185) Unclear Unclear High risk  Unclear Unclear Low risk  Unclear 
Long JW 2010 (139) Low risk Unclear High risk Unclear Unclear Unclear Unclear 
Lu JM 2007 (180) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Lu XY 2010 (205) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Ma LB 2012 (170) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
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publication year 
Sequence 
generation 
Allocation 
concealmen
t 
Blinding of 
participant
s 
Blinding of 
personnel 
Blinding of 
outcome 
assessors 
Incomplete 
outcome 
data 
Selective 
outcome 
reporting 
Ma WH 2010 (169) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Ma XM 2013 (178) Low risk  Unclear High risk  High risk Unclear Low risk  Unclear 
Mei T 2014 (186) Low risk  Unclear High risk  Unclear Unclear Low risk  Unclear 
Mi L 2008 (204) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Mou Y 2011 (168) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Qian M 2011 (140) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Shi CR 2013 (99) Low risk  Unclear High risk  High risk Unclear Low risk  Unclear 
Song SH 2015 (144) Unclear Unclear High risk  Unclear Unclear Low risk  Unclear 
Sun H 2015 (196) Unclear Unclear High risk  Unclear Unclear Low risk  Unclear 
Sun RF 2007 (203) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Sun RH 2014 (187) Unclear Unclear High risk  Unclear Unclear Low risk  Unclear 
Sun RL 2014 (188) Unclear Unclear High risk  Unclear Unclear Low risk  Unclear 
Tian AP 2011 (202) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Tian J 2015 (197) Low risk Unclear High risk  Unclear Unclear Low risk  Unclear 
Wang N 2011 (167) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Wang NL 2010 (201) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Wang YF 2011 (166) High risk  High risk  High risk  High risk Unclear Low risk  Unclear 
Wang YJ 2011 (165) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Wei X 2013 (164) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Wu CY 2014 (189) Low risk  Unclear High risk  Unclear Unclear Low risk  Unclear 
Wu GZ 2012 (200) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Wu YX 2007 (163) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Wu YX 2015 (198) Unclear Unclear High risk  Unclear Unclear Low risk  Unclear 
Xiao HW 2010 (162) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Xu JJ  2014 (190) Low risk  Unclear High risk  Unclear Unclear Low risk  Unclear 
Xue CL 2009 (100) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Yang L 2011 (161) High risk Unclear High risk  High risk Unclear Low risk  Unclear 
Yang MF 2014 (143) Unclear Unclear High risk  Unclear Unclear Low risk  Unclear 
Yang YS 2014 (150) Unclear Unclear High risk  Unclear Unclear Low risk  Unclear 
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t 
Blinding of 
participant
s 
Blinding of 
personnel 
Blinding of 
outcome 
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Incomplete 
outcome 
data 
Selective 
outcome 
reporting 
Ye WW 2009 (160) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Yuan JQ 2013 (146) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Zhang HB 2011 (159) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Zhang HX 2014 (191) Unclear Unclear High risk  Unclear Unclear Low risk  Unclear 
Zhang L 2014 (137) Unclear Unclear High risk  Unclear Unclear Low risk  Unclear 
Zhang Q 2011 (148) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Zhang TL 2011 (158) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Zhao HW 2010 (157) Low risk  Unclear High risk  High risk Unclear Low risk  Unclear 
Zhao JH 2010 (156) High risk  High risk  High risk High risk Unclear Low risk  High risk  
Zhao YY 2014 (192) Low risk  Unclear High risk  Unclear Unclear Low risk  Unclear 
Zhao ZY  2004 (152) High risk High risk  High risk  High risk Unclear Low risk  Unclear 
Zheng Y 2008 (155) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Zheng ZY  2014 (193) Unclear Unclear High risk  Unclear Unclear Low risk  Unclear 
Zhong JQ 2011 (138) Low risk Unclear Low risk Low risk Low risk Low risk Unclear 
Zhong X 2005 (153) High risk  High risk  High risk  High risk Unclear Low risk  Unclear 
Zhou JW 2011 (199) Unclear Unclear High risk  High risk Unclear Low risk  Unclear 
Zhou L 2012 (147) High risk  High risk  High risk  High risk Unclear Low risk  High risk  
Zhu JF 2012 (154) Unclear Unclear High risk High risk Unclear Low risk  Unclear 
Zhuang Q 2011 (179) High risk  High risk  High risk  High risk Unclear Unclear High risk  
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7.3.4 Effects of the Intervention 
Urticaria Activity Score 
Four studies used UAS to assess disease activity (99, 140, 181, 184). As add-on therapy to 
second-generation antihistamine, one study indicated that CHM reduced UAS score by 0.45 
points at the end of treatment when compared with second-generation antihistamine alone ([-0.58, 
-0.32]) (140). One study reported UAS percentage score change from baseline (99). Statistical 
difference was not found between groups (MD: 0.14 [-0.25, 0.53]). The remaining two studies 
(181, 184) reported the number of participants who achieved UAS score changes of 30% or 
higher after receiving treatments. When the data were pooled, CHM as add-on therapy did not 
increase the number of participants achieving UAS score improvements of 30% or higher when 
compared with antihistamines (RR: 1.16 [1.00, 1.35], I
2 
= 15%, p = 0.05). 
Effective Rate 30 
The data of ER 30 from 13 studies (100, 145, 148, 152, 153, 199–206) were pooled to evaluate 
the effects of CHM as add-on therapy to antihistamines. The results showed that CHM could 
provide additional benefits in improving chronic urticaria symptoms by 30% or more compared 
with antihistamines alone (RR: 1.19 [1.10, 1.27], I
2 
= 54%) (see Table 7.4). 
Sensitivity and subgroup analyses were conducted to explore the substantial statistical 
heterogeneity (54%) (see Table 7.4). As none of the studies reporting ER 30 were assessed as 
low risk bias for sequence generation, an alternative method was used to explore statistical 
heterogeneity. After excluding studies judged as high risk of bias for sequence generation, 
sensitivity analysis involving 11 studies still found CHM as an add-on therapy favourable and 
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reduced the statistical heterogeneity to 33%. Subgroup analysis according to the various 
antihistamine agents suggested that CHM as an add-on therapy increased the number of 
participants achieving improvement in symptoms by 30% or more compared with cetirizine (RR: 
1.20 [1.08, 1.33], I
2 
= 0%), and levocetirizine (RR: 1.27 [1.09, 1.49], I
2 
= 63%). The statistical 
heterogeneity was removed when cetirizine was used as co-intervention and comparator, but 
remained substantial when levocetirizine was applied. Statistical difference was not found in 
comparison with loratadine (RR: 1.35 [0.79, 2.31], I
2 
= 74%) or mizolastine (RR: 1.06 [0.99, 
1.15], I
2
 = 0%). 
Table 7.4: Effect Size Analysis: Chinese Herbal Medicine as Add-on Therapy v. 
Antihistamines for Chronic Urticaria: ER 30 
Subgroup No. of 
studies 
No. of cases 
analysed 
(I/C) 
Effect estimate 
(RR, 95% CI, I
2
) 
References 
NA 13 601/576 1.19 [1.10, 1.27], 
54 % 
(100, 145, 148, 152, 153, 199-
206) 
Sensitivity 
analysis: 
excluding high 
RoB SG 
11 508/488 1.22 [1.14, 1.31], 
33 % 
(100, 145, 148, 199-206) 
Cetirizine 3 121/115 1.20 [1.08, 1.33], 0 
% 
(100, 204, 206) 
Loratadine 2 70/70 1.35 [0.79, 2.31], 
74 % 
(145, 199) 
Levocetirizine 4 235/225 1.27 [1.09, 1.49], 
63 % 
(200, 202, 203, 205) 
Mizolastine 2 93/88 1.06 [0.99, 1.15], 
0% 
(152, 153) 
Notes: C: comparator; CHM: Chinese herbal medicine; CI: confidence interval; ER 30: effective rate based on 
Chinese Medicine guideline; I: intervention; NA: not applicable; RR: risk ratio; RoB: risk  of bias assessment; SG: 
sequence generation 
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Symptom Severity Reduction Index 30 
CHM as an add-on therapy also improved the outcome SSRI 30. Meta-analysis of 57 studies 
showed that additional CHM increased the number of participants who achieved an improvement 
in symptoms of 30% or more when compared with antihistamine alone (RR: 1.19 [1.14, 1.24], I
2 
= 80%) (see Table 7.5). Again, sensitivity and subgroup analyses were conducted due to high 
statistical heterogeneity (80%). Studies deemed at low risk of bias for sequence generation were 
included to perform sensitivity analysis. Although the effect size increased, the statistical 
heterogeneity was still high (RR: 1.27 [1.12, 1.44], I
2 
= 85%) (see Table 7.5). 
As most of the included studies adhered to a treatment duration of four weeks, subgroup analysis 
of this treatment duration was performed (see Table 7.5). No noteworthy change was observed in 
the amount of statistical heterogeneity (RR: 1.16 [1.10, 1.22], I
2 
= 80%). Subgroup analysis by 
comparators found CHM as an add-on therapy increased the chance of achieving SSRI 30 when 
compared with cetirizine (RR: 1.27 [1.12, 1.43], I
2 
= 75%) and levocetirizine (RR: 1.14 [1.04, 
1.24], I
2 
= 41%). The statistical heterogeneity of both groups decreased, especially the 
levocetirizine group, with an acceptable level. No statistical difference was found between CHM 
as an add-on therapy and loratadine groups, and heterogeneity increased (RR: 1.29 [0.97, 1.74], 
I
2 
= 89%). 
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Table 7.5: Effect Size Analysis: Chinese Herbal Medicine as Add-on Therapy v. Antihistamines for Chronic Urticaria: SSRI 30 
Subgroup No. of 
studies 
No. of 
cases 
analysed 
(I/C) 
Effect estimate (RR, 95% 
CI, I
2
) 
References 
NA 57 2981/2781 1.19 [1.14, 1.24], 80 % (99, 139–144, 146, 147, 149-151, 154–198) 
Sensitivity 
analysis: Low 
RoB SG 
11 493/347 1.27 [1.12, 1.44], 85 % (99, 139, 141, 157, 178, 186, 189, 190, 192, 195, 197) 
Cetirizine 11 577/539 1.27 [1.12, 1.43], 75 % (99, 139, 141, 149, 154, 155, 160, 172, 180, 183, 184) 
Loratadine 5 194/187 1.29 [0.97, 1.74], 89 % (163, 175, 177, 190, 195) 
Levocetirizine 4 202/199 1.14 [1.04, 1.24], 41 % (142, 143, 158, 173) 
Treatment 
duration four 
weeks/one 
month 
37 1965/1812 1.16 [1.10, 1.22], 80 % (99, 139, 140, 143, 144, 146, 147, 154–159, 161-167, 169, 
170, 172–176, 178, 180–185, 189, 192, 197) 
Notes: C: comparator; CHM: Chinese herbal medicine; CI: confidence interval; I: intervention; MD: mean difference; NA: not applicable; RR: risk ratio; RoB: 
risk of bias assessment; SG: sequence generation; SSRI 30: effective rate based on Symptom Severity Reduction Index 
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In addition to the consideration of comparators and treatment duration, subgroup analysis was 
performed according to the frequently used CHM formula or compound products (see Table 7.6). 
Most CHM formulae or compound products provided additional benefits to antihistamines in 
achieving SSRI 30, such as Yu ping feng san 玉屏风散 (RR: 1.13 [1.06, 1.20], I2 = 34%), CG 
(from gan cao甘草) 复方甘草酸苷 (RR: 1.11 [1.01, 1.22], I2 = 68%) and Dang gui yin zi 当归
饮子 (RR: 1.28 [1.05, 1.56], I2 = 0%). No statistical difference was observed when Xiao feng san
消风散 (RR: 1.05 [0.86, 1.29], I2 = 31%) and Qi feng granules 芪风颗粒 (RR: 1.06 [0.83, 1.36], 
I
2 
= 91%), as add-on therapies, were compared with antihistamines. Substantial statistical 
heterogeneity was still detected in more than half of the subgroups. 
 Table 7.6: Effect Size Analysis: Individual Chinese Herbal Medicine Formulae as Add-on 
Therapy v. Antihistamines for Chronic Urticaria: SSRI 30 
CHM formula No. of 
studie
s 
No. of 
cases 
analysed 
(I/C) 
Effect estimate  
(RR, 95% CI, I
2
) 
References 
Compound 
glycyrrhizin 
capsules 
6 354/328 1.11 [1.01, 1.22], 
68 % 
(151, 154, 182, 193, 197, 
198) 
Dang gui yin zi 2 66/68 1.28 [1.05, 1.56], 
0 % 
(99, 158) 
Qi feng granules 2 119/105 1.06 [0.83, 1.36], 
91 % 
(170, 172) 
Total glycosides of 
peony 
8 406/377 1.20 [1.01, 1.43], 
84 % 
(139, 149, 150, 165, 168, 188, 
191, 192) 
Tripterygium 
glycosides 
3 319/304 1.32 [1.10, 1.58], 
69 % 
(140, 161, 176) 
Xiao feng san 2 66/66 1.05 [0.86, 1.29], 
31 % 
(146, 177) 
Yu ping feng san 9 438/412 1.13 [1.06, 1.20], 
34 % 
(142, 156, 162, 164, 178, 183, 
184, 186, 194) 
Notes: CHM: Chinese herbal medicine; CI: confidence interval; MD: mean difference; RR: risk ratio; SSRI 30: 
effective rate based on Symptom Severity Reduction Index 
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Relapse rate 
The pooled data of two studies (152, 153) indicated that CHM as an add-on therapy reduced the 
risk of relapse (relapse rate) in comparison with antihistamines (RR: 0.27 [0.14, 0.54], I
2 
= 0%). 
Dermatology Life Quality Index 
The outcome related to QoL was reported in one study. Additional CHM improved the DLQI 
score of participants with chronic urticaria by 0.68 points when compared with antihistamines 
(MD: -0.68 [-0.92, -0.44]) (140). 
7.3.5 Adverse Events 
Most studies reported AEs except for 22 studies (100, 145, 148, 151–154, 161, 167, 171, 174, 
179, 184, 186, 189, 194, 196, 198, 200, 201, 204, 206). Among these studies, seven studies 
reported no AEs (158, 162, 177, 183, 199, 202, 205) and five mentioned the nature of the events 
without specifying the number of AEs (135, 137, 138, 146, 165). The frequencies of AEs were 
calculated in the remaining studies. The number of AEs in participants who received CHM 
combined with antihistamine was 249, which was slightly higher than AEs reported for 
antihistamine use alone (228). The most commonly observed AEs in the add-on therapy group 
were somnolence (96 cases), gastrointestinal events (71 cases), dry mouth (17 cases) and 
dizziness (nine cases). AEs in the antihistamine group included somnolence (93 cases), dry 
mouth (45 cases), dizziness (18 cases), gastrointestinal events (16 cases) and fatigue (14 cases). 
Gastrointestinal events mainly involved diarrhoea, stomach discomfort and nausea, and were 
more frequently reported in participants who received CHM (see Table 7.7). 
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7.3.6 Publication Bias 
Potential publication bias should be noted for ER 30 (13 studies) and SSRI 30 (57 studies) since 
the funnel plots showed asymmetry in the distribution of studies (see Figures 7.2 and 7.3). 
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Table 7.7: Adverse Events of Included Randomised Controlled Trials: Chinese Herbal Medicine as Add-on Therapy v. 
Antihistamines for Chronic Urticaria 
First author, 
publication year 
Adverse events 
Bai WJ 2011 (177) None  
Bao LX 2008 (176) I: Dry mouth (7), somnolence (7), fatigue (7), gastrointestinal discomfort (2), menstruation deferred (2). C: dry 
mouth (5), somnolence (5), fatigue (5) 
Chen CS 2015 (194) NS 
Chen JY 2014 (181) I: Somnolence (2), stomach discomfort (2). C: dizziness (1) 
Chen XB 2011 (145) NS 
Cheng Y 2010 (175) I: Somnolence (3), dry mouth (1), nausea (1), poor appetite (1). C: somnolence (4), dry mouth (1) 
Deng D 2012 (174) NS 
Ding QY 2007 (173) I: Somnolence (3), dizziness (1). C: dizziness (2), dry mouth (5), constipation (2) 
Feng S 2015 (195) I: Dizziness and lack of strength (1), dry mouth (1). C: somnolence (1) 
Fu YH 2011 (141)* I: Diarrhoea (1), abdominal pain (1), somnolence (4), headache (2), nausea (1). C1: Dry mouth (2), somnolence (5), 
fatigue (3), headache (2). C2: dry mouth (1), diarrhoea (1). C3: dry mouth (2), diarrhoea (2), abdominal pain (1) 
Guo XY 2014 (182) Somnolence (16) 
Huang SY 2012 (206) NS 
Jiang YP 2009 (172) I: Somnolence (2), dizziness (1). C: dizziness (2), dry mouth (3) 
Jiang YP 2011 (151) NS 
Jie SH 2014 (135) Abdominal discomfort (NS) 
Leng J 2014 (136) I: Somnolence and dizziness (1). C: dry month (4), constipation (2) 
Li CH 2014 (183) None  
Li ZL 2013 (171) NS 
Liao C 2014 (184) NS 
Lin YP 2012 (149) I: Diarrhoea (3), somnolence (1). C: somnolence (2) 
Lin ZF 2014 (142) I: Somnolence, dizziness, tired and inattention (6). C: somnolence, dizziness, tired and inattention (7) 
Liu Y 2014 (185) I: Dizziness (1), mild swelling of lower limbs (1). C: dizziness (2), mild swelling of lower limbs (1), feel hot (1) 
Long JW 2010 (139) I: Drowsiness, dizziness and weakness (8), mild diarrhoea (2). C: drowsiness, dizziness and weakness (7) 
Lu JM 2007 (180) I: Abdominal discomfort (3), poor appetite (3). C: dry mouth (4), fatigue (4) 
Lu XY 2010 (205) None  
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First author, 
publication year 
Adverse events 
Ma LB 2012 (170) I: Somnolence (9), dry mouth (2). C: somnolence (6), dry mouth (4), dizziness (2), constipation (2) 
Ma WH 2010 (169) I: Somnolence (2), dry mouth (2). C: somnolence (2), headache (2) 
Ma XM 2013 (178) I: Nausea, stomach discomfort (3). C: dry mouth (2), fatigue (1), increased appetite (1) 
Mei T 2014 (186) NS 
Mi L 2008 (204) NS 
Mou Y 2011 (168) Total: Somnolence (5) 
Qian M 2011 (140) I: Nausea and vomiting (4), dizziness (3), insomnia (3), palpitation (3), hair loss (3). C: somnolence (C3:4, C2:3), 
dizziness (C3:1), body discomfort (C3:1) 
Shi CR 2013 (99) I: None. C1: dizziness (1), somnolence (1). C2: Diarrhoea (2) 
Song SH 2015 (144) I: Somnolence and headache (3), diarrhoea (2). C1: somnolence (3), headache and dizziness (2), liver function index 
slightly higher (1). C2: Loose stool and abdominal discomfort (3), nausea (1) 
Sun H 2015 (196) NS 
Sun RF 2007 (203) I: Somnolence (3), stomach discomfort (1), dry mouth (1). C: somnolence (4), stomach discomfort (1), dry mouth (2) 
Sun RH 2014 (187) I: Dizziness (1), dry month (1), somnolence and lack of strength (2). C: dry month (3), somnolence (3), 
gastrointestinal discomfort (2), constipation (3) 
Sun RL 2014 (188) I: Diarrhoea (2). C: somnolence, lack of strength and dry mouth (1) 
Tian AP 2011 (202) None  
Tian J 2015 (197) I: Somnolence, slow reaction, dizziness (3). C: somnolence, slow reaction, dizziness (4) 
Wang N 2011 (167) NS 
Wang NL 2010 (201) NS 
Wang YF 2011 (166) I: Somnolence (3), gastrointestinal discomfort (2). C: somnolence (2), dry mouth (4), constipation (2) 
Wang YJ 2011 (165) Somnolence (NS), headache (NS), nausea (NS) 
Wei X 2013 (164) I: Dizziness and fatigue (2), dry mouth (1). C: dizziness (1), somnolence (1) 
Wu CY 2014 (189) NS 
Wu GZ 2012 (200) NS 
Wu YX 2007 (163) I: Somnolence (2), headache (3), stomach discomfort (1), diarrhoea (1). C: somnolence (3), dizziness (2), dry mouth 
(2), fatigue (1)  
Wu YX 2015 (198) NS 
Xiao HW 2010 (162) None  
Xu JJ 2014 (190) I: Somnolence (2), dry mouth (1). C: somnolence (1), dry month (2), constipation (1) 
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First author, 
publication year 
Adverse events 
Xue CL 2009 (100) NS 
Yang L 2011 (161) NS 
Yang MF 2014 (143) I: Somnolence (3), headache (2). C1: somnolence (3), hiccups (3), nausea (1). C2: NS 
Yang YS 2014 (150) I: Diarrhoea (20), somnolence (4). C: somnolence (6) 
Ye WW 2009 (160) I: Somnolence (3), abdominal distension (4). C: somnolence (4) 
Yuan JQ 2013 (146) Somnolence (NS), dry mouth (NS), poor appetite (NS) 
Zhang HB 2011 (159) I: Somnolence (2), headache (1), nausea (1). C: somnolence (2), headache (2) 
Zhang HX 2014 (191) I: Somnolence (1), diarrhoea (4). C: somnolence (2) 
Zhang L 2014 (137) Somnolence, headache, gastric acid increased, nausea and vomiting (NS) 
Zhang Q 2011 (148) NS 
Zhang TL 2011 (158) None 
Zhao HW 2010 (157) I: Somnolence (4). C: dry mouth (2) 
Zhao JH 2010 (156) I: Somnolence (5). C: dizziness (4) 
Zhao YY 2014 (192) I: Somnolence (2), nausea (1), diarrhoea (3). C: somnolence (4), nausea (3) 
Zhao ZY 2004 (152) NS 
Zheng Y 2008 (155) I: Somnolence (5), gastrointestinal discomfort (3). C: somnolence (4) 
Zheng ZY  2014 (193) I: Somnolence (3), dizziness (2). C: somnolence (2) 
Zhong JQ 2011(138) Gastrointestinal disturbance (NS), drowsiness (NS), paraesthesia (NS), ‘and so on’ (NS) 
Zhong X 2005 (153) NS 
Zhou JW 2011 (199) None  
Zhou L 2012 (147) I: Somnolence and dry month (3). C: somnolence and dry month (2) 
Zhu JF 2012 (154) NS 
Zhuang Q 2011 (179) NS 
Notes: C: Control; I: Intervention; NS: not stated 
 Figure 7.2: Funnel Plot of Chinese Herbal Medicine as Add-on Therapy v. Second-
Generation Antihistamines for Chronic Urticaria: ER 30 
Notes: CHM: Chinese herbal medicine; ER 30: effective rate based on Chinese Medicine guideline 
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Figure 7.3: Funnel Plot of SSRI 30 (Chinese Herbal Medicine as Add-on Therapy v. 
Second-Generation Antihistamines for Chronic Urticaria) 
Notes: CHM: Chinese herbal medicine; SSRI 30: effective rate based on Symptom Severity Reduction Index 
7.4 Discussion 
7.4.1 Effects of Interventions 
Meta-analysis suggested CHM as add-on therapies to second-generation antihistamines 
improved the clinical outcomes of patients with chronic urticaria. UAS was used in four 
studies, but only one study used it as indicated in clinical practice guidelines (10). This single 
study suggested that CHM as an add-on therapy to antihistamines improved UAS. The usage 
of UAS in the other three studies differed from prescribed use. Therefore, the clinical 
relevance is uncertain. 
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ER 30 and SSRI 30 were the most frequently used outcomes in the included studies. Meta-
analysis suggested that CHM as add-on therapy to antihistamines could increase the number 
of participants who achieved the improvement in symptoms of chronic urticaria by 30% or 
more. However, substantial statistical heterogeneity was detected for pooled data of both ER 
30 and SSRI 30. Sensitivity analysis and subgroup analysis were performed to explore 
heterogeneity based on sequence generation, treatment duration, comparators and individual 
CHM formula. The statistical heterogeneity was reduced to an acceptable level for only a few 
subgroups, such as the individual herbal formula Yu ping feng san 玉屏风散 (I2 = 34%), 
Dang gui yin zi 当归饮子 (I2 = 0%) and Xiao feng san消风散 (I2 = 31%). Further, the pooled 
data from nine studies of Yu ping feng san 玉屏风散 indicated a favourable effect of this 
formula with low levels of statistical heterogeneity, which suggests this formula may be 
useful for clinical practice. No change or increase in heterogeneity were observed for most 
subgroups. The reasons for statistical heterogeneity remained unclear, despite subgroup 
analyses to account for different factors. 
7.4.2 Safety 
The most commonly reported AEs for participants who received add-on therapies were 
similar to those experienced by those in the antihistamines group. Somnolence was the most 
frequently reported AE in both groups. This was surprising because second-generation 
antihistamines are believed to have fewer sedating effects. Other commonly observed AEs in 
the CHM as add-on therapy groups were gastrointestinal events. This might be related to 
CHM and has been found in other health conditions (125). Overall, CHM as an add-on 
therapy to second-generation antihistamines was well tolerated by patients with chronic 
urticaria. 
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7.4.3 How Chinese Herbal Medicine Might Work 
Anti-allergy and anti-inflammation are two important pharmacological action mechanisms 
targeting the pathogenesis of urticaria (10). Six frequently used herbs (fang feng 防风, huang 
qi 黄芪, dang gui 当归, gan cao 甘草, jing jie 荆芥 and bai zhu 白术) and one formula, Yu 
ping feng 玉屏风散 (fang feng 防风, huang qi 黄芪 and bai zhu 白术), have been shown to 
have anti-allergic or/and anti-inflammatory actions in experimental studies in vivo or in vitro. 
The ethanol extract of fang feng 防风 has been shown to suppress the production of 
inflammatory mediators, such as NO and prostaglandin E2 (PGE2), and pro-inflammatory 
cytokines, such as tumour necrosis factor-α (TNF-α) and IL-6 in lipopolysaccharide (LPS)-
induced murine macrophages (RAW 264.7 cells) (207). This cell model is commonly used for 
the examination of anti-inflammatory activities. The anti-inflammatory action of fang feng 防
风 extract may result from the inhibition of nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) binding activity and p38 mitogen activated protein kinases 
(MAPKs) phosphorylation (208, 209), two important transcription factors in the regulation of 
inflammation. In rats with induced dermatitis, induced ear swelling and ear inflammation 
were inhibited by oral use of huang qi 黄芪 aqueous extract (210). In rats with induced 
allergic dermatitis, the level of total serum IgE was reduced with topical application of huang 
qi 黄芪 ethanol extract. Additionally, it could suppress the expression of NF-κB (130). The 
levels of inflammatory mediators (PGE2, histamine and 5-hydroxytryptamine) were inhibited 
using dang gui 当归 volatile oils in rats with acute inflammation (211). Gan cao 甘草 is a 
key herb used in CM and has been shown to possess both anti-allergic and anti-inflammatory 
properties (127, 131, 212). Flavonoids from gan cao 甘草, such as liquiritigenin, 18β-
glycyrrhetinic acid and licochalcone D, potently inhibited the degranulation of RBL-2H3 
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cells, reducing the release of allergic inflammation mediators such as histamines (131, 212). 
In ovalbumin-induced mice, the scratching behaviour and IgE production could be also 
inhibited by liquiritigenin and 18β-glycyrrhetinic acid (131). Jing jie 荆芥 and bai zhu 白术 
have been shown to inhibit allergic reactions in animal models (133, 134, 213). In the plasma 
of rats with mast cell-mediated immediate-type hypersensitivity, systemic allergic reaction 
was dose-dependently inhibited by jing jie 荆芥 aqueous extract. Further, it significantly 
reduced histamine levels (133). Bai zhu 白术 extract greatly inhibited the oedema in 
carrageenan-induced rat paw oedema (213). 
Yu ping feng san 玉屏风散 and its extracts have been investigated for their anti-allergic and 
anti-inflammatory effects in vitro and in vivo (214–216). In mice with Th2 cell-mediated 
allergic contact dermatitis, ear thickness, ear inflammation and infiltration of inflammation 
cells were reduced after Yu ping feng san 玉屏风散 was administered at 6.5 g/kg (214). This 
is associated with the reduction of IL-4 levels in the ear tissue, suggesting the anti-allergic 
and anti-inflammatory effects of Yu ping feng san 玉屏风散 may be due to the reduction of 
IL-4 (214). The expressions of pro-inflammatory cytokines (such as IL-1β, IL-6 and TNF-α) 
in LPS-induced RAW264.7 cells were suppressed by Yu ping feng san 玉屏风散 extract in a 
dose-dependent mode (215). These anti-inflammatory effects may be due to the suppression 
of key inflammatory enzymes, namely inducible NO synthase (iNOS) and cyclo-oxygenase-2 
(COX-2), partly through NF-κB pathway (216). 
7.4.4 Limitations and Implications for Research and Clinical Practice 
The most commonly observed outcomes in the included studies were ER 30 and SSRI 30. ER 
30 was recommended by CM practice guidelines (63). Despite an extensive search, no 
reference was found for SSRI 30. While these two outcomes assessed the disease activity of 
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the two key urticaria symptoms (wheals and pruritus) and reflected the clinical focus, they are 
not commonly used in international studies. These outcomes were not validated following 
internationally recognised standards. This limits the findings’ translation into clinical practice 
to some extent. Outcomes recognised internationally should be considered for future clinical 
trials to evaluate the efficacy of CHM for chronic urticaria. 
The recurrence of chronic urticaria symptoms (wheals and pruritus) bothers patients and has 
significant impact on HR-QoL (10, 14–17). One included study reported DLQI, with some 
promising results. HR-QoL should be given more focus in future trials. The challenge in the 
treatment of chronic urticaria is to achieve effective control to prevent recurrence of 
symptoms. Relapse rate was mentioned in several studies. However, no consensus on the 
definition of relapse rate was reached. Relapse rate needs to be specified clearly. 
7.5 Conclusion 
CHM as an add-on therapy to second-generation antihistamines could enhance clinical 
responses in improving symptoms of chronic urticaria by 30% or more, and appears to be 
well tolerated by patients. However, the certainty of the findings is limited by factors 
including the methodological flaws of included studies, substantial statistical heterogeneity 
and uncertain validity of outcomes. 
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Chapter 8. Systematic Review 3: 
Compound Glycyrrhizin for Psoriasis Vulgaris 
8.1 Background 
Findings from Chapters 6 and 7 have shown CHM to be effective for chronic urticaria. For 
psoriasis vulgaris, several SRs have been identified that evaluate the efficacy and safety 
CHM. Four previous SRs of RCTs (28–31) evaluated topical CHM for psoriasis vulgaris, and 
one SR (96) evaluated oral CHM. All reviews suggested that CHM was more effective than 
WM. The limitation of these SRs was the inclusion of some outcomes that are not recognised 
internationally. The evidence related to QoL was lacking in these SRs. Further, all five SRs 
provided evidence from a general perspective (overall CHM) and focused on high level 
evaluation of CHM as an intervention. No reviews that examined the efficacy of a particular 
herb formula or product were identified. 
One CHM product called compound glycyrrhizin (CG), with its key constituent glycyrrhizin 
extracted from gan cao 甘草 , is commonly used in clinical practice in China for both chronic 
urticaria and psoriasis vulgaris. CG has been evaluated for chronic urticaria and shows 
promising effects as an add-on therapy to second-generation antihistamines (see Chapter 7). 
To date, one review was identified that compared CG with acitretin for psoriasis vulgaris (see 
Section 8.2), but no review of this product has been identified to determine its effectiveness 
as an add-on therapy to conventional therapy. Therefore, the third SR focused on the add-on 
effect of CG to conventional therapy for psoriasis vulgaris. This chapter has been published 
in the journal Current Medical Research and Opinion (85). 
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8.2 Introduction 
Psoriasis is a chronic, genetic, systemic and inflammatory disorder, which affects one in 50 
people globally (13). Psoriasis vulgaris is the most common type of psoriasis representing 
approximately 80–90% of psoriasis patients (13). Patients may progress to other types of 
psoriasis, such as erythrodermic or pustular types, because of inappropriate therapies or 
infection (12, 13). In addition to disfigured skin lesions that itch, research has linked psoriasis 
with an increased risk of cardiovascular disease, diabetes and cancer among other morbidities 
(13). 
Guideline-recommended conventional therapy for psoriasis vulgaris includes topical 
therapies (for example, corticosteroids), phototherapy (NB-UVB) and systemic agents (for 
example, acitretin) (12, 13). Although these therapies are effective, AEs associated with long-
term use remains a major concern for patients (12, 13). There is evidence that the risks of 
conventional therapies include local and systemic side effects from topical corticosteroids, 
skin cancer with methoxsalen (psoralen) and ultraviolet A radiation (PUVA) or teratogenicity 
with systemic retinoids (217, 218). In addition, patients’ individual perceptions of disability 
from psoriasis, and preference for therapies may affect adherence. These factors need be 
taken into consideration for the treatment of chronic conditions such as psoriasis (217, 218). 
Up to 50% of patients with skin conditions in the United States (US) and United Kingdom 
use herbal medicines in conjunction with conventional therapy (24–26). 
Gan cao 甘草 (radix glycyrrhizae or liquorice root) is a key herb used in CM. Clinically, gan 
cao 甘草 has been used for a range of skin conditions including dermatitis, eczema and 
psoriasis (219, 220). CG is a manufactured product that contains glycyrrhizin and other 
ingredients (aminoacetic acid, methionine), with glycyrrhizin (glycyrrhizic acid) as the key 
component. It is also known as ‘Stronger Neo-Minophagen C’, and was originally used to 
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improve liver function abnormalities in chronic liver disease in Japan (221). In recent years, 
CG has also been used for immunological skin conditions (for example, psoriasis) in China 
due to its anti-inflammatory activity and immune-modulating effect (222). 
A systematic review on concurrent use of CG with acitretin for psoriasis vulgaris concluded 
that combining CG with acitretin was more effective than using acitretin alone, with fewer 
AEs (223). This review evaluated the additional benefit and safety of adding CG to all kinds 
of conventional therapies for psoriasis vulgaris. 
8.3 Methods 
Five English databases (PubMed, Embase, CINAHL, CENTRAL and AMED), one Japanese 
database (CiNii) and four Chinese databases (CBM, CNKI, CQVIP and Wanfang Data) were 
searched from inceptions to July 2015. Search terms were grouped according to intervention 
(glycyrrhizin and variants), condition (psoriasis and variants), and study design (randomly, 
randomised and variants), with adjustments for each database. Identified citations were 
exported to Endnote reference management software for further screening. 
RCTs comparing CG plus guideline-recommended conventional therapy with the same 
conventional therapy alone for psoriasis vulgaris were included (12, 13). The primary 
outcome was the proportion of patients achieving PASI 60 (that is, 60% or greater reduction 
in PASI score). PASI 60 is recommended in Consensus of diagnosis and treatment of 
psoriasis vulgaris in integrative medicine published in China (94). PASI 50/70 are considered 
treatment goals based on international guidelines (12, 95). As suggested in previous SRs (28, 
96), PASI 60 was frequently used in RCTs in China as the primary outcome. Secondary 
outcomes included PASI 90 (clinically cured), measures of HR-QoL (such as DLQI), relapse 
rate and AEs. 
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Data were extracted independently by two reviewers (Jingjie Yu and Claire Zhang). These 
reviewers evaluated methodological quality using the risk of bias tool developed by the 
Cochrane Collaboration (89). Disagreement was resolved through discussion or consultation 
with a third reviewer (Meaghan Coyle). 
Outcome data were analysed using Review Manager 5.3 software (97). Dichotomous data 
were expressed as RR and continuous data expressed as MD, with 95% CI. RD was presented 
as the actual difference in risk between the intervention and control groups. Fixed effects 
analysis was used. Statistical heterogeneity was evaluated using the I
2
 statistic. Subgroup 
analysis was planned according to conventional therapy type and preparation type of CG, 
while publication bias was assessed by visual inspection of funnel plots. This review protocol 
was registered in PROSPERO (CRD42015027763). 
8.4 Results 
Electronic database searches retrieved 724 potentially relevant citations. After removal of 
duplicates, 444 records were screened. Through title and abstract screening, 413 records did 
not meet the inclusion criteria. Exclusions included studies of conditions other than psoriasis 
vulgaris, non-RCTs and irrelevant outcomes. Further review of full text was required for 31 
articles, and 11 RCTs met the inclusion criteria (see Figure 8.1). All trials were conducted in 
China and published in Chinese language journals between 2006 and 2014. A two-arm 
parallel design was applied for all included studies except one, which used a three-arm design 
(224). The sample size of the largest study was 200 (225) and the smallest was 66 (226) (see 
Table 8.1). 
In total, 1,200 patients with psoriasis vulgaris completed these trials in hospital outpatient or 
inpatient departments. Seven studies (224–230) stated the disease stages of participants, 
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including progressive and stationary stages. The severity of psoriasis vulgaris was mentioned 
as mild to severe in three studies (225–227). Participants suffered from psoriasis vulgaris 
from one month (224) to 39 years (230). The mean age of participants ranged from 30.5 (231) 
to 40.3 years (232). Participants received treatment for four (224, 227, 230, 233) or eight 
weeks (225, 226, 228, 229, 232), with one study providing treatment for up to 12 weeks (234). 
Follow-up after two months was conducted in one study (231). 
8.4.1 Intervention and Co-intervention/Comparator 
The intervention group used CG and specific conventional therapy, while the comparison 
group used corresponding conventional therapy alone (see Table 8.2). CG was administered 
orally or intravenously. Capsules or tablets were given orally three times per day in seven 
studies (226, 229-234), with the dosage being prescribed as 50 or 75 mg in four studies (229, 
231, 232, 234). The remaining three studies described administration of CG as two or three 
capsules/tablets each time (226, 230, 233). Infusion was used with 40–60 ml or 80 mg of CG 
in four studies (224, 225, 227, 228). All studies administered CG within the suggested daily 
dosage (235, 236). 
Five studies used CG (Stronger Neo-Minophagen C) imported from Japan (225, 228, 230, 
232, 234), while two studies used CG products manufactured in China with the same 
chemical composition (229, 233). No information relating to the manufacturing source of CG 
was mentioned in the remaining studies. Conventional therapy included topical 
corticosteroids (230, 231, 233), NB-UVB (224, 227, 232), acitretin (225, 226, 234) and a 
combination of the above agents (228, 229). Dosing scheme of conventional therapy was 
consistent with guidelines (12, 13).  
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Figure 8.1: PRISMA Flow Chart of Study Selection Process: Compound Glycyrrhizin 
as Add-on Therapy v. Conventional Therapy for Psoriasis Vulgaris 
Notes: CG: Compound Glycyrrhizin; RCT: randomised controlled trial 
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Table 8.1: Characteristics of Included Randomised Controlled Trials: Compound Glycyrrhizin as Add-on Therapy v. Conventional 
Therapy for Psoriasis Vulgaris 
First 
author, 
publication 
year 
Country; 
setting 
Blinding; 
number 
of arms  
Treatment 
duration; 
follow-up 
duration 
Stage; 
severity 
Duration of 
psoriasis 
No. of 
participants 
randomised/
assessed; 
dropouts 
Age: mean 
(SD) (or 
range); 
gender M/F 
Intervention Control 
Du, 2014 
(229) 
China; 
hospital 
outpatients 
NS; 2 8 w; 0 I: PS and 
SS; NS 
17.5 (4.13) 
y 
I: 60/60; 0 I: 31.24 (9.45); 
39/21 
CG, acitretin, 
NB-UVB 
Acitretin, NB-
UVB 
C: PS 
and SS; 
NS 
18.4 (4.4) y C: 58/58; 0 C: 32.93 
(11.72); 37/21 
Huang, 
2014 (228)  
China; 
hospital 
patients 
(NS) 
NS; 2  8 w; 0 I: PS; NS 8.6 (1.8) y I: 45/45; 0 I: 43.5 (3.6); 
25/20 
CG, 
mometasone 
furoate 
cream, 0.1 % 
tretinoin 
cream, NB-
UVB 
Mometasone 
furoate cream, 
0.1 % tretinoin 
cream, NB-
UVB 
C: PS; 
NS 
8.2 (2.3) y C: 45/45; 0 C: 45.3 (5.8); 
23/22 
Jiang, 2014 
(226)  
China; 
hospital 
out/inpatie
nts 
NS; 2  8 w; 0 I: PS; 
psoriasis 
lesion 
area ≥ 
40 % 
BSA 
6.5 y I: 34/34; 0 I: 33.5; 18/16 CG, acitretin Acitretin 
C: PS; 
psoriasis 
lesion 
area ≥ 
40 % 
BSA 
5.7 y C: 32/32; 0 C: 37.5; 17/15 
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First 
author, 
publication 
year 
Country; 
setting 
Blinding; 
number 
of arms  
Treatment 
duration; 
follow-up 
duration 
Stage; 
severity 
Duration of 
psoriasis 
No. of 
participants 
randomised/
assessed; 
dropouts 
Age: mean 
(SD) (or 
range); 
gender M/F 
Intervention Control 
Luo, 2006 
(232) 
China, 
outpatients 
NS; 2  8 w; 0 I: NS; 
NS 
1.47 y I: 51/51; 0 I: 38.15 (20-
61); 27/24 
CG, NB-
UVB, 
moisture 
cream 
NB-UVB, 
moisture cream 
C: NS; 
NS 
1.31 y C: 46/46; 3 C: 40.22 (19-
63); 24/22 
Liu, 2008 
(225) 
China; 
hospital 
patients 
(NS) 
NS; 2  8 w; 0 I: NS; 
psoriasis 
lesion 
area ≤ 
30 % 
BSA 
3.36 (5.72) 
y 
I: 100/100; 0 I: 37.00 
(10.50); 71/29 
CG, acitretin Acitretin 
C: NS; 
psoriasis 
lesion 
area ≤ 
30 % 
BSA 
3.42 (5.46) 
y 
C: 100/100; 0 C: 37.50 
(10.25); 70/30 
Ma, 2011 
(231) 
China; 
hospital 
out/inpatie
nts 
NS; 2  4 w; 2 m NS; NS 6.7 y (2 m–
30 y) 
I: 47/47; 0 Total: 30.5 
(19-66); 46/44 
CG, 
mometasone 
furoate cream 
mometasone 
furoate cream C: 43/43; 0 
Wu, 2010 
(224) 
China; 
hospital 
inpatients 
NS; 3 4 w; 0 Total: PS 
and SS; 
NS 
8.7 y (1 m–
20 y) 
I: 42/42; 0 Total: 32.6 
(21-59); 66/54 
CG, NB-
UVB 
C1: NB-UVB 
C2: CG C1: 40/40; 0 
C2: 38/38; 0 
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First 
author, 
publication 
year 
Country; 
setting 
Blinding; 
number 
of arms  
Treatment 
duration; 
follow-up 
duration 
Stage; 
severity 
Duration of 
psoriasis 
No. of 
participants 
randomised/
assessed; 
dropouts 
Age: mean 
(SD) (or 
range); 
gender M/F 
Intervention Control 
Wang, 2014 
(233) 
China; 
hospital 
outpatients 
NS; 2  4 w; 0 I: NS; 
NS 
5.8 (1.2) y I: 60/60; 0 I: 37.4 (2.9); 
39/21 
CG, desonide 
cream 
desonide cream 
C: NS; 
NS 
5.6 (1.5) y C: 60/60; 0 C: 38.6 (3.1); 
31/29 
Yao, 2010 
(230) 
China; 
hospital 
patients 
(NS) 
NS; 2 4 w; 0 Total: PS 
and SS; 
NS 
1–39 y I: 48/48; 0 I: 42.3; 27/21 CG, 
compound 
flumetasone 
ointment 
compound 
flumetasone 
ointment 
C: 44/44; 0 C: 38.9; 25/19 
Yang, 2014 
(227) 
China; 
hospital 
outpatients
/inpatients 
NS; 2 4 w; 0 I: PS and 
SS; PASI 
≥ 10 
6.4 (2.5) y I: 65/65; 0 I: 37.4(6.1); 
35/30 
CG, NB-
UVB 
NB-UVB 
C: PS 
and SS; 
PAS I≥ 
10 
6.2 (2.4) y C: 60/60; 0 C: 35.5 (6.4); 
32/28 
Zhang, 2014 
(234)  
China; 
hospital 
patients 
(NS) 
NS; 2  8–12 w; 0 I: NS; 
NS 
6.3 (5.0) y I: 60/60; 0 I: 37.1 (9.6); 
37/23 
CG, acitretin Acitretin  
C: NS; 
NS 
5.7 (4.2) y C: 60/60; 0 C: 35.6 (8.9); 
35/25 
CG: Compound Glycyrrhizin; C: Control; I: Intervention; m: months; NB-UVB: narrow-band UVB; NS: not stated; PASI: Psoriasis Area and Severity Index; PS: progressive 
stage; SS: stationary stage; w: weeks, y: years 
  
 
162 
Table 8.2: Intervention/Comparators of Included Randomised Controlled Trials: Compound Glycyrrhizin as Add-on Therapy v. 
Conventional Therapy for Psoriasis Vulgaris 
First author, 
publication year 
Compound glycyrrhizin 
preparation type and 
dosage 
Country of 
compound 
glycyrrhizin 
manufacture 
Conventional 
therapy 
Dosage and administration 
Du, 2014 (229) Capsule, 50 mg po tid  China NB-UVB; Acitretin NB-UVB, qod; acitretin, 10 mg po bid  
Huang, 2014 (228) Injection, 60–80 ml ivgtt 
qd for 10 days 
consecutively, 
intermittent for four days  
Japan Mometasone 
furoate cream; 
0.1 % tretinoin 
cream; NB-UVB 
Mometasone furoate cream, topical use; 0.1 % tretinoin 
cream, 30–50 mg topical use, qn; NB-UVB, twice a 
week 
Jiang, 2014 (226) Capsule, two capsules po 
tid  
NS Acitretin 0.4–0.7 mg/kg·d as initial oral dosage, adjusted dosage 
based on condition severity and medication tolerance, 
10–20 mg qd as maintenance dosage 
Luo, 2006 (232) Tablet, 75 mg po tid  Japan NB-UVB NB-UVB, thrice a week 
Liu, 2008 (225) Injection, 60 ml ivgtt qd 
for 20 days consecutively 
Japan Acitretin 30 mg po qd for 45 days consecutively, 20 mg po qd as 
rest dosage 
Ma, 2011 (231) Tablet, 50 mg po tid  NS Mometasone 
furoate cream 
Topical use, qd 
Wu, 2010 (224) Injection, 40 ml ivgtt qd 
for 10 days  
NS NB-UVB NB-UVB, qod, 10 sessions in total 
Wang, 2014 (233) Capsule, three capsules 
po tid 
China Desonide cream Topical use, tid  
Yao, 2010 (230) Tablet, three tablets po 
tid 
Japan Compound 
flumetasone 
ointment 
Topical use, bid 
Yang, 2014 (227) Injection, 80 mg ivgtt qd  NS NB-UVB Twice a week 
Zhang, 2014 (234) Tablet, 75 mg po tid Japan Acitretin 20–40 mg/d as initial oral dosage, adjusted dosage 
based on condition severity and medication tolerance, 
10–20 mg qd as maintenance dosage 
Notes: bid: twice daily; ivgtt: intravenously guttae; mg: milligram; ml: milliliter; NB-UVB: narrow-band UVB; NS: not stated; po: administrated orally; qd: once daily; qod: 
every other day; tid: three times daily     
8.4.2 Outcome Measures 
Clinical response was evaluated by PASI 60 in all studies and all but one used PASI 90 (228). 
Relapse rate was reported in one study (231). However, the definition of relapse rate was not 
specified. None of the included studies reported DLQI. All but one study (228) reported AEs. 
8.4.3 Risk of Bias Assessment 
Four studies used random number tables to allocate participants and were judged as low risk 
for sequence generation (227, 229, 233, 234). One study was assessed as high risk because 
participants were assigned to different groups based on visiting order (231). No clear 
description of sequence generation was provided in the remaining six studies. Therefore, they 
were deemed an unclear risk. All studies were assessed as posing an unclear risk for 
allocation concealment due to a lack of detailed information. Blinding was not applied to 
participants or personnel in any of the included studies. Therefore, all studies were judged as 
high risk for this domain. Blinding of outcome assessors was not mentioned for the included 
studies and all were assessed as unclear risk. Dropouts related to AEs caused by NB-UVB 
were reported in one study (232), and the number was balanced between the two groups. 
Hence, it is unlikely to cause bias. No dropouts were reported for the remaining studies. 
Consequently, all studies were judged as low risk for incomplete outcome data. None of the 
studies reported details of trial registration or had published protocols, and all were assessed 
as unclear risk for selective outcome reporting (see Figure 8.2).  
 Figure 8.2: Risk of Bias Assessment: Compound Glycyrrhizin as Add-on Therapy v. 
Conventional Therapy for Psoriasis Vulgaris 
8.4.4 Effects of the Intervention 
Add-on Effect of CG to Conventional Therapy 
Meta-analysis showed that the chance of achieving PASI 60 (RR: 1.30 [1.21, 1.40], I
2 
= 6%, 
RD: 19%) or PASI 90 (RR: 1.37 [1.21, 1.56], I
2 
= 0%, RD: 14%) was higher in those who 
received CG plus conventional therapy than in those who received conventional therapy 
alone. Statistical heterogeneity was low. 
Subgroup Analysis by Therapy Type 
Pooled data from three studies (230, 231, 233) showed significant improvement in the 
number of people achieving PASI 60 (RR: 1.46 [1.23, 1.74], I
2 
= 0%, RD: 24%) and PASI 90 
(RR: 1.44 [1.07, 1.94], I
2 
= 0%, RD: 14%), when CG was used as an add-on therapy to 
topical corticosteroids. In addition, the combination therapy reduced the relapse rate in one 
study (RR: 0.34 [0.21, 0.54], RD: -68%) (231) (see Figure 8.3). 
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Compared to NB-UVB alone, the combination of CG and NB-UVB was more likely to 
increase the number of people achieving PASI 60 (RR: 1.19 [1.07, 1.33], I
2 
= 0%, RD: 14%) 
in three studies (224, 227, 232). A significant difference was also found for PASI 90 (RR: 
1.41 [1.16, 1.73], I
2 
= 53%, RD: 18%), but with moderate statistical heterogeneity. Additional 
subgroup analysis, including two studies (224, 227) with the same treatment duration, 
reduced the heterogeneity (RR: 1.28 [1.05, 1.56], I
2 
= 0%, RD: 16%). 
Meta-analysis including three studies (225, 226, 234) suggested that CG plus acitretin was 
superior to acitretin alone in terms of PASI 60 (RR: 1.30 [1.15, 1.47], I
2 
= 0%, RD: 19%) and 
PASI 90 (RR: 1.30 [1.01, 1.68], I
2 
= 0%, RD: 10%) (see Figure 8.3). 
Subgroup Analysis by CG Preparation Type 
As an add-on therapy to NB-UVB, the treatment effect of oral CG was not different to 
infusion in terms of PASI 60 (test for subgroup differences: Chi² = 0.91, df = 1 [P = 0.34], I²= 
0%), or PASI 90 (test for subgroup differences: Chi² = 2.54, df = 1 [P = 0.11], I² = 60.6%). 
Similarly, no difference was found for PASI 60 (test for subgroup differences: Chi² = 0.09, df 
= 1 [P = 0.76], I² = 0%) or PASI 90 (test for subgroup differences: Chi² = 0.01, df = 1 [P = 
0.94], I² = 0%) between oral use and infusion of CG as add-on therapy to acitretin (see Table 
8.3). 
 Figure 8.3: Forest Plot of Compound Glycyrrhizin as Add-on Therapy v. Conventional 
Therapy for Psoriasis Vulgaris: PASI 60 and PASI 90 
Notes: Aci: acitretin; CG: Compound Glycyrrhizin; CS: topical corticosteroid; CT: conventional therapy; NB-
UVB: narrow-band UVB; PASI 60: 60% or greater reduction of PASI score; PASI 90: 90% or greater reduction 
of PASI score 
Table 8.3: Effect Size Analysis: Subgroup Analysis According to Preparation Type of Compound Glycyrrhizin 
Comparison  Outcome 
measures 
Preparation 
type 
Number of studies (studies: 
first author, year) 
Number of 
participants analysed 
Effect estimate (RR, 95 % CI, 
95 % CI, I
2
; RD %) 
CG plus NB-UVB v. 
NB-UVB 
PASI 60 Tablet  1 study (Luo 2006 [232]) 97 RR: 1.32 [1.01, 1.73]*; NA; 
20 % 
Injection  2 studies (Wu 2010, Yang 
2014 [224, 227]) 
207 RR: 1.15 [1.02, 1.28]*, I
2
=0%; 
12 % 
Test for subgroup differences: Chi² = 0.91, df = 1 (P = 0.34), I² = 0% 
PASI 90 Tablet  1 study (Luo 2006 [232]) 97 RR: 2.45 [1.13, 5.28]*; NA; 
22 % 
Injection  2 studies (Wu 2010, Yang 
2014 [224, 227]) 
207 RR: 1.28 [1.05, 1.56]*, I
2
=0%; 
16 % 
Test for subgroup differences: Chi² = 2.54, df = 1 (P = 0.11), I² = 60.6 % 
CG plus acitretin v. 
acitretin 
PASI 60 Tablet/capsule Two studies (Jiang 2014, 
Zhang 2014 [226, 234]) 
186 RR: 1.33 [1.11, 1.58]*, I
2
=0%; 
21% 
Injection One study (Liu 2008 [225]) 200 RR: 1.28 [1.08, 1.51]*; NA; 
18% 
Test for subgroup differences: Chi²=0.09, df = 1 (P = 0.76), I² = 0% 
PASI 90 Tablet/capsule Two studies (Jiang 2014, 
Zhang 2014 [226, 234]) 
186 RR: 1.29 [0.95, 1.76], I
2 
= 0 %; 
12 % 
Injection One study (Liu 2008 [225]) 200 RR: 1.32 [0.85, 2.05]; NA; 8 % 
Test for subgroup differences: Chi² = 0.01, df = 1 (P = 0.94), I² = 0 % 
Note: CI: confidence interval; NA: not applicable; NB-UVB: narrow-band UVB; PASI: Psoriasis Area and Severity Index; RD: risk difference; RR: risk ratio; *: significantly 
different 
 
8.4.5 Adverse Events 
All but one study (228) reported AEs. The reported number of AEs was similar in the 
intervention and control groups (101 v. 102, respectively) (see Table 8.4). Five of the 
included studies reported that AEs were related to CG (224, 226, 229, 230, 232). Among 
them, two studies suggested that the addition of CG could reduce AEs caused by acitretin or 
NB-UVB (226, 232); another three studies (224, 229, 230) found CG might increase blood 
pressure (two cases) and cause oedema (seven cases), such as bimalleolar oedema, or oedema 
on the dorsum of feet and eyelids. The remaining AEs were consistent with the safety profile 
of conventional therapy. 
8.4.6 Publication Bias 
The risk of publication bias appeared to be low as illustrated in the symmetrical appearance 
of the funnel plot for PASI 60 (11 studies) (see Figure 8.4). 
Table 8.4: Adverse Events of Included Randomised Controlled Trials: Compound Glycyrrhizin as Add-on Therapy v. Conventional 
Therapy for Psoriasis Vulgaris 
Study Adverse events Authors’ conclusion 
Du, 2014 
(229)  
I: dry skin and eyes (3), mild increase in blood pressure (2) Compound glycyrrhizin may cause 
increase of blood pressure, but protect 
liver function. Other AEs were caused 
by conventional therapies 
C: mild red skin and itch (4), mild increase of ALT and AST (2) 
Huang, 
2014 
(228) 
NS NS 
Jiang, 
2014 
(226) 
I: dry skin, mouth and lips (22), high aminotransferase (1), hyperlipidaemia (2) Adding compound glycyrrhizin could 
reduce the AEs of liver caused by 
acitretin 
C: dry skin, mouth and lips (30), high aminotransferase (3), hyperlipidaemia (4) 
Liu, 2008 
(225) 
I: dry mouth (26), skin itch (4), abnormal liver function (1), gastrointestinal reaction (5) No additional AE was caused by 
compound glycyrrhizin C: dry mouth (21), skin itch (3), abnormal liver function (1), gastrointestinal reaction (4) 
Luo, 2006 
(232) 
I: mild redness (3) Adding compound glycyrrhizin could 
reduce the AEs caused by NB-UVB C: redness (eight in total, three  were severe) 
Ma, 2011 
(231) 
I: skin redness and itch (3) Mild AEs were caused by the 
pharmacotherapy drugs C: skin redness and itch (4) 
Wang, 
2014 
(233) 
I: dry skin (1) Both treatments are safe for psoriasis 
vulgaris C: red skin (1) 
Wu, 2010 
(224) 
I: skin pigmentation and dryness for all cases, skin itch (5), red skin (3), skin redness and 
burning sensation (2), bimalleolar oedema (1), oedema on the dorsum of feet and eyelid 
(1) 
Both treatments are safe for psoriasis 
vulgaris 
C1: skin pigmentation and dryness for all cases, skin itch (6), red skin (4) 
C2: skin itch exacerbation (1), bimalleolar oedema and oedema on the dorsum of feet (1) 
Yang, 
2014 
(227) 
I: red skin and burning sensation (7) Both treatments are safe for psoriasis 
vulgaris C: none 
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Study Adverse events Authors’ conclusion 
Yao, 2010 
(230) 
I: red and itchy skin (4), oedema (5) Both treatments are safe for psoriasis 
vulgaris C: red and itchy skin (5) 
Zhang, 
2014 
(234) 
Dry skin and lips, scale and red skin, itch skin (NS) Both treatments are safe for psoriasis 
vulgaris 
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Figure 8.4: Funnel Plot of Compound Glycyrrhizin as Add-on Therapy v. Conventional 
Therapy for Psoriasis Vulgaris: PASI 60 
Notes: PASI 60: 60% or greater reduction of PASI score 
8.5 Discussion 
Meta-analysis indicated that the addition of CG significantly increased the number of patients 
achieving PASI 60 by 19% and PASI 90 by 14% when compared with conventional therapy 
alone. Specifically, the add-on effect of CG was shown when used as an adjunct therapy to 
topical corticosteroids, NB-UVB and acitretin. The addition of CG to topical corticosteroids 
increased the number of patients achieving PASI 60 by 24% compared with topical 
corticosteroid alone. The findings from this review suggest that a combination of CG and 
topical corticosteroids enhances clinical response greatly. As add-on therapy to acitretin, CG 
also increased the chance of achieving PASI 60 and PASI 90, confirming findings previously 
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reported (223). In addition, the treatment effect of CG did not differ when used orally or 
intravenously. The administration of CG is flexible and convenient in clinical practice. 
The finding of low statistical heterogeneity in several meta-analyses was surprising. This may 
be due in part to the use of a standardised manufactured product CG with similar duration 
(four or eight weeks), and dosing regimen for conventional therapy in line with clinical 
practice guidelines. There were insufficient data to confirm the long-term add-on effect of 
CG to conventional therapies. Adding CG to conventional therapies could increase efficacy 
of treatment and shorten the treatment duration required. This would reduce the risk of side 
effects from long-term use of conventional therapies. 
Gan cao 甘草 extracts, in particular glycyrrhizin and its derivatives, have proven benefits for 
skin disorders in experimental studies. Glycyrrhetinic acid inhibits the oedema response to 
capsaicin in mice ears by preventing vascular permeability induced by vasoactive agents 
(237); glycyrrhizin treatment reduced the number of human melanoma cells after UVB 
irradiation (238). Further, the ammonium salt of glycyrrhizin has anti-inflammatory 
properties (239) and glycyrrhizin prevented ICAM-1 expression through inhibition of the 
ERK/p38 MAPK and NF-κB signaling pathways in keratinocytes (222). 
In addition, two per cent topical preparation of glycyrrhetinic acid is a potent inhibitor of the 
enzyme 11β-hydroxysteroid dehydrogenase (11β -OHSD), which is present in diseased skin 
such as psoriasis and eczema (240). In the presence of glycyrrhetinic acid, the anti-
inflammatory activity of hydrocortisone could be greatly enhanced, which is beneficial for 
inflammatory cutaneous disorders (240). Consistently, the findings of this review also 
indicate that adding CG could greatly enhance the efficacy of corticosteroids. 
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AEs reported in included trials suggest that CG may increase blood pressure and cause 
oedema. Hypokalemia and/or hypertension have been reported with intravenous use of CG 
for hepatitis (241). Allergic reactions, including hives and anaphylaxis, were identified in a 
review of adverse drug reactions (ADR) to CG injection in China (242). Variation in 
ingredients and impurities in CG injections have been reported among manufacturers (243), 
which may be potential source of ADR (244). Patients with cardiovascular disease or 
hypertension who are receiving CG should be monitored, and greater caution should be used 
for intravenous use of CG than for than oral administration. 
8.5.1 Limitations 
The included studies were methodologically flawed. Potential bias may be caused by unclear 
methods of randomisation, lack of blinding and selective outcome reporting. Adequately 
powered, appropriately randomised, double-blinded, placebo-controlled trials with sufficient 
reporting are warranted. 
HR-QoL was not assessed in any study. Although psoriasis is not a life-threatening condition, 
it impedes sufferers’ QoL. Further studies should incorporate assessments of patients’ clinical 
symptoms and QoL. One study (231) reported relapse rates without describing the criteria 
used. Recurrence is an ongoing issue for patients and dermatologists and can be difficult to 
manage clinically. Follow-up should be included in further studies to monitor the long-term 
effects of CG. 
The additional benefit of adding CG to conventional therapy has been demonstrated in this 
review. However, the combination of therapies that could achieve greater clinical response 
remains uncertain. Three studies reported severity of participants’ disease but were unable to 
perform subgroup analysis. The sample size in subgroup analyses was relatively small, which 
may overestimate the true effects (89). Network meta-analysis or clinical trials with adequate 
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sample sizes are needed to determine which combinations of CG and conventional therapy 
can provide the most efficacious treatment option for psoriasis vulgaris. 
ADR/AE of CG described in the literature (245) have not been documented in the report of 
the National Centre for ADR monitoring in China. As little information was provided in the 
included studies, and due to a lack of standard reporting items for ADR and AE (245, 246), 
the safety profile of CG is incomplete. Issues common to herb injection more broadly include 
overdose, menstruum, drop speed of infusion and drug incompatibility, which may cause 
ADR or AE (245, 246). 
8.6 Conclusion 
CG plus conventional therapy appears to provide enhanced clinical response using PASI 60 
and 90 as measurements. Further, it does not increase the frequency of AEs for patients with 
psoriasis vulgaris. However, the findings should be interpreted with caution due to the 
significant methodological limitations of included studies. The long-term add-on effect is 
uncertain. Studies that are more robust are required to evaluate CG to confirm these benefits. 
  
 
175 
Chapter 9. Patient Experiences of Using Chinese Herbal Medicine for 
Chronic Skin Conditions: A Qualitative Study 
9.1 Introduction 
Interest in CAM is increasing (247, 248). Many studies have examined the use and 
prevalence of CAM in a variety of patient groups and settings (247, 249, 250), including 
people with skin conditions (24, 25, 251). Most of these studies report quantitative data, with 
relatively few studies exploring patients’ experiences of using CAM. 
Data from the National Health Interview Survey in the US showed CAM use to be high in 
people with skin conditions (84.5%), although a small minority (1.1%) used CAM to treat the 
skin condition (25). In a survey on CAM use in people attending a contact dermatitis clinic, 
CAM was used to treat the skin condition in 30% of participants, with CHM accounting for 
18% of CAM use (251). The survey identified higher CAM use among Indo-Asian patients. 
Participants based their decision to use CAM on recommendations from friends and family 
members with skin disease, advice from an orthodox health care professional, or media (print 
or digital). 
As one of the popular forms of CAM, CHM has been increasingly evaluated in term of its 
efficacy and safety in randomised trials. However, there is a lack of information about the 
experiences of people who use CHM to treat chronic skin conditions (the end user’s 
perspective). To address this gap, the researcher conducted in-depth interviews with people 
who have used CHM for two common chronic skin conditions: chronic urticaria and psoriasis 
vulgaris. This provided important evidence for translating the clinical evidence (see Chapters 
6–8) into effective CM clinical practice. 
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9.2 Aim 
The purpose of this study was to explore people’s realities of living with a chronic skin 
condition, either chronic urticaria or psoriasis vulgaris, and their experiences using CHM to 
manage the condition. This project examined the impact of the conditions on their health and 
everyday lives (for example, time for management, financial cost and social impact), the 
factors that motivate people to seek out CHM for these skin conditions and the experiences of 
using CHM for chronic skin conditions. 
9.3 Significance of the Study 
Use of CAM is increasing, with many people opting to treat skin conditions with CAM 
(including CHM). While clinical trials and SRs evaluate the efficacy and safety of CHM for 
skin conditions, there is little information on the motivators that lead people to choose CHM 
to manage their skin condition and their experiences with CHM. Through semi-structured 
interviews with people living with either chronic urticaria or psoriasis vulgaris, the findings 
of this project provided valuable information that may inform clinical decision-making and 
guide future research of CHM use for dermatological conditions. 
9.4 Study Design 
The method for this study is qualitative description. Qualitative description seeks to provide a 
‘rich description of the experience/event/process depicted in easily understood language’ 
(252). This project explored the experiences of people with chronic skin conditions in terms 
of the impact of the condition on their health and life, and their experiences in using CHM. 
Therefore, it is highly suited to qualitative descriptive methods. Individual, in-depth 
interviews were conducted with people who have used CHM to manage psoriasis vulgaris or 
chronic urticaria. 
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9.5 Method 
Data were collected via semi-structured interviews. An interview guide was developed (see 
Appendix 4) that guided the interview and was reviewed throughout the project as new 
themes emerged. No additional changes were required. 
9.5.1 Sample Selection 
The sample for the study was drawn from people who have consulted a CM practitioner for 
treatment of chronic urticaria (defined as urticaria present on most days for six weeks or more) 
or psoriasis vulgaris, and who have received CHM in Australia or China within the last five 
years. Participants were aged between 18 and 80 years and able to read and speak English or 
Chinese. Written informed consent was obtained prior to interview (see Appendix 5), 
including consent to audio recording. People with conditions other than chronic urticaria or 
psoriasis vulgaris, or using CM therapy other than CHM, or with severe health conditions 
such as cardiovascular or renal dysfunction were excluded. 
9.5.2 Sample Size 
It was anticipated that approximately 20 participants in Australia and 20 participants in China 
would be recruited to the study. Gender balance was not required. The final number was 
determined by theoretical or population saturation (253). 
9.5.3 Participant Recruitment 
In Australia, recruitment adopted several strategies: 
1. Advertisements were placed in the waiting rooms of local CM practitioners’ clinics 
and the RMIT University Health Sciences Clinic (see Appendix 6). 
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2. Information about the study was provided to new and existing CM patients who 
presented to the RMIT University Health Sciences Clinic. 
3. The study was promoted through support groups for people with psoriasis vulgaris 
and chronic urticaria after obtaining permission from support group moderators. 
In China, potential participants were identified by dermatologists on attendance at the 
Department of Dermatology in Guangdong Provincial Hospital of Chinese Medicine. 
Additionally, poster advertisements were placed in the department waiting room. Potentially 
eligible participants were approached directly by research personnel when they visited the 
Department of Dermatology of this hospital to discuss the details of the study and to invite 
them to participate. 
9.5.4 Data Collection 
Eligible participants were provided with written information about the research study, and 
any questions were answered by research personnel. If the person was eligible and agreed to 
participate, an interview time was arranged and written informed consent was obtained. 
Interviews were conducted in both Australia and China. For participants located in the 
Melbourne metropolitan area, interviews were conducted either at RMIT or at the participants’ 
home if more convenient. In China, interviews were conducted at Guangdong Provincial 
Hospital of Chinese Medicine, Guangzhou. 
Each interview took approximately 30–60 minutes. Interviews were semi-structured and 
followed an interview guide (see Appendix 4), which covered experiences with the condition 
in terms of impact on health and daily life, reasons for choosing CHM, and experiences with 
using CHM for the condition. 
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An audio recording of the interview was made and for interviews conducted in English, a 
second researcher was present to record additional non-verbal details of the interview. This 
was not possible for interviews conducted in China, so the interviewer recorded non-verbal 
details while conducting the interview. Interviews were conducted in English or Chinese 
(Mandarin) depending on the participant’s preference. 
The content to be covered in the interview was unlikely to raise concerns for participants or 
researchers. Regardless, participants were advised at the time of obtaining informed consent 
that any information they provided would remain confidential, and that audio-files and 
transcripts would be de-identified and stored in a locked filing cabinet or in a password-
protected computer. 
Participants were advised that they could decline to respond to any question they did not wish 
to answer. The researcher observed the verbal and non-verbal responses of the participant 
throughout the interview. If the participant looked uncomfortable or expressed concerns with 
the question or line of questioning, they were asked if they would prefer not to answer that 
question, and whether they wished to proceed with the interview. The participants were 
advised that if they were upset, they could discuss the issues further with one of the study 
investigators (Tony Zhang). If they wanted to lodge a complaint, the contact details of ethics 
committee from RMIT and the Guangdong Provincial Hospital of Chinese Medicine were 
provided on the Patient Informed Consent Form (PICF) (see Appendix 5). 
9.5.5 Data Analysis 
Thematic content analysis was used to explore the data. Interviews were transcribed in full 
and verbatim in the original language. Transcripts were de-identified and uploaded to QSR 
NVivo 11 software (QSR International) for data management and coding. Transcripts were 
coded line by line using ‘open coding’ to label common themes. Participants’ identifiable 
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information was replaced with pseudonyms. This data management and coding process 
involved several steps: 
• Read and re-read the transcripts and supporting field notes to become familiar with 
the data. 
• Establish initial coding. 
• Identify the tentative themes. 
• Revise the themes, checking against the codes and datasets. 
• Define and name the themes. 
Preliminary data analysis was conducted after each interview to determine whether changes 
to the interview guide were required. No changes were made to the interview guide during 
data collection. Preliminary data analysis was conducted in the original language of the 
interview, and themes and sub-themes were translated into English (if required) for further 
discussion and analysis. Members of the research team met regularly throughout data analysis 
to ensure consistency and to guide the next stage of analysis. Data coding was completed by 
Jingjie Yu and checked by Lingling Yang. 
9.5.6 Ethical Issues 
The protocol for this study has been approved by the RMIT College Human Ethics Advisory 
Network (No. BSEHAPP 29–15 XUE) (see Appendix 7) and the Ethics Committee of 
Guangdong Provincial Hospital of Chinese Medicine in China (B2016–104) (see Appendix 
8). Data collection commenced after ethical approval was obtained at each site. 
Participants were informed about the purpose of the study and were given the opportunity to 
ask questions. When participants were satisfied that they understood the project and had any 
questions answered, they were asked to provide written consent on the PICF (see Appendix 
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5). Both the participant and the researcher signed the consent form and the participant 
received a copy for their records. The PICF explains the voluntary nature of participation, the 
participant’s right to withdraw from the project at any stage, and that data collected will 
stored in a non-identifiable, confidential way. 
9.6 Study Rigour 
The importance of a rigorous approach to ensure the trustworthiness of the research findings 
has been highlighted (254–256). Key concepts suggested by Guba (1981) (257) include 
credibility, transferability, dependability and confirmability. To ensure rigour, the following 
steps were taken: 
1. Credibility: This refers to whether the study data collected are what was intended. The 
researchers who conducted the interview also performed transcription, and reviewed 
the audio and transcriptions several times to ensure familiarity with the content. Field 
notes were used to support the interview findings. The research team have CM 
clinical experience and met regularly (weekly or fortnightly as required) for peer 
debriefing. Negative cases analyses were used to allow for consideration of alternate 
explanations and ideas. While member checking (review of the transcript by study 
participants for accuracy) has been suggested as the gold standard for ensuring 
credibility, Sandelowski (2008) (258) suggested that the process for member checking 
may lead to confusion if participants change the information. Member checking was 
not used in this study. 
2. Transferability: This refers to the generalisability of the findings to a similar setting. 
Detailed description of the findings from participant interviews will allow users to 
transfer information to a setting with similar characteristics to those included in this 
study. 
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3. Dependability: This step refers to the ability to obtain the same results should the 
work be repeated in the same context and manner. This was addressed in this study by 
providing a clear and detailed description of the methods. This allows for scrutiny of 
the methods and the possibile replication of the study. 
4. Confirmability: This refers to the objectivity of data. This study used an audit trail to 
document interpretations, discussions and thought processes of the research team. 
This was evidenced through a clear history of coding and categorisation, and minutes 
of research team discussion. 
9.7 Pilot Interview 
One pilot interview was conducted separately to the main data collection, using the same 
inclusion criteria. The pilot interview allowed the researcher to develop an interview 
technique and test the interview guide for validity (see Appendix 4). Following the pilot 
interview, no revision was made to the interview guide. Data from the pilot were not used in 
the final analysis. 
9.8 Data Security 
In-depth interviews were audio-recorded and the recording transferred onto a password-
protected computer for storage. The audio recording file label did not include identifiable 
information. Transcription was done by Jingjie Yu (for interviews conducted in Chinese) and 
Dr Meaghan Coyle (for interviews conducted in English). Transcriptions of recordings are 
stored on a password-protected computer. Transcriptions were de-identified by replacing real 
names with pseudonyms. The researchers have retained participants’ names, pseudonyms and 
demographic information on a password-protected computer. The password is known only to 
the research team. Hard copies of de-identified transcriptions and field notes will be kept in a 
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locked filing cabinet. Data will be stored for a minimum of seven years from the publication 
date, as per the Australian code for the responsible conduct of research (259). 
9.9 Results 
Participant recruitment in Guangzhou, China occurred in July and August 2016, and 
recruitment in Australia was from September 2015 to November 2016. Recruiting 
participants in Australia was more challenging. While it was anticipated that 20 participants 
would be recruited from each site, the saturation of qualitative data provided by participants 
occurred before this target was reached, and recruitment was ceased. 
9.9.1 Demographic Information on the Participants 
Sixteen participants in Guangzhou, China and five participants in Melbourne, Australia were 
recruited in this study (see Table 9.1). Nine participants suffered from psoriasis vulgaris with 
duration from 2.5 months to 24 years. The duration of 10 participants with chronic urticaria 
was from eight months to 10 years. Two participants were affected with both conditions and 
the disease duration was from three months to four years. The number of female and male 
participants was almost equal (11 females, 10 males). The age of participants ranged from 20 
to 59 years. All but one participant received CHM in China and were Chinese, with eight 
originating from Guangdong Province (Canton) in southern China. Most participants were 
tertiary educated. Most participants were professionals, except for six students. Two 
respondents were CM practitioners. 
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Table 9.1: Demographics of Participants in Qualitative Interviews 
No. Disease Age Gender Duration Ethnicity Education Employment 
CHN 
001 
Psoriasis/ 
Urticaria 
20 Male 4/2 years Chinese 
(Cantonese) 
Graduate Student  
CHN 
002 
Urticaria 29 Female 4 months Chinese 
(non-
Cantonese) 
High 
school 
Education 
CHN 
003 
Psoriasis 34 Male 3 years Chinese 
(non-
Cantonese) 
TAFE Unemployed  
CHN 
004 
Urticaria 30 Male 8 months Chinese 
(non-
Cantonese) 
Graduate Manager  
CHN 
005 
Urticaria 36 Female 8 years Chinese 
(non-
Cantonese) 
Graduate Marketing  
CHN 
006 
Psoriasis 54 Male 9 years Chinese 
(Cantonese) 
High 
school 
Marketing  
CHN 
007 
Psoriasis 59 Male 7 years Chinese 
(Cantonese) 
High 
school 
Lift worker 
CHN 
008 
Psoriasis/Ur
ticaria 
24 Female 3 
months/2 
years 
Chinese 
(Cantonese) 
Graduate Cinema 
management 
CHN 
009 
Psoriasis 30 Female 2.5 
months 
Chinese 
(non-
Cantonese) 
Graduate Publisher 
CHN 
010 
Psoriasis 35 Male 5 years Chinese 
(non-
Cantonese) 
Graduate Accountant 
CHN 
011 
Psoriasis 29 Male 8 years Chinese 
(Cantonese) 
Graduate  Finance 
officer  
CHN 
012 
Psoriasis 56 Male 5 years Chinese 
(Cantonese) 
Graduate  Law 
enforcement 
officer 
CHN 
013 
Psoriasis 36 Female 7 years Chinese 
(non-
Cantonese) 
Post 
graduate  
University 
lecturer  
CHN 
014 
Urticaria 30 Female 10 years Chinese 
(non-
Cantonese) 
Post 
graduate   
Doctor 
CHN 
015 
Urticaria 30 Female 5 years Chinese 
(Cantonese) 
Post 
graduate  
Doctor  
CHN 
016 
Urticaria 30 Female 10 years Chinese 
(Cantonese) 
TAFE  Clerk 
AU 
001 
Psoriasis 41 Female 24 years Caucasian Post 
graduate  
Student  
AU 
002 
Urticaria 21 Male 2 years Chinese 
(non-
Cantonese) 
Post 
graduate  
Student  
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No. Disease Age Gender Duration Ethnicity Education Employment 
AU 
003 
Urticaria 25 Female 3 years Chinese 
(non-
Cantonese) 
Post 
graduate  
Student  
AU 
004 
Urticaria 23 Female 6 years Chinese 
(non-
Cantonese) 
Post 
graduate  
Student  
AU 
005 
Urticaria 24 Male 2 years Chinese 
(non-
Cantonese) 
Post 
graduate  
Student  
 
9.9.2 Themes Emerging From the Interviews 
Through ‘open coding’ line by line, themes emerging from the experiences of participants 
living with a chronic skin condition included ‘experience of symptoms’, ‘a bleak future’, ‘the 
learning curve’, ‘living with disease’, ‘pros and cons of conventional treatment’ and ‘paying 
for relief’. Themes about participants’ motivators to seek CHM as treatment were identified. 
They were categorised into ‘beliefs and experience’, ‘want an alternative’ and ‘practitioner 
selection’. Six themes related to participants’ experiences of using CHM for chronic skin 
conditions were discovered: ‘tailoring the treatment’, ‘response to treatment’, ‘managing 
CHM’, ‘concern about CHM’ and ‘value for money’. 
Experience of symptoms 
Participants suffered from the symptoms that are typical to these two conditions. Participants 
recalled how their symptoms first occurred, starting with small lesions such as red spots, 
which then enlarged to erythema. In one participant with psoriasis vulgaris, this gradually 
spread to cover the whole body. The erythema often occurred with skin scaling and 
participants felt their skin was dry and itching. When the scales were removed one participant 
experienced tight skin in the lesion area and was eager to apply moisturiser, especially in 
winter. 
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The most annoying symptom was pruritus for people with urticaria, which was excruciating 
for most participants. Participants described the sensation of urticaria as if their whole body 
was bitten by mosquitoes at the same time, as a burning sensation, or as if they were 
stimulated continuously with needles. Most of them could not stand this feeling: 
Just imagine your whole body is bitten by many mosquitoes, you feel 
uncomfortable even bitten by one, just imagine the feeling that you got full body of 
rash bitten by them. (就是你想象全身很多蚊子咬的那种感觉，就是你一个蚊子
包你都会很难受，你想象全身的蚊子包那种感觉 ). (Participant CHN 005 
chronic urticaria) 
And the itchy feeling come with heat, you feel very itchy and hot, a little bit, not too 
obvious, just you can feel it. (而且有热热的那种痒，就是那种热辣的那种痒，
有一点点，不是很明显啊，就是可以感觉到有种热辣的那种). (Participant 
CHN 005 chronic urticaria) 
Wheals often occurred after meals or at night, and disappeared within one hour. The 
frequency of symptom occurrence differed over time and symptoms came every day at the 
peak time. In addition to wheals and pruritus, a few participants mentioned that they suffered 
from gastrointestinal symptoms, such as diarrhoea, and encountered breathing difficulties: 
I felt chest tightness. As I told another doctor, I suffered from laryngeal oedema and 
I said my symptoms were very serious. Previously, I had some small red dots on my 
body, but they become more serious this time. Besides, my lips were swollen, my 
eyes were swollen and my face was swollen as well. Then, I felt my chest tightness. 
(就是胸闷，然后就是，那个那个，然后后来那天去看另外一个医生说，可能
是喉头水肿，然后我说这个就已经很严重了，然后以前呢，那次，第一次发，
也就是身上有些小红斑，就是小红团，结果现在这次发呢，就后面就很严重，
就是嘴唇肿，眼睛肿，就是脸肿，然后就是，又胸闷). (Participant CHN 005 
chronic urticaria) 
Participants with both chronic urticaria and psoriasis vulgaris emphasised the recurrence of 
disease, or that the symptoms came and went. Generally, compared with the long-term 
manifestation of psoriasis vulgaris, the symptoms of chronic urticaria occurred rapidly and 
were relieved quickly. For example, wheals often disappeared within one hour. However, 
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frequent occurrence of symptoms was commonly observed in participants with chronic 
urticaria. 
Participants found several things triggered or aggravated their skin conditions. For psoriasis 
vulgaris, participants suffered from exacerbation of symptoms after drinking alcohol, staying 
up late or eating seafood. During the winter, the symptoms could be worse. It is interesting to 
note that one participant with psoriasis vulgaris experienced exacerbation before and during 
menstruation: 
Another factor is period, I assume it has big influence … I mean the menstrual 
period, one week before period and in that week, new lesions might occur. (还有个
就是经期，我觉得影响蛮重的…就是生理期，生理期的前一周，和生理期的
那一周，就明显的会长新的出来). (Participant CHN 009 psoriasis vulgaris) 
For chronic urticaria, the occurrence of symptoms could be triggered or aggravated by 
temperature change, diet, sleep and anxiety. Seafood was a common factor that caused the 
condition. One participant with chronic urticaria suffered from wheals and pruritus after 
eating calamari. The wheals and pruritus occurred easily due to temperature or mood changes, 
such as anxiety. Intermittent sleep with low quality also contributed to one participant’s 
condition:  
Yeah, [eating] those squid, octopus, etc, will trigger [urticaria]. (对，就是鱿鱼什么
的，章鱼啊，那种都会). (Participant CHN 015 chronic urticaria) 
A Bleak Future 
All participants expressed concerns about their futures to varying degrees since being 
affected with psoriasis vulgaris or chronic urticaria. Most participants had a negative reaction 
to the disease diagnosis. For psoriasis vulgaris, participants felt dysphoric, fearful and even 
desperate about their futures due to the disease. One woman experienced a flood of emotion 
when she heard the diagnosis of psoriasis vulgaris. She cried immediately and was confused 
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about the reasons she had been inflicted with this condition. Another participant felt 
preoccupied when she was diagnosed: 
I think I would always want to blame myself or wonder what I’d done or something 
like that … I was very preoccupied with wondering things like that. (Participant AU 
001 psoriasis vulgaris) 
Participants felt depressed about their appearance and anxious about other people’s 
misunderstandings of the contagiousness of psoriasis vulgaris. A few participants became 
irritable since suffering from the disease. Moreover, participants were uncertain and worried 
about disease inheritance and progression in the future: 
I think … people usually think niu pi xuan (psoriasis) is quite severe, and are not 
sure its infectiousness. (我觉得……正常人的理解会觉得牛皮癣是很严重的吧，
而且还不知道传不传染). (Participant CHN 009 psoriasis vulgaris) 
First of all, I have mentioned before, whether it’s genetic? Secondly, I worry about 
comorbidity. As I am young now, the disease doesn’t affect me too much now. 
However, it could influence other parts of my body later, which brings more 
problems. Thirdly, I can’t imagine how it’s going on when I become older. I have 
considered these issues. (第一个就刚刚说到的，不知道它会不会有一个遗传性，
呃然后第二个，第二个就是说，后续的话，因为现在毕竟我，现在来说呢还
年轻，它反复起来其实问题也不大，可是我也担心它如果将来会不会有严重
性的发展，其实我了解到它后续的那个发展，可能会延续到四肢啊或者身体
的其他部位，那就可能会更加麻烦一点，然后第三个就是再往后发展的话，
特别是到了年纪比较大的时候，它的发展情况又是怎么样自己也没有个底). 
(Participant CHN 011 psoriasis vulgaris) 
Similarly, participants were not sure when the disease would go and whether it could be 
cured. It became most difficult for them to accept the relapsing nature of the disease, 
prompting anxiety about work intensity or QoL. One participant also expressed concern 
about development of other health conditions in the future. This participant was aware that 
other conditions, such as cancer, hypertension, are known comorbidities of psoriasis vulgaris: 
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Hmm it is one concern that when it can be cured, another concern is whether it 
could be cured? Because not all the patients can be cured, that doctor said, someone 
may not … one patient friend told me, he even doesn’t know what is relapse (laugh) 
because the condition never went (嗯什么时候好是一个问题，还有就是能不能
好也是个问题？因为不是所有人都好的，那医生说，可能有些人他就没
有……因为有个病友就说，他就说，我连什么叫复发都不知道（笑）。因为
从来没有好过). (Participant CHN 009 psoriasis vulgaris) 
For chronic urticaria, participants felt their diagnosis was inconceivable and they felt 
dysphoric and even desperate about the diagnosis. One woman thought that her face was 
disfigured by wheals and likened her appearance to a pig’s face. Participants were worried 
that they could not concentrate on work and study due to the recurrence and long-term 
manifestation of pruritus or wheals. Major concerns for their future included laryngeal 
oedema, as mentioned by one participant. She was anxious that it could threaten her life:  
Nowadays my most concern is not my skin, the wheal, but laryngeal oedema. I am 
worried about that if it happens suddenly when I am sleeping, I will die. Several 
days ago, a western medicine doctor prescribed steroid medication, which could be 
used when I can’t take a breath. Then I can call hospital for first-aid. I feel horrible 
about this. Does laryngeal oedema mean the disease becomes more serious? （我现
在困扰最大的啊，就是，我反倒不在那个皮肤，那个风团了，我现在困扰最
大的是这个，我担心喉头水肿。因为我，前两天，有时候晚上睡觉睡着睡着
我说，我会不会睡着睡着，突然喉头水肿了，然后我就，就过不了气，就人
就完蛋了，就担心这个东西，所以后来那个时候，有隔西医，有个看西医的
给我开的那个激素药嘛，如果真的晚上突然发现呼吸不行了，赶紧激素下去，
然后打，然后去医院急救，就听起来我就觉得很恐怖，所以现在对我困扰最
大的就是这个，真的就是到了这个喉头水肿这个，到底是不是这个病更严重
了。). (Participant CHN 005 chronic urticaria) 
Participants who suffered from both conditions at the same time reported becoming more 
fearful and dysphoric about psoriasis vulgaris. Unlike chronic urticaria, they thought the 
image of psoriasis vulgaris would exist persistently, perhaps even for their whole lives.  
For both psoriasis vulgaris and chronic urticaria, participants were uncertain about the 
possibility and time required to achieve cure for the diseases. They might have to continue 
using medication all the time as the symptoms came and went, which could result in side 
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effects. The uncertainty of disease severity and treatment effects made participants anxious, 
dysphoric and desperate. In terms of diet, they had to consider the possibility that food could 
trigger or exacerbate the disease. This undermined their confidence and caused them to have 
concerns about their future. 
However, three participants were accepting of the disease, despite the impacts the conditions 
might have on their lives in the future. One participant considered psoriasis vulgaris as only a 
skin problem that did not affect internal organs. Similarly, the other participant did not regard 
chronic urticaria as a significant health issue. Through knowledge gathered from the internet, 
the third participant had already anticipated the diagnosis of psoriasis vulgaris. He thought it 
was most important to receive treatment as soon as possible.  
The Learning Curve 
Most participants had little knowledge about the condition before its onset, except for two 
participants with chronic urticaria, both whom were doctors. One doctor considered that low 
quality sleep contributed to her disease, as she had to take care of her baby during the night. 
She perceived that treatment should focus on improving constitution and enhancing healthy 
qi through CHM (according to her professional knowledge). The other doctor researched the 
disease and treatments using textbooks or advice from teachers. 
Other participants began learning about the condition and treatment through the internet. For 
instance, participants with psoriasis recognised that the disease was not contagious, and CHM 
might be more beneficial than WM. Participants with chronic urticaria ‘listened to their body’ 
and noticed that alternative exposure to coolness and warmth would trigger the skin disease. 
All participants began to pay attention to self-management. One participant sought 
supplementary treatments by themselves, using products such as grape seed. 
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Living with Skin Disease 
Both psoriasis vulgaris and chronic urticaria had significant impacts on participants’ daily 
lives. The primary concern for participants with psoriasis vulgaris was physical disfigurement. 
One participant described his embarrassment when a large amount of scale fell from his skin 
in public, which might not be accepted by others easily. Another woman also described her 
embarrassment in a dancing class because her lesions of psoriasis vulgaris could be observed 
when she was wearing a leotard. Clothing was described as a factor that prohibited a man 
from playing sports: 
I was in a dancing class and … I was embarrassed to wear the leotard because … 
you could see some psoriasis. (Participant AU 001 psoriasis vulgaris). 
For many participants with psoriasis vulgaris, it was not easy to interact with other people. 
They were afraid to talk about their condition and avoided their social networks. The large 
amount of erythema and scale made other people feel uncomfortable and they were 
concerned about its contagiousness. One participant mentioned that leisure activities with 
friends were also reduced due to the disease. The main leisure activity in his community was 
swimming, but he did not wish to join in: 
It will also have impact on appearance. When other people see you, they are also 
afraid of it, the peeling skin, it always falls off, so it is, like this, and then people 
know, know you have this skin condition. (然后也影响外观呢，别人看到你也怕
一点呢，老是掉皮，这样子啦，就这样子啦，现在就是人家就是知道，知道
你这样子). (Participant CHN 007 psoriasis vulgaris) 
For example, we live in a coastal area, so they would like to go swimming; I just 
went with them for very few times. (比如说我们那里近海边，每次那么出去游泳
的话，去玩的话都很少出去). (Participant CHN 003 psoriasis vulgaris) 
Psoriasis vulgaris also influenced general health, such as a general lack of energy. Some 
participants had to stop working, while one reported losing their job due to the disease. For 
this participant, the economic burden was significant after the loss of income, with a child to 
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be raised. Another impact on participants’ daily lives was sleep. The large amount of scale in 
the bed made participants feel uncomfortable, making it difficult to sleep. In summer, this 
discomfort worsened due to increased perspiration. Participants scratched the skin in response 
to itch, which might cause bleeding and pain. If they experienced pain they applied ointment. 
However, the ointment made participants feel sticky during sleep. These experiences 
influenced their sleep. In addition to the effects on sleep, a few female participants held 
concerns about pregnancy or the potential for their babies to inherit psoriasis vulgaris: 
Sometimes feel itchy. Right? … On top of that, I always have scale, falling on the 
bed … I have to clean it up every time … It is quite hot and humid these days, the 
scale mixed with perspiration, it is very sticky, very hard for me to fall asleep. (它有
时候痒嘛，是不是？ … 嗯，再加上呢，你老是脱屑，它这个皮老是在那，全
部都是个在那个床上啊，每次都要清理的 … 这段时间在湿热天，它掉到那里，
出点汗，一沾酒是沾到身上，也是睡不着 ). (Participant CHN 003 psoriasis 
vulgaris) 
Another concern is that, I am worrying about my newborn baby, afraid of the 
genetic influence. (还有因为刚生完小孩嘛，怕这个有遗传，有影响 ). 
(Participant CHN 013 psoriasis vulgaris) 
For chronic urticaria, participants felt absent-minded and could not concentrate on work due 
to bothersome symptoms, such as pruritus or gastrointestinal changes like cramps, bloating 
and diarrhoea. This resulted in low work efficiency. For example, participants tried to control 
pruritus to help them concentrate on work or study. For one participant, the impact was 
significant and affected their university entrance examination, resulting in another year of 
study. Gastrointestinal changes like abdomen pain and diarrhoea forced one participant to 
take sick leave, and try multiple therapies, such as medication and moxibustion, to relieve 
serious diarrhoea: 
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For a long time, that is, you can reduce the feeling of itch by your mind and 
thoughts. You will think that do not care too much about it, but there is no way you 
cannot prevent feeling itchy, or ignore it, and if feel painful, you will not 
unconsciously touch it, but for itchiness, you will touch it unconsciously. If you 
touch it, it will be more itchy, and then it will spread. (时间长了，就是，你可以
用意念趋势去减轻它，不太在意它，但是痒不可以，你没有办法忽略它，而
且这个疼不会下意识地碰它，但是痒你会下意识地用手去碰它，然后你一碰
它，它就更痒，然后它会扩散). (Participant AU 003 chronic urticaria) 
The most serious thing for this time was the symptoms of gastrointestinal reaction, 
it was really serious, I took some days off from work, and I could barely handle my 
daily life (laugh) … You see, too many times of diarrhoea, maybe more than 10 
times a day, just long-lasting watery diarrhoea, and it was not relieved after taking 
pills, so I took medicine, and then had moxibustion, anyway, just keep warm at 
home, I tried everything I could (laugh), took medicines and other stuff, it took 
three to four days to feel better. (最严重的就是这次是有这种胃肠道的症状，这
个是真的很影响，就是就已经请病假了。然后就完全生活很难自理（笑） … 
你说，腹泻次数太多了，一天可能十几次，就是持续的水样泻，然后就是吃
药也不能缓解么，然后就吃药，然后艾灸，反正在家里面然后什么持续保暖
啊，然后各种吧（笑），就喝药或者是各种搞了一下，三四天吧，这样才收
下来). (Participant CHN 014 chronic urticaria) 
In addition, pruritus made it difficult for them to fall asleep. Disrupted sleep would have 
further influence on study or work efficiency. As sport could potentially trigger chronic 
urticaria, participants took part in fewer sports activities to avoid symptoms like wheals or 
angioedema: 
It is greatly related to sleep. Now I remember, because if itch occurs when [I] sleep 
at night, I can't sleep, especially sleep, the light sleep, at the beginning period of 
sleep. It will have great influence and last. (睡眠是一个很大的关系，才想起来，
因为晚上睡觉的时候它会很痒，就是睡不着，尤其是睡觉，浅睡眠，就是你
开始睡觉的那一段时间，它会影响很大，它会一直痒). (Participant AU 003 
chronic urticaria) 
A few participants with chronic urticaria felt embarrassed about their appearance and 
reluctant to participate in social activities. One woman pointed out that her condition was 
misunderstood as a sexually transmitted infection by the senior people with minimal 
knowledge of the condition: 
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When I first have this, I was scared about seeing people, because they will laugh at 
me, and people see the wheals on my skin, they may think I have sexual disease … 
The first is that, when I have the symptoms of urticaria on my face, my face will 
look very ugly. Besides, sometimes there will be much redness on my arms; they 
may think you touched something not clean especially the old, sometimes … some 
old people are always mislead by the media, for example, sometimes when I go to 
the hospital, they will say such a young girl have caught the sexual disease, which is 
embarrassing. (基本上是不敢太出去见人的，因为大家看了都会笑，然后平时
走在路上的时候，人家看我身上长那种风团、风块，他会认为我是不是有性
病之类的玩意儿 … 第一个就是，因为我脸上得荨麻疹的话，会肿成像猪头一
样特别难看。然后第二个就是有时候我身上胳膊都出来一片一片的红块啊，
她们就会认为是不是沾了不干净的东西，尤其是一些老年人，就是有时候跟
他们 … 有些老年群体受新闻误导比较多，比如有时候去医院的时候他们就是
说一个小姑娘年纪轻轻得什么性病就是这样的，挺尴尬的). (Participant AU 
004 chronic urticaria) 
Some participants were concerned about the occurrence of urticaria during their pregnancy 
because they had to stop taking medication and suffer the painful symptoms. They were also 
unsure whether the condition could be hereditary. 
Paying for Relief 
Due to the disease, participants had to spend money to relieve the symptoms. The cost of 
WM treatment was acceptable for one participant. However, others thought the expense of 
WM treatment was high, especially for long-term use. They could not afford it without 
medical insurance, particularly students. Other costs included the expense of supplementary 
agents such as grape seed, which one participant believed was beneficial.: 
To talk about health insurance, medical fee, you see if I use that ointment, like a 
moisturiser or a desonide ointment. Each of them are more than 20¥. But they are 
free for me now. (医保的话，那你费用，你看如说我涂那些东西，一个润肤的，
一个地奈德都二十几块一那个什么，全都是人家免费供给我的). (Participant 
CHN 007 psoriasis vulgaris) 
Pros and Cons of Conventional Treatment 
All participants recognised that the advantage of WM treatment was the rapid onset of relief. 
WM treatment (for example, corticosteroid ointment) could reduce skin lesions of psoriasis 
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vulgaris and improve skin condition significantly, but relapse was quite common. Participants 
had to persist with the treatment for a long period. The experience of using some WM agents 
was negative. Participants felt that coal tar looked disgusting and smelt bad: 
But I have to use this ointment (clobetasol propionate compound ointment) very 
frequently … if I use it today but not tomorrow, it will be fine. However, I must use 
it the day after tomorrow. (就是说你这个药膏 (复方丙酸氯倍他索软膏) ，你得
总抹 … 就是说比如说我今天抹了，第二天你没抹，可能问题不大，但是第三
天就一定要抹了). (Participant CHN 013 psoriasis vulgaris) 
For chronic urticaria, participants pointed out that antihistamine could relieve pruritus 
instantly, but the effect was short-lived. Wheals and pruritus came again on other days after 
taking medication. In addition, one woman described that antihistamine lengthened her next 
menstrual period:  
As time interval (for onset of relief) getting longer and longer and it cannot prevent 
attacking at next time. It means that you taking the medicine today ensure the 
effects today or tomorrow, only these two days. (越来越长，而且它不能够防止就
是下一次，就是你今天吃了这个药只能保持今天或者明天，这两天的时间). 
(Participant AU 003 chronic urticaria) 
Beliefs and Experience 
Participants chose CHM as treatment for psoriasis vulgaris and chronic urticaria based on 
their beliefs of CHM or personal experience using CHM. The use of CHM is a part of the 
culture and way of life for people born and living in Canton. It is a common for Guangzhou 
residents to have herbal soup and herb tea. One participant with chronic urticaria mentioned 
that her first experience with CHM was as a child. Her parents made soup using various 
herbal formulae that were adapted according to the weather (this fits with the CM theory of 
the external environment affecting the individual’s health). Herbs were easily accessible in 
the herbal pharmacy or herbal market. For local Cantonese participants, the choice of CHM 
was influenced by cultural background. Participants originating from outside Guangdong 
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Province also trusted in CHM and were influenced by their family members. One participant 
with chronic urticaria had belief in CHM because she could see the raw herbs to be used in 
the decoction. The reputation of the hospital was a reassuring aspect for participants seeking 
CHM: 
Especially in Guangdong, it is very common that people in Guangdong really prefer 
to cook soup. That is the culture of soup. Many people cook soup … in summer … 
like the summer solstice, they used cicada slough, Chinese watermelon and pearl 
barley. Sometimes look at the condition of the stool, if they feel uncomfortable, they 
will buy Glabrous greenbrier rhizome soup, eat dishes, what other else is eating the 
food that is nourishing, like the ginseng … nourishing. (而且更广东嘛，广东不是
很喜欢煲汤嘛，就是那种汤文化。就很多人就会，就普通百姓也知道哪些能
祛湿啊。就我们中医理论的祛湿，像我妈也懂啊。夏天…就是什么天啊，就
夏至什么的，他们就用蝉蜕啊，冬瓜，加薏米。有时候大便怎么样，他们自
己感觉不舒服也会买土茯苓煲汤，什么的。滋补的也会啊，花旗参啊，清补
的也会). (Participant CHN 015 chronic urticaria) 
Yes. Since I was child, my family have more belief in traditional Chinese medicine. 
(对，从小我们家人就比较信任中医这个方面). (Participant AU 003 chronic 
urticaria) 
The selection of CHM was also influenced by personal knowledge. Participants obtained the 
information on CHM from the internet, books or professional medical study. They believed 
CHM could improve personal constitution and treat the root (underlying factor) of the disease, 
since CHM emphasised individual treatment and general regulation for the whole body. 
Participants expected that CHM could reduce the relapse of their skin disease with fewer side 
effects. Moreover, the factor motivating participants to seek CHM treatment was their 
personal experience of using CHM for other conditions and achieving satisfying results: 
That's right, if they've experienced this and feel good, they will believe it. (对，如
果他们体验过这个东西，觉得比较好，他们就比较信这个东西). (Participant 
CHN 015 chronic urticaria) 
More confident than western medicine at least. As CHM mainly improves 
constitution, treat the root (underlying factor) of disease, it should be. (至少比西医
有（信心）很多，因为中药主要还是从改善体质，治本吧，应该是 ). 
(Participant CHN 009 psoriasis vulgaris) 
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In addition, participants showed particular interest and fascination with herbal medicine. One 
woman with psoriasis vulgaris described the whole experience of using CHM, which she 
really enjoyed:  
I think I was open but I did have a particular fascination with herbs … so I would, 
probably would’ve been disappointed if I didn’t get herbs … although the taste and 
the smell was … not very nice, I actually really enjoyed the whole experience of … 
of getting the bags of herbs and making the decoctions. (Participant AU 001 
psoriasis vulgaris) 
Want an Alternative 
The factors that motivated participants to choose CHM included the unsatisfying AEs of WM 
treatment. For instance, the blood test of one participant with psoriasis vulgaris indicated 
abnormal liver function after taking MTX. He decided to choose CHM as an alternative: 
Because I take the methotrexate, at that moment, the doctor didn’t tell me it affected 
liver when he prescribed it, I took for a while, and the next time I went there, 
another doctor asked me to take a blood test, the result showed the value of 
transaminase was too high, he told me to stop taking it, then I asked, he told me it 
affects the function of liver. Then I didn’t dare to take it, and stopped it. I did not 
take it anymore from then. I came here, and ask prescription here, starting to take 
the Chinese medicine. (因为吃那个甲氨蝶呤，吃了，当时，他没有告诉我说吃
那个甲氨蝶呤片对肝那个影响，他开的时候也没说，连续吃。后来，再去开
药的时候，有一个医生就是说，你先去验验血，一验血，那个转氨酶升的很
高，那个他说你你要停了，不能吃了，那我才问，他说影响肝功能嘛，影响
那个，那我就不敢吃了，那我就转过来，就没有再吃了，我就停了，那个药
我就没有再吃了，我就过来，过来这种中医院这边开，吃中药). (Participant 
CHN 006 psoriasis vulgaris) 
Due to the side effects of WM treatment, participants wanted an alternative to manage the 
symptoms of psoriasis vulgaris or chronic urticaria: 
I am not particularly dependent on western medicine; I do not want to continue to 
take western medicine, because I think it has some impact on my menstrual period. 
The period may turn to be longer. (本身我对西药不是特别的依赖，我不太想一
直服用它，因为我觉得它有些影响我的经期。我的经期会，就时间会变长). 
(Participant AU 003 chronic urticaria) 
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Practitioner Selection 
Through the interviews, participants also described how they came to choose their CM 
practitioners, which was also related to participants’ motivators to seek CHM. Participants 
selected the CM practitioner based on the practitioners' profile on the internet or 
recommendation by other patients and even WM doctors: 
Hmm … website of Hao dai fu (laugh). (额…好大夫网站（笑）). (Participant 
CHN 009 psoriasis vulgaris) 
Well, I will absolutely see the doctor's resume, that kind of reference. (额，肯定是
看医生的简历，那个介绍). (Participant CHN 007 psoriasis vulgaris) 
Tailoring the Treatment 
The administration of CHM included oral or topical use, depending on the aim of treatment 
and participants’ preferences. Oral use of CHM decoction was commonly observed, which 
was often brewed by participants or their family members. The decoction could be applied 
topically as well, such as in a bath to remove scales of psoriasis vulgaris and soothe the dry 
skin. Tablets and granules were chosen by participants who were unable to make CHM 
decoctions, which was more convenient. Individual treatment was highlighted during the 
treatment and modification of formula was applied if needed. For instance, the CHM formula 
was modified if new lesions occurred or when the participant was menstruating. CHM was 
often combined with WM treatments like corticosteroid ointment or antihistamines: 
Hmm I just use it locally … only for lesions. (额我一般就擦洗 … 就有问题的地
方才擦洗). (Participant CHN 009 psoriasis vulgaris) 
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Response to Treatment 
With the exception of three participants, all others experienced positive responses to CHM 
treatment. For most participants, CHM improved symptoms of disease significantly, such as 
scale and erythema for psoriasis vulgaris or wheals for chronic urticaria. 
For psoriasis vulgaris, two participants mentioned that CHM reduced the scale obviously, 
with the size of erythema shrinking for one participant. Three participants pointed out that 
CHM could prevent the occurrence of new lesions and control disease progression, although 
they found no dramatic improvement for existing lesions. No side effects arising from CHM 
were mentioned by participants. When CHM was combined with acitretin (a retinoid drug), it 
reduced the skin dryness of one participant. 
Hmm, I found my skin looked good on the day before I came here for subsequent 
visit. That is scale, the erythema became atrophic. In general, improvement 
occurred. I felt quite pleasantly surprised at that time (laugh). (嗯，那时候过来复
诊的前一天，发现皮肤好很多。就是皮屑，就是那个斑有萎缩的症状，就是
好转了。那时候就特别的惊喜（笑）). (Participant CHN 009 psoriasis vulgaris) 
In addition to the improvement of skin symptoms, CHM also made participants with psoriasis 
vulgaris more energetic, relieved emotional discomfort and reduced the frequency of 
common colds. Once the usage of CHM was stopped, the symptoms of one participant 
returned. The efficacy of CHM varied due to differences in preparation. One participant 
experienced better efficacy with decoction than granules. However, another participant 
thought granules provided better efficacy because he could guarantee the intake of required 
dosage due to the convenience of usage. In one participant with chronic urticaria, taking 
CHM treatment for one week resolved symptoms of wheals and pruritus, although she did not 
indicate whether they recurred. 
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Unlike WM treatment, CHM had no impact on her menstrual period. Relapse of urticaria 
symptoms for participants was also reduced by CHM. One participant achieved clinical cure 
(no symptoms) for up to five years after taking CHM. In some cases, CHM in combination 
with WM controlled disease progression and reduced the usage of WM gradually. In addition 
to improvement in skin condition, CHM was beneficial to general health, with some 
participants describing an improvement in their mood. However, a few participants found it 
took a long time to achieve improvement in symptoms with using CHM. Further, the 
symptoms might return once the treatment was ceased. Gastrointestinal reaction after taking 
CHM was mentioned by one participant. 
For example, like the formula prescribed by Professor X … for instance I have to 
take Western medicine once in two days, which means the symptoms can be gone 
only when I take it after one day. Then I took the Chinese medicine from Professor 
X, I may take it once in three days, and … four days later. Last time (five years ago) 
it was cured by this method. Just take a rest, and the rest time became longer, I 
found that I didn’t have to take the Western medicine. It can be cured only by using 
Chinese medicine. (比如说那个…X 教授的那个，给我开的药，就是，比如说
我以前是两天我就要吃一次那个，就是，隔一天我就要吃一次西药那才能够
消下去，然后吃 X 教授的（中）药，吃完可能就会隔两天，然后过段时间可
能隔三天，我上次（五年前）也是这么好的，就是隔,隔，然后间隔的时候越
来越长，我发现不用吃西药了，光吃中药也好了 ). (Participant CHN 005 
chronic urticaria) 
Not all participants reported benefits. One man with psoriasis vulgaris reported no change in 
the lesions but experienced improvement in his general health (such as increased energy). 
This was the reason that he persisted with CHM. Another woman with chronic urticaria also 
had no improvement in skin symptoms. She insisted on using CHM due to the reputation of 
the CM doctor. Moreover, the symptoms of one man with chronic urticaria got worse, with 
eruption of wheals after taking CHM for one week. However, he thought it might be a sort of 
initial reaction to CHM. He felt it was necessary to wait for improvement over time. 
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Based on personal positive treatment experience, participants wanted to spread the word and 
recommended CHM to more patients suffering psoriasis vulgaris or chronic urticaria. One 
participant, who was a CM practitioner, pointed out that she would take patients’ individual 
conditions into consideration when recommending CHM, such as patients’ age or occupation. 
Managing CHM 
The most common preparation type of CHM prescribed by CM practitioner was decoction. In 
addition to traditional CHM decoction, CHM products included granules, capsules and tablets. 
They became another option for people seeking CHM as treatment. Participants suggested 
that granules were more convenient than CHM decoction. The granule method was handy 
and easy to make for drinking, which was not as time-consuming as decoction. Participants 
could follow the treatment scheme easily. 
Some participants thought following CHM regimes was not burdensome or difficult. 
However, some thought it was hard to manage. For instance, participants mentioned that it 
was inconvenient and time-consuming to make the CHM decoction. They had to monitor the 
time for making CHM decoction. The taste of CHM, regardless of decoction or granule, was 
the most unacceptable factor for most participants. They found it unpalatable to drink because 
of the bitter taste and the presence of granules that did not dissolve into liquid. Participants 
felt nausea and had no appetite: 
It is not easy to make the decoction. Because, like my family, the old people can 
make the decoction. If there is no old person at home, after going back home for 
dinner, and then making the decoction, it will waste a lot of time. However, for the 
granule, it has not been proved that has effect, and is expensive as well. The granule 
seems to be afforded by patients themselves. And then because this is personalised 
treatment, a Chinese herbal medicine product is certainly not so good. For 
personalised treatment, you have to prescribe formula, for the formula, the granule 
is more expensive, and then, the efficacy is uncertain. I am not sure the efficacy of 
granule when compared with decoction … But it's really troublesome to make 
decoction. But if you want to have a try, by the way I have not tried it before. Is 
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there some kind of service for making decoction? (就是不方便要煲药。因为像我
家里有老人家就可以煲，那家里没有老人家，下班后回去做饭，吃完然后再
煲药，那也很花时间。但是颗粒剂的话，又不确定它的疗效，而且又贵很多，
颗粒剂好像是自费。然后因为这个是个体化治疗，中成药肯定没那么好啊。
那你个体化治疗的话，你也要配方，配方的话，颗粒有又比较贵，然后，疗
效就…你…不确切嘛。我不知道这个方这样吃，跟药材煲出来…但是你药材
煲确实是挺麻烦的。但是如果你要剂的话呢，我倒是没试过，不是说有那种
代煎吗？). (Participant CHN 015 chronic urticaria) 
I mean, those, granules mixed up with multiple CHM herbs, it tastes worse than the 
decoction, the dreg, really hard to swallow … The granules cannot be dissolved 
completely, they were underneath, you were not sure whether eat them or not, and I 
ate them, felt like vomit[ing] after that. (我说的颗粒是那种很多中药混合的那种
颗粒，真的你捞出来然后吃那个，真的比那个汤药难喝多了，后面那个渣子，
根本就很难吃下去……就它一般不可能完全溶解，它都是会在后面，会有一
些那种剩下的，吃也不是，不吃也不是，然后就吃完，然后就觉得吃了就想
吐的那种). (Participant CHN005 chronic urticaria) 
Adherence to CHM decreased due to a lack of access to some herbs, busyness at work or 
study and personal preference on the preparation type of CHM. For example, one participant 
described that she could not purchase all the herbs (ingredients) shown in the prescription 
once she moved location due to study. She preferred to use CHM capsules instead of 
decoction. In addition, one woman mentioned that she was afraid of raw herb formula that 
contained insects as ingredients. It was unacceptable for her to drink such CHM. She 
preferred CHM granules: 
The doctor asked me whether I drunk decoction, then I had a look at the formula, 
many insect ingredients were involved, because I am scared of insects, so I told him 
that I would have the granule, they were convenient as well. (医生当时也问我他说
你是要煎煮的，然后我看了一下药方，虫类的特别多，然后我这个人比较怕
虫，所以我跟他说我就要颗粒的，也比较方便). (Participant AU 004 chronic 
urticaria) 
Concern about CHM 
It was believed by most participants that CHM was safe and had fewer side effects compared 
with WM. However, a few participants were still concerned about the side effects of CHM 
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after long-term use. They assumed that CHM had toxicity and could affect their health (for 
example, liver dysfunction):  
Although CHM may regulate your health, it is also a burden to body if you take a 
long time, because CHM involves the toxicity and pharmacological effects, my 
main concern is that if I take the CHM every day for a long term, it may bring some 
pressure and burden to body and other aspects. Because I have concern about the 
toxicity of the CHM, I sometimes worry about this … mainly from friends or 
relatives, anyway we have an old saying ‘every medicine is toxic’, so this is my 
main concern, because it always has some side effects after long time accumulation, 
regardless of what substance. (因为毕竟吃中药它虽然会调理身体，但是长期吃
中药对身体来说也是一个负担，因为中药它毕竟它的那个药理性或者说毒性
还是一定有的，主要也会担心它长期，每天喝这个中药的话，对身体，各个
方面会有一定的压力和一定的负担，因为我自己也担心就是中药它也会有那
个一定的毒性，会有这方面的担心 … 主要是从朋友啊亲戚方面知道，反正我
们有句古话叫’是药三分毒’嘛，所以就主要是这方面担心，因为所有的东西它
累积长了时间，它始终会有一定的副作用嘛，不管是什么样的东西 ). 
(Participant CHN 011 psoriasis vulgaris) 
In addition, one participant pointed out that some patients had less trust in the preparation of 
CHM. They thought the valuable herbs would be removed if the hospital made the decoction 
for them: 
For many old people, they would rather make decoction by themselves than ask 
anybody else to do it, even though they do not have the tools to decoct at home, 
they will buy or borrow, just not to ask the hospitals to do it. They think the 
hospitals may cheat on them, for example, there are many precious herbs in the 
prescription, but in reality they only add a little into the decoction. (很多上了年纪
的婆婆和爹爹们，他们都宁愿回去自己煎都不会让人代煎，就算是家里也没
有这种煎药的工具，他们也会就是说想方设法的去借或者去买，就是不会代
煎，就是他们就会觉得医院会坑他们，就是开的药方放了很珍贵的中药，但
是实际上煎的时候只给你加那么一点点). (Participant AU 004 chronic urticaria) 
One participant with chronic urticaria had more trust in manufactured CHM products, such as 
granules, than CHM formulae with raw herbs prescribed by CM practitioners. However, one 
participant perceived the efficacy of granules might not be comparable with decoctions. This 
was because preparing granules involves less work than boiling herbs in decoction: 
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It seems that granule does not have effects. Among the herbs of CHM decoction … 
that kind of ingredients, due to interaction, it may have effect, but the granule is to 
put each granule together and mix with water, I suppose it will not generate effects. 
(就是它那种作用出不来啊。很多药物之间会有…那种成分，在相互作用，可
能会有那样子的，但是你那个颗粒就是形成单独的颗粒，冲的话，我觉得你
也不会产生什么). (Participant CHN015 chronic urticaria) 
Value for Money 
Participants held various views on the cost of CHM or CHM in combination with WM. 
Generally, the cost of CHM was acceptable or reasonable for most participants. One 
participant perceived that their response to CHM was worth the cost. However, some 
participants believed that the expense of CHM was high, especially when used in 
combination with WM. For participants without medical insurance support, such as students, 
the cost of CHM alone or in combination with WM was high due to long-term use: 
For Chinese herbal medicine, then I used to get also other treatments combined with 
Chinese herbal medicine, so I feel that the cost-effective, Chinese medicine may 
have a relatively a good response for the cost, comparing with western medicine. 
(中药的话，我那个中药主要还配合其他的治疗，所以我感觉，可能西药的，
就是性价比来说，中药可能是比较好的性价比 ). (Participant AU 003 chronic 
urticaria) 
The impact is not big because [it is] RMB 20 for one pack, one pack for two days, 
which means RMB 10 for one day. It is acceptable for me. (这个影响不大吧，因
为一剂药 20 多块钱，然后分两天喝，一天就是 10 块钱。这个倒能接受). 
(Participant CHN 009 psoriasis vulgaris) 
9.10 Discussion 
This study described patients’ experiences living with psoriasis vulgaris or chronic urticaria, 
and their experience using CHM for these two conditions. Participants experienced the 
typical symptoms of the conditions, such as erythema and scale for psoriasis vulgaris, and 
wheals and pruritus for chronic urticaria. These symptoms imposed physical and 
psychological burdens on participants, and significantly affected their QoL. 
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Key themes 
Symptoms such as itching/scratching, flaking/scaling and pain were reported by participants 
in this study. These symptoms have been reported in a multicentre qualitative study in the US 
(260). Pariser et al. explored patients’ experiences living with psoriasis, and found the most 
bothersome symptoms were itching/scratching, flaking/scaling (non-scalp areas) and skin 
pain (260). These were reported to have a significant impact on social life. Similar 
experiences were reported by participants in this study, with low quality sleep due to 
scratching, skin pain, dealing with scaling, and impact on work and study efficiency, sports, 
food and clothing selection. 
Previous studies suggested that psoriasis affected patients’ psychological wellbeing, which 
included lowered self-esteem, anxiety, sexual dysfunction and depression (18, 19). Another 
qualitative study showed that emotional impact was the most frequently reported effect (260). 
The psychological burden was also highlighted by participants with psoriasis vulgaris in this 
study. The long-term manifestation of disfigured appearance caused psychological conditions, 
such as depression and anxiety. They were worried about other people’s misunderstandings 
of the contagiousness of psoriasis vulgaris. The comorbidity of disease was another concern 
for participants.  
It has been reported that chronic urticaria results in functional limitation including mobility 
(17), pain (16, 17), energy (17), sleep (14–17) and mood changes including depression, life 
stress, social interaction and emotional reactions (14–17). These were also confirmed in this 
study, with the exception of limitation of mobility, which was rarely mentioned. O’Donnell et 
al. (17) assessed mobility using the Nottingham Health Profile, which asks a series of 
questions about physical abilities. Over half of the participants had delayed pressure urticaria 
(DPU). Participants with DPU had greater mobility limitations than those with uncomplicated 
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chronic urticaria did. However, questions about mobility were not specifically asked during 
the interview in this study. In addition, it was uncertain whether participants in this study 
suffered from DPU, as the causes of chronic urticaria were not documented. 
This study found that the distress from long-term symptoms and uncertainty about disease 
progression in participants with psoriasis vulgaris was greater than in participants with 
chronic urticaria. Participants with both conditions were uncertain about the occurrence and 
absence of symptoms, and the effects of treatments. These triggered anxiety, dysphoria and 
desperation about their future. As the symptoms of chronic urticaria came and went rapidly, 
participants had less of a focus on appearance. They simply felt dysphoric about the frequent 
occurrence of wheals and pruritus, or in more severe cases, laryngeal oedema. Compared 
with chronic urticaria, the impact of psoriasis vulgaris on social life was far reaching. The 
disfigured appearance of people with psoriasis vulgaris might prevent participants from 
attending social activities. However, participants with chronic urticaria can take medication 
to relieve symptoms rapidly and continue social activities. 
Factors triggering or aggravating their skin conditions also bothered participants’ in their 
daily lives. They had to be careful about potential trigger factors that may cause the 
occurrence of symptoms. For psoriasis vulgaris, the factors were drinking alcohol or staying 
up late. One participant described that her menstrual cycle could also exacerbate psoriasis 
vulgaris. This finding was consistent with previous understandings that various dermatoses, 
including psoriasis, peak at or around the time of menstruation (261). The risk factors 
described in clinical guidelines were also confirmed in this study (10, 12, 13). Chronic 
urticaria could be triggered or aggravated by temperature change, diet, sleep and anxiety. 
Seafood could trigger or exacerbate both psoriasis vulgaris and chronic urticaria. 
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Conventional treatment has a rapid effect, but carries a high relapse rate or short-lived effect. 
However, long-term use of conventional treatments resulted in unsatisfying side effects that 
made participants lose confidence in conventional treatments. Based on participants’ own 
beliefs and experiences, they sought CHM as alternative. At the mercy of culture and 
professional education background, participants believed and expected that CHM could 
improve personal constitution, treat the root (underlying factor) of the disease and reduce 
relapse rates with fewer side effects. In addition, the motivator of one participant to choose 
CHM was her interest and fascination with herbs. She enjoyed the CHM treatment experience. 
Most participants reported a satisfactory response to CHM. In addition to the improvement of 
skin symptoms, CHM also regulated the general health of participants. It made participants 
more energetic, improved their mood and reduced the frequency of the common cold. 
Moreover, CHM was well tolerated and could reduce relapse rates. CHM did not have a 
negative impact on participants’ menstruation. Rather, it appeared to regulate it. The cost of 
CHM was acceptable for most participants. 
However, a few participants pointed out that it took a long time to achieve improvement 
using CHM. Participants also found CHM hard to manage, as making CHM decoctions was 
time-consuming and inconvenient. The most painful thing for some participants was to drink 
CHM as it was unpalatable and caused nausea in some. CHM also caused gastrointestinal 
reactions.  
Very little research has examined the preferences of patients relating to herbal medicine. One 
US survey suggested that patients preferred capsules/pills and tinctures due to the ease of 
administration, taste and time constraints (262). These preferences were echoed by 
participants in this study. Manufactured CHM products, such as granules, capsules and 
tablets, were considered an easy option to use. Participants believed that granules could 
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increase their adherence and guarantee better efficacy since the CHM products were easy to 
take quickly. Moreover, one participant trusted CHM products that were developed through 
rigorous assessments of clinical trials instead of prescription by CM practitioner. However, 
some participants preferred raw herbs or decoction in this study. They had belief or 
experience of better efficacy with decoctions compared with manufactured CHM products. 
Similarly, Griffin et al. (262) found some participants perceived raw herbs or tinctures to be 
more potent or concentrated. 
Participants in this study also expressed concern about the side effects and cost of CHM for 
long-term use. These were also mentioned in the study of Griffin et al. (262). In addition, 
participants considered it important to tailor the treatment method to suit participants’ 
responses and expectations. Patients’ preferences for treatment should be considered. 
Limitations of the Study 
Several limitations of this study should be acknowledged. Only one Caucasian who received 
CHM treatment in Australia was recruited. Other participants were Chinese and received 
treatments in China. When comparing this study with Griffin et al. (262), similarities on the 
preference of CHM preparation (such as the preference for capsules) were discovered. 
However, difference was also observed in terms of participants’ motivators to choose CHM 
and preferred preparation types. These might be due to cultural difference between countries. 
Griffin et al. (262) conducted a survey of patients at a community acupuncture clinic in the 
US. However, most participants in this study were from China and received CHM from 
hospital outpatient departments in China. While some similarities were observed between 
preferences in the US and China, it remains uncertain whether the same similarities or 
differences exist between China and Australia. In addition, participants in China were from 
one province only (Guangdong/Canton), which may not be representative of the whole of 
 
209 
China. As some participants in this study mentioned, they were influenced by the culture in 
Canton and preferred CHM treatment. Furthermore, this study only recruited participants 
who selected CHM and explored their motivators to choose CHM. For participants who 
chose not to seek CHM as treatment, their reasons for not choosing CHM remain unclear. 
Implications for Clinical Practice and Research 
This study provided implications for both clinical practice and research. Patients’ experiences 
living with psoriasis vulgaris and chronic urticaria and their expectations for treatment should 
be taken into consideration when determining treatment strategy. Treatment should not only 
focus on improving skin symptoms, but also focus on patients’ QoL and psychological issues. 
As one study mentioned, patients’ experiences should be taken into consideration in the 
assessment and treatment of disease (263). The expectation of participants for treatments in 
this study was to reduce relapse with no side effects and to be easy to access. This 
expectation should also be considered when formulating the treatment. Further, it is better to 
inform patients about what to expect with treatment, such as differences in the onset of 
treatment effect between CHM and WM. For example, many of WM treatments act quickly, 
while CHM can take longer to achieve clinical changes. 
Patients can be informed and educated through multiple sources, such as the internet or 
patient seminars. It is interesting to note that 34% of participants selected CHM based on 
personal research or the internet (262). To guarantee better efficacy of CHM, it is important 
to improve patients’ experiences of using CHM, such as preparation type and taste of CHM. 
Ideally, convenient and palatable CHM products should be developed. This will increase 
patients’ adherence and contribute to an improvement in symptoms. 
In addition, it is valuable to explore participants’ consideration who choose not to seek CHM 
as treatment. This can highlight their belief and concern about CHM, which will be helpful to 
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idenfity the gap of CHM in the management of chronic urticaria and psoriasis vulgaris. 
Knowing what patients did not like may address some of the reasons why people did not 
choose CHM. For example, some patients indicated that CHM is not easy to use, due to the 
taste or time required to prepare the CHM. To an extent, the taste of the herbs can be changed, 
although practitioners would need to consider whether such changes would reduce the 
therapeutic effect of the formula. Further, knowing that patients are time-limited may mean 
that granules are easier for patients, would increase adherence, and may make CHM a more 
attractive treatment option.  
9.11 Conclusion 
Patients living with psoriasis vulgaris and chronic urticaria experience physical and 
psychological burdens in their lives. Patients’ experiences and expectations should be 
considered when formulating CHM treatment. Knowing patients’ expectations and real 
experiences is helpful to communicate with patients about their therapeutic options. The 
collaboration between patients and practitioners (therapeutic partnership) plays a critical role 
in clinical decision-making and therapeutic outcomes. 
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Chapter 10. General Discussion and Conclusions 
10.1 Introduction 
Chronic urticaria and psoriasis vulgaris are two common chronic skin conditions, which are 
related to immune dysfunction and triggered by external factors (10–13). Both conditions 
place considerable health-related burdens on patients, and have ongoing economic effects on 
individuals and healthcare systems (13–22). For both conditions, WM can provide rapid relief 
of symptoms. However, challenges remain in relation to unsatisfying side effects and a lack 
of treatment response for some patients after long-term use (10, 12, 13, 23). CAM has 
become an option for patients. The use of CAM, including herbal medicine for skin 
conditions, is increasing (24–26). It is valuable to evaluate and synthesise the evidence on 
CHM for both conditions, as gaps have been identified. 
This project addressed these gaps through a systematic evaluation of the ‘whole evidence’ 
from classical literature and comprehensive SRs on modern literature. When translating the 
evidence about CHM into clinical practice, patients’ experiences and expectations of using 
CHM should be considered. Further, a qualitative study was conducted to explore patients’ 
experiences of living with chronic urticaria and psoriasis vulgaris and using CHM to manage 
the conditions. 
10.2 Summary of Findings 
Classical literature research was conducted on the ZHYD (Encyclopaedia of traditional 
Chinese medicine), which is one of the largest digital collections of CM classical books. 
Among the citations related to urticaria and psoriasis vulgaris in classical literature, the most 
frequently reported formulae and herbs were identified. Xiao feng san消风散 was the most 
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commonly used formula for urticaria in the classical books, which is still used in current 
clinical practice (see Chapter 3). For psoriasis vulgaris, the most frequently reported formula 
was Sou feng shun qi wan 搜风顺气丸, which is not consistent with contemporary textbooks 
or clinical guidelines (see Chapter 3). Although no similarities were found in formulae used 
for both conditions, several herbs were used, including fang feng 防风, jing jie 荆芥, gan cao 
甘草 , qiang huo 羌活 , dang gui 当归 and chuan xiong 川芎 . These herbs are also 
recommended in current textbooks or clinical guidelines (see Chapter 3). 
Evidence from clinical studies was evaluated through SRs of RCTs following the rigorous 
method outlined by the Cochrane handbook (89). Two SRs on CHM for chronic urticaria 
showed that CHM alone or as add-on therapy to second-generation antihistamines, improved 
symptoms of chronic urticaria by 30% or more when compared with second-generation 
antihistamines. However, these findings were limited by uncertain validity (for example, 
generalisability of results to the population and variations of the instructions) of outcome 
measures used in most studies. A few studies reported validated outcomes such as UAS and 
DLQI, with findings suggesting that CHM was promising in improving symptoms (UAS) and 
HR-QoL (DLQI) of patients with chronic urticaria. CHM was well tolerated by patients with 
chronic urticaria. The number of AEs in patients who received CHM was lower than those 
who used CM and the main AEs were gastrointestinal reactions. It may be effective and safe 
to use CHM alone or as add-on therapy to second-generation antihistamines in the treatment 
of chronic urticaria. In addition, the methodological limitations of the included studies should 
be taken into consideration when interpreting these findings. Future clinical research 
following appropriate randomisation, allocation and blinding methods with validated 
outcomes is needed to provide robust evidence. 
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SRs on CHM for chronic urticaria also identified several commonly evaluated formulae and 
key herbs. Yu ping feng san 玉屏风散, Dang gui yin zi 当归饮子 and Xiao feng san 消风散 
were among the most frequently used formulae in clinical studies. Further, all three formulae 
are recommended by textbooks and clinical guidelines (see Chapter 3). Xiao feng san 消风散 
was the most frequently reported formula in classical literature (see Chapter 4). This formula 
has been evaluated in the SR (Chapter 7) and has a history of use that extends back to the 
classical literature. Xiao feng san 消风散 is also recommended in contemporary clinical 
textbooks and guidelines. These factors in combination suggest Xiao feng san 消风散 can be 
considered a promising formula in the treatment of chronic urticaria. 
Further, Yu ping feng san 玉屏风散 and Dang gui yin zi 当归饮子 were recommended and 
evaluated in clinical studies, but were not found in the classical literature. There are several 
possible reasons why these formulae were not found in classical literature. First, this project 
may not have identified all the relevant citations related to urticaria in classical literature. A 
comprehensive search of the ZHYD was conducted using eight terms, but other terms may 
have been used for urticaria in the classical literature that were not used by this project. In 
addition, the ZHYD does not cover all the classical CM books. Second, formulae names may 
vary while the herb ingredients remain the same. This project based frequency calculations on 
formula name. Therefore, it is possible that some citations that included the same ingredients 
as Yu ping feng san 玉屏风散 and Dang gui yin zi 当归饮子, but were named differently, 
were not included. Accordingly, these two formulae may have been used in classical 
literature but were not identified by this project. Third, the judgment criteria used to assess 
eligibility of citations (see Chapter 4) may have excluded some citations relating to urticaria. 
So, while Yu ping feng san 玉屏风散 and Dang gui yin zi 当归饮子 were not identified in 
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classical literature, these two formulae may be considered in clinical practice based on 
syndrome differentiation. 
The key herbs identified from SRs of chronic urticaria were fang feng 防风, huang qi 黄芪, 
dang gui 当归, gan cao 甘草, jing jie 荆芥 and bai zhu 白术. These herbs were described in 
both classical literature and textbooks and clinical guidelines (see Chapters 3 and 4). Jing jie 
荆芥 and fang feng 防风 can disperse external wind to stop itch. Huang qi 黄芪 tonifies 
Lung and Spleen qi to secure the exterior. Bai zhu 白朮 tonifies Spleen qi to assist securing 
the exterior. Dang gui 当归 nourishes Blood and harmonises nutritive level. Gan cao 甘草 
regulates the Stomach and Spleen, and harmonises all formula ingredients. Chronic urticaria 
is a condition caused by internal (underlying) and external factors. The internal factor is 
deficiency of qi and Blood, or failure of defensive qi in protecting the exterior. It can be 
triggered by external pathogenic attack, such as wind-heat or wind-cold. When influenced by 
other factors such as food or emotional disharmony, the disease can develop into other 
syndromes like dampness in the Stomach and Intestine, qi and Blood stagnation and stasis. 
The frequently used herbs in SRs, which were also described in classical literature, targeted 
the key pathogenesis of chronic urticaria from a CM perspective. 
The most frequently reported herbs and formulae in RCTs of CHM for chronic urticaria were 
selected for a general review of experimental studies (see Chapters 6 and 7). Herbs fang feng 
防风, huang qi 黄芪, dang gui 当归, gan cao 甘草, jing jie 荆芥 and bai zhu 白术 appeared 
to have anti-inflammatory, anti-allergenic and/or antipruritic actions. Yu ping feng san 玉屏
风散 (consisting of fang feng 防风, huang qi 黄芪 and bai zhu 白术) and its extract also 
showed anti-allergic and anti-inflammatory effects in vitro and in vivo. This explains the 
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potential mechanism of these herbs and their combinations in the treatment of chronic 
urticaria. 
As previous SRs on psoriasis vulgaris focused on the evaluation of CHM as an intervention 
(28–31), no reviews were identified that examined the efficacy of a particular herb, formula 
or product. In addition, gan cao 甘草 was used in the treatment of both chronic urticaria and 
psoriasis vulgaris in classical literature. Moreover, CG for chronic urticaria was also 
evaluated in this thesis. Therefore, the third SR focused on the add-on effect of CG to 
conventional therapy for psoriasis vulgaris. CG as add-on therapy to conventional therapy 
enhanced clinical response in terms of PASI 60 or 90, and did not increase the frequency of 
AEs for patients with psoriasis vulgaris. However, readers should be cautious when 
interpreting the findings due to methodological flaws of included studies. The long-term add-
on effect was uncertain. More robust evidence evaluating CG is needed, such as a randomised, 
double-blinded, placebo-controlled design. Experimental evidence indicated that CG had 
anti-inflammatory and immune-modulating effects. 
It should be noted that the herb gan cao 甘草 was used for both urticaria and psoriasis 
vulgaris. Gan cao 甘草 was the most frequently used herb in classical literature for chronic 
urticaria. However, it did not appear in the most frequently used herb list in psoriasis classical 
literature. In modern clinical evidence, CG with extract from gan cao 甘草  as a key 
constituent has been used in both chronic urticaria and psoriasis. This indicates gan cao 甘草
and its extracts can be used in the treatment of both conditions. Gan cao 甘草 is often 
considered to harmonise the ingredients of a formula. Despite this, its actions are more 
targeted than simply harmonising formulae. Gan cao 甘草 also possesses both anti-allergic 
and anti-inflammatory properties, and CG has anti-inflammatory and immune-modulating 
effects. These provide inspiration and suggestions for clinical practice and further research 
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into the actions of gan cao 甘草. It is not solely a harmonising ingredient; it also has anti-
allergic and anti-inflammatory qualities. 
When translating evidence into practice, it is valuable to consider practicalities, such as 
patients’ experiences and expectations of using CHM. The qualitative description method 
was used to explore patients’ experiences living with these two conditions and using CHM. 
This study interviewed 16 participants in Guangzhou, China and five participants in 
Melbourne, Australia. The findings suggested that participants living with psoriasis vulgaris 
or chronic urticaria perceived a bleak future due to their conditions. They reported both 
physical and psychological burdens due to the typical symptoms of the conditions, which had 
significant effects on their QoL. Most participants began with conventional treatment, which 
delivered a rapid onset and short-lived effect. Participants increasingly expected accessible 
treatments that could reduce relapse rates with no side effects. Based on participants’ own 
beliefs, knowledge and experiences, they sought CHM as treatment. Most participants 
experienced a satisfactory response to CHM, but found it difficult to manage the traditional 
decoction. Convenient, palatable CHM products were preferred by most participants. 
10.3 Limitations of this Project 
Several limitations of this project should be acknowledged. The ZHYD, which is a 
comprehensive collection of a wide range of books from the last 2,000 years, was used to 
conduct classical literature research. While larger collections of classical CM books exist 
(such as Chinese materia medica 中华本草全书 with over 6,000 classical CM books), the 
ZHYD, covering 1,100 classical CM books, was chosen for this project. As a digitalised 
collection, the ZHYD was easily searchable and accessible, and includes key books 
considered representative of classical literature. As highlighted previously, terms for both 
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urticaria and psoriasis vulgaris may exist that were not selected for use in this project. 
Inclusion of any additional terms may alter the results. 
The findings from SRs were limited by the quality of included studies. The methodological 
flaws of the included studies could not be ignored in all three SRs. The methodology issues 
relating to the included studies have been highlighted in each SR (see Chapters 6–8). For 
instance, information regarding blinding in most studies was insufficient, which made the 
outcome assessment less reliable. A few studies provided a detailed description for the 
generation of a randomised sequence. However, it was unclear or inappropriate for the 
remaining studies. Inadequate data on the generation of a randomised sequence might cause 
potential selection bias. The information of blinding for majority studies was insufficient, 
which made outcome assessment less reliable (89). In addition, most studies included in SRs 
on CHM for chronic urticaria employed the outcome ER 30 and SSRI 30 with uncertain 
validity. These two outcomes were not commonly observed in international studies. The lack 
of adherence to internationally recognised standards makes their validity uncertain. In 
addition, very few studies included in these SRs used outcomes related to HR-QoL or relapse 
rates to assess treatments. The recurrence of symptoms had significant impacts on patients’ 
QoL. 
For two SRs (Chapters 6 and 7), the database search was limited to English and Chinese 
databases. An additional Japanese database was searched for the third SR (see Chapter 8). 
While the search included nine to 10 databases, searching in additional databases (such as 
Korean databases that include studies of CM) may provide more evidence on the use of CHM 
for both conditions. In terms of patient recruitment, most included studies did not specify the 
subtype of chronic urticaria. It remains uncertain whether CHM is effective for patients with 
specific subtypes, such as chronic spontaneous urticaria or DPU. In terms of the use of CHM 
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in the included RCTs, standardised formulae were used for all patients during the trials. This 
differs from the approach used in clinical practice, where the use of CHM is based on 
syndrome differentiation. It is unknown how the results from the SRs are applicable to 
clinical practice.  
The limitation of qualitative study was related to geographic and cultural factors. Only one 
Caucasian who received CHM treatment in Australia was interviewed. Other interviews were 
conducted among participants who were Chinese and received treatments in China. It remains 
uncertain whether the same similarities or differences in patients’ experience exist between 
China and Australia. Moreover, participants in China came from one province only, which 
may not be representative of the whole of China. 
10.4 Implications for Clinical Practice 
This project provided a comprehensive assessment of the ‘whole evidence’ for clinical 
decision-making. Some formulae and herbs identified from classical literature were described 
in contemporary textbooks and clinical guidelines, and were also shown to be effective in the 
clinical trials. These formulae or herbs can be used in clinical practice. For instance, Xiao 
feng san 消风散 can be a formula for chronic urticaria. Herbs fang feng 防风, huang qi 黄芪, 
dang gui 当归, gan cao 甘草, jing jie 荆芥 and bai zhu 白术 for chronic urticaria could be 
considered as modifications for the basic formula based on syndrome differentiation. Yu ping 
feng san 玉屏风散 and Dang gui yin zi 当归饮子 can also be taken into consideration based 
on syndrome differentiation because they were recommended by textbooks and clinical 
guidelines. For formulae or herbs not described in classical literature, contemporary 
guidelines or clinical evidence, practitioners should consider their use based on patient 
syndrome differentiation and practitioner’s experience. 
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For psoriasis vulgaris, formulae identified from classical literature were not consistent with 
current textbooks or clinical guidelines. Further, it was uncertain whether these formulae 
were evaluated in the clinical trials as most formulae in SRs (28–31) were self-designed. 
Making a judgment about similarity of formulae based on herb ingredients in the absence of a 
common formula name is difficult and open to criticism. The approach in this study was to 
use the formula name when checking for consistency of use across different types of evidence. 
For example, Tao hong si wu tang桃红四物汤 consists of shu di huang 熟地黄, dang gui 当
归, bai shao 白芍, chuan xiong 川芎, tao ren 桃仁 and hong hua 红花. Practitioners or 
investigators may modify the basic formula with jiang can 僵蚕 (commonly used for itch) 
according to individual symptoms or experience. The name of the formula might be changed 
(for example, the new formula with added jiang can 僵蚕 may be named as a self-designed 
formula), but the core formula remains Tao hong si wu tang桃红四物汤. While consistency 
was not found in formulae for psoriasis vulgaris, this does not mean that consistency does not 
exist. However, in the absence of consistency in formulae, consistency was found in herbs. 
Herbs fang feng 防风, jing jie 荆芥, gan cao 甘草, dang gui 当归 and chuan xiong 川芎 
were among the most frequently found in classical literature, and are also recommended by 
current textbooks or clinical guidelines (see Chapter 3). These herbs could be considered on 
an individual basis in clinical practice as modifications for the basic formula. In addition, 
manufactured CHM products, such as CG, can become an option for both chronic urticaria 
and psoriasis vulgaris. 
Patients experienced both physical and psychological burdens due to chronic urticaria and 
psoriasis vulgaris. They expected accessible treatments that could reduce relapse rates with 
no side effects. Patients’ experiences and expectations should be considered when 
formulating CHM treatment. Patient involvement in care could increase patients’ adherence 
 
220 
and help achieve satisfactory effects, particularly if patients were prescribed their preferred 
CHM preparation types. Knowing patients’ expectation and real experiences improves 
communication between patients and practitioners. Treatment processes require better 
collaboration between patients and practitioners. 
10.5 Implications for Further Research 
Formulae or herbs identified from classical literature can be potential targets in clinical trials 
or experimental studies for drug discovery where evidence is lacking. SRs identified 
weaknesses of included studies, such as methodology flaws and the use of outcomes with 
uncertain validity. This informs future research in several ways. First, clinical registration or 
protocol should be available or published before the results are published, which can increase 
transparency in reporting of clinical trials. No registration or protocols were found for the 
studies included in this project. Insufficient detail in reporting study methods further adds to 
the lack of clinical trial transparency. 
In addition to following a rigorous standard methodology to conduct clinical studies, public 
involvement in health research is becoming increasingly common (264, 265). It is defined as 
when patients and members of the public become involved in the design, conduct and 
dissemination of research (264–266). This increases the relevance of research and improves 
research quality, such as identification of research priorities and outcome measures, and 
acceptability of data collection procedures (264, 265). The findings from qualitative study in 
this project showed patients expected treatment that can reduce relapse rates and result in 
fewer side effects after long-term use. The treatment goal and outcomes used in the 
assessment of treatment effect should focus on patients’ expectations. Patients preferred 
convenient CHM products that were palatable and easy to take. Therefore, granules or 
capsules can be considered, which could increase patients’ adherence. As suggested by 
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Mullins et al. (266), patient-centredness in the design of clinical trials motivated patients to 
participate or continue participating in clinical trials. Comparison of the efficacy of CHM 
products and decoction should be conducted to evaluate efficacy and safety to alleviate 
patients’ concerns. 
10.6 Conclusion 
This project evaluated the evidence from classical literature, clinical studies and patients’ 
experiences of CHM for chronic urticaria and psoriasis vulgaris. Evidence from classical 
literature suggested the most frequently used formulae and herbs for both conditions in 
ancient CM works, which can guide contemporary clinical practice and new therapeutic 
development. SRs of clinical evidence produced through this project suggested that CHM 
was well tolerated and had promising benefits in improving clinical outcomes. These 
provided evidence of efficacy and safety for clinical decision-making, CM education and 
further research. Pharmacological actions of key herbs from the SRs include anti-
inflammatory, anti-allergenic, antipruritic and immune-modulating actions. This could 
partially explain the mechanisms of CHM in the treatment of both conditions. Findings from 
qualitative interviews suggested that patients suffered both physical and psychological 
burdens due to the conditions. Based on beliefs and experience, they chose CHM and 
expected that it could reduce relapse with no side effects and be easy to take. Understanding 
patients’ experiences and expectations can assist with communicating with patients and 
formulating CHM treatment. This can increase patients’ compliance in using CHM and 
contribute valuable information for future research study design. 
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Appendices 
Appendix 1 Search Terms for Chronic Urticaria 
Search Terms for Chinese Language Databases: 
Conditions 
荨麻疹 OR瘾疹 OR隐疹 OR风疹块 OR风团 OR 风疹团 
Interventions 
中医 OR 中西医 OR 中医疗法 OR 辨病论治 OR 辨证 OR 辨证论治 OR 辨症施治 OR 辩
证 OR 汉方 OR 祖国医学 OR 传统医学 OR 传统治疗 OR 传统疗法 OR 替代医学 OR 替
代治疗 OR 中国传统医学 OR 民族医药 OR 民族医学 OR 草药 OR 中草药 OR 中药 OR 
中药疗法 OR 中西药 OR 传统医药 OR 中成药 OR 植物药 OR 中医治法 OR 治则 OR 中
医疗法 OR 熏洗 OR 薰洗 OR 浸洗 OR 药浴 OR 洗浴 OR 外洗 OR 沐足 OR 足浴 OR 浴
足 OR 灌肠 OR 热熨 OR 热敷 OR 敷脐 OR 药烘 OR 足疗 OR雾化 OR中药外敷 OR外
敷 OR蒸熏 OR蒸薰 OR熏蒸 OR薰蒸 
Study Designs 
系统评价 OR meta OR 荟萃分析 OR 系统分析 OR 综述 OR进展 OR 概况 OR 现状 OR 
近况 OR 临床观察 OR 临床评估 OR 临床试验 OR 临床效果 OR 临床研究 OR 疗效 OR 
评价研究 OR 前瞻性 OR 随访 OR 对比研究 OR 多中心 OR 随机 OR 对照 OR 病例报告 
OR 病例研究 OR 病例分析 OR 病例报道 
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Search Terms for English Language Databases: 
Conditions 
Wheal OR hives OR urticaria 
Interventions 
Traditional Chinese Medicine OR Chinese Traditional Medicine OR Chinese Herbal Drugs 
OR Chinese Drugs, Plant OR Medicine, Traditional OR Ethnopharmacology OR 
Ethnomedicine OR Ethnobotany OR Medicine, Kampo OR Kanpo OR TCM OR Medicine, 
Ayurvedic OR Phytotherapy OR Herbology OR Plants, Medicinal OR Plant Preparation OR 
Plant Extract OR Plants, Medicine OR Materia Medica OR Single Prescription OR Chinese 
Medicine Herb OR Herbal Medicine OR Herbs 
Study Designs 
Review articles: Systematic 
Randomized Controlled Trial: randomized controlled trial OR controlled clinical trial OR 
randomized OR placebo OR drug therapy OR randomly OR trial OR groups 
Other Studies: cohort studies OR case-control studies OR comparative study OR risk factors 
OR cohort OR compared OR groups OR case control OR multivariate OR case series 
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Appendix 2 Search Terms for Psoriasis Vulgaris 
Search Terms for Chinese Language Databases: 
Conditions 
银屑病 OR白疕 OR松皮癣 OR掌跖脓疱病 
Interventions 
甘草酸 OR美能 OR甘草甜素 OR强力宁 OR甘毓 
Study Designs 
临床观察 OR 临床评估 OR 临床试验 OR 临床效果 OR 临床研究 OR 疗效 OR 评价研究
OR前瞻性 OR随访 OR对比研究 OR多中心 OR随机 OR对照 OR病例报告 OR病例研
究 OR 病例分析 OR 病例报道 
Search Terms for English Language Databases: 
Conditions 
Skin Diseases, Papulosquamous OR Psoriasis OR Psoria* OR Arthritis, Psoriatic OR 
Pustulosis of Palms and Soles OR Pustulosis Palmaris et Plantaris OR Palmoplantaris 
Pustulosis OR Pustular Psoriasis of Palms and Soles 
Interventions 
Glycyrrhizic Acid OR glycyrrhizic acid OR glycyrrhizin OR glycyrrhizinic acid OR 
glycyrrhizic acid OR licorice OR liquorice OR Stronger Neo-minophagen C OR Compound 
Glycyrrhizin 
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Study Designs 
Randomized controlled trial OR controlled clinical trial OR randomized OR randomised OR 
placebo OR drug therapy OR randomly OR trial OR groups 
Search Terms for Japanese Language Database: 
Conditions 
乾癬 OR 白疕 OR 銀屑病 OR 松皮癣 OR 掌蹠膿疱症 
Interventions 
グリチルリチン OR グリシルリジン OR 強力ネオミノファーゲンシー OR 强力宁 OR 
甘毓 
Study Designs 
臨床観察 OR 臨床評価 OR 臨床試験 OR 臨床効果 OR 臨床研究 OR 効果 OR 評価研究 
OR 前向き研究 OR フォローアップ OR 比較研究 OR 比較試験 OR 多施設 OR ランダ
ム OR 無作為 OR コントロール OR 対照 OR 症例報告 OR 事列研究 OR ケーススタデ
ィ OR 症例分析 OR 症例報告 
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Appendix 3 Examples of Data Extraction Forms 
Characteristics 
First author; 
publication year; 
country; setting 
Study design; 
blinding; 
number of 
arms 
Treatment 
duration; total 
number of 
treatments; 
follow-up 
duration 
Stage; severity; 
duration of 
condition (mean 
[SD] or range) 
No. of participants 
randomised/assessed; 
dropouts  
Age (mean 
(SD) or 
range); gender 
(M/F) 
Intervention Comparator 
 
 
              
Intervention 
First author, 
publication year 
Syndromes CM principle of 
treatment  
Intervention Details Comparator 
(specify) 
Dosage and 
administration 
 
 
      
Outcomes 
First author, publication year Symptom severity Quality of life Relapse rate Adverse events 
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Appendix 4 Interview Guide 
                                                                       Study ID: ____________________ 
Qualitative study: Patient experiences of using CHM for chronic skin conditions 
Interview guide 
The questions below are examples of questions that may be used to guide interviews with participants. The 
order of questioning may vary depending on participants’ responses, and may be subject to minor revisions 
throughout the duration of the project. 
 
1. Tell me about your skin condition. 
a. When did you first discover you had psoriasis/chronic urticaria? 
b. How did you feel when it was diagnosed? 
c. What symptoms did you have for your condition? 
d. Do you still have psoriasis/chronic urticaria now? 
i. (If yes) Is the condition always there or does it come and go? 
e. How has having psoriasis/chronic urticaria affected your life? 
f. What impact has it had on your physical health? 
g. What impact has it had on your sleep and energy levels? 
h. What impact has it had on your emotional health? 
i. What impact has it had on work or study? 
j. What impact has it had on your social life and relationships? 
k. What impact has it had on your finances? 
l. Do you think that your condition will affect your life in the future? 
 
2. Can you tell me what treatments you have tried for your condition? 
a. What sort of results did you get from that/those treatments? 
b. What led you to decide to use Chinese medicine? 
c. How did you find the Chinese medicine practitioner you saw? 
 
3. Tell me what it was like to use the Chinese herbs. 
a. Can you describe the Chinese herbs you received? 
b. How often did you have to use them? 
c. What sort of changes did you notice when using the Chinese herbs? 
d. What sort of impact did the Chinese herbs have on your finances? 
e. If you had a friend with the same skin condition, what would you tell them about Chinese 
herbs? 
 
4. We’ve covered quite a few topics here, is there anything else you’d like to add? 
 
Demographic data 
a. Age 
b. Gender 
c. Postcode 
d. Ethnicity 
f. Education 
g. Employment 
 
Date of interview 
Time of interview   
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Appendix 5 Participant Information and Consent Form 
 
 
 
The Participant Information and Consent Form (PICF) 
 
 
INVITATION TO PARTICIPATE IN A RESEARCH PROJECT 
 
 
PARTICIPANT INFORMATION  
 
Project Title: Qualitative study: Patient experiences of using CHM for chronic skin 
conditions 
 
Investigators:  
 
Prof. Charlie Xue, BMed, PhD; Registered Chinese medicine practitioner 
Head of School of Health Sciences, RMIT University 
charlie.xue@rmit.edu.au 
9925 7360 
 
Dr. Tony Zhang, BMed, MPH, PhD; Registered Chinese medicine practitioner 
Head of Discipline of Chinese Medicine, RMIT University 
tony.zhang@rmit.edu.au 
9925 7758 
 
Dr. Meaghan Coyle, PhD; Registered Chinese medicine practitioner 
Research Fellow, Discipline of Chinese Medicine, RMIT University 
meaghan.coyle@rmit.edu.au 
9925 7678 
 
Prof. Chuanjian Lu, MD, PhD 
Vice-President, Dermatologist, Guangdong Provincial Hospital of Chinese Medicine 
Luchuanjian888@vip.sina.com 
 
Mr Jingjie (Jason) Yu, MMed; Registered Chinese medicine practitioner 
PhD Candidate, RMIT University 
s3472604@student.rmit.edu.au 
9925 7678  
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Dear Sir/Madam, 
You are invited to participate in a research project being conducted by RMIT University 
through the China-Australia International Research Centre for Chinese Medicine. Please 
read this sheet carefully and be confident that you understand its contents before deciding 
whether to participate. If you have any questions about the project, please ask one of the 
investigators.  
Who is involved in this research project? Why is it being conducted? 
We are looking to explore people’s experiences of living with a chronic skin condition who 
have used CHM to manage the condition. Currently, there is very little information available 
on this topic, and we think it’s important for us to know. We are inviting approximately 40 
people who have either psoriasis or chronic urticaria to participate in this study. 
This research study is part of Mr Jingjie (Jason) Yu’s PhD project. It is being conducted by 
collaboration between RMIT University and Guangdong Provincial Hospital of Chinese 
Medicine. The project is being supervised by Prof Charlie Xue, Prof Chuanjian Lu, Dr Tony 
Zhang, and Dr Meaghan Coyle. The results will be presented in aggregate at conference 
presentations and journal publication. You will not be identified in any way. 
The project has been approved by RMIT College Human Ethics Advisory Network (No. 
BSEHAPP 29–15 XUE) and funded by RMIT University in conjunction with Guangdong 
Provincial Hospital of Chinese Medicine. 
Why have you been approached? 
You have been approached to participate as you have been previously diagnosed with chronic 
urticaria or psoriasis vulgaris, and consulted Chinese medicine practitioners for treatment. 
You may have heard about this study through recruitment posters displayed in a clinic or 
hospital, through contact from the RMIT Teaching Clinic or after enquiring about a clinical 
trial. 
What is the project about? What are the questions being addressed? 
This project is a qualitative interview. This project will explore the experiences of people 
with chronic urticaria (hives) or psoriasis vulgaris in terms of the impact of the condition on 
their health and life, and their experiences in using CHM. A total of approximately 40 people 
will be interviewed individually. Each interview will take approximately 30–60 minutes. 
If I agree to participate, what will I be required to do? 
If you agree to participate in the study, you will be provided with all the details about the 
study, and any questions will be answered by the research investigator. Once you sign this 
participant information consent form (PICF), an interview time will be arranged. Interviews 
can be conducted either at RMIT (RMIT School of Health Sciences Research Hub, Building 
201, Level 3) or at your home if more convenient. 
You will spend approximately 30–60 minutes participating in this interview. Several 
questions will be asked by a researcher, which covers the key topics outlined below: 
1. Your experiences with the condition in terms of impact on health and daily life. 
2. What led you to choose Chinese herbal medicine? 
3. What have been your experiences with using Chinese herbal medicine for the 
condition? 
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An audio recording of the interview will be made and a second researcher may be present to 
record additional non-verbal details (such as gestures) of the interview. Interview will be 
conducted in English or Chinese (Mandarin) according to your preference. 
What are the possible risks or disadvantages? 
If you participate in this project, there are no perceived risks outside your normal day-to-day 
activities. Some of the questions may be embarrassing or make you feel uncomfortable. You 
have the right to decline to answer particular questions, or to withdraw from the study at any 
time. The information you provide will be confidential, and will not be accessible to anyone 
outside of the research team. 
If you have any concerns about the responses to any of the questions asked or if you find 
participation in the project distressing, you should contact one of the investigators Dr Tony 
Zhang as soon as convenient. Dr Tony Zhang will discuss your concerns with you 
confidentially and suggest appropriate follow-up, if necessary. You may contact the RMIT 
Ethics committee or GPHCM ethics committee for concerns that you would prefer them 
handled by someone outside the research team.   
What are the benefits associated with participation? 
The findings from this project will provide valuable information which may inform clinical 
practice and guide future research of Chinese herbal medicine for dermatological conditions. 
This may improve patients’ experience using Chinese herbal medicine. 
What will happen to the information I provide? 
Your information will only be used for the purpose of this research project and it will only be 
disclosed with your permission, except as required by law. Information that you provide will 
be identifiable. Where possible and appropriate, identifiable information will be replaced 
with pseudonyms. Identifiable information will be stored on a password-protected computer, 
or in a locked filing cabinet. Data will be stored for a minimum of seven years from the date 
of publication. 
Only the researchers involved in the study will have access to this information. Any 
information that you provide can be disclosed only if: 
(1) it is to protect you or others from harm 
(2) a court order is produced 
(3) you provide the researchers with written permission. 
You have the right to request access to the information collected and stored by the research 
team about you. You also have the right to request that any information with which you 
disagree being corrected. You have the right to withdraw from the study, and you may 
request your identifiable data be disposed of. Once the interviews have been transcribed, any 
identifiable information will be removed. Up until this point, you are able to request 
identifiable information be disposed of. This will be undertaken according to institutional 
policy, where electronic data will be deleted from storage facilities and hard copies of data 
will be disposed of in confidential waste bins. 
Findings from this project will be published in international peer-reviewed journals, and will 
be presented at national and international conferences. You will not be identified in any 
publications from the study. The findings will also be included in the PhD thesis of Mr 
Jingjie (Jason) Yu which, once approved, will be submitted to the RMIT University Research 
Repository. 
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What are my rights as a participant? 
 The right to withdraw from participation at any time 
 The right to request that any recording cease 
 The right to have any unprocessed data withdrawn and destroyed, provided it can be 
reliably identified, and provided that so doing does not increase the risk for the 
participant 
 The right to have any questions answered at any time. 
Whom should I contact if I have any questions? 
Any study related questions should be directed to Mr. Jingjie (Jason) Yu at 03 9925 7678. 
What other issues should I be aware of before deciding whether to participate? 
Before deciding you should assess the requirements of the research for face to face interview. 
Interview will take approximately 30–60 minutes plus travel time. A $20 voucher will be 
provided to you in appreciation of your time. You should consider if you can commit the time 
required to complete the study. 
 
Yours sincerely 
Investigators:  
Prof. Charlie Xue  
 
Dr. Tony Zhang  
 
Dr. Meaghan Coyle  
 
Prof. Chuanjian Lu  
 
Mr Jingjie (Jason) Yu 
 
 
 
If you have any concerns about your participation in this project, which you do not wish to 
discuss with the researchers, then you can contact the Ethics Officer, Research Integrity, 
Governance and Systems, RMIT University, GPO Box 2476 VIC 3001. Tel: (03) 9925 2251 
or email human.ethics@rmit.edu.au 
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CONSENT TEMPLATE 
1. I have had the project explained to me, and I have read the information sheet. 
 
2. I agree to participate in the research project as described. 
 
3. I agree: 
 
 to be interviewed 
 that my voice will be audio recorded 
 
4. I acknowledge that: 
 
(a) I understand that my participation is voluntary and that I am free to withdraw 
from the project at any time and to withdraw any identifiable data previously 
supplied until the point of de-identification. 
(b) The project is for the purpose of research. It may not be of direct benefit to me. 
(c) The privacy of the personal information I provide will be safeguarded and only 
disclosed where I have consented to the disclosure or as required by law. 
(d) The security of the research data will be protected during and after completion 
of the study. The overall findings from data collected during the study will be 
published, and a report of the project outcomes may be presented at a 
conference. Any information which will identify me will not be used. 
 
Participant’s Consent 
Participant:  Date:  
(Signature) 
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Appendix 6 Recruitment Poster  
 
 
Do you have chronic urticaria or psoriasis? Tell us your experience living with it and 
using Chinese herbal medicine! 
Researchers at RMIT University are conducting a study to explore the experiences of people with chronic 
urticaria (hives) or psoriasis vulgaris in terms of the impact of the condition on their health and life, and their 
experiences in using CHM. This project has been approved by the RMIT College Human Ethics Advisory 
Network (No. BSEHAPP 29-15 XUE). 
If you are eligible to participate, you will be interviewed for 30–60 minutes about your experience living with 
skin disease and using Chinese herbal medicines for it. 
Your participation will contribute to valuable information which may inform clinical practice, and guide future 
research of Chinese herbal medicine for dermatological conditions. This may improve your and other patients’ 
experience of using Chinese herbal medicine. 
You will be eligible for this study if you:  
 
If you or your friends are interested in this project, please contact Dr Jingjie (Jason) Yu or Dr Meaghan Coyle  
Ph: 03 9925 7678 
Email Meaghan: meaghan.coyle@rmit.edu.au  
 Have previously been diagnosed with chronic urticaria or 
psoriasis vulgaris 
 Used Chinese herbal medicine for the condition 
 Are aged from 18-65 years 
 Are able to speak and read English 
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Appendix 7 Human Research Ethics Approval Letter from RMIT University  
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Appendix 8 Human Research Ethics Approval Notice from Guangdong 
Provincial Hospital of Chinese Medicine
 
278 
Appendix 9 List of Herbs Used in This Thesis 
Pinyin Name 
Simplified Chinese 
Characters 
Scientific Name Pharmaceutical Name 
Ai ye 艾叶 Artemisia argyi Lévl. et Vant. Artemisiae Argyi Folium 
Ba ji tian 巴戟天 Morinda officinalis How Morindae Officinalis Radix 
Bai bian dou 白扁豆 Dolichos lablab L. Lablab Semen Album 
Bai bu 百部 
1. Stemona sessilifolia (Miq.) Miq.  
2. Stemona japonica (Bl.) Miq.  
3. Stemona tuberosa Lour.  
Stemonae Radix 
Bai fan 白矾 Potassium aluminium sulfate Alumen 
Bai hua she she 
cao 
白花蛇舌草 Hedyotis diffusa Willd. Hedyotis diffusae Herba 
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Bai jie zi 白芥子 
1. Sinapis alba L.  
2. Brassica juncea (L.) Czern. et Coss. 
Sinapis Semen 
Bai lian 白蔹 Ampelopsis japonica (Thunb.) Makino Ampelopsis Radix 
Bai shao 白芍 Paeonia lactiflora Pall. Paeoniae Radix Alba 
Bai xian pi 白鲜皮 Dictamnus dasycarpus Turcz. Dictamni Cortex 
Bai zhi 白芷 
1. Angelica dahurica (Fisch. ex Hoffm.)  Benth. et Hook. f. 
2. Angelica dahurica (Fisch. ex Hoffm.) Benth. et Hook. f. 
var. formosana (Boiss.) Shan et Yuan 
Angelicae Dahuricae Radix 
Bai zhu 白朮 Atractylodes macrocephala Koidz. 
Atractylodis Macrocephalae 
Rhizoma 
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Ban xia 半夏 Pinellia ternata (Thunb.) Breit. Pinelliae Rhizoma 
Bi ma zi 蓖麻子 Ricinus communis L. Ricini Semen 
Bing lang 槟榔 Areca catechu L. Arecae Semen 
Bo he 薄荷 Mentha haplocalyx Briq. Menthae Haplocalycis Herba  
Cang er zi 苍耳子 Xanthium sibiricum Patr. Xanthii Fructus 
Cang zhu 苍朮 
1. Atractylodes lancea (Thunb.) DC.  
2. Atractylodes chinensis (DC.) Koidz. 
Atractylodis Rhizoma 
Cao wu 草乌 Aconitum kusnezoffii Reichb. Aconiti Kusnezoffii Radix 
Cao wu tou 草乌头 Aconitum kusnezoffii Reichb. Aconiti Kusnezoffii Radix 
Cha 茶 Camellia sinensis [Syn. Thea sinensis] NA 
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Chai hu 柴胡 
1. Bupleurum chinense DC. 
2. Bupleurum scorzonerifolium Willd. 
Bupleuri Radix 
Chan tui 蝉蜕 Cryptotympana pustulata Fabricius Cicadae Periostracum 
Che qian zi 车前子 
1. Plantago asiatica L. 
2. Plantago depressa Willd. 
Plantaginis Semen 
Chen pi 陈皮 Citrus reticulata Blanco Citri Reticulatae Pericarpium 
Chi shao 赤芍 
1. Paeonia lactiflora Pall. 
2. Paeonia veitchii Lynch  
Paeoniae Radix Rubra  
Chi xiao dou 赤小豆 
1. Vigna umbellata Ohwi et Ohashi  
2. Vigna angularis Ohwi et Ohashi   
Vignae Semen 
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Chong wei zi 茺蔚子 Leonurus japonicus Houtt. Leonuri Fructus 
Chuan xiong 川芎 Ligusticum chuanxiong Hort. Chuanxiong Rhizoma 
Chun hua hu zhi 
zi 
春花胡枝子 Lespedeza dunnii Schindle Lespedezae dunnii herba  
Ci ji li 刺蒺藜 Tribulus terrestris L. Tribuli Fructus 
Cu 醋 Vinegar NA 
Da feng zi 大风子 Hydnocarpus anthelmintica Pierre NA 
Da fu pi 大腹皮 Areca catechu L. Arecae Pericarprium 
Da huang 大黄 
1. Rheum palmatum L. 
2. Rheum tanguticum Maxim. ex Balf. 
3. Rheum officinale Baill. 
Rhei Radix et Rhizoma 
Da qing yan 大青盐 Sodium chloride  Halitum 
Da qing ye 大青叶 Isatis indigotica Fort Isatidis Folium 
 
283 
Da zao 大枣 Ziziphus jujuba Mill. Jujubae Fructus 
Da zao jiao 大皂角 Gleditsia sinensis Lam. Gleditsiae Sinensis Fructus 
Dan shen 丹参 Salvia miltiorrhiza Bge. 
Salviae Miltiorrhizae Radix et 
Rhizoma 
Dan zhu ye 淡竹叶 Lophatherum gracile Brongn. Lophatheri Herba 
Dang gui 当归 Angelica sinensis (Oliv.) Diels Angelicae Sinensis Radix 
Dang shen 党参 
1. Codonopsis pilosula (Franch.) Nannf. 
2. Codonopsis pilosula Nannf. var. modesta (Nannf.) L. T. 
Shen 
3. Codonopsis tangshen Oliv. 
Codonopsis Radix 
Di fu zi 地肤子 Kochia scoparia (L.) Schrad. Kochiae Fructus 
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Di gu pi 地骨皮 
1. Lycium chinense Mill. 
2. Lycium barbarum L. 
Lycii Cortex 
Di huang 地黄 Rehmannia glutinosa Libosch. Rehmanniae Radix 
Di long 地龙 
1. Pheretima aspergillum (E. Perrier)  
2. Pheretima vulgaris Chen 
3. Pheretima guillelmi (Michaelsen) 
4. Pheretima pectinifera Michaelsen 
Pheretima 
Diao yang chen 吊扬尘 Buddleja lindleyana Fort. NA 
Du huo 独活 Angelica pubescens Maxim. f. biserrata Shan et Yuan Angelicae Pubescentis Radix 
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Duan shi gao 煅石膏 Hydrated calcium sulfate Gypsum Ustum 
Fa ban xia 法半夏 Pinellia ternata (Thunb.) Breit. Pinelliae Rhizoma Praeparatum 
Fang feng 防风 Saposhnikovia divaricata (Turcz.) Schischk. Saposhnikoviae Radix 
Fang ji 防己 Stephania tetrandra S. Moore Stephaniae Tetrandrae Radix 
Feng mi 蜂蜜 
1. Apis cerana Fabricius 
2. Apis mellifera Linnaeus.  
Mel 
Fu ling 茯苓 Poria cocos (Schw.) Wolf Poria 
Fu ling pi 茯苓皮 Poria cocos (Schw.) Wolf Poriae Cutis 
Fu ping 浮萍 Spirodela polyrrhiza (L.) Schleid. Spirodelae Herba 
Fu zi 附子 Aconitum carmichaelii Debx. 
 Aconiti Radix Lateralis 
Praeparata 
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Gan cao 甘草 
1. Glycyrrhiza uralensis Fisch. 
2. Glycyrrhiza inflata Bat. 
3. Glycyrrhiza glabra L. 
Glycyrrhizae Radix et Rhizoma 
Gan song 甘松 Nardostachys jatamansi DC.  Nardostachyos Radix et Rhizoma 
Gao ben 藁本 
1. Ligusticum sinense Oliv. 
2. Ligusticum jeholense Nakai et Kitag. 
Ligustici Rhizoma et Radix 
Ge gen 葛根 Pueraria lobata (Willd.) Ohwi Puerariae Lobatae Radix 
Gou qi zi 枸杞子 Lycium barbarum L. Lycii Fructus 
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Gou teng 钩藤 
1. Uncaria rhynchophylla (Miq.) Miq. ex Havil. 
2. Uncaria macrophylla Wall. 
3. Uncaria hirsuta Havil. 
4. Uncaria sinensis (Oliv.) Havil. 
5. Uncaria sessilifructus Roxb. 
Uncariae Ramulus cum Uncis 
Gui zhi 桂枝 Cinnamomum cassia Presl Cinnamomi Ramulus 
He huan pi 合欢皮 Albizia julibrissin Durazz. Albiziae Cortex 
He shi 鹤虱 Carpesium abrotanoides L. Carpesii Fructus 
He shou wu 何首乌 Polygonum multiflorum Thunb. Polygoni Multiflori Radix 
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Hong hua 红花 Carthamus tinctorius L. Carthami Flos 
Hong huo ma 红活麻 Urtica amgustifolia Fisch. Ex Hornem. NA 
Hu ma ren  胡麻仁 Lespedeza dunnii Schindle Lespedezae dunnii herba  
Hua jiao 花椒 
1. Zanthoxylum schinifolium Sieb. et Zucc. 
2. Zanthoxylum bungeanum Maxim. 
Zanthoxyli Pericarpium 
Hua pi  桦皮 Betula luminifera NA 
Hua shi 滑石 Hydrated magnesium silicate  Talcum 
Huai bai pi 槐白皮 Sophora japonica L. NA 
Huai hua 槐花 Sophora japonica L. Sophorae Flos 
Huai mi 槐米 Sophora japonica L. Sophorae Flos 
Huang bai 黄柏 Phellodendron chinense Schneid. Phellodendri Chinensis Cortex 
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Huang bo 黄柏 Phellodendron chinense Schneid. Phellodendri Chinensis Cortex 
Huang la 黄蜡 NA NA 
Huang lian 黄连 
1. Coptis chinensis Franch. 
2. Coptis deltoidea C. Y. Cheng et Hsiao 
3. Coptis teeta Wall.  
Coptidis Rhizoma 
Huang qi 黄芪 
1. Astragalus membranaceus (Fisch.) Bge. var. mongholicus 
(Bge.) Hsiao 
2. Astragalus membranaceus (Fisch.) Bge. 
Astragali Radix 
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Huang qin 黄芩 Scutellaria baicalensis Georgi Scutellariae Radix 
Huo ma cao 火麻草 Urtica amgustifolia Fisch. Ex Hornem. NA 
Huo xiang 藿香 
1. Pogostemon cablin (Blanco) Benth. 
2. Agastache rugosa (Fisch. & Mey.) O. Ktze. 
Pogostemonis/Agastaches Herba 
Ji ji 及己 Chloranthus serratus NA 
Ji li 蒺藜 Tribulus terrestris L. Tribuli Fructus 
Ji xue teng 鸡血藤 Spatholobus suberectus Dunn Spatholobi Caulis 
Jiang can 僵蚕 
1. Bombyx mori Linnaeus. 
2. Beauveria bassiana (Bals.) Vuillant 
Bombyx Batryticatus 
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Jiao hong 椒红 
1. Zanthoxylum schinifolium Sieb. et Zucc. 
2. Zanthoxylum bungeanum Maxim. 
Zanthoxyli Pericarpium 
Jie geng 桔梗 Platycodon grandiflorum (Jacq.) A. DC. Platycodonis Radix 
Jie zi 芥子 
1. Sinapis alba L.  
2. Brassica juncea (L.) Czern. et Coss. 
Sinapis Semen 
Jin yin hua 金银花 Lonicera japonica Thunb. Lonicerae Japonicae Flos 
Jing da ji 京大戟 Euphorbia pekinensis Rupr. Euphorbiae Pekinensis Radix 
Jing jie 荆芥 Schizonepeta tenuifolia Briq. Schizonepetae Herba 
Jing tian 景天 Hylotelephium erythrostictum (Miq.) H. Ohba NA 
Jiu 酒 Liquor NA 
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Ju hua 菊花 Chrysanthemum morifolium Ramat. Chrysanthemi Flos 
Ku shen 苦参 Sophora flavescens Ait. Sophorae Flavescentis Radix 
Ku xing ren 苦杏仁 
1. Prunus armeniaca L. var. ansu Maxim. 
2. Prunus sibirica L. 
3. Prunus mandshurica (Maxim.) Koehne 
4. Prunus armeniaca L. 
Armeniacae Semen Amarum 
Lang ya cao 狼牙草 Indigofera pseudotinctoria Mats. NA 
Lian qiao 连翘 Forsythia suspensa (Thunb.) Vahl Forsythiae Fructus 
Ling yang jiao 羚羊角 Saiga tatarica Linnaeus Saigae Tataricae Cornu 
Liu huang 硫黄 Sulfur Sulfur 
Liu zhi 柳枝 Salix babylonica NA 
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Long gu 龙骨  Fossilised bone - various species 
Fossilia Ossis Mastodi (Draconis 
Os)
a,b
 
Lu jiao jiao 鹿角胶 
1. Cervus elaphus Linnaeus 
2. Cervus nipponTemminck 
Cervi Cornus Colla 
Lu jiao shuang 鹿角霜 
1. Cervus elaphus Linnaeus 
2. Cervus nipponTemminck 
Cervi Cornu Degelatinatum 
Ma chi xian 马齿苋 Portulaca oleracea L. Portulacae Herba 
Ma huang 麻黄 
1. Ephedra sinica Stapf 
2. Ephedra equisetina Bge. 
3. Ephedra intermedia Schrenk et C.A. Mey. 
Ephedrae Herba  
Mai dong 麦冬 Ophiopogon japonicus (L.f) Ker-Gawl. Ophiopogonis Radix 
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Mai men 麦门冬 Ophiopogon japonicus (L.f) Ker-Gawl. Ophiopogonis Radix 
Man jing zi 蔓荆子 
1. Vitex trifolia L. var. simplicifolia Cham. 
2. Vitex trifolia L.  
Viticis Fructus 
Mang cao  莽草 Illicium lanceolatum A.C. Smith. NA 
Man shan hong 满山红 Rhododendron dauricum L. Rhododendri Daurici Folium 
Mang xiao 芒硝 Hydrated sodium sulfate Natrii Sulfas 
Mu bie zi 木鳖子 Momordica cochinchinensis (Lour.) Spreng. Momordicae Semen 
Mu dan pi 牡丹皮 Paeonia suffruticosa Andr. Moutan Cortex 
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Mu li 牡蛎 
1. Ostrea gigas Thunberg 
2. Ostrea talienwhanensis Crosse 
3. Ostrea rivularis Gould 
Ostreae Concha 
Mu tong 木通 
1. Akebia quinata (Thunb.) Decne.  
2. Akebia trifoliata (Thunb.) Koidz.  
3. Akebia trifoliata (Thunb.) Koidz. var. australis (Diels) 
Rehd. 
Akebiae Caulis 
Mu xiang 木香 Aucklandia lappa Decne. Aucklandiae Radix 
Niu bang zi 牛蒡子 Arctium lappa L. Arctii Fructus 
Niu li zi bing 
gen 
牛李子并根 Rhamnus davurica NA 
Niu xi 牛膝 Achyranthes bidentata Bl. Achyranthis Bidentatae Radix 
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Nü zhen zi 女贞子 Ligustrum lucidum Ait. Ligustri Lucidi Fructus 
Pao jiang 炮姜 Zingiber officinale Rosc.  Zingiberis Rhizoma Praeparatum 
Qian hu 前胡 Peucedanum praeruptorum Dunn Peucedani Radix 
Qian li guang 千里光 Senecio scandens Buch.-Ham. Senecionis Scandentis Herba 
Qiang huo 羌活 
1. Notopterygium incisum Ting ex H. T. Chang 
2. Notopterygium franchetii H. de Boiss.  
Notopterygii Rhizoma et Radix 
Qiang wei gen 蔷薇根 Rosa multiflora NA 
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Qin jiao 秦艽 
1. Gentiana macrophylla Pall.  
2. Gentiana straminea Maxim.  
3. Gentiana crassicaulis Duthie ex Burk. 
4. Gentiana dahurica Fisch.  
Gentianae Macrophyllae Radix 
Qing dai 青黛 
1. Baphicacanthus cusia (Nees) Bremek.  
2. Polygonum tinctorium Ait. 
3. Isatis indigotica Fort. 
Indigo Naturalis 
Qing fen 轻粉 Mercurous chloride Calomelas 
Qing xiang ye 青葙叶 Celosia argentea NA 
Quan xie 全蝎 Buthus martensii Karsch Scorpio 
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Ren gong niu 
huang 
人工牛黄 N/A Bovis Calculus Artifactus 
Ren shen 人参 Panax ginseng C. A. Mey. Ginseng Radix et Rhizoma  
Rou cong rong 肉苁蓉 
1. Cistanche deserticola Y. C. Ma 
2. Cistanche tubulosa (Schrenk) Wight 
Cistanches Herba 
Rou gui 肉桂 Cinnamomum cassia Presl  Cinnamomi Cortex 
San qi 三七 Panax notoginseng (Burk.) F.H.Chen Notoginseng Radix et Rhizoma 
Sang bai pi 桑白皮 Morus alba L.  Mori Cortex 
Sang ji sheng 桑寄生 Taxillus chinensis (DC.) Danser Taxilli Herba 
Sang ye 桑叶 Morus alba L.  Mori Folium 
Shan yao 山药 Dioscorea opposita Thunb. Dioscoreae Rhizoma 
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Shan zha 山楂 
1. Crataegus pinnatifida Bge. var. major N.E. Br. 
2. Crataegus pinnatifida Bge.  
Crataegi Fructus 
Shan zhu yu 山茱萸 Cornus officinalis Sieb. et Zucc. Corni Fructus 
She chuang zi 蛇床子 Cnidium monnieri (L.) Cuss. Cnidii Fructus 
She dan zhi 蛇胆汁 Snake bile NA 
She xian cao  蛇衔草 Potentilla kleiniana NA 
Sheng jiang 生姜 Zingiber officinale Rosc. Zingiberis Rhizoma Recens 
Sheng ma 升麻 
1. Cimicifuga heracleifolia Kom. 
2. Cimicifuga dahurica (Turcz.) Maxim 
3. Cimicifuga foetida L. 
Cimicifugae Rhizoma 
 
300 
Shi chang pu 石菖蒲 Acorus tatarinowii Schott Acori Tatarinowii Rhizoma 
Shi gao 石膏 Hydrated calcium sulfate Gypsum Fibrosum 
Shi hu 石斛 
1. Dendrobium nobile Lindl. 
2. Dendrobium chysotoxum Lindl. 
3. Dendrobium fimbriatum Hook. 
Dendrobii Caulis 
Shou wu teng 首乌藤 Polygonum multiflorum Thunb. Polygoni Multiflori Caulis 
Shu di huang 熟地黄 Rehmannia glutinosa Libosch. Rehmanniae Radix Praeparata 
Shu fu pian 熟附片 Aconitum carmichaelii Debx. 
 Aconiti Radix Lateralis 
Praeparata 
Shui niu jiao 水牛角 Bubalus bubalis Linnaeus Bubali Cornu 
Shuo diao 蒴藋 Sambucus javanica Reinw. NA 
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Tao ren 桃仁 
1. Prunus persica (L.) Batsch 
2. Prunus davidiana (Carr.) Franch. 
Persicae Semen 
Tao zhi 桃枝 Prunus persica (L.) Batsch Persicae Ramulus 
Tian ma 天麻 Gastrodia elata Bl. Gastrodiae Rhizoma 
Tian nan xing 天南星 
1. Arisaema erubescens (Wall.) Schott 
2. Arisaema heterophyllum Bl.  
3. Arisaema amurense Maxim. 
Arisaematis Rhizoma 
Tian qi 田七 Panax notoginseng (Burk.) F.H.Chen Notoginseng Radix et Rhizoma 
Tu fu ling 土茯苓 Smilax glabra Roxb. Smilacis Glabrae Rhizoma 
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Tu si zi 菟丝子 
1. Cuscuta australis R. Br. 
2. Cuscuta chinensis Lam. 
Cuscutae Semen 
Wei ling xian 威灵仙 
1. Clematis chinensis Osbeck  
2. Clematis hexapetala Pall. 
3. Clematis manshurica Rupr. 
Clematidis Radix et Rhizoma 
Wu gong 蜈蚣 Scolopendra subspinipes mutilans L. Koch Scolopendra 
Wu mei 乌梅 Prunus mume (Sieb.) Sieb. et Zucc. Mume Fructus 
Wu shao she 乌梢蛇 Zaocys dhumnades (Cantor) Zaocys 
Wu wei zi 五味子 Schisandra chinensis (Turcz.) Baill. Schisandrae Chinensis Fructus 
Xi he liu 西河柳 Tamarix chinensis Lour. Tamaricis Cacumen 
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Xi xin 细辛 
1. Asarum heterotropoides Fr. Schmidt var. mandshuricum 
(Maxim) Kitag. 
2. Asarum sieboldii Miq. var. seoulense Nakai  
3. Asarum sieboldii Miq.  
Asari Radix et Rhizoma 
Xiao hong shen 小红参 Rubia yunnanensis NA 
Xiong huang 雄黄 Arsenic disulfide Realgar 
Xu chang qing 徐长卿 Cynanchum paniculatum (Bge.) Kitag. 
Cynanchi Paniculati Radix et 
Rhizoma 
Xuan shen 玄参 Scrophularia ningpoensis Hemsl. Scrophulariae Radix 
Yang ti teng 羊蹄藤 Bauhinia championi NA 
Ye ge 野葛 Pueraria lobata (Willd.) Ohwi Puerariae Lobatae Radix 
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Ye jiao teng 夜交藤 Polygonum multiflorum Thunb. Polygoni Multiflori Caulis 
Yi yi ren 薏苡仁 Coix lacryma-jobi L. var. mayuen (Roman.) Stapf Coicis Semen 
Yin chai hu 银柴胡 Stellaria dichotoma L. var. lanceolata Bge. Stellariae Radix 
Yin chen 茵陈 
1. Artemisia scoparia Waldst. et Kit.  
2. Artemisia capillaris Thunb.  
Artemisiae Scopariae Herba 
Yin yu  茵芋 Skimmia reevesiana Fortune. NA 
Yu li ren 郁李仁 
1. Prunus humilis Bge. 
2. Prunus japonica Thunb. 
3. Prunus pedunculata Maxim.  
Pruni Semen 
Yu zhu 玉竹 Polygonatum odoratum (Mill.) Druce Polygonati Odorati Rhizoma 
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Yuan hua 芫花 Daphne genkwa Sieb. et Zucc. Genkwa Flos 
Yuan zhi 远志 
1. Polygala tenuifolia Willd. 
2. Polygala sibirica L.  
Polygalae Radix 
Zao jiao 皂角 Gleditsia sinensis Lam. Gleditsiae Sinensis Fructus 
Zhang nao 樟脑 Cinnamomum camphora (L.) Presl. Camphoraa,b 
Zhi gan cao 炙甘草 
1. Glycyrrhiza uralensis Fish. 
2. Glycyrrhiza inflata Bat. 
3. Glycyrrhiza glabra L. 
Glycyrrhizae Radix et Rhizoma 
Praeparata cum Melle 
Zhi he shou wu 制何首乌 Polygonum multiflorum Thunb. 
Polygoni Multiflori Radix 
Praeparata 
Zhi mu 知母 Anemarrhena asphodeloides Bge. Anemarrhenae Rhizoma 
 
306 
Zhi qiao 枳壳 Citrus aurantium L. Aurantii Fructus 
Zhi shi 枳实 
1. Citrus aurantium L. 
2. Citrus sinensis Osbeck 
Aurantii Fructus Immaturus 
Zhi zhu hua 踯躅花 Rhododendron dauricum L. Rhododendri Daurici Folium 
Zhi zi 栀子 Gardenia jasminoides Ellis Gardeniae Fructus 
Zhu ling 猪苓 Polyporus umbellatus (Pers.) Fires Polyporus 
Zhu sha 朱砂 Mercuric sulfide  Cinnabaris 
Zhu shen  猪肾 Pig's kidney NA 
Zhu zhi 猪脂 Lard NA 
Zi bei fu ping 紫背浮萍 Spirodela polyrrhiza (L.) Schleid. Spirodelae Herba 
Zi cao 紫草 
1. Arnebia euchroma (Royle) Johnst.  
2. Arnebia guttata Bunge 
Arnebiae Radix 
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Zi hua di ding 紫花地丁 Viola yedoensis Makino Violae Herba 
Zui yu cao 醉鱼草 Buddleja lindleyana Fort. NA 
NA Not available 
